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1 EXECUTIVE SUMMARY 
 
 
1.1 Background  
 
1. The 1998 Scottish Health Survey included questions to estimate the scale of 
alcohol dependence in Scotland.  It recorded that 10% of male drinkers and 3-
4% of female drinkers replied affirmatively to one or more of three questions 
designed to identify alcohol dependence.  All three questions were answered 
affirmatively by 1% of male drinkers but less than 0.5% of female drinkers. 
 
2. Untreated alcohol dependence results in levels of drinking, which substantially 
increase the risk of stroke, cirrhosis of the liver, brain damage and several 
forms of cancer and are associated with substantially increased mortality. 
 
3. Following initial detoxification a longer term programme of treatment is 
required to prevent relapse into heavy drinking and dependence.  A number of 
different psychosocial and pharmacological interventions are available to 
prevent relapse. These are the focus of this HTA. 
 
4. The Plan for Action on Alcohol Problems was published in January 2002 
(Scottish Advisory Committee on Alcohol Misuse (SACAM), 2002) and 
covers a wide range of social, economic and clinical aspects of the misuse of 
alcohol in Scotland including chronic heavy drinking.  This Health 
Technology Assessment provides policy makers, planners and those working 
in the field of relapse prevention in alcohol dependence with a part of the 
information required to implement the Plan. 
 
5. People with established alcohol dependence are likely to require treatment 
mainly within Tier 3 (Specialist Alcohol Problem Services) or Tier 4 
(Regional Specialist Services) of the Scottish Executive’s Draft Alcohol 
Problems Support and Treatment Framework.  Thus this HTA will be of 
primary interest to those concerned with these specialist tiers.  However 
aspects of relapse prevention may happen in Tier 1 (Local Services) or 
Tier 2 (Specialist Support).  
 
6. There is no agreed definition of alcohol dependence.  When possible the 
pragmatic criterion that a process of detoxification has been undergone has 
been preferred.  However, a range of criteria are used by investigators in 
clinical trials and exclusive use of any single criterion would force many 
studies to be discarded.  
 
 
1.2 Objectives of this Health Technology Assessment 
 
The objectives of this Health Technology Assessment were to answer the following 
questions: 
 
1. Which approach or combination of approaches (pharmacological and 
psychosocial) will yield the maximum maintenance of recovery amongst the 
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population of those with alcohol dependence who have undergone 
detoxification? 
 
2. What is the most effective and efficient approach to delivering the individual 
interventions (or combination of interventions) taking into account the 
different risk groups, locations, durations of treatment, etc? 
 
 
1.3 Health Technology Assessment Evidence 
 
1. This Health Technology Assessment used systematic literature searching to 
identify evidence published in scientific literature.  It also used evidence 
submitted by professional groups, patient groups, manufacturers, other 
interested parties and experts and undertook primary research with patients to 
elicit their views and preferences. 
 
2. For clinical effectiveness, a number of comprehensive reviews of treatment for 
alcohol problems were consulted and also reviews of specific interventions.  
Studies particularly relevant to patients with alcohol dependence were 
extracted from these reviews.  Additional relevant studies were identified and 
an analysis was carried out to estimate the effects of treatment in a form 
suitable for input to the HTBS economic model.  
 
3. The patient issues component used published scientific literature, materials 
from Alcoholics Anonymous, and a qualitative study of patient attitudes 
commissioned by HTBS. 
 
4. The economic evaluation critically appraised the economic models contained 
in the literature. HTBS developed a simple, transparent model to combine the 
clinical effectiveness and epidemiology data with the costs of therapies and 
diseases to inform on the cost-effectiveness of five psychosocial and three 
pharmacological therapies to prevent relapse in people who are alcohol 
dependent.  The main source of cost data was Information Services Division 
(ISD), part of Common Services Agency (CSA), itself part of Scottish 
Executive Health department (SEHD). 
 
5. The current provision of services for prevention of relapse in alcohol 
dependence in Scotland was assessed by two postal surveys.  One of these was 
targeted at NHS specialist services and the other at non-NHS providers. 
 
 
1.4 Clinical Effectiveness 
 
1. A number of psychosocial interventions were found to be of value in 
preventing relapse in alcohol dependence.  The total combined success rates, 
in terms of abstinence or controlled drinking at the trial end (varying between 
6 months and beyond one year), in trials of those psychosocial treatments 
judged effective, was 43% for patients in the intervention groups and 28% for 
those receiving control treatments. In common with clinical trials in many 
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other areas of medicine, these may overestimate the absolute benefits 
attainable in clinical practice. 
 
2. The HTBS meta-analysis suggested similar, statistically significant, beneficial 
effect sizes for four types of psychosocial treatment.  The odds ratios for 
abstinence or controlled drinking at the end of the clinical trial compared with 
patients offered control treatments were: Behavioural Self-Control Training 
(OR=1.86 [95%CI 1.03,3.36]); Motivational Enhancement Therapy (OR=2.19 
[95%CI 1.20,3.98]); Family Therapy (OR=1.81 [95%CI 1.26,2.61]); and 
Coping/Communication Skills Training (OR=2.33 [95%CI 1.44,3.76]). 
 
3. Behavioural Self Control Training showed benefit when compared to 
ineffective controls.  However, the only trial, which focused on the unique 
defining features of BSCT and included the more general features in both 
treatment groups did not show a benefit.  Thus there is no proof of superiority 
over other CBT based approaches. 
 
4. Motivational Enhancement Therapy (MET) has mixed evidence.  It shows 
efficacy over ineffective controls.  However, it was slightly less effective than 
AA based treatment in outpatients in Project MATCH.  This may be due to the 
short course of treatment given.  It is suggested that MET form an important 
initial element in a course of psychosocial treatment but should not be the sole 
intervention available. 
 
5. Although marital/relationship therapy has shown a beneficial effect it should 
be recognized that this approach is only usually feasible in those with relatives 
willing to invest substantial effort in the treatment and with the consent of the 
patient.  Thus it is an option for treatment of only some patients.  An exception 
to this is the Community Reinforcement Approach, which has been shown to 
be effective when a contractual element with non-family members has been 
tested. 
 
6. Brief Interventions appear to be of unproven efficacy in patients with 
established alcohol dependence and the current evidence does not suggest that 
this is a promising approach.  The ‘Relapse Prevention’ model of treatment is 
also unproven. 
 
7. Acamprosate and naltrexone are pharmacological treatments intended to 
reduce relapse.  They are sometimes described as anti-craving agents. Both 
were found to be effective, the combined success rates, in terms of abstinence 
or controlled drinking at the trial end (varying between 3 months and one 
year), in trials of these treatments was 36% for treated patients and 26% for 
those receiving placebo treatments.  These may overestimate absolute benefits 
attainable in clinical practice. 
 
8. Disulfiram, which causes illness when taken with alcohol, was found to be 
ineffective if taken without supervision to ensure compliance.  One good 
clinical trial and some supporting evidence supports the use of disulfiram with 
supervision. 
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9. All the evidence for effectiveness of pharmacological treatments is obtained 
from studies in which they were adjunctive to psychosocial treatments.  Thus 
the psychosocial treatment should preferably be organised prior to starting 
medication. 
 
10. Within a specialist unit protocols should be available for all treatment options 
to ensure standardized and consistent treatment.  These protocols should be 
closely based on methods that have been proven effective in clinical trials. 
 
11. Evidence suggests that practical help with problems such as housing, debt, and 
claiming benefits is likely to contribute to control of alcohol problems.  Thus 
close liaison with Local Authority services such as Social Work and Housing 
and groups able to deliver such help is essential. 
 
12. Encouragement to attend AA meetings has been shown to have benefit. 
Explanation of the aims and philosophy of AA during treatment will allow 
patients to make an informed choice.  As with other psychosocial treatment 
approaches, cooperation with, rather than coercion into, AA treatment appears 
essential for benefit to be obtained. 
 
13. The effectiveness of relapse prevention interventions delivered by the 
Councils on Alcohol has not been tested in clinical studies.  Where counsellors 
are practising treatments, which have been shown to be effective in other 
settings there is likely to be benefit. 
 
 
1.5 Patient issues 
 
1. In reply to the HTBS survey only 36% of NHS specialist services carrying out 
psychosocial interventions indicated that they had patient information sheets 
or leaflets for any of these interventions.  It is recommended that such 
information should be available for all interventions. 
 
2. A qualitative study is being undertaken for HTBS, to explore patients’ 
treatment preferences and also to elicit factors, which, are felt to prevent 
relapse to drinking.  The aim is to describe the experiences and preferences of 
individuals for pharmacological or psychosocial interventions, or a 
combination of both, for the treatment for alcohol dependence.  This will be 
achieved by undertaking in-depth one-to-one interviews with 45 patients in 3 
NHSScotland Trusts. 
 
3. Data have, so far, been analysed from interviews with 32 people and this 
Interim Report presents the results of the preliminary analysis.  Of the 32 
interviews analysed so far, twenty were with men and twelve with women.  
Their ages range from thirty to seventy-two years.  Four people were still 
drinking in a harmful way, and the longest period of abstinence at the time of 
interview was two years. 
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4. Issues to emerge include: 
 
· Participation in residential or day case relapse services may currently depend 
on the way services are structured locally, rather than patient choice 
· Lack of understanding of terms such as cognitive behaviour therapy and 
motivational enhancement need to recognised in patient literature 
· Participants valued activities such as anger management, stress/anxiety 
management and relaxation exercises, coping skills, assertiveness training 
and rehearsing difficult situations within a safe environment 
· Women who had experienced ‘women only’ group work had a preference for 
women only groups, but conversely men may have a preference for mixed 
sex group work 
· Individual therapy sessions may be valued for the depth of work they enable 
· Flexibility of times and venues was valued 
· All participants recognised that AA works well for many people, but most of 
them felt that it was not suitable for them. 
· Awareness of services other than Alcoholics Anonymous may be low and 
may require better promotion. 
 
5. It is clear from the results of clinical studies that all interventions are of 
limited effectiveness. It is thus worth providing a range of options of proven 
efficacy. Treatment should be individualised taking account of patients’ 
expectations, needs and wishes with the understanding that these needs may 
change and the treatment plan may need to adapt to this. 
 
 
1.6 Economic Evaluation 
 
1. The economic evaluation compared the costs and consequences of eight 
therapies in comparison to a standard care package. The relevant outcomes 
were disease endpoints being alcohol dependence, alcoholic psychosis 
(including alcohol-related brain damage), liver cirrhosis, epilepsy, chronic 
pancreatitis, cancer, strokes and death. 
 
2. For each therapy, the costs and consequences for 1,000 patients complying 
with the therapy are modelled and compared to the costs and consequences for 
1,000 patients receiving a standard care package. This involves: 
 
· defining and costing each intervention 
· applying the clinical effectiveness odds ratio for the intervention to the 
epidemiology for the cohort to calculate the number of patients likely to be 
in the various disease endpoints 
· calculating the costs to NHSScotland of the disease endpoints; and  
· calculating an incremental cost or saving per additional abstinent patient. 
 
3. The results show that four of the five psychosocial interventions (Coping 
Skills, Behavioural Self Control Training, Motivational Interviewing and 
Marital and Family Therapy) produce net savings per incremental abstinent 
patient.  That is the cost of the treatment is less than the savings available to 
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NHSScotland.  These savings arise because the improved abstinence rate 
results in a lower incidence of diseases, thereby saving inpatient hospital stays 
and other disease related costs.  
 
4. Acamprosate is less cost effective than these psychosocial interventions but 
more cost effective than naltrexone and disulfiram.  Sensitivity analysis shows 
that the ranking of therapies is robust 
 
5. A serious limitation of the model is the absence of data on relapse rates 
beyond the relatively short trial periods.  There are also concerns about 
generalising from trials to treating patients in a Scottish setting.  Further 
research and evidence is thus needed to give more definitive estimates of the 
long-term effectiveness of all the therapies in a Scottish setting. 
 
 
1.7 Organisational Issues 
 
1. Randomised controlled trials testing matters related to the organisation of 
specialist alcohol services are scarce.  Thus recommendations with regard to 
organisational issues are based on clinical expert judgement. 
 
2. Alcohol services are highly suited to ‘joint working’, as recommended by the 
Joint Futures Group, involving specialist mental health and social work 
addiction services and non statutory agencies with joint resourcing and 
management of community care services. 
 
3. Treatment should be individualised taking account of patients’ expectations, 
needs and wishes with the understanding that these needs may change and the 
treatment plan may need to adapt to this. 
 
4. Certain subgroups such as young people, the homeless, those with co-morbid 
mental health problems, have special service needs and providers should 
ensure that the service is responsive and accessible to all. 
 
5. Specialist services must make themselves aware of mutual help (AA) and non-
statutory agencies operating in their area and co-ordinate their approach, 
making this information available to individuals within their care.  Informing 
patients about AA and non-statutory agencies should be part of the overall 
relapse prevention strategy. 
 
6. Controlled use of alcohol may be an appropriate treatment goal for those with 
less severe alcohol problems.  However, as will usually be the case in the 
specialist setting, abstinence should be the goal for severe dependence, where 
controlled use is rarely sustainable and especially when there is evidence of 
alcohol related organ damage.  If controlled use / harm minimisation is the 
considered preferred goal of the individual there must still be options for 
intervention e.g. referral to a non-statutory agency or outpatient motivational 
sessions. 
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7. An improved information collection system is required. (ISD are currently 
changing the way in which information is collected, for instance from GP 
contacts). 
 
8. A regularly updated comprehensive directory of alcohol services including 
residential treatment would be beneficial. This should be useable by all 
participating agencies and provide accurate outcome data (as recorded and 
analysed) as well as a greater understanding of progress through the treatment 
system. 
 
9. It is essential to have a longer term measurement of quality and effectiveness. 
Future measurements of outcome should cover longer periods post 
intervention e.g. up to 5 years. 
 
10. More research and evidence are needed regarding the benefits of different 
settings for psychosocial interventions e.g. group vs. individual, inpatient vs. 
outpatient vs. day unit, intensity and length and frequency of sessions etc. 
 
 
1.8 Draft Recommendations 
 
1. Patients value group and one-to-one psychosocial therapies.  Certain 
subgroups such as young people, the homeless and those with co-morbid 
mental health problems, have special service needs and providers should 
ensure services are responsive and accessible to all. 
 
2. Coping Skills, Behavioural Self Control Training, Motivational Interviewing 
and Marital/Family Therapy have been proven to be clinically and cost 
effective in this HTA and are recommended treatment options.  They should 
be administered by appropriately trained and competent professionals using 
standardized protocols.  Other psychosocial therapies were less effective and 
are not recommended. In particular, Brief Interventions are not effective in 
this population of patients with established alcohol dependence.  
 
3. Alcoholics Anonymous provide group therapies using the 12-step approach in 
hundreds of groups across Scotland.  This service is free to the NHS and the 
12-step approach has been shown to be effective.  Consequently NHS service 
providers should be aware of local AA groups and offer this as an alternative 
treatment. However, pressure to attend AA groups is not recommended. 
 
4. People with alcohol dependence have a high chance of relapse in the longer 
term.  Non-statutory agencies can be a responsive source of long term support 
and information.  Specialist agencies should ensure that clients are aware of 
locally available services.  
 
5. Disulfiram given under supervision and acamprosate are recommended as 
options for treatment in addition to psychosocial therapies, with acamprosate 
being the most cost effective.  The treatments have different mechanisms of 
action and associated side effects and so choice of treatment should be 
considered carefully on an individual patient basis. 
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6. Naltrexone does not have Marketing Authorisation in the UK for prevention of 
relapse in alcohol dependence and is less cost effective than acamprosate, so it 
is not recommended for use in NHSScotland. 
 
7. Specialist unit protocols should be available for all treatment options to ensure 
standardised and consistent treatment.  Clear patient information leaflets 
should be available for each intervention.  
 
8. For all therapies, both psychosocial and pharmacological, evidence of 
effectiveness is only available over short time periods of 3-12 months and in 
trial settings.  Collection of longer-term audit data, evaluating patient outcome 
and resource consequences of alcohol relapse, in various Scottish settings, is 
required to refine further these recommendations.  Improved information on 
the numbers of Scots who are alcohol dependent and who would benefit from 
such services, and the availability of resources to meet these demands, is also 
required.  
 
 
1.9 Consultation 
 
1. This HTA is currently at the stage of open consultation and comments on this 
Consultation Assessment Report should be submitted to Ms Susan Quinn, 
Medical Writer, by 17 September 2002 (see section 2.3 for further details). 
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2 INTRODUCTION AND OBJECTIVES 
 
 
2.1 Introduction 
 
The Scottish Health Plan (Scottish Executive Health Department, 2001) made a clear 
commitment relating to alcohol misuse.  In particular it stated that we will develop a 
plan for action on alcohol misuse, bringing together what needs to be done by all 
concerned, including the Executive. Prevention and services for people with alcohol 
problems will lie at the heart of the plan. 
 
This Plan for Action on Alcohol Problems was published in January 2002 (Scottish 
Advisory Committee on Alcohol Misuse (SACAM), 2002) and covers a wide range of 
social, economic and clinical aspects of the misuse of alcohol in Scotland.  The Plan 
notes that “Two current exercises will add in the next year or two to our 
understanding of how best to address the whole range of alcohol problems, including 
chronic heavy drinking.  These are work by the Scottish Intercollegiate Guidelines 
Network (SIGN) on the management of alcohol problems by primary care 
professionals and by the Health Technology Board for Scotland (HTBS) on relapse 
prevention”.  This report fulfils the second of these commitments.  
 
This HTBS Health Technology Assessment will consider interventions to prevent 
relapse in those who are alcohol dependent and have undergone detoxification.  It will 
link in closely to the SEHD initiative, particularly in terms of organisation of services. 
 
The relapse prevention therapies studied in this HTBS assessment are mainly given in 
secondary care settings and so this assessment will complement the SIGN guideline 
on management of alcohol dependence in primary care (due to be completed early in 
2003 – see Appendix 2).  
 
The Health Technology Board for Scotland (HTBS) uses the internationally 
recognised definition of Health Technology Assessment (HTA) (INAHTA, 2000) 
which describes HTA as a multidisciplinary field of policy analysis that studies the 
medical, social, ethical and economic implications of the development, diffusion and 
use of health technology.   
 
The HTA considers four components as identified in Figure 2 - 1   Health Technology 
Assessment (HTA) process: clinical effectiveness, economic aspects, patient issues 
and organisational considerations. The assessment report presents the evidence 
relating to each of these sections and a final discussion and recommendations bring 
together the key aspects from each section. 
 
This HTA follows the process published by HTBS (Health Technology Board for 
Scotland (HTBS), 2001) This involves the submission of evidence from a wide 
variety of sources, expert staff to undertake the analyses, a multidisciplinary expert 
Topic Specific Group (TSG) to collect and critique evidence and analyses, quality 
assurance (QA) by the HTBS Governance Board and wide-ranging open consultation 
and expert review.  
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In this HTA, national and international evidence is critically appraised, taking account 
of Scottish circumstances, so that clear, practical recommendations can be made to the 
National Health Service in Scotland (NHSScotland).  This detailed, scientific 
assessment report will be updated after the open consultation period, to become the 
final Health Technology Assessment Report.  At the final stage, two other summary 
documents will be produced.  The Advice to NHSScotland will be aimed at policy 
makers, NHS Board decision makers and healthcare professionals.  An Understanding 
HTBS Advice document will also be published explaining to patients, carers and the 
public how the evidence was reviewed and the reasons for the HTBS 
recommendations. 
 
 
2.2 Objectives 
 
The objective of this Health Technology assessment is to answer the following 
questions: 
 
1. Which approach or combination of approaches will yield the maximum 
maintenance of recovery amongst the population of those with alcohol 
dependence who have undergone detoxification? 
 
2. What is the most effective and efficient approach to delivering the individual 
interventions (or combination of interventions) taking into account the 
different risk groups, locations, duration of treatment, etc? 
 
The health interventions considered fall into two categories, pharmacological and 
psychosocial.  This latter category covers a wide range from the purely psychological 
to those that attempt to intervene practically in many areas of social welfare and 
functioning. 
 
A number of subsidiary questions were identified by our expert advisers, during the 
planning phase of this HTA.  These were used to focus on the selection of literature 
and the review process.  These questions are included as Appendix 3.  
 
 
2.3 Current stage of assessment: Open consultation 
 
This Health Technology Assessment is currently at the stage of open consultation and 
comments on this Consultation Assessment Report should be submitted by 17 
September 2002 to Ms Susan Quinn. 
 
Electronic files in plain text or in MS Office packages are preferred, but paper copies 
will be accepted.  Comments may be sent via email to squinn@htbs.org.uk or posted 
to the Health Technology Board for Scotland, Delta House, 50 West Nile Street, 
Glasgow G1 2NP.  Fax +44 (0)141 248 3778. 
 
In the month following consultation, all comments will be posted on the HTBS 
website (www.htbs.co..uk).  Please indicate if you do not wish your comment to be 
posted on the world wide web.  Also, please mark any confidential information, 
so that this can be removed before uploading to the web.  
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Consultation comments will be incorporated into the Final Assessment Report, as 
considered appropriate by the HTBS team.  Individual replies to comments will not be 
made, unless specifically requested.  
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Figure 2 - 1   Health Technology Assessment (HTA) process 
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3  BACKGROUND 
 
 
3.1 Alcohol misuse in Scotland 
 
Scotland has a significant alcohol misuse problem.  This has been highlighted in the 
Scottish Executive’s Plan for Action on Alcohol Problems (Scottish Advisory 
Committee on Alcohol Misuse (SACAM), 2002).  Planning services for treatment of 
alcohol problems requires an understanding of the existing treatment services and a 
prediction of the volume of service required, in addition to knowledge of the clinical 
and cost effectiveness of treatments.  This Health Technology Assessment addresses 
the particular problems of relapse prevention in that subgroup of drinkers who are 
alcohol dependent.  Service planning for these patients is complicated by the 
difficulty of defining the group of patients who want, or would benefit from, relapse 
prevention interventions. 
 
The misuse of alcohol can lead to a wide range of physical, psychological and social 
problems and places a significant burden on the workload of the NHS.  This burden 
results from damage not only to the harmful or problem drinker but also to other third 
parties affected by the excessive drinking.  The Plan for Action estimates that alcohol 
problems cost Scotland at least £1 billion each year.  Much of this is accounted for by 
reduced productivity and human costs.  The direct costs of alcohol problems (£449M 
annually) to health, social work and criminal justice systems incur more than drug 
misuse (£382M), Alzheimer’s disease (£155M), schizophrenia (£121M) and stroke 
(£118M).  Alcohol problems therefore impose a substantial financial burden on 
Scottish society, the considerable costs to statutory agencies draining resources from 
other priorities.  
 
There is no single culture surrounding drinking in Scotland.  It extends across age 
groups, genders, ethnic and religious groups, urban and rural areas.  This 
heterogeneity must be borne in mind when planning services and interpreting clinical 
and cost effectiveness reviews.  In addition, problems, such as access to appropriate 
and sensitive services, that may be experienced by groups including homeless people, 
older people, users of illegal drugs, minority ethnic groups, disabled people and 
people in rural areas must be identified and addressed. 
 
The association between alcohol and drug misuse should be recognised both in 
treatment approaches and overall service planning.  The similarities and differences 
between alcohol and drug problems are discussed in the Plan for Action, with some 
approaches to treatment being noted to be applicable to both.  There has been concern 
that alcohol has run a poor second to drugs in terms of service development in recent 
years.  Redressing this imbalance will be an important issue in the Plan for Action 
service recommendations. 
 
The links between severe problem drinking, homelessness and imprisonment are also 
well known and important factors in assessment of relapse prevention services.  
 
The Plan for Action on Alcohol Problems (Scottish Advisory Committee on Alcohol 
Misuse (SACAM), 2002) has highlighted concerning trends in alcohol use in Scotland 
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against which the current initiatives are set.  The following are statistics taken from 
the Plan for Action. 
 
· 44% of all men and 26% of all women are drinking more than twice the 
recommended daily benchmarks (>8 units for men; >6 units for women) on 
their heaviest drinking day 
 
· Alcohol related death rates for women have doubled in the last decade (from 
13.4/100 000 in 1990 to 31.2/100 000 in 2000) 
 
· In 1990 alcohol related deaths accounted for 1 in 100 deaths in Scotland.  By 
1999 this had risen to 1 in 40.  These figures might in part reflect  altered 
recording although there is evidence for liver deaths that this is not the 
explanation. More than 2/3rds of alcohol related deaths are of men. 
 
 
3.2 Treatment strategy and settings 
 
Treatment for alcohol dependence may be considered to have two distinct but 
interrelated arms.  Firstly, helping the individual to stop or reduce alcohol use.  This 
may require supervised detoxification.  The second arm of treatment is to help the 
individual live a life of abstinence or controlled drinking depending on the goal of 
treatment, the ethos of the service and the individual’s preference.  This understanding 
that detoxification is only the start of the story in the treatment of alcohol dependence 
is of major importance to all agencies involved in healthcare.  Long-term benefit 
relies on the development of life skills and methods that enable individuals to 
maintain the desired changes in their use of alcohol.  It is this second arm of treatment 
under the title of Relapse Prevention that will be focused on in this assessment. 
 
Detoxification and relapse prevention, although distinct processes, have an important 
relationship in terms of timing (Stages of Change, Prochaska and Di Clemente 1992).  
Detoxification may only improve long-term outcome if the individual has reached a 
crucial point in their attitude toward drinking.  The early transition from 
detoxification, whether inpatient or outpatient, to adapting to life without alcohol may 
be a crucial period for long-term outcome.  This may be the point where 
pharmacological interventions have a role. 
 
Relapse prevention may involve psychosocial (a combination of psychological and 
social) and pharmacological interventions.  They are characteristically most intensely 
carried out in the few weeks immediately following detoxification, and may also be 
part of a longer-term intervention aimed at reducing overall harm caused by alcohol.  
The main aims are to support, motivate and encourage effective coping skills.  
Introduction to other agencies in the treatment ‘system’ can be part of the overall 
relapse prevention strategy. 
 
Agencies carrying out relapse prevention interventions will be described later in this 
section of the report.  However, it should be mentioned here that the interventions 
described are, for the most part, carried out by specialist alcohol services.  Generalist 
interventions (e.g. as carried out by GPs, general medical and even general psychiatric 
wards) are usually limited to ‘opportunistic’ interventions.  These latter interventions 
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involve screening for alcohol problems, identifying hazardous or harmful drinkers and 
offering minimal (brief) interventions, aimed at reducing drinking to low risk levels.  
More seriously impaired or dependent individuals may be referred on to specialist 
services although some generalists feel more able to offer intensive treatments.  Other 
interventions, which are currently usually commenced in a specialist service, eg.  
Acamprosate, may be best continued in a generalist setting with ongoing monitoring 
by the specialist service.  This ‘shared care’ is a current area of development in 
substance misuse managements generally.  The NHS Executive (1995) defines shared 
care as ‘the joint participation of specialists and GPs (and other agencies as 
appropriate) in the planned delivery of care for patients with a drug (alcohol) misuse 
problem, informed by an enhanced information exchange beyond routine discharge 
and referral letters.  It may involve the day-to-day management by the GP of the 
patients medical needs in relation to his or her drug (alcohol) misuse.  Such 
arrangements would make explicit which clinician was responsible for different 
aspects of the patients treatment and care.’ 
 
 
3.3 Health Consequences of High Levels of Drinking 
 
The health consequences of drinking beyond the levels that have been shown to be 
safe are many and varied.  Harmful alcohol use often persists over many years, 
although some drinkers may have intermittent periods of prolonged sobriety.  Those 
with a pattern of harmful alcohol use may present as dependent seeking help, 
intoxicated, in withdrawal, with physical or psychiatric co-morbidity, in the wake of 
an accident, with social problems or having infringed the law.  
 
Prolonged harmful alcohol use often leads to serious health disorders affecting the 
nervous system (Korsakoff’s Syndrome, alcoholic dementia, peripheral neuropathy), 
the liver (cirrhosis, alcoholic hepatitis), the gastrointestinal system (oropharangeal 
cancer, gastritis, upper gastrointestinal bleeding, pancreatitis), the cardiovascular 
system (cardiomyopathy, hypertension), the respiratory system (laryngeal cancer), 
and the haematological system (anaemia, bleeding disorders).  In addition, the risk to 
the foetus in a pregnant alcohol misuser is well recognised. 
 
A recent study of the incidence of Korsakoff’s Syndrome in East Glasgow (Jauhar & 
Ramaya) highlighted a sharp increase in this presentation in recent years, amongst the 
highest incidence reported anywhere in the world. 
 
Harmful alcohol use is commonly associated with psychiatric illness.  Harmful 
drinking may be a response to underlying depressive illness or may itself precipitate 
depression. It can cause, or sometimes develops alongside, anxiety disorders.  Alcohol 
is associated with a high proportion of completed and attempted suicides.  Harmful 
drinkers can present with erectile impotence and decreased libido.  Dependent 
drinkers in withdrawal may develop delirium tremens. Alcoholic hallucinosis / 
psychosis may occur secondary to prolonged heavy alcohol use.  
 
A quantitative discussion of the long-term health expectations of heavy drinkers is 
given in section 3.20.  
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3.4 Social and Economic Consequences of Problem Drinking 
 
Alcohol dependence often leads to severe social and economic consequences for 
individuals and their families. Harmful alcohol use is associated with violence 
(domestic and otherwise), family stress, problems at work (including loss of job), 
financial strain and social isolation.  The social exclusion that may result from 
problem drinking may lead to homelessness and offending behaviour.  There is an 
association with theft and other crimes (including homicide) committed under the 
influence of alcohol.  Alcohol contributes to road accidents due to intoxicated 
pedestrians as well as intoxicated drivers. 
 
 
3.5 The Prevalence of Alcohol Dependence 
 
Standard definitions of dependence are given in full in Appendix 4.  The definition 
commonly used, and upon which hospital discharge data and mortality data are coded, 
uses the International Classification of Disease (ICD-10) (World Health Organisation, 
1992) diagnostic categories.  This requires the presence of three or more of the 
following for a diagnosis of dependence: 
 
1. a strong desire or sense of compulsion to take alcohol 
2. impaired capacity to control alcohol taking behaviour 
3. a physiological withdrawal state 
4. evidence of tolerance to the effects of alcohol 
5. preoccupation with alcohol use (to the detriment of alternative pleasures or 
interests) 
6. persistent alcohol use despite clear evidence of harmful consequences 
 
The true prevalence of alcohol dependence, according to this definition, is difficult to 
estimate.  This is because dependent individuals will not necessarily present for 
medical treatment.  However, various estimates have been made from concomitant 
evidence.  
 
A high proportion of the Scottish population currently drinks.  Only 7% of men and 
12% of women aged 16-74 said that they did not currently drink.  At mid 2000 there 
were estimated to be 1,972,394 men and 2,141,658 women of age 16 or over in 
Scotland.  This suggests a population of about 1.8 million male and 1.9 million female 
drinkers.  
 
The Scottish Health Survey 1995 estimated that the numbers of Scottish adults 
exceeding the weekly-recommended limits of 21 units for men and 14 units for 
women were 33% of men and 13% of women.  In the same year 8% of men were 
drinking above 50 units per week and 1% of women were drinking above 35 units per 
week.  These levels are known to have a harmful effect on the drinkers’ health.  In 
absolute terms they represent about 160,000 men and 19,000 women drinking at 
harmful levels. 
 
Drinking at a harmful level does not necessarily mean the drinker is alcohol 
dependent.  The Scottish Health Survey 1998 contained three statements designed to 
assess dependence:  'There have been occasions when I felt unable to stop drinking'; 'I 
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have had a drink first thing in the morning to steady my nerves or get rid of a 
hangover'; and 'I have found that my hands were shaking in the morning after 
drinking the previous night'. 
 
Looking at the three items on physical dependence, 90% of current male drinkers said 
none of the three items applied to them, 7% said one applied, 2% two items and 1% 
all three items.  Among current female drinkers, the corresponding figures were 96% 
none, 3% one item.  Precise figures are not given for two and three items but they are 
noted as being less than 0.5%:  An average ‘dependence score’ of 0.05 is given for 
women which would suggest that about 0.3% answered three items affirmatively*. 
The likelihood of agreeing with one or more of these three items was highest among 
16-24 year olds in both sexes, and then decreased with age.  These figures suggest 
that 180,000 men and 34,000 women might answer one or more items affirmatively. 
However,18,000 men and 5,700 women would answer all three of these dependence 
items affirmatively.  
 
Self reported information on drinking must always be interpreted with caution.  
Cross-sectional surveys have been found to underestimate per-capita consumption 
judged from alcohol sales figures.  However, the figures given above would appear to 
give reasonable bounds on the size of patient group that might benefit from specialist 
alcohol services.  If we assume that it includes all those who would answer 
affirmatively to the three dependence items but will not exceed the numbers drinking 
harmfully, the number of men lies between 18,000 and 160,000 and the number of 
women between 5,700 and 19,000. 
 
The number who might use services will not necessarily equal the number who might 
benefit.  Some measure of current usage of inpatient services can be gauged from ISD 
hospital discharge figures for 1999/0, which show 3,268 discharges from psychiatric 
hospitals and 4,398 discharges from non-psychiatric hospitals with a diagnostic code 
of F10.2, alcohol dependence syndrome (not necessarily as primary diagnosis).  This 
total of 7,666, of course, does not include the numbers undergoing detoxification in 
the community and receiving other treatments not involving hospital admission.  
These may constitute significant numbers.  
 
The Plan for Action on Alcohol Problems (Scottish Advisory Committee on Alcohol 
Misuse (SACAM), 2002) gives the following rates:  
 
· In 1999, 1 in 40 (or 1,595) deaths were reported as alcohol related (the 
majority of these have a diagnosis of alcohol dependence and alcoholic liver 
disease:  51% alcoholic liver disease; 44% alcohol dependence; 13% acute 
intoxication; 1% alcoholic psychosis).  (It is believed that alcohol is often 
omitted as a factor on the death certificate in deaths where alcohol was only 
a contributing factor, such as deaths from haemorrhagic stroke, cancer of the 
head and neck, suicide, burns, drowning or injuries – see below). 
 
· An estimated 0.7% (107, 685) of all GP consultations in Scotland were for 
alcohol related diagnoses in 2000; of these, 69% were due to alcohol 
                                                 
* If we assume the highest value for two items (0.5%) we have 0.03x1+0.005x2+Yx3=0.05 and hence 
Y=0.0033. 
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dependence, 21% due to alcohol intoxication, 5% due to physical / organ 
damage (including alcohol liver disease), 3% due to alcohol psychosis and 
2% due to unspecified problem drinking / excess consumption. 
 
· 3 in 100 of acute hospital inpatient admissions had an alcohol related 
diagnosis; of which 28.5% were diagnosed as acute intoxication, 26.2% 
(8,618) as alcohol dependence, 24.7% as alcohol problems, 17.1% as organ 
damage (including liver), 11% as alcohol poisoning (many of which were 
linked to overdoses) and 1% as alcoholic psychosis. 
 
· 15% (4,432) of all psychiatric hospital admissions had an alcohol related 
diagnosis; over 2/3rds of these had a diagnosis of alcohol dependence 
(71.4% (3,164) alcohol dependence, 20% (885) alcohol problems, 7.5% 
(332) alcoholic psychosis, (including alcohol-related brain damage), 2.6% 
(113) acute intoxication, 0.9% (40) other, 0.2% (9) organ damage including 
liver, 0.02% (1) alcohol poisoning). 
 
· Men are twice as likely as women to be admitted to an acute or psychiatric 
hospital for alcohol related problems 
 
 
3.6 Special Subgroups 
 
A number of subgroups within the alcohol dependent population may present special 
problems in treatment. These include those with comorbid mental illness, those with a 
dual alcohol and substance misuse problem, those presenting through the Criminal 
Justice System, homeless alcohol misusers and those people, often quite young, 
whose memory and judgement are impaired as a result of brain damage. In addition, 
slightly different presentations may exist in different ethnic groups. 
 
3.6.1 Comorbidity 
 
Surveys show that about a third of acute psychiatric inpatients with severe and 
enduring mental health problems also have an alcohol problem.  Such a ‘dual 
diagnosis’ adds to an individual’s difficulties, complicates their treatment and may 
well delay their recovery (Scottish Advisory Committee on Alcohol Misuse 
(SACAM), 2002).  The Greater Glasgow Alcohol Strategy (Greater Glasgow Health 
Board, 2000) notes that consultant psychiatrists from all parts of Glasgow report an 
increase in the proportion of patients in psychiatric hospitals where schizophrenia or 
depressive illness are complicated by alcohol misuse. 
 
3.6.2 Dual Substance Dependence 
 
There is growing evidence of people misusing alcohol along with other drugs, both 
street-purchased and prescribed such as benzodiazepines or methadone with 
unpredictable short and long-term consequences.  The Plan for Action notes that in 
1999 / 2000, 1 in 10 of those attending drug services reported use of alcohol as a 
problem in addition to their drug problem (Scottish Drug Misuse Database ISD 2001). 
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3.6.3 Alcohol Problems in Offenders 
 
Over 50% of male prisoners in the UK were drinking hazardously in the year before 
coming into prison (Psychiatric Morbidity Among Prisoners ONS 1997).  In a survey 
of 50% of all untried prisoners in Scotland in 1993, 22% of the prisoners had alcohol 
related problems (Greater Glasgow Health Board, 2000).  In a review of the medical 
history of all 906 men admitted to Barlinnie Prison during January 1998, 10% were 
suffering from serious withdrawal symptoms on admission. 
 
The Scottish Prison Service (SPS) assesses all prisoners on admission for addictions 
using a general screening questionnaire, and for those screened positive, using its 
Common Addictions Assessment Tool (CAART).  Thereafter a treatment and care 
plan is developed for each prisoner. Although a significant proportion of prisoners on 
admission have alcohol problems, there is no access to alcohol in prison and hence 
there is no use of acamprosate, disulfiram or naltrexone.  Treatment includes 
detoxification and psychosocial interventions including the 12 step programme. AA 
has a presence in 11 out of 16 SPS establishments, with structured 12 step 
programmes in 3 establishments. 
 
3.6.4 Homelessness and Alcohol Problems 
 
Scotland has over 5,000 homeless people. Studies among ‘rough sleepers’ show that 
50% are alcohol dependent. More than half of a sample of homeless people in Greater 
Glasgow in 1999 were drinking hazardously, increasing from 37% of 16-24 year olds 
to 63% of those aged 55 and over; men (60%) more than women (16%) (Kershaw et 
al., 2000). 
 
In Greater Glasgow a multidisciplinary Homelessness Addiction Team with 
representation from social work, housing and Greater Glasgow Primary Care Trust 
(Glasgow Problem Drug Service and the Alcohol and Drug Directorate) has been 
formed.  Particular problems that they have identified in dealing with the homeless 
include: 
 
· a proportion of people who do not wish any help 
· limited access to services and a lack of facilities specifically for the homeless 
· ensuring referrals are appropriate  
· considerable co-morbidity. 
 
3.6.5 Alcohol vs Drug Misuse 
 
The Plan for Action points out the similarities and differences between drug and 
alcohol problems.  Links noted are the influence on both by a wide range of 
overlapping social and cultural factors, the fact that many children who drink or 
smoke also try illegal drugs and that many adult drug users also have alcohol 
problems.  However, the numbers of people both using and misusing alcohol in 
Scotland far exceeds the number using illegal drugs. In 1997 there were 82 drug 
related deaths recorded by the Registrar General in Greater Glasgow compared with 
351 alcohol related deaths, although both are likely to be under reported.  From 1991 
to 1995 there were 3,857 drug related emergency hospital admissions compared with 
19,296 alcohol related emergency hospital admissions.  Alcohol continues to have a 
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much greater negative impact on health than misuse of illegal drugs (Greater Glasgow 
Health Board, 2000).  Although there are probably neurochemical and psychological 
overlaps between dependence on all psychoactive substances, and there are many 
similarities between the psychological ‘first-line’ treatments, the range of problems 
experienced by people who misuse alcohol differ in many respects from those 
experienced by drug misusers, as do the effects on society and on their families. 
People with drug and alcohol problems may need different types of services. 
 
 
3.7 Organisation of NHSScotland 
 
The National Health Service in Scotland (NHSScotland), like the NHS in other parts 
of the UK, provides comprehensive health care for its citizens, and is free at the point 
of use.  It is funded mainly by direct taxation in the form of income tax and National 
Insurance Contributions, with a small proportion of funding coming from patient 
charges such as for dental care and prescriptions.  A key advantage of the UK’s 
funding system is its fairness, providing maximum separation between an individual’s 
financial contributions and their use of health care.  After social security payments, 
health is the biggest single component of public expenditure. 
 
Total mortality and morbidity rates are higher in Scotland than in England, reflecting 
differences in their populations, environmental and socio-economic factors. 
NHSScotland has core aims of improving the health of the population and reducing 
inequalities in health. There are five clinical priorities: coronary heart disease, cancer, 
mental health, children and young people, and older people.  
 
In the UK, 83% of health spending is publicly funded (with the figure for Scotland 
higher still) compared to the European Union (EU) average of 75%.  NHSScotland 
has around 132,000 staff, including more than 63,000 nurses, midwives and health 
visitors and over 8,500 doctors. There are also more than 7,000 family practitioners, 
including doctors, dentists, opticians and community pharmacists, who are 
independent contractors providing a range of services within the NHS in return for 
various fees and allowances. 
 
The Scottish Executive Health Department (SEHD) leads the central management of 
NHSScotland.  It oversees the work of 15 NHS boards responsible for planning health 
services for people in their area and, through the boards, the activities of the 28 acute 
and primary care NHS Trusts responsible for providing services to patients and the 
community.  Primary Care Trusts, which include specialist mental health services,  
have been developing Local Health Care Co-operatives (LHCCs), which initially 
involved only general practitioners but are now evolving into multi-professional 
organisations.  The aim of LHCCs is to allow local decision-making (with 
involvement of local communities) to improve health and health care.   
 
A number of special Health Boards also exist which have Scotland-wide remits for 
specific functions. For example, NHS Education for Scotland commissions education 
and training for some NHS staff and HTBS provides advice on the clinical and cost-
effectiveness of new and existing technologies. 
More information about the health service in Scotland can be obtained from 
www.show.scot.nhs.uk and www.scotland.gov.uk/publications/recent.asp.  
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3.8 Structure and aims of current services 
 
NHS specialist services engaging in relapse prevention for alcohol dependence are 
incorporated in Primary Care Trusts. The other statutory services focusing particularly 
on relapse prevention interventions are those provided by Social Work services 
through Local Authorities. In addition non statutory services provide considerable 
assistance to people with severe alcohol problems and their families, to the extent that 
the statutory services could not cope in their absence. For example, in Glasgow they 
make an indispensable contribution to the overall provision of services (Greater 
Glasgow Health Board, 2000). 
 
There has been progress in the treatment of alcohol problems over the years with 
improvement in the range of options available for relapse prevention. This is probably 
secondary to positive changes in the attitudes of the medical profession and increased 
recognition of the harm caused by alcohol related problems in the UK. However, local 
service development in Scotland has been extremely varied probably as a result of 
local funding policies rather than on the basis of objective needs assessment. 
Development of training and research resources has also been patchy and generally 
limited. 
 
It is clear that no one agency can meet all the needs of people experiencing alcohol 
problems. A combined and co-ordinated treatment ‘system’ (so termed by Heather, 
1995) is required recognising the contribution of statutory and non-statutory services 
and guiding individuals appropriately through the care pathway. The Treatment 
Framework of the Plan for Action on Alcohol Problems should guide local agencies 
on strategic development. Attention should be paid to adequate services at all tiers of 
service and to avoiding duplication of effort between agencies and diversion of scarce 
resources from vital areas of care. For example, it is important that the development 
of the primary care based tier does not reduce the number of trained staff available in 
specialist tiers delivering relapse prevention to those with established alcohol 
dependence. Joint planning across Social Work, Health and non statutory sectors 
should take account of such possibilities. 
 
Specialist agencies may be able to increase efficiency by focusing their efforts on 
delivering existing treatments of proven efficacy and attempting to minimise 
duplication and overlap with programmes offered by other agencies involved in the 
same individual’s care. Relapse prevention should not be seen as a treatment in 
isolation but should be a component part of all treatment programmes (Raistrick & 
Heather, 1998).  As indicated in Section 3.5, in addition to using specialist agencies, 
problem drinkers seek the services of a range of other NHS facilities.  
 
Non specialist NHS services, therefore, also need to remain aware that detoxification 
or treating the presenting alcohol related physical disease is only one part of the 
process of treating alcohol dependence and clear understanding of how to access the 
care pathway (treatment system) for alcohol dependence is necessary. This 
understanding of the care pathway integrating specialist and non specialist, statutory 
and non statutory agencies is relevant to all agencies within and accessing the 
treatment system. 
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With respect to specific treatment options there is a need for a balanced response to 
alcohol misuse. Those at risk of becoming dependent on alcohol but not yet 
experiencing serious problems may respond well to minimal interventions (Scottish 
Intercollegiate Guidelines Network (SIGN), 2002). Those with established 
dependence on alcohol require a more intensive approach. 
 
Details of the nature and extent of services for treatment of alcohol dependence in 
Scotland were collected by HTBS in two surveys in 2001. Results of these surveys are 
given in section 3.18 
 
3.8.1 Defining Success 
 
Establishing reliable processes to obtain outcome measures for the effectiveness of 
available treatments is a problem. Laboratory investigations, corroborative histories 
and self-reporting questionnaires are currently used patchily throughout Scotland with 
no standardised approach. Definition of relapse is a key issue in outcome 
measurement. The consumption of 8 units for a man or 6 units for a woman in a single 
day is a commonly agreed research definition of relapse for someone in treatment for 
alcohol dependence. Different considerations would apply to those not meeting the 
criteria for dependence, where the treatment goal may be harm-free drinking. 
 
 
3.9 The Draft Alcohol Problems Support and Treatment Services Framework 
 
New proposals for the structure of alcohol services in Scotland are currently under 
consideration. The Draft Alcohol Problems Support and Treatment Frameworks’s aim 
is “to provide equitable, accessible and inclusive services to address the needs of 
those who experience problems with alcohol and those affected by others’ alcohol 
problems” (Scottish Executive Health Department, 2002). The Framework proposes a 
tiered approach to provide services with interaction between the tiers for integrated 
and comprehensive service provision.  The tiers are: 
 
· community based tier – local approaches to alcohol problems with the 
promotion of positive health through community plans, and information from 
a variety of media. 
· Tier 1 Local services – meets the support and treatment needs of the majority 
of people with alcohol problems and operates at the level of primary care 
teams, social work teams and Alcohol Action Teams, with support from 
NHS24. 
· Tier 2 Specialist support – provided by staff who give advice, training and 
support to those providing local services and provide a link to specialist 
alcohol problem services. 
· Tier 3 Specialist alcohol problem services – operating from within a Primary 
Care Trust, usually in conjunction with local general mental health services, 
and provide a range of specialist services. 
· Tier 4 Regional specialist services – may be based in a research or academic 
unit to provide particular expertise, as part of a managed clinical network.  
 
Within tier 1 the Framework identifies a number of groups who have difficulties 
accessing mainstream services and who should be identified locally.  These groups 
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include young people (including vulnerable groups such as looked after children, 
homeless, offenders), women who are experiencing or have experienced domestic 
abuse, people in areas of social exclusion, people in rural areas, disabled people, 
ethnic minorities, homeless people, older people, and gay and transgender people.  
Within tier 2 there is a need for services for people with mental health problems, 
criminal justice services, and support for prisoners.  Within tier 3 there should be 
specialist alcohol problem services, specialist services for young people, people with 
co-morbidity (alcohol +/- substance misuse +/- mental illness. Tier 4 is envisaged as 
dealing with complex alcohol problems and would include relapse prevention in 
patients with alcohol-related neuropsychiatric problems or brain damage, and those 
with sever co-morbidity. 
 
 
3.10 HTBS surveys of Scottish services 
 
In order to evaluate the nature and range of services for prevention of relapse 
provided in Scotland two postal surveys were carried out. The first of these addressed 
the services within NHSScotland and was sent to all major specialist alcohol units. 
Twenty-seven questionnaires were sent out of which four questionnaires were 
mistakenly sent to different individuals within the same service and the number of 
questionnaires expected to be returned was therefore reduced to 23. Of these, 22 were 
completed and returned including at least one from each NHS Board. Limited data on 
the one service, which did not complete the questionnaire was obtained via telephone 
contact The questionnaire is shown in Appendix 5 and narrative and tabular results 
are in Appendices 7 and 8.  
 
The second survey attempted to assess the provision of relapse prevention services by 
non-NHSScotland care providers. This was a briefer questionnaire and is shown in 
Appendix 6. One hundred and twenty-three (123) questionnaires were sent out and 43 
returned. Compiling a full listing of such providers is not an easy task and it was 
decided to risk inappropriate, or possibly multiple, contacts with some providers in 
order to maximize appropriate contacts. Thus it is difficult to interpret these response 
rates in terms of coverage of services. 
 
The figures given for Scottish service provision in the following sections are based on 
the data obtained from these surveys. 
 
 
3.11 Psychosocial Interventions 
 
Psychosocial interventions for relapse prevention are based around ‘talking therapies’, 
which can involve one to one, couple, family or group approaches and encourage self-
help as part of the treatment and support options. These interventions are numerous, 
having more than 40 different ‘brand names’, although certain ingredients are 
common to almost all (e.g. the therapeutic alliance) and they can broadly be grouped 
into four main categories. These are – therapies aimed at: 
 
 
1. Building motivation 
2. Cognitive restructuring 
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3. Behavioural and coping skills training 
4. Implementing the Twelve Step Model based on the Alcoholics Anonymous 
approach 
 
Definitions of individual psychosocial interventions are provided in Appendix 9. 
 
Effective motivation building in alcohol dependent patients is based on Motivational 
Enhancement Therapy (MET) or Motivational Interviewing.  
 
Motivational Interviewing / Enhancement Therapy focuses on eliciting the 
individual’s intrinsic motivation for change (Miller & Rollinick, 1991) and contains 
certain therapeutic strategies.  These include expressing empathy, avoiding argument, 
detecting and ‘rolling with’ resistance, highlighting discrepancies in the history and 
drawing out the individual’s own discomfort about the behaviour. 
 
This approach, utilising the individual’s own skills and resources, is shared generally 
by client centred approaches e.g. Solution Focused Therapy (Berg & Miller, 1992). 
 
Therapies aimed at cognitive restructuring include Cognitive Behavioural Therapy 
(CBT) and elements of Relapse Prevention Therapy and Coping Skills Training (as 
opposed to behavioural coping strategies).  In Relapse Prevention Therapy individuals 
unlearn the patterns of drinking behaviour, implement substitute behaviours and 
rehearse healthier approaches to dealing with situations that previously triggered 
thoughts of drinking. Relapse Prevention Therapy models include that of Marlatt 
(Marlatt & Gordon, 1985), which also encompasses social skills training and 
behavioural coping strategies, and Gorski’s CENAPS (Early Warning Signs) 
approach (Gorski & Miller, 1982).  This approach involves a series of procedures to 
help the drinker to become aware of their habitual warning signs of relapse, develop 
and implement plans for coping with each sign and develop a lifestyle to prevent the 
occurrence of the sequence of changes leading to a lapse. 
 
Therapies aimed at behavioural and coping skills often focus on general skills (such 
as communication and assertion skills) rather than on specific skills for avoiding 
substance use.  They include Social Skills Training, Coping Skills Training, Stress 
Management, the Community Reinforcement Approach (Azrin et al., 1982), where 
emphasis is placed on changing the individual’s social environment by developing 
rewarding employment, leisure activities and relationships that do not involve alcohol, 
Behavioural Self Control Training (using simple self contracted goals and self 
rewards for their achievement) and Behavioural Marital / Couples Therapy (with the 
aim of increasing the level of positive reinforcement exchanged by the couple). 
 
Therapies involving families or couples are usually in this last category of behavioural 
/ coping skills. Other marital or family therapy approaches draw on systems theory in 
both formulating the hypothesis about distress and planning interventions. 
Group therapy is a commonly used procedure but often poorly defined.  Groups can 
be run according to various psychotherapeutic principles and, in some cases, 
according to no clear principles at all. 
 
Twelve Step Programmes are based on the Alcoholics Anonymous (AA) model 
referring to the stages of growth through which the individual must progress in order 
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to achieve and maintain sobriety. The individual is expected to acknowledge the need 
for help and aim for complete abstinence. 
 
 
3.12 Psychosocial Interventions within NHSScotland 
 
Psychosocial interventions used in NHS specialist services in Scotland, based on the 
HTBS survey, are shown by Health Board in Table 3 - 1  Psychosocial Interventions 
in NHS Secondary Care.  One or more of these is offered formally in 90% of 
specialist services. 
 
 
Table 3 - 1  Psychosocial Interventions in NHS Secondary Care 
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Lomond & Argyll · ·    · · · ·   · · 
Renfrewshire & Inverclyde · · ·    · · ·    · 
Ayrshire & Arran. · · ·  · · · · · · · ·  
Borders.              
Dumfries & Galloway · · ·    · · · ·    
Fife · · ·    · · · · ·   
Forth Valley · · ·    · · ·     
Grampian · · · ·    · ·     
Greater Glasgow · · ·  · · · · · ·   · 
Highland · · ·  · · · · · · · · · 
Lanarkshire ·  ·    · ·  ·    
Lothian · · · · ·  · · ·    · 
Orkney · · ·    · · ·   ·  
Shetland*              
Tayside · · ·     · ·   · · 
Western Isles · · ·  · · · · · · ·   
* No specialist services in Shetland 
 
In the NHS, among specialist services offering psychosocial interventions for alcohol 
problems, Motivational Interviewing and Coping Skills Training appear to be 
universally used. 
 
For Motivational Interviewing (MI) the number of sessions offered ranged from 2-10, 
or up to 3 weeks depending on the service and the individual. About 20% of services 
using the therapy acknowledged having protocols for this. MI was usually carried out 
on a one to one basis and in a non-residential setting. Very few services attempted to 
audit the intervention.  Staff carrying out the therapy were most often internally 
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trained but external training has occurred in the past. Only in a few cases was it 
declared that staff had no training in the technique. 
 
For Coping Skills (CS) Training the number of sessions offered ranged from 4-10 or 
up to 4 weeks, with over half of the services noting that this varied depending on the 
individual.  About 15% of the services carrying out this therapy reported having 
protocols.  CS was carried out in one to one and group settings, usually non-
residentially. Very few services attempted to audit the intervention.  Staff are most 
often internally trained but external training did occur.  
 
Stress Management was used in 95% of specialist services offering psychosocial 
interventions.  The number of sessions, setting and training of staff were as for 
Coping Skills Training.  About 10% of the services carrying out this therapy 
acknowledged having protocols. 
 
Brief Interventions (BI) were used in 89% of services offering psychosocial 
interventions.  The number of sessions ranged from 1-10, with over half of the 
services noting that this varied depending on the individual.  Over 1/3 of services 
carrying out this therapy reported having protocols.  Although this intervention may 
have been expected to be carried out entirely on a one to one basis, some services 
noted using the technique in a group setting.  Although mostly carried out non 
residentially there was some use of BI in residential settings which may suggest an 
‘opportunistic’ application (eg. by specialist staff liasing to general wards).  Only one 
service appeared to audit interventions of this sort. Both internal and external training 
took place. 
 
CBT was used in 84% of specialist services offering psychosocial interventions.  The 
number of sessions ranged from 4-10, or up to 4 weeks, but was noted to be variable 
in over half of the services.  About 20% of the services carrying out this therapy 
acknowledged having protocols.  CBT was most commonly carried out on a one to 
one basis and usually in a non-residential setting.  Very few services attempted to 
audit the intervention. Most staff training was external but additional in-house training 
did occur. 
 
Social Skills (SS) Training was used in 79% of specialist services offering 
psychosocial interventions.  The number of sessions, setting and training of staff were 
as for Coping Skills Training.  About 20% of services carrying out this therapy 
reported having protocols. 
 
Other less common interventions included: 
 
· Community Reinforcement Therapy (acknowledged by 40% of the 
specialist services offering psychosocial interventions); 
· Couples Therapy (35%); 
· Behavioural Marital / Couples Therapy (25%); 
· Family Therapy (20%); 
· ‘Relapse Management’(20%); 
· Twelve Step Facilitation Approach (10%, or 2 services). 
 
Non-specific counselling was noted to take place in 36.8% of these NHS services. 
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Relapse Prevention Groups were acknowledged in 40% of services offering 
psychosocial interventions.  Some, if not all, have written protocols. Greater Glasgow 
NHS Board, for instance, uses a standardised protocol based on the Marlatt model 
(Larimer et al., 1999) throughout its 4 centres.  
 
Various other psychosocial interventions were acknowledged including Anger 
Management, Assertiveness Training, Solution Focussed Therapy, Anxiety 
Management, Alcohol Education Groups, Supportive Counselling and ‘Relaxation 
and Exercise’ Groups. 
 
A number of services offered tailored groups e.g. Women’s Groups. 
 
For each of these interventions a number of outcome measures are cited as being 
used, these varying from service to service, presumably in terms of frequency as well 
as form.  Outcome measures used included laboratory investigations (Gamma GT, 
Mean Cell Volume, Liver Function Tests), diaries, self-report, rating scales and 
questionnaires (self-report and therapist), timeline follow back and collateral 
information.  The rating scales and questionnaires cited were Drug-Taking 
Confidence Questionnaire 8, Readiness to Change questionnaires, the Christo 
Inventory, the Alcohol Related Problems Questionnaire, client satisfaction 
questionnaires and CBT rating scales. 
 
Eleven percent (11%) of NHS specialist services carrying out psychosocial 
interventions did not use routine outcome measures. 
 
Only 36% of NHS specialist services carrying out psychosocial interventions 
indicated that they had patient information sheets or leaflets for any of these 
interventions. These are included as Appendix 10. 
 
 
3.13 Psychosocial Interventions in Non NHS Services 
 
In the non NHS day services which we surveyed, of those responding to the 
questionnaire 42% carried out non-specific counselling, 25% used Person-Centred 
Counselling, 21% used Social Skills Training, 21% offered support and advice, 17% 
used Motivational Interviewing and 17% used some form of Group Therapy.  Other 
interventions included psychodynamic counselling, Stress Management, 
Assertiveness Training, Solution Focussed Therapy, Complementary Therapy, 
Couples Therapy and Family Therapy. 
Although counsellors from the Councils on Alcohol are usually centrally trained by 
Alcohol Focus Scotland using a CBT based approach, the Councils on Alcohol 
responding to the survey acknowledged a range of approaches: a CBT based approach 
(47%), non-specific / eclectic counselling (41%), Person Centred Counselling (23%), 
Social Skills Training (18%), Motivational Interviewing (19%), Stress Management 
(6%) as well as support and advice, Couples, Family and Group work. 
 
Social Work services responding to the questionnaire were few in number. The 
information obtained from those responding would suggest that a range of validated 
psychosocial interventions might be offered including CBT, Motivational 
Interviewing and Social Skills Training as well as non-specific counselling. 
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Of non NHS residential rehabilitation services surveyed the returned information 
suggests that a range of interventions are being offered including non-specific 
counselling, CBT based counselling, Person Centred Counselling, Task Centred 
Counselling, Positive Modelling, Social Learning Theory, Anger Management and 
Group Work. 
 
Of non-NHS residential homeless services surveyed only 46% acknowledged offering 
psychosocial interventions for alcohol dependence. Interventions most commonly 
offered included support and advice, non-specific counselling, Twelve Step 
Facilitation and Social Skills Training. Less frequently offered interventions included 
CBT based interventions, Brief Interventions, Motivational Interviewing, Work 
Theory, Health Education, Problem Solving, Group Therapy and Vocational Training. 
 
Private care facilities (e.g. Priory and Castle Craig) were not sent the survey 
questionnaire.  The Priory (Langside) offers a service which includes detoxification as 
an inpatient or outpatient aimed at achieving abstinence, CBT, problem solving, 
family therapy, couple therapy, post treatment planning, continuing weekly aftercare 
and self-help group meetings within the hospital.  Castle Craig adopts a 12 step 
approach in a residential setting and aims for abstinence. 
 
3.13.1 Alcoholics Anonymous 
Founded in 1935, Alcoholics Anonymous (AA) has a long history of providing 
confidential support and advice to those with alcohol problems.   
Alcoholics Anonymous is organised by and for people with a drinking problem. The 
only requirement for membership is a desire to stop drinking. There are numerous 
local groups throughout Scotland who may be contacted directly.  
 
HTBS did not survey Alcoholics Anonymous facilities / meetings. However, a large 
quantity of information was submitted from AA as evidence. 
The trustees of the AA General Service Board decided in 1968 to begin conducting 
anonymous surveys of the membership.  These surveys are repeated at three yearly 
intervals and provide a continuing view of the demographic changes in alcohol related 
problems over the last 34 years. 
The 1968 survey clarified the need for AA to work more closely with professionals in 
the field, and culminated in the formation of a Professional Relations Committee 
(now Cooperation With the Professional Community).  Succeeding surveys have 
underlined the importance of outside help in pointing dependent people toward AA 
and in providing additional help during sobriety. In 1998, 34% of members were 
introduced to AA through treatment facilities, 11% by court order, and 17% by a 
counselling agency or health care provider.  Before coming to AA, 60% of members 
received some type of treatment or counselling, and 75% of those members said it 
played an important part in directing them to AA.  After coming to AA, 62% of 
members received some type of treatment or counselling, and 83% of those believe it 
was important to their recovery. As in the past several surveys, 75% report that their 
doctors know they are in AA. 
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There are numerous branches of AA in Scotland.  There are 228 weekly meetings in 
Glasgow alone and 934 over the whole of Scotland. 
The philosophy and approach of AA is well documented in numerous publications.  In 
particular, AA consider that alcohol dependence, once established, is a permanent 
condition which can only be controlled by complete abstinence.  The 12 step 
facilitation is designed to help achieve this objective (Appendix 11). 
 
 
3.14 Pharmacological Interventions 
 
Pharmacological interventions used in alcohol dependence for prevention of relapse 
include deterrent medication, such as disulfiram (Antabuse), which induces illness if 
the individual consumes alcohol, acamprosate (Campral), an NMDA receptor 
modulator, specifically designed to prevent alcoholic relapse, and naltrexone (Revia), 
an opioid antagonist currently unlicensed for this indication in the UK. 
 
3.14.1 Disulfiram 
 
Disulfiram is indicated as an adjuvant in the treatment of carefully selected and 
cooperative patients with drinking problems.  It should be combined with appropriate 
supportive treatment.  It is supplied as 200mg tablets and the manufacturers 
recommend an initial dose of four tablets, which is reduced by one tablet daily to a 
maintenance dose of one or half a tablet continuing for up to six months.  The 
individual taking disulfiram regularly in sufficient dose will, on consuming alcohol, 
experience an unpleasant reaction (flushing of the face and upper body, throbbing 
headache, palpitation, dyspnoea, tachycardia, nausea, vomiting and with large doses 
of alcohol, arrhythmias, hypotension and collapse).  The reaction occurs about 10 
minutes after ingestion of alcohol and may last several hours.  The severity of this 
reaction shows a great deal of individual variation and, rarely, the reaction can be life 
threatening.  Conversely some individuals have no or mild reactions on standard 
doses and higher doses may be required.  Even small amounts of alcohol can lead to 
unpleasant systemic reactions and therefore care must be taken when using other 
medicinal products and toiletries.  It is advisable for patients to carry a card warning 
of the danger of administration of alcohol.  The patient is told the nature of the 
reaction prior to prescription of the drug. 
 
There are several contraindications to using disulfiram including cardiac failure, 
coronary artery disease, previous history of cerebrovascular accident, hypertension, 
pregnancy, breast feeding, severe personality disorder, suicidal risk or psychosis 
(which is thought may be exacerbated by disulfiram’s action on dopamine b-
hydroxylase).  Additional caution is required in renal failure, hepatic or respiratory 
disease, diabetes mellitus, epilepsy and the concurrent use of anti-convulsant, anti-
coagulant and anti-hypertensive medication. 
 
The medication is recommended to be administered daily, but can also be given twice 
or thrice weekly (at 3-4 day intervals) as the action lasts for about 7 days after the last 
dose.  This may be of practical importance if administration is supervised e.g. at a day 
hospital, by a workplace nurse, community psychiatric nurse or practice nurse.  As 
with all medications there are problems with compliance, perhaps related to the 
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individual’s prior understanding that a lapse is imminent, perhaps related to side 
effects which include lethargy and loss of libido.  
 
Disulfiram is described as an adjunct to psychosocial intervention (not specified) and 
is not, for instance, intended for use as a monthly repeat prescription with minimal 
doctor / patient interaction. 
 
3.14.2 Acamprosate 
 
Acamprosate, has been licensed in the UK since 1995 for abstinence maintenance 
therapy for up to 1 year in motivated alcohol dependent patients.  Its chemical 
structure is similar to the naturally occurring amino acid neuromediators, taurine and 
gamma aminobutyric acid (GABA) and it is believed that it may act by binding to 
NMDA receptors in the brain, modulating the up-regulation of NMDA receptors 
which occurs on alcohol withdrawal, enhancing GABA inhibitory neurotransmission 
and antagonising glutamate excitation, thus suppressing putative biochemically based 
craving in response to learned cues (e.g. feeling stressed, passing a bar or being in the 
company of others drinking alcohol).  It is possible also that its action reduces the 
likelihood of reinstatement of dependence symptoms if a lapse occurs.  For this reason 
acamprosate should continue to be prescribed despite occasional lapses, if there is 
evidence that those lapses are significantly less severe than previously.  However, 
there is no point in continuing the medication if significant relapses occur.   
 
The recommended dosage is 2x333mg tablets three times per day over a 1 year 
treatment period.  The dosage is reduced to 4 tablets per day (2 morning, 1 midday, 1 
night) in those weighing less than 60 kg.  It is licensed only for patients between 18 
and 65 years of age. 
 
Pharmacokinetic studies showed very large inter-subject variations in bioavailability. 
Mean bioavailability was reduced by about 20% when tablets were taken with food.  
It appears to be excreted primarily via the kidneys and is contraindicated in renal 
dysfunction (serum creatinine over 120 micromols/l).  Other contraindications are 
hypersensitivity, severe hepatic failure (Childs Pugh Classification C), pregnancy and 
breast feeding.  Adverse effects are usually mild and transient and are predominantly 
gastrointestinal (diarrhoea, nausea, vomiting, abdominal pain) and dermatological 
(pruritis, occasional maculopapular rash and rare cases of bullous skin reactions have 
been reported). 
 
As it takes 5-7 days to reach therapeutic levels (elimination half-life 18 hours) 
Acamprosate should be started soon after detoxification.  
 
As with disulfiram, acamprosate, is currently recommended to be combined with 
counselling.  
 
3.14.3 Naltrexone 
 
Naltrexone, an opioid antagonist, is not licensed in the UK for use in alcohol 
dependence.  It has been licensed for this use in the Republic of Ireland and several 
other EC countries since 1996, as part of a comprehensive treatment programme for 
alcohol dependence to reduce the risk of relapse to heavy drinking, support abstinence 
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and reduce alcohol craving.  It may act by breaking the desire for the next drink by 
blocking the pleasure or ‘high’ which would normally result from sampling alcohol.  
It is reviewed in this assessment because it is used off-licence in 5 Scottish NHS 
Boards Table 3 - 2  Pharmacological Treatments in NHS Secondary Care. 
 
The recommended dosage is one 50 mg tablet per day. An initial treatment period of 
three months is suggested but longer-term treatment can be considered. 
 
Serious side effects of naltrexone are rare but the most commonly reported side 
effects include nausea (9.8%), headache (6.6%), dizziness (4.4%), nervousness 
(3.8%), fatigue (3.6%), difficulty sleeping (3.0%), vomiting (2.6%), anxiety (2.0%), 
and somnolence (2.0%).  The incidences were estimated over 12 weeks by Croop et al 
(1997). 
 
Contraindications are acute hepatitis, liver failure, current dependence on opiates, 
current use of opioid containing medication and hypersensitivity.  
 
 
3.15 Pharmacological Interventions in NHS Specialist Services in Scotland 
 
The Greater Glasgow ‘Shared Care’ protocol for the use of acamprosate and the 
Lothian protocol for the use of naltrexone can be found in Appendix 12 and Appendix 
13 
 
In our survey of NHS specialist alcohol services all used acamprosate and disulfiram. 
In addition 5 services used named patient / off licence prescribing of naltrexone (see 
Table 3 - 2  Pharmacological Treatments in NHS Secondary Care).  No other 
medications are routinely used in Scotland for relapse prevention in alcohol 
dependence.  Combinations of acamprosate and disulfiram are used in 57% of 
services.  Combinations of naltrexone and disulfiram are used in one service.  There 
was no noted use of combinations of naltrexone and acamprosate. 
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Table 3 - 2  Pharmacological Treatments in NHS Secondary Care 
 
NHS Board/PCT acamprosate disulfiram naltrexone 
Lomond & Argyll · ·  
Renfrewshire & Inverclyde · · · 
Ayrshire & Arran. · · · 
Borders. · ·  
Dumfries & Galloway · ·  
Fife · ·  
Forth Valley · ·  
Grampian · · · 
Greater Glasgow · · · 
Highland · ·  
Lanarkshire · ·  
Lothian · · · 
Orkney · ·  
Shetland*    
Tayside · ·  
Western Isles · ·  
 
* No specialist services in Shetland 
 
In the majority of NHS specialist services medical staff of all grades (SHO to 
Consultant) prescribed acamprosate and disulfiram.  In the services without medical 
staff, as well as many of those with medical staff, GPs would prescribe these 
medications on the advice of the team or in co-ordination with the team, if local NHS 
Board prescribing arrangements permit. 
 
In services prescribing naltrexone this was always done by consultant medical staff 
attached to the specialist team. 
 
3.15.1 Disulfiram 
 
Fifty-two percent (52%) of specialist services used supervised administration if 
required.  Supervision may be by CPN / Practice Nurse / Alcohol Unit Nursing staff 
or relatives (18% of services using supervision acknowledged this method – see 
Appendix 14 for useful information for the patient, partner / supervising person and 
supervising doctor (Lothian NHS Board)), place of work or the community pharmacy. 
 
Most of the services commence disulfiram in both inpatient and outpatient settings 
with initial proposed duration between services varying from 1 month to 1 year (41% 
of services considered the proposed duration to be variable / indefinite depending on 
factors such as patient response). 
 
Protocols exist for the use of disulfiram in 9% of services. 
 
All services noted that psychosocial interventions were used in combination with 
disulfiram but, for instance, one service commented that this was simply the ‘normal 
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clinic regime’.  The most commonly acknowledged interventions to be used in 
combination with disulfiram were CBT and Motivational Interviewing. Also noted 
were Relapse Prevention Groups, ‘Group Work’, ‘Counselling’, ‘Abstinence 
Maintenance’ and ‘Specific Antabuse adjunctives’. 
 
The goal of treatment was abstinence in 76.2% of services, with 14.3% citing the goal 
as either abstinence or reduced consumption / controlled drinking and 4.8% citing the 
goal as reduced consumption. 
 
The outcome measures most commonly used were derived from laboratory tests 
(28.6% of services), self-report (19% of services) and diaries (14.3% of services) with 
cumulative abstinence duration (CADs), collateral information and alcometer 
readings also used. One service used no outcome measures. 
 
Only one service (Forth Valley) noted auditing the use of disulfiram. 
 
3.15.2 Acamprosate 
 
Nine percent (9%) of services acknowledged enlisting a third party to supervise 
administration of the medication. 
 
Most services commenced the use of acamprosate on both an inpatient and outpatient 
basis. 
 
The initial proposed duration of treatment varied between services from 1 month to 1 
year (47% of services answering the question cited 1 year). 
 
Protocols exist for the use of acamprosate in 48% of services (see Appendix 12 for 
shared care protocol from Greater Glasgow). 
 
All NHS specialist services used psychosocial interventions in combination with 
acamprosate, the most commonly acknowledged being Motivational Interviewing, 
Relapse Prevention Therapy, CBT and Group Work.  Also noted were ‘counselling’, 
Social Skills Training, Abstinence Maintenance, ‘specific acamprosate adjunctives’ 
and 1 service noted using the ‘normal clinic regime’. 
 
Fifty-seven percent (57%) of services cited abstinence as the goal of treatment, 29% 
of services cited either abstinence or controlled drinking as the goal, and 19% of 
services cited controlled drinking as the goal. 
 
The most commonly used outcome measures were laboratory investigations (38% of 
services), including gamma GT, MCV, LFTs, self-report (19%), diaries (14%) and 
CADs (14%). 
 
Twenty-eight percent (28%) of services audited the use of acamprosate. 
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3.15.3 Naltrexone 
 
Of the 5 services using naltrexone, 2 services set no special condition for 
administration, 1 service insisted on regular consultant review, and 2 services used 
some form of supervision of treatment. 
 
Four out of the five services commenced naltrexone on both an outpatient and 
inpatient basis.  One service commenced naltrexone on an outpatient basis only. 
 
The initial proposed duration was reported as six months to one year in one service, 
one year in one service, indefinite in two services. 
 
Lothian has a protocol for prescribing naltrexone for alcohol dependence (Appendix 
13).  
 
All services prescribing naltrexone used psychosocial interventions in combination 
with the medication although the type of intervention was not specified. 
 
Two services cited abstinence as the goal of treatment.  One service cited either 
abstinence or controlled drinking as the goal of treatment. 
 
The outcome measures used were laboratory tests (4 services), self-report (2 services) 
and diaries (1 service). 
 
The use of naltrexone is not audited by these services. 
 
 
3.16 The Care Pathway 
 
For the psychosocial and pharmacological interventions described above it should be 
noted that in most services these are not carried out in isolation but as part of an 
ongoing relationship with individuals in contact with the service.  Examples of care 
pathways were provided by a number of services.  Those for Forth Valley and 
Dykebar (Renfrewshire & Inverclyde Health Board) have been included in Appendix 
15 and perhaps illustrate more similarities than differences in the care of individuals 
from the moment of their referral to the alcohol problems service.  The use of non-
statutory agencies in the treatment system is well illustrated. 
 
The minimum aftercare package offered to most individuals on discharge from 
hospital following alcohol detoxification varies from service to service, with one 
service suggesting that there may be no aftercare package, and others offering a 
follow up appointment by the keyworker (CPN, Day hospital nursing staff, 
Community Addiction Team, medical staff) at the base alcohol unit or at home 
depending on geographical factors.  Others offer an increasingly intense aftercare 
package with outpatient clinic appointments and CPN visits, immediate (next day) 
follow-up by the home detox team and regular follow-up thereafter for several weeks 
(eg. every 2 days for 6 weeks),  Day Hospital attendance for a relapse prevention 
programme or referral to the waiting list for the Relapse Prevention Group, 1 to 1 
psychological intervention, periodic Motivational Interviewing sessions (eg. 8-10 
-    -   35 
weekly), on-going drop-in facility, referral to other agencies eg. Social Work, if 
requested, and consideration of anti-relapse agents eg. acamprosate. 
 
The Argyll and Bute service offers respite admissions as well as the availability of 24-
hour contact with the unit and outreach clinic appointments if geographically suitable.  
Areas without NHS statutory alcohol services will advise individuals to utilise local 
voluntary services e.g. counselling / befriending services, Social Work Alcohol 
Support Groups, AA and Councils on Alcohol. 
 
There seems to be no standardised approach to aftercare with many of the above 
elements / options being employed in various combinations presumably tailored to the 
need of the individual and local resources. 
 
The external agencies most frequently used by NHS specialist services when 
arranging aftercare are AA, Social Work day services and Councils on Alcohol with 
non statutory residential rehabilitation services being used more moderately and the 
least used agencies being residential homeless services and private care. 
 
 
3.17 Default, non-adherence and recurrent relapse 
 
One issue worth considering is that of default or non-adherence with interventions 
offered.  About 25% of services report that their approach to this may include 
discharge back to GP care.  Other reports involve various degrees of assertive 
outreach including offering 1-2 follow-up appointments or contacting the patient by 
letter to ascertain their desire for further contact, perhaps individuals with more severe 
problems having more aggressive follow-up. 
 
In the case of recurrent relapse, almost all services reported either continued contact 
or at least no restriction on re-referral.  
 
Miller (1985) notes that a simple hand-written note or telephone call after the first 
visit, or after a missed visit, can double or triple the likelihood that a client will return. 
This ‘active’ interest in the individual with alcohol problems appears to be reflected in 
most of the services surveyed.  
 
 
3.18 Services available for alcohol related problems 
 
The provision of services for individuals with alcohol related problems can be 
categorised into non-specialised (General Practitioners and other Primary Care staff, 
A & E Departments, General hospitals, General Psychiatric services, Social services 
and Criminal Justice services and employment-related schemes) and specialised 
(statutory (NHS and Social Work), voluntary and private).  Non-specialised workers 
are routinely encountering individuals with alcohol problems in their day-to-day work 
with perhaps only the most seriously affected being referred on to specialist services.  
Statutory NHS specialist alcohol services may range from a single CPN with an 
alcohol remit to a fully integrated residential and community based addiction service.  
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3.18.1 NHS Specialist Services 
 
The Plan for Action on Alcohol Problems (Scottish Advisory Committee on Alcohol 
Misuse (SACAM), 2002) states that ‘the general perception is that service coverage in 
Scotland is patchy and fragmented and there is disparity in support and treatment 
available across Scotland’.  The HTBS survey of specialist services confirms that 
some gaps in the service exist.  There is also an apparent deficit in formal staff 
training and accreditation.  The variability in service provision may reflect historical 
factors and the enthusiasms of individual consultants and other service developers 
rather than regional differences in morbidity. 
 
In recent years the emphasis has shifted from inpatient to outpatient treatment. 
Inpatient services continue to exist, sometimes with dedicated beds for alcohol / 
addiction problems, sometimes using general adult psychiatry beds and occasionally 
using general medical beds.  Inpatient care may be restricted to the more complex 
cases, for instance those with a lack of social support, the homeless, those with co-
morbid psychiatric or severe physical illness, those at risk of suicide and those with a 
dual dependence. 
 
As shown in the HTBS survey, there is wide regional variation in NHS specialist 
service provision with areas such as Shetland offering no specialist NHS alcohol 
services and areas such as Greater Glasgow, Ayrshire and Arran and Lanarkshire 
having a relatively large service, though these need to be seen in the context of local 
needs.  
 
At the most specialised end of the spectrum (referred to as ‘tier 4’ in the Plan for 
Action Services Framework) there is an assumption that the individuals with the most 
complex needs are seen.  Most people with alcohol problems are not in this category 
and will be seen at lower tiers of service, with GPs often being the first and only 
source of advice for a substantial proportion of those with alcohol problems.  It is 
estimated that ‘less than one in ten individuals with alcohol related problems are in 
contact with a specialist agency’ (Unnithan et al., 1994). 
 
 
3.18.2 Inpatient services 
 
Only certain areas provide specialist inpatient-based services.  From the survey those 
areas with no acknowledged specialist inpatient beds at all were Grampian, parts of 
Lanarkshire covered by Hairmyres Hospital and Shetland. Forth Valley, Fife and 
Orkney will use a very limited number of general adult psychiatry, or general medical 
beds (Orkney – 1 bed) for alcohol problems if necessary. South Glasgow and Western 
Isles have no dedicated beds for alcohol problems but provide inpatient care using 
general adult psychiatry beds.  All other areas have dedicated beds for patients with 
alcohol problems (61% of all services surveyed). 
 
From the survey the number of inpatient beds specifically dedicated to alcohol 
problems in NHS specialist services in Scotland is about 100 beds.  Table 3 - 3  
Breakdown of NHS Bed Usage per NHS Board. 
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Of these services with dedicated alcohol beds 50% have nursing staff specifically 
trained in alcohol / substance misuse care to cover these beds. 
61% of services use adult psychiatric acute admission beds for alcohol problems, 
including 63% of the services, which did not acknowledge any form of inpatient 
based service, and 53% of the services, which were considered to have inpatient based 
alcohol services (inc. South Glasgow and W. Isles as noted above).  
 
From the survey the number of general adult psychiatry acute admission beds in 
Scotland used specifically for care of patients with alcohol problems at any one time 
is estimated to be about 30 beds.  (Table 3 - 3  Breakdown of NHS Bed Usage per 
NHS Board.) 
 
 
Table 3 - 3  Breakdown of NHS Bed Usage per NHS Board 
NHS 
BOARD 
 
DEDICATED 
ALCOHOL  
BEDS 
GEN. 
ADULT 
PSYCH. 
BEDS 
(in use at one 
time) 
TOTAL 
BEDS 
(in use at 
one time) 
POPULATION BEDS per 
100 000 
Borders 1.5 0.8 2.3 106,389 2.16 
Dumfries & 
Galloway 
4* 2 6 147,280 4.07 
Lothian 12 0 12 774,528 1.55 
Ayrshire & 
Arran 
6(+6)** 0 18 374,545 4.81 
G. Glasgow 19-21 6 25-27 897,053 2.90 
Renfrewshire & 
Inverclyde 
11*** 4 15*** 290,000 5.17(some 
beds daytime 
only) 
Lomond & 
Argyll 
14 0 14 136,046 10.30 
Lanarkshire 7 8 15 559,150 2.68 
Forth Valley 0 2 2 275,806 0.76 
Tayside 12 0**** 12 391,397 3.07 
Fife 0 4.4 4.4 348,214 1.26 
Grampian 0 0 0 532,110 0 
Highlands 6 0 6 210,418 2.85 
W. Isles 0 1-2 
(probably) 
1-2 28,476 3.51(only used 
for alc. problems 
if needed) 
Orkney 0 1 1 19,794 5.05(as above) 
Shetland 0 0 0 22,855 0 
General Adult Psychiatry (GAP) beds recorded are those used specifically by the Specialist team for 
their patients for treatment of alcohol problems  
 
* Dumfries and Galloway has 4 dedicated beds for either alcohol or substance misuse 
** Ayrshire and Arran has ‘6 beds for alcohol detoxification and 12 beds for residential dual diagnosis 
services which at any one time are used by approximately 50% alcohol users (and also drug users)’ 
(C.Lind,Consultant Psychiatrist, Personal Communication, 13 March 2002) 
*** Renfrewshire and Inverclyde have 11 dedicated beds but those in Inverclyde (7 beds) are in 
daytime use only with severely unwell patients, including those at risk of seizures, being admitted to 
general adult psychiatric beds 
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**** There are approximately 300 alcohol related admissions/year to General Adult Psychiatry beds in 
Tayside. An average length of stay of 12 days would lead to 10 GAP beds in use for primary alcohol 
problems at any one time.  
 
3.18.3 Outpatient services 
 
These can be divided into community, day hospital and outpatient based services.  
 
22% of services surveyed have no community based alcohol service.  
22% of services surveyed have no out patient based alcohol service.  
61% of services surveyed have no day patient based services.  
17% of services are solely community based – Borders, Orkney, parts of Fife and 
Lanarkshire. 
 
There are no services which are solely inpatient based   
 
The staffing of these services varies widely. Table 3 - 4  Staff Numbers per NHS 
Board Area (whole time equivalent posts) 
 
74% of services have a Consultant Psychiatrist in or leading the team. 
26% of services do not have any medical staff. 
33% of services have psychology staff of some kind. 
33% of services have Occupational Therapy staff. 
14% of services have additional Social Work staff. 
 
Table 3 - 4  Staff Numbers per NHS Board Area (whole time equivalent posts) 
AREA CONSULTANT 
PSYCHIATRISTS 
OTHER 
MEDICAL 
STAFF 
NURSING 
STAFF 
PSYCHOLOGY 
STAFF 
OCCUPATIONAL 
THERAPY 
STAFF 
SOCIAL 
WORK 
STAFF 
Lomond & 
Argyll 
0.2 0.4 9.25 0 0 0 
Renfrewshire. 
& 
Inverclyde 
 0.5  1.3 8.2 0.1 0 0 
Ayrshire & 
Arran 
1.2 1.0 27.0 0 1.0 0 
Borders 0 0 2.0 0 0 0.5 
Dumfries& 
Galloway 
1.0 1.0 9.0 0 1.0 0 
Fife 0 0 3.0 0 0 0 
Forth 
Valley 
0.2 0 6.0 0 0 0 
Grampian 0.5 1.0 2.5 0 0 0 
G.Glasgow 4.4 7.6 53.3 2.4 4.0  
Highland  0.2 1.6 36.2 0 0 1.0 
Lanarkshire 2.0 2.2 22.0 1.7 2.0 0 
Lothian 1.6 1.66 21.5  0.5  1.5  0.5 
Orkney 0 0 1 0 0 0 
Shetland 0 0 0 0 0 0 
Tayside 1.0 2.0 18.5 0 0 0 
W.Isles 0.0 0 2.0 0 0 0 
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3.18.4 NHS Generalist Services 
 
Specialist services are resourced to meet the needs of only the small percentage of 
those most severely affected by alcohol related problems.  Generalist services provide 
the bulk of treatment and preventative work.  They may be divided into Primary Care 
and Non-Specialist Hospital care.  These two components interact through, for 
example, specialist staff offering clinics in primary care; joint work systems such as 
home detoxification; or delivery of training programmes for Primary Care staff. 
 
The Plan for Action notes ‘GPs are often the first source of advice about alcohol 
problems.  They play a vital role in identifying and tackling such problems and 
referring patients for appropriate help’.  The GGHB Alcohol Strategy Consultation 
document (Greater Glasgow Health Board, 2000), notes that in a randomised survey 
of 227 GGHB GPs, many GPs had large numbers of patients with serious alcohol 
related problems.  Very few of these GPs had a special interest in alcohol problems. 
Seventy percent (70%) of GPs said they employed brief intervention techniques, 
almost 90% employed home detoxification and over 60% employed some form of 
counselling technique (not specified).  Few had access to nursing or counselling staff 
trained in the management of alcohol related problems. Current work reviewed later 
in this report shows that effective specialist psychosocial and pharmacological 
treatments are available for alcohol dependent patients and that brief intervention is 
not sufficient for those with established alcohol dependence. Thus clear evidence 
based decision processes for referral to specialist services and greater accessibility of 
these services would allow GPs to offer a more complete service. 
 
The HTBS survey did not assess the capacity of generalist services for treating 
alcohol problems, but in the case of this HTA, it could be assumed that the bulk of 
generalist intervention (not including input from Councils on Alcohol to GP 
surgeries) is brief intervention, ‘support and advice’ and the prescribing of medication 
(eg. benzodiazepines for detoxification; acamprosate for relapse prevention). 
 
Accident & Emergency Departments have a role in recognising alcohol related 
problems and can be appropriate settings in which to offer help, for instance through 
the use of brief intervention techniques for less severe cases or by referral on to an 
appropriate agency within the ‘treatment system’. 
 
Significant numbers of admissions to General Hospital medical wards have current 
alcohol related problems.  ‘There is little evidence that most problem drinkers 
entering hospital are having their drinking problem recognised, assessed and 
appropriate action then taken’ (Greater Glasgow Health Board, 2000). Intervention 
may be limited to the immediate management of alcohol withdrawal.  There may be, 
however, the opportunity for some psychosocial intervention on medical wards, 
perhaps more so than in the primary care setting, given the lengthier period of time in 
contact with the individual.  It is not clear to what extent this may be occurring.  
 
The Liaison Psychiatrist can advise and educate not only on the immediate 
management of alcohol withdrawal but also on appropriate subsequent referral to 
specialist agencies.  
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Specialist Alcohol Liaison Nurses are few in number but may provide useful support 
to general hospital wards in terms of both the management of alcohol related 
problems and the education and training of generalist health care professionals. 
Lothian and East Glasgow currently provide this Alcohol Liaison Nurse service. 
 
General Psychiatric Services see a large proportion of the alcohol misusers referred to 
the psychiatric services overall, including the specialist addiction services.  Many 
problem drinkers are admitted to acute psychiatric beds with few of the supervising 
consultants or nursing staff having a specialist addiction training.  
 
 
3.18.5 Non NHS Services  
 
Table 3 - 5  Non-NHS Services Distribution (and returned survey numbers in bold) 
shows the distribution of non-NHS services which have at least some role in the care 
of individuals with alcohol problems.  This does not take into account the numerous 
AA meetings, which occur throughout Scotland on a daily basis (Section 6). 
 
Table 3 - 5  Non-NHS Services Distribution (and returned survey numbers in 
bold) 
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Day and Counselling facilities 
Council 
On Alcohol 
7 
(3) 
6 
(2) 
5 
(1) 
1 
(1) 
2 
(1) 
1 4 
(1) 
2 9 
(1) 
12 
(4) 
2 
(1) 
9 
(1) 
1 
(1) 
 2  
Social 
Work 
1 5 1   1  2 12 
(2) 
 3 
(1) 
1   3  
City 
Council 
  1   1  1 1        
Church of 
Scotland 
        1 
(1) 
  1    1 
Salvation 
Army 
       1         
Other 
Voluntary 
 1 1 1  1  3 5 
(1) 
  4 
(1) 
 2 
(1) 
1 1 
Residential Rehabilitation Facilities 
Social 
Work 
          1      
City 
Council 
                
Church of 
Scotland 
1       1 
(1) 
1 1  1     
Salvation 
Army 
 1       1        
Other 
Voluntary 
       2 2 
(1) 
  2 
(1) 
    
Residential homelessness facilities 
Social         1        
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Work 
City 
Council 
        4   2     
C. of 
Scotland 
           1 
(1) 
    
Salvation 
Army 
           1 
(1) 
    
Other non- 
Statutory  
 3 
(2) 
     2 
(2) 
10 
(3) 
  5 
(1) 
  7 
(2) 
 
TOTAL 9 16 8 2 2 4 4 14 47 13 6 27 1 2 13 2 
Number 
per 105  
7 6 2 2 1 1 2 3 5 6 1 4 5 9 3 7 
 
Areas with 5 or more services per 100,000 of population are Greater Glasgow, 
Lomond and Argyll, Renfrewshire and Inverclyde, Highland, Orkney, Shetland, and 
Western Isles.  Areas with 2 or less are Ayrshire and Arran, Borders, Dumfries and 
Galloway, Fife, Forth Valley, and Lanarkshire.  These figures do not take account of 
differences in demand or difficulties in accessing the services. 
 
Day Facilities (which, in this report, include all non-residential facilities irrespective 
of hours of opening, intensity of workload, type of intervention etc.) make up the bulk 
(71%) of non-NHS services (even excluding AA from these statistics) – largely 
through the numerous facilities provided by Councils on Alcohol (52% of day 
facilities); Social Work services make up the next largest group (24%) of facilities 
(Community Alcohol Teams are not included in these figures). 
 
Residential Homeless services provide 21% of non-NHS facilities identified 
(excluding AA) through various charitable organisations including Cyrenians (19% of 
residential homeless facilities) and, in Glasgow, the Talbot Association (16%), as well 
as city councils (16%). 
 
Many of the homeless facilities identified do not have a special remit for dealing with 
alcohol problems and over 50% of facilities returning the questionnaire did not offer 
any psychosocial interventions to deal with these problems.  Nonetheless, people with 
alcohol problems seem to account for a significant proportion of individuals using 
those facilities. 
 
Greater Glasgow has most in the way of residential homeless facilities (42%), with 
Edinburgh and Lothian ( 25%), Tayside ( 19%), Renfrewshire and Inverclyde (8%) 
and Grampian ( 6%) making up the rest of identified facilities of this nature. 
 
A large proportion of homeless people have evidence of severe alcohol related 
problems.  There is an apparent lack of availability of specialist addictions services 
for homeless people with alcohol problems, although the Rough Sleepers Initiative 
(RSI) and in Glasgow the development of the Homeless Addictions Team is a step 
towards tackling this issue.  The GGHB Alcohol Strategy Consultation Document 
(Greater Glasgow Health Board, 2000) recognised that liaison between statutory 
addiction services and hostels was poor.  Glasgow Council on Alcohol hold regular 
weekly surgeries at Glasgow City Council Hostels. 
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Residential Rehabilitation facilities are few in number (14 facilities, 9-10% of 
identified non-NHS facilities). Five (36%) are provided by the Church of Scotland, 
with two (14%) provided by the Salvation Army and only one (7%) provided by 
Social Work services. 
 
The facilities are in Greater Glasgow, four (29%), Edinburgh & Lothian, three (21%), 
Grampian, three (21%), and one (7%) each in Highland, Renfrewshire and Inverclyde, 
Lomond & Argyll and Lanarkshire. 
 
3.18.6 Social Work Services 
 
The social services are in an ideal position to recognise and assess individuals with 
alcohol problems through their contact with many ‘at risk’ groups as part of the work 
of child and family teams, community care teams and prison social work teams. In 
addition the specialist addiction Social Work services provide intervention in terms of 
advice, information, ‘counselling’, advocacy, support and care planning.  They are 
also involved in purchasing services such as rehabilitation. 
 
The development of Community Addiction Teams (CATs) may create a greater 
resource for outpatient care though there is also concern that this expanding tier 3 
service could result in redistribution of staff from NHS specialist ‘tier 4’ services.  
 
The survey of existing non-NHS alcohol facilities included 14 Social Work facilities 
making up 13% of non-NHS facilities surveyed.  A further 17 facilities were 
identified post survey from SACAM information taking the total to 31 facilities 
identified (18% of the total non-NHS facilities eventually identified).  Ninety-three 
percent (93%) of these were day facilities with 1 residential rehabilitation facility and 
one residential homeless facility.  The Social Work facilities are mostly to be found in 
Greater Glasgow (42%), with other facilities located in Lanarkshire, Grampian, 
Tayside, Lomond and Argyll, Renfrewshire and Inverclyde, Lothian, Fife and 
Ayrshire and Arran. 
 
It appears that a range of validated psychosocial interventions (E.g. Motivational 
Interviewing, Social Skills Training) may be offered by social work services. 
 
3.18.7 Non-statutory facilities 
 
Non-statutory services may have charitable or independent status.  The Plan for 
Action (Scottish Advisory Committee on Alcohol Misuse (SACAM), 2002) points to 
the ‘strong contribution already made by voluntary organisations in providing 
prevention, education, treatment and support services’ and notes their good value for 
money.  Non-statutory services may better meet the needs of marginalized subgroups 
and communities than statutory services. 
 
The contribution of Alcoholics Anonymous to non-statutory services in Scotland was 
not assessed in the survey but they are discussed separately later in this report 
(Section 0). 
 
Eighty-seven (87) non-statutory facilities were surveyed.  An additional 32 Council 
on Alcohol sub offices and 10 other facilities identified post survey from SACAM 
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information were not surveyed.  The total number of non-statutory facilities (not AA) 
identified was therefore 129. 
 
Sixty-seven percent (67%) are day facilities, mostly Councils on Alcohol (72%), 10% 
are residential rehabilitation facilities, largely Church of Scotland (38%), and 23% are 
residential homeless facilities. 
 
The Scottish Executive provides core funding for Alcohol Focus Scotland (AFS), 
which, in turn, has the function of supporting local Councils on Alcohol. Councils on 
Alcohol appear to be the largest non-NHS service in the field of alcohol problems 
identified in the survey, with a rigorous selection and training process resulting in 
counsellor accreditation.  The psychosocial intervention termed ‘alcohol counselling’ 
by many of the facilities is a CBT based approach.  The average number of clients 
engaged or re-engaged in a month per facility is 24.  Clients remain engaged in the 
service for a variable period of time taking individual needs into account but the 
average length of treatment / contact is probably about 3-4 months. 
 
Church of Scotland Board of Social Responsibility services may vary from facility to 
facility.  The Board has five residential rehabilitation facilities plus a day service 
centre responding to a range of alcohol related challenges.  The ‘counselling’ methods 
used are person-centred, along similar lines to Motivational Interviewing with 
psychodynamic approaches also employed. (Victoria View is a residential 
rehabilitation facility in Glasgow with seven staff, where 12-16 beds are provided for 
alcohol problems.  The mean length of stay is 26 weeks. Psychosocial interventions 
include intensive group therapy, family therapy and individual counselling.  Funding 
is through social work and local authority.  Ronachan House is a residential 
rehabilitation facility in Lomond and Argyll area, with eight staff, offering 6-8 month 
stays (depending on need) for up to 20 residents.  Psychosocial Interventions include 
work programme, group work, individual counselling, educational input and leisure 
activities.  Malta House is a rehabilitation unit in Edinburgh, with nine staff, offering 
6 month programmes for up to 15 residents with drug / alcohol dependence.  
Psychosocial interventions include group work, counselling, physical work and 
activities.  Deeford House is a rehabilitation unit in Grampian region with seven full 
time and two part time staff, offering an average stay of approximately 12 weeks for 
up to 17 clients (four in a satellite house).  Psychosocial interventions include group 
meetings, one to one counselling and anger management.  Beechwood House is a 
rehabilitation unit in the Highland area, with 22 staff, providing a 4 week intensive 
assessment and intervention programme with optional access to a further 10 week 
programme for individuals seeking support in re-establishing a pattern of alcohol free 
living.  Funding for these interventions is through social work.  The Health Board 
funds supported accommodation for those attending the local NHS day service – 
information gathered from SACAM survey and independent sources). 
 
3.18.8 Private Care  
 
Private care facilities (e.g. The Langside Priory and Castle Craig) were not sent the 
survey questionnaire.  The Langside Priory offers a service which includes 
detoxification as an in- or outpatient aimed at achieving abstinence, CBT, problem 
solving, family therapy, couple therapy, post treatment planning, continuing weekly 
aftercare and self-help group meetings within the hospital (aftercare is provided free 
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of charge for as long as required).  Castle Craig adopts a 12 step approach in a 
residential setting and aims for abstinence. The treatment program includes group 
therapy, individual therapy, didactic lectures, video films, individual readings and 
written assignments.  Funding e.g. in Glasgow is via social work and subcontracted 
with GGHB; in Highland region, health board funding occurs for the first 6 week 
intensive period and thereafter social work funding is required).  There is a similar 
smaller facility in Aberdeen. 
 
3.18.9 Services for Alcohol Dependent Offenders 
 
Prison services have not been addressed although the SACAM survey identified a 
number of prison liaison facilities involving collaboration between social work or 
Councils on Alcohol and the Scottish Prison Service. 
 
 
3.19 Demand vs Service Distribution 
 
In the consultation process prior to publication of the Plan for Action ‘patchiness’ in 
service provision throughout Scotland was noted.  This perception was borne out by 
the HTBS survey of specialist alcohol services (Section 3.10).  Services appear 
fragmented, perhaps leaving some without access to what should be minimum care.  
This is particularly noticeable in certain rural areas.  It may also be that different 
populations have different needs and, for instance, rural communities may face 
specific circumstances and difficulties when providing treatment for alcohol 
problems: distance, geographical location, lack of social support, fear of stigma etc. 
may constitute barriers to treatment and complicate rehabilitation and follow up 
procedures.  
 
Some services appear to be comparatively well provisioned but may, nonetheless, be 
working beyond their capacity, with pressure on resources and long waiting lists.  For 
instance, 84% of the most deprived people in Scotland live in Greater Glasgow area.  
The rates of general hospital and psychiatric admissions for alcohol related diagnoses 
are 10 times greater for people in the most deprived, compared to the most affluent 
areas.  The greater levels of socio-economic deprivation in Glasgow mean that for 
some alcohol related problems the area probably has higher rates than any other 
health authority in the UK (Greater Glasgow Health Board, 2000).  The Plan for 
Action (2002) notes that men living in the most deprived areas of Scotland are 7 times 
more likely to die an alcohol related death than those in the least deprived areas. 
 
 
3.20 Long-term health expectation in alcohol dependence 
 
3.20.1 Effects of chronic and acute exposure to alcohol 
 
The economic evaluation of relapse prevention interventions in this assessment relates 
the costs of the interventions to the benefits obtained from a reduction in the adverse 
effects of alcohol on health.  In order to do this it is necessary to evaluate the impact 
of alcohol on the health of alcohol dependent patients. 
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Drinking large amounts of alcohol alters the chance of developing many diseases and 
is also associated with increased risks of accidents and suicide.  Some of these effects 
appear to be related to chronic heavy drinking whilst other may be related to acute 
intoxication.  However, whether the nature of these effects is different in alcohol 
dependent individuals from those who drink similar quantities without developing 
dependence is unclear.  For the purposes of this assessment it seems reasonable to 
assume that the risks of diseases associated with chronic drinking are similar whether 
or not dependence is present and also that alcohol dependent individuals are likely to 
be drinking in quantities which carry a risk similar to the highest levels of risk seen in 
the population in general.  However, whether dependent drinkers account for a high 
proportion of events associated with acute intoxication is less clear.  This is because 
many such events may be experienced by occasional heavy drinkers.  For this reason 
it seems reasonable to restrict the consideration within the economic model to illness 
associated with chronic drinking.  However, it must be recognized that any benefit of 
treatment will only reflect a part of the potential benefit to the health service of 
treatment of alcohol dependence since alcohol dependent drinkers will also 
experience the heightened risks associated with acute intoxication, for example 
accidents.  The possible extent of this underestimation can be roughly gauged from 
the following discussion of the Australian National Alcohol Indicators Project 
(NAIP). 
 
3.20.2 The Australian National Alcohol Indicators Project 
 
The Australian National Drug Research Institute published a report on alcohol-caused 
deaths and hospitalisations as part of the NAIP.  The report used relative risks of 
disease comparing high alcohol intake with low or moderate drawn from a paper by 
English (1995), subsequently updated by Gutjahr (Gutjahr et al., 2001).  From these, 
combined with information on the drinking levels in Australia and the total disease 
burden, the amount of disease attributable to drinking was calculated.  These figures 
are of considerable relevance because they show which of the many diseases affected 
by alcohol are likely to have the biggest clinical and economic impact.  The report 
identifies 19 events/conditions associated with acute intoxication and 15 conditions 
associated with chronic drinking as partially or wholly attributable to high-risk 
alcohol consumptions.  An additional two conditions, stroke and suicide, are classified 
as ‘mixed’ since they are associated with both acute and chronic drinking.  The 
relative impacts of these classes of health events can be judged from the total alcohol-
caused deaths, life-years lost, hospitalisations and bed-days associated with them. 
 
Table 3 - 6  Impact on health of acute and chronic drinking (Australia) 
 Acute intoxication Chronic drinking Mixed 
Males    
Deaths 695 1061 540 
Person-years lost 22743 15675 10076 
Hospitalisations 31366 14670 3463 
Bed-days 156476 95049 25115 
Females    
Deaths 218 328 449 
Person-years lost 6246 5309 2933 
Hospitalisations 13517 6165 3122 
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Bed-days 60865 41052 25238 
 
From this it can be seen that the adverse health effects of acute intoxication represent 
a considerable burden to the health service.  Just over 50% of total bed-days 
attributable to alcohol were taken up by such events.  Hence it is conceivable that 
health service benefits from effective treatments could be twice as large as we 
estimate from our model.  However, this would only be under the unlikely 
circumstance that almost all of the acute drinking events were in alcohol dependent 
people. 
 
The impact of each chronic and ‘mixed’ event can be judged from the table below 
which shows them in descending order of total bed-days in the NAIP report. 
 
Table 3 - 7  Total bed-days from diseases associated with chronic or ‘mixed’ 
drinking patterns (Australia) 
Conditionc Deaths  PYLLd Hosp. Bed-
days 
Alcohol dependence 257 4335 13043 85294 
Stroke 726 4019 4716 43247 
Alc. Liver cirrhosis 683 11108 3222 25654 
Chronic pancreatitis 13 151 1516 8377 
Suicide 264 8985 1868 7105 
Epilepsy 31 794 1730 6453 
Oropharyn.cancer 55 637 395 3708 
Hypertension 38 216 417 1836 
Female breast cancer 51 715 371 1810 
Oesophageal cancer 54 532 225 1670 
Laryngeal cancer 31 300 182 1485 
Oesophageal varices 2 28 473 1205 
Liver cancer 65 659 161 1158 
Alc. Cardiomyopathy 109 1481 146 873 
Alc. poly neuropathy 0 0 32 240 
Psoriasis 0 0 40 122 
Cholelithiasis* -1 -6 -1118 -3784 
Sub-total 2,378 33,954 27,419 186,453 
* Alcohol is protective for cholelithiasis 
 
The only beneficial effect of very heavy drinking appears to be an effect on gall 
bladder stones (cholethiasis).  The risk at the highest levels of consumption appear to 
about half that at low levels.  Clinically this is not a benefit comparable to the harm 
since cholethiasis is almost never a fatal condition.  However, the NAIP report shows 
a saving in hospital bed-days, which may be economically important.  Ignoring 
adverse effects of alcohol will tend to undervalue treatment for dependence whilst 
ignoring benefits will do the opposite.  Thus the decision to ignore this effect should 
be carefully considered.  However, there are several potential adverse effects, which 
we have already disregarded due to the unavailability of satisfactory information 
about the relationship between them and the specific type of drinking we are 
discussing.  Furthermore, there are several small but proven adverse associations 
which can be reasonably disregarded as minor effects but which roughly counter-
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balance the bed-days gained through any protective effect on cholelithiasis.  Of these 
we have chosen to disregard hypertension, oesophageal varices, and psoriasis. 
3.20.3 Categorisation of drinking by associated risk 
 
In the study by Gutjahr (Gutjahr et al., 2001) the relative risks for each disease are 
estimated from meta-analysis of published studies.  Three levels of drinking are 
considered relative to abstinence.  These are described as low, hazardous, and harmful 
but definitions of these are not given in the report.  The UK Medical Council on 
Alcohol (http://www.medicouncilalcol.demon.co.uk/handbook/glossary.htm) defines 
these terms as follows. 
 
· Low risk Intake unlikely to be associated with the development of 
alcohol-related harm if taken over 7 days   (males < 21 units/week, 
females < 14 units/week) 
· Hazardous drinking Intake likely to increase the risk of developing 
alcohol-related harm (males 22-50 units/week females 15-35 units/week)  
· Harmful drinking A pattern of drinking associated with the development 
of alcohol-related harm (males > 50 units/week females> 35 units/week ) 
 
One unit corresponds approximately to 8g of pure ethanol and hence these figures 
translate to  
 
· Low risk  (males < 24 g/day, females < 16 g/day) 
· Hazardous drinking (males 25-57 g/day, females 17-40 g/day)  
· Harmful drinking (males > 57 g/day, females> 40 g/day) 
 
3.20.4 Concordance between epidemiological studies 
 
The risk ratios calculated by Gutjahr (Gutjahr et al., 2001) between harmful and low 
risk drinking for the diseases partially explained by  chronic drinking are compared in 
the following table with those quoted by other meta-analytic reports.  These other 
reports are discussed below. 
 
Table 3 - 8  Comparison of reported risk ratios for harmful drinking from three 
sources.  (95% CI in brackets) 
Conditionc Gutjahr 
2001 
Bagnardi 
2001 
Mazzaglia 
2001 
Stroke 
7.72f 1.79m  
3.0 Haemorrhagic 
      2.3 Ischaemic        
Chronic pancreatitis *   
Epilepsy 7.52f   
6.83m   
Oropharyn.cancer 5.39 6.01 (5.5,6.6)  
Hypertension 1.79f  2.05m     
Female breast cancer 1.66f 2.71 (2.3,3.1)  
Oesophageal cancer 4.36 4.23 (3.9,4.6)  
Laryngeal cancer 4.93 3.95 (3.4,4.6)  
Oesophageal varices 9.54   
Liver cancer 3.60 1.86 (1.5,2.3)  
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· Risk Ratios are not given for chronic pancreatitis but the attributable 
fraction is estimated as 0.84. 
F=female, M=male  
 
Bagnardi’s (Bagnardi et al., 2001) figures are for alcohol consumption greater than 
100g/day. There are appreciable differences between the two sources in estimates for 
female breast cancer and for liver cancer. Bagnardi also identifies five additional 
cancers as increased by alcohol intake greater than 100g/day. These are Stomach 
(RR=1.32 95% CI 1.2,1.5), Colon and Rectum (RR=1.38 95% CI 1.3,1.5), Lung 
(RR=1.08 95% CI 1.0,1.2), Ovary (RR=1.53 95% CI 1.0,2.3), and Prostate (RR=1.19 
95% CI 1.0,1.4). Alcohol increases the risk of each of these rather less than the 
cancers included in the NAIP report. However, the contribution that each cancer 
makes to the total burden of alcohol related morbidity will depend on the relative risk, 
the proportion of heavy drinkers, and on the absolute risk. The Scottish Health 
Statistics (1999) give numbers of registration for 1996 which can be used to assess 
this impact. This is a rough calculation and has been done for a population of which 
8% are heavy drinkers. It also ignores the raised risks at intermediate levels of alcohol 
consumption. However, the relative impact of these cancers for men or women is 
insensitive to these assumptions. 
 
Table 3 - 9  Estimates of Scottish cancers attributable annually to heavy 
drinking 
 RR - Bagnardi  N (1996) Attributable 
Oropharyn.cancer 6.01 (5.5,6.6) 24 7 
Female breast cancer 2.71 (2.3,3.1) 3,295 397 
Oesophageal cancer 4.23 (3.9,4.6) 840 172 
Laryngeal cancer 3.95 (3.4,4.6) 351 67 
Liver cancer 1.86 (1.5,2.3) 252 16 
Stomach cancer     1.32 (1.2,1.5) 993 25 
Colon and rectum 1.38 (1.3,1.5) 3,567 105 
Lung 1.08 (1.0,1.2) 4,806 31 
Ovary 1.53 (1.0,2.3) 615 25 
Prostate 1.19 (1.0,1.4) 2,027 30 
 
From this simple calculation it appears that the five additional cancers identified by 
Bagnardi each add more to the disease burden than either liver or oropharyngeal 
cancer.  They also add 216 attributable cases to the 659 from the other cancers. Hence 
we have included all ten cancers when calculating the economic impact of alcohol. 
 
Mazzaglia defined heavy drinking to be more than 40 g/day when calculating 
estimates of the risk of stroke (Mazzaglia et al., 2001) with alcohol.  The report 
included one cross-sectional study, 15 case-control and nine cohort studies in the 
investigation of chronic drinking and stroke incidence.  The report does not attempt to 
meta-analyse the results and hence is difficult to interpret.  There is inconsistent 
evidence concerning ischaemic stroke.  All seven case-control studies for which odds 
ratios are reported found raised risks, which were between 2.4 and 15.3.  Three 
studies yielded values around 2.9.  However, three prospective cohort studies yielded 
relative risks of 0.4, 0.8 and 2.0, the former being significantly less than one and the 
latter significantly greater.  Random effects inverse variance weighted mean results 
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(HTBS calculation) for these figures gives an OR of 2.3 (95% CI 0.8,6.75).  Thus the 
effect is not statistically significant but suggests some increase in incidence.  By 
contrast, all but one of ten studies (4 case-control, 6 cohort) gave significantly raised 
risks for haemorrhagic stroke.  The inverse variance weighted mean odds ratio was 
3.0 (95%CI 1.1,8.6).  There was considerable heterogeneity between studies for both 
ischaemic and haemorrhagic stroke.  In the latter case this was almost entirely due to a 
single study (Berger et al., 1999) which found a reduction in stroke.  The finding of a 
marked difference in additional risk between men and women (NAIP) is not 
supported in this study, most studies in only men returning relative risks close to the 
mean.  The NAIP report included the large, anomalous study by Berger, which was in 
male US physicians and it is likely that this will have strongly skewed the comparison 
of males and females.  The NAIP authors note that the position with respect to alcohol 
and stroke is currently being reviewed in Australia – which suggests some uncertainty 
about the results used in the report.  Thus we have preferred the evidence from 
Mazzaglia as presented above.  
 
3.20.5 Suicide 
 
Relative risks for suicide are difficult to determine.  There is a good discussion of this 
in the International Guide for Monitoring Alcohol Consumption and Harm 
http://www.who.int/substance_abuse/PDFfiles/guidemontr_alcohlconsum.pdf in 
which it is recommended that Relative Risk estimates be based upon well-conducted 
studies from, ideally, the country to which they are to be applied, or at least from 
culturally and economically similar countries.  This WHO publication includes 
suicide as an effect of acute drinking rather than ‘mixed’ and for the economic 
modelling in this report we will not include suicide but note that this may be an 
additional conservative element in our analysis. 
 
3.20.6 Alcoholic cardiomyopathy and polyneuropathy  
 
As shown in the NAIP report, alcoholic cardiomyopathy and polyneuropathy – 
although specifically associated with alcohol – are not major contributors to clinical 
costs.  Cardiomyopathy contributes to alcohol associated mortality and hence would 
be of interest in an analysis which costed lost life-years.  Alcoholic polyneuropathy is 
a rare condition.  Hence neither is explicitly accounted in the economic analysis for 
this report. 
 
3.20.7 Alcoholic psychosis 
 
Alcoholic psychosis, which was one of the main outcomes considered in the report on 
which our economic model is based (Schadlich & Brecht, 2000) was classified by 
NAIP to be primarily a result of acute episodes of heavy drinking and hence does not 
appear in Table 3 - 7  Total bed-days from diseases associated with chronic or 
‘mixed’ drinking patterns (Australia)However, this is potentially misleading as it 
appears to be a result of amalgamating several different conditions including ICD-10 
F10.0 (Acute intoxication) F10.4 (Withdrawal state with delirium) F10.5 (psychotic 
disorder) F10.6 (Amnesic syndrome) and F10.7 (Residual and late-onset psychotic 
disorder).  The latter categories are predominantly associated with chronic drinking 
and are included in this HTBS assessment. 
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Specific risk ratios were not found for these conditions but their impact was estimated 
using Scottish data on hospital episodes (Scottish Health Statistics) compared with 
hospital episodes for cirrhosis.  This is a fairly crude procedure for accounting a 
complex mixture of psychological diseases and we note that a subgroup of patients 
will have chronic debilitating mental problems that have substantial clinical and 
economic costs and are not acknowledged in our model. 
 
3.20.8 Alcohol associated diseases accounted in the HTBS model 
 
Thus the total disease impact of chronic drinking, which we consider in this report 
includes the following: 
 
· Alcohol dependence 
· Stroke  
· Alcoholic Liver cirrhosis 
· Cancer 
o Oropharyngeal  
o Female breast  
o Oesophageal  
o Laryngeal  
o Liver  
o Stomach  
o Colon and rectum 
o Lung 
o Ovary 
o Prostate 
· Chronic pancreatitis 
· Epilepsy 
· Alcoholic psychosis including organic brain damage 
 
These conditions fall into two categories, which are handled differently in our 
analysis.  Cancer, stroke and cirrhosis are major events likely to be fatal or, if 
survived, have appreciable downstream effects upon the patients.  For these we 
calculate the proportion of patients likely to suffer a first event of each type.  Chronic 
pancreatitis, epilepsy and alcoholic psychosis are likely to cause ongoing problems 
and we calculate the likely burden of each illness in a patient up till the occurrence of 
one of the severe events considered above or death. 
 
3.20.9 Disease incidence 
 
To calculate the probability that a person develops any one of the partially attributable 
conditions when exposed to a hazardous level of alcohol exposure it is necessary to 
know the probability of doing so at low alcohol exposure and the relative risks as 
discussed above.  If the proportion of cases attributable to alcohol is not great the 
population incidence may be taken as reflecting the baseline risk with only second 
order errors in calculation of risk to hazardous drinkers.  If this assumption is not 
credible then a correction based on the prevalence of hazardous drinking should be 
used. 
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3.20.9.1 Cancer 
 
Incidence figures for all forms of cancer are routinely collected but other, non-
notifiable, disease incidences must be estimated from other sources.  The cancer 
incidences for the Scottish population have been taken from the Scottish Health 
Statistics 1999.  They are based on observations made in 1996. 
 
3.20.9.2 Stroke 
 
Warlow et al. (1996) quoted eleven different studies of stroke incidence.  The 
averaged age specific incidences per 100,000 were as follows: 
 
Table 3 - 10  Estimates of the age specific incidence of stroke 
Age 0-44 45-54 55-64 65-74 75-84 85+ 
Incidence 13 96 278 664 1409 2089 
 
These figures include ischaemic stroke, primary intracerebral haemorrhage, and 
subarachnoid haemorrhage.  The same source reports that in seven incidence studies 
of first ever stroke about 80% of strokes were ischaemic, 10% were primary 
intracerebral haemorrhage, 5% were subarachnoid haemorrhage and 5% were of 
unknown aetiology.  For the purpose of this assessment we will assume that the 
unclassified strokes were predominantly ischaemic and that the age distribution was 
roughly similar for ischaemic and haemorrhagic strokes.  
 
Hart et al. (2000) followed a cohort of Scottish residents aged between 45 and 64 for 
twenty years and estimated stroke incidence.  They found strokes in 472 (6.7%) of 
7052 men and in 557 (6.7%) of 8354 women.  This can be roughly compared with the 
figures from Warlow et al.,(1996).  Over twenty years the chance of stroke in a 55 
year old would be [1-(1-278/100,000)10x (1-664/100000)10 ]x100% = 9%.  This is 
somewhat higher than the 6.7% observed by Hart, however it is strongly dependent on 
age, the chance in a 45 year old can be calculated to be 3.7% whilst that in a 65 year 
old would be 18.2% (ignoring competing mortality).  Thus it appears that the two 
sources of data give similar results. 
 
The very simple model of disease being used in our economic assessment requires 
some mean stroke risk and a time horizon to be chosen. We have used a 20 year 
horizon and used baseline risks for people aged 45 at the start of this period. 
 
3.20.9.3 Liver disease and cirrhosis 
 
Becker et al. (1996) followed 13285 subjects age 30 to 79 over 12 years in 
Copenhagen. Self-reported drinking levels, which were not independently verified, 
were compared with the incidence of liver disease and cirrhosis 
 
A very steep increase in both liver disease and cirrhosis was found with alcohol intake 
in both sexes.  The base-line risk was that in the lowest, non-abstinent, group (12-72 
g/week of ethanol).  Relative to this group men and women who fulfilled the ‘harmful 
drinking’ criterion had greater than 7 times the risk of cirrhosis and 4 times the risk of 
any alcohol-related liver disease.  The highest levels of drinking observed (>120 g/d 
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for men and between 48 and 70 g/d for women) carried relative risks of around 17 for 
cirrhosis and 8 for any liver disease. 
 
The baseline risks can be roughly estimated from the figures given in the paper as: 
Table 3 - 11  Estimates of population base-line risks of liver disease 
Men Any alcohol-related liver disease 1.5 per 1000 per year 
 Cirrhosis 0.52 per 1000 per year 
Women Any alcohol-related liver disease 0.76 per 1000 per year 
 Cirrhosis 0.23 per 1000 per year 
 
Any age variation in these rates could not be calculated from the information 
supplied. 
 
The very large variation in risk with alcohol intake complicates the use of these 
figures in predicting rates for an alcohol dependent population.  In the population 
from the Copenhagen City Heart Study discussed in this paper the mean relative risk 
for the 5% of the population with the highest drinking rate was 16.5 in men whilst the 
relative risk of any liver disease was 8.1.  These figures were not calculable for 
women but the similarity of relative risks in men and women at their respective levels 
of ‘harmful’ drinking suggests using the same relative risks in each group.  In the 
absence of information based on a Scottish population, we have used these figures in 
the present calculations. 
 
3.20.10  Mortality in harmful drinkers 
 
In order to calculate the expected pattern of alcohol related disease in a cohort of 
harmful drinkers it is necessary to have some information about the likelihood of 
dying without developing such a disease.  Some studies of heavy drinkers have 
suggested that this is much higher than in the population in general. 
 
Chen et al. (2001) followed up 418 alcohol dependent patients detoxified within a 
psychiatric hospital in Taiwan.  The mean age of the patients was 39.4 years and 91% 
were male.  The total follow-up was 1268 person years during which 83 deaths were 
observed.  Life table estimates suggested that only 50% survived for 10 years (mean 
survival 9.9 years).  Sixty three deaths were non-violent and of these 34% were 
gastrointestinal (predominantly liver disease) and 18% were cardiovascular. 
 
Table 3 - 12  The numbers and causes of death (Chen et al., 2001) 
Violent deaths  20 
Accident 16 
Suicide 2 
Homicide 2 
Non violent deaths  63 
Cancer 6 
Cardiovascular 15 
Gastrointestinal 28 
Respiratory 2 
Others/unknown 12 
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Denison et al. (1995) followed up 1123 male alcoholics in Sweden for one year 
following detoxification in a psychiatric hospital.  The mean age was 46.5 years. 
Ninety-seven (8.6%) of these patients died – this compares with 6% in the first year of 
the Taiwan study, possibly reflecting the older age.  
 
 
Table 3 - 13  The numbers and causes of death Denison et al. (1995) 
Violent deaths  23 
Trauma 10 
Intoxication 13 
Non violent deaths  74 
Cancer 5 
Cardiovascular (IHD) 20 
Liver cirrhosis 6 
Cerebrovascular disease 5 
Epilepsy 5 
Others/unknown 33 
 
The authors note that ethanol was the sole agent in 8 of the 13 intoxication deaths and 
was involved in 3 others.  One of these three and the two cases not involving ethanol 
appear to have been suicide. 
 
An interesting finding in both these studies is the rather low proportion of deaths, 
which were attributed to somatic diseases, which are accepted as frequently alcohol-
related.  In the Swedish study only 16% of deaths were due to cirrhosis, malignancy 
or stroke.  The proportion in the Taiwanese study may have been higher – up to 37% - 
however, all liver disease was amalgamated and hence it cannot be determined 
exactly.  From the point of view of this HTA it is important to know this proportion 
as, in calculating the incidence of these conditions, all other deaths are taken as 
‘censoring’ events.  For our calculation we have taken 20%. 
In calculating the burden of these alcohol related diseases in men we have assumed a 
mortality rate amounting to 50% over 10 years.  Of course, this information does not 
define the entire relationship of mortality to age.  Thus we have assumed a 
proportional hazards model based on the empirical hazards from Scottish life tables 
and calculated the hazard ratio, which gives a 50% chance of dying from any cause 
over 10 years to a 45 year old man.  This gives a rather startling relative hazard of 
death for an alcohol dependent man compared with the general population of 12.1. 
 
Very little information concerning mortality in alcohol dependent women is contained 
in the two studies discussed above.  The study in Taiwan included 9% of women and 
who accounted for 3 of the 83 deaths.  Thus the relative risk for a woman compared to 
a man was (3/9)/(80/91) = 0.38.  However, no information is given about the age 
distribution in the male and female groups.  In this study we have assumed that the 
relative risk of death for an alcohol dependent woman compared to an alcohol 
dependent man would be the same as that for a non-alcohol dependent woman 
compared to a non-alcohol dependent man.  This is also calculated from Scottish life 
table data. 
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3.21 Mortality in the Scottish population 
 
The health consequence attributable to harmful drinking can only be seen in 
comparison with the incidences of the same diseases in a non-alcohol-dependent 
population.  These can be calculated in a similar fashion but require an estimate of the 
(much lower) mortality rate in moderate drinkers. This is because the lower risk of 
disease is partially compensated by the higher life expectancy allowing more time for 
disease to develop. We have used 1998 age and sex specific death rates for Scotland 
as reported in Scottish Health statistics 1999. In this, predominantly non-alcohol-
dependent, group we assume that the proportion of mortality due to alcohol related 
diseases may be ignored. 
 
3.21.1 Calculation of life-time probabilities of severe alcohol related disease. 
 
3.21.1.1 Method 
 
The health prospects of a typical non-alcohol dependent person are assumed to be 
reflected in the official Scottish health statistics.  We initially calculate the probability 
of developing one of the alcohol-related cancers, stroke or liver cirrhosis using age 
and sex specific cancer and mortality rates from Scottish Health Statistics 1999 and 
stroke and cirrhosis rates as described above.  For these major events we only 
calculate first occurrences.  Thus each event is considered as censoring for all others. 
We calculated events in each five years period and then added them to get the total 
events in this period – i.e. assuming non-overlapping disease groups.  The disease-
free survivors for the following period was then calculated as the initial group minus 
the total events.  
 
The same calculation was done for the alcohol-dependent group with two differences.  
Firstly the incidence rates for each disease were the rates used above multiplied by the 
appropriate risk ratio from the epidemiological studies.  Secondly not all death was 
considered censoring.  This was because a larger proportion of deaths in these patients 
might be expected to be causally related to the alcohol-related events and death itself 
is much more common in alcohol-dependent patients.  Hence this second order effect 
could not be ignored. 
 
Rates of hospitalisation for less serious events were then calculated using proportions 
relative to cirrhosis.  These were derived either from Scottish Health Statistics 1999 
or, failing this, from the Australian NAIP report. An important potential source of 
underestimation in this calculation is that each case of cirrhosis was taken as a single 
hospitalisation.  Thus we believe that these estimates are conservative. 
 
For inclusion in the economic analysis all events were discounted at 6%.  Because no 
timings could be estimated for hospitalisations, the discounting was approximated 
using the same factor as the cirrhosis. 
 
3.21.1.2 Men 
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We take a base case of a 45 year old man and compare this with the health profile of 
the general male population.  During twenty years our model predicts the following 
major events in 1000 individuals (figures in brackets are discounted at 6% p.a.): 
Table 3 - 14  Expectations of stroke, cancer, or cirrhosis in men 
 Alcohol dependent Non-alcohol dependent 
Death 936 318 
Stroke (all types) 43 (26) 33 (18) 
Cancer* 88 (53) 97 (50) 
Cirrhosis 102 (72) 10 (6) 
*As listed above 
 
In addition we would expect the following hospitalisations: 
 
Table 3 - 15  Expectations of hospitalisation for other disease in men 
 Alcohol dependent 
Alcoholic psychoses1 571 (403) 
Chronic pancreatitis2 44 (31) 
Epilepsy2 41 (29) 
Alcohol dependence1 814 (575) 
 
1These figures are based on the recorded ratios of these events compared with 
hospitalisations for cirrhosis in the Scottish Health Statistics. Thus the hospitalisations 
for alcohol dependence may be rather lower than might be expected if many patients 
are treated only as outpatients. 
2These figures are based on the ratio of events to hospitalisations for cirrhosis quoted 
in the NAIP report. 
 
3.21.1.3 Women 
 
We take a base case of a 45 year old woman and compare this with the health profile 
of the general female population.  During twenty years our model predicts the 
following major events in 1000 individuals (figures in brackets are discounted at 6% 
p.a.): 
 
Table 3 - 16  Expectations of stroke, cancer, or cirrhosis in women 
 Alcohol dependent Non-alcohol dependent 
Death 785 268 
Stroke (all types) 53 (31) 33 (18) 
Cancer* 146 (93) 125 (73) 
Cirrhosis 52 (35) 4 (3) 
* As listed above 
 
In addition we would expect the following hospitalisations: 
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Table 3 - 17  Expectations of hospitalisation for other disease in women 
 Alcohol dependent 
Alcoholic psychoses1 160 (107) 
Chronic pancreatitis2 32 (22) 
Epilepsy2 50 (34) 
Alcohol dependence1 260 (175) 
 
1These figures are based on the recorded ratios of these events compared with 
hospitalisations for cirrhosis in the Scottish Health Statistics. Thus the hospitalisations 
for alcohol dependence may be rather lower than might be expected if many patients 
are treated only as outpatients. 
2These figures are based on the ratio of events to hospitalisations for cirrhosis quoted 
in the NAIP report. 
 
There is also calculated to be an additional burden of non-cirrhotic liver disease, 
which we estimate to be an extra 24 cases (18 discounted at 6% p.a.) per 1000 
alcohol-dependent population for men and 22 (16 discounted at 6% p.a) for women. 
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4 SOURCES OF EVIDENCE 
 
The Health Technology Assessments undertaken by the HTBS use international 
evidence from a range of sources:  published literature, grey literature (e.g. academic 
and government reports, website publications, conference abstracts) and information 
submitted from a variety of interested parties. 
 
The following interested parties were invited to submit evidence for the Assessment 
(those marked * did not reply and those marked + did not have anything additional to 
contribute): 
 
Professional / Specialist Groups  
Church of Scotland Board of Social Responsibility 
Centre for Alcohol & Drug Studies, University of Paisley (*/+) 
Scottish Association of Health Councils 
Royal College of Physicians Edinburgh  
Royal College of Physicians London 
Strathclyde University (*/+) 
Royal College of Nursing Scottish HQ (+) 
Royal College of Physicians & Surgeons Glasgow (+) 
Centre for Drug Misuse Research, University of Glasgow (+) 
Fife Alcohol Advisory Service (*/+) 
British Psychological Society (Scottish Branch) (*/+) 
The Medical Council on Alcoholism 
Association of Directors of Social Work 
Royal College of General Practitioners (+) 
Community Psychiatric Nurses Association (*/+) 
Royal College of Psychiatrists Scottish Division (+) 
Intercollegiate Group on Alcohol Problems (*/+) 
Royal Free and University College Medical School 
Scottish Executive Health Department 
 
Patient Groups 
Alcoholics Anonymous 
Alcohol Concern (+) 
Beechwood House (*/+) 
Phoenix House (*/+) 
Alcohol Focus Scotland 
Renewal Clinics Ltd  
The Priory Hospital Glasgow (*/+) 
 
Manufacturers  
Alpharma AS  
Merck Pharmaceuticals 
DuPont Pharmaceuticals Ltd 
 
Literature searches for systematic reviews, for randomised controlled trials of 
effectiveness and for previous cost-effectiveness studies were carried out and are 
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detailed in the appropriate sections.  All searches will be updated during the 
consultation period.  
 
Two surveys of Scottish service provision have been undertaken by HTBS. 
 
Researchers at Caledonian University have undertaken a qualitative study of patient 
attitudes and concerns relating to relapse prevention. 
 
Alcoholic Anonymous have provided a wide variety of information on the role of 
their own organization and given a patient-centred view of many other issues. 
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5 CLINICAL EFFECTIVENESS 
 
5.1 Summary 
 
Psychosocial and pharmacological interventions were evaluated using published 
reviews and information supplied by pharmaceutical manufacturers.  Following this a 
meta-analysis was carried out to estimate the proportion of patients who had achieved 
abstinence or controlled drinking at the end of the study when treated with various 
pharmacological or psychosocial interventions for prevention of relapse in alcohol 
dependence.  In the following section all treatment effects are expressed as the odds 
of one of these successful outcomes compared to patients treated with control 
treatments.  Control treatments were often judged to have only placebo effects. 
 
The population to whom these results apply is difficult to define precisely.  Almost all 
trials of pharmacological treatment enrolled patients who had undergone 
detoxification.  However, trials of psychosocial treatments are generally less 
proscriptive.  Studies were selected when patients were described as dependent or 
alcoholic.  They were not selected if patients were described as problem drinkers or 
were obtained through population screening.  
 
The aim of treatment may be abstinence or controlled drinking and will be decided by 
agreement between the clinician and the patient.  Effective treatment packages should 
be available for either of these aims. 
 
The following points relate to psychosocial treatments. 
 
· The meta-analysis suggested similar, statistically significant, beneficial 
effect sizes for Behavioural Self-Control Training (OR=1.86 [95%CI 
1.03,3.36]), Motivational Enhancement Therapy (OR=2.19 [95%CI 
1.20,3.98]), Family Therapy (OR=1.81 [95%CI 1.26,2.61]) and 
Coping/Communication Skills Training (OR=2.33 [95%CI 1.44,3.76]). 
Treatment of control groups varied and, since some control treatments may 
have been effective, these estimates may be conservative. 
  
· Behavioural Self Control Training (BSCT) appears to show benefit when 
compared to ineffective controls.  However, the only trial that focused on the 
unique defining features of BSCT and included the more general features in 
both patient groups did not show a benefit.  
 
· Motivational Enhancement Therapy (MET) shows efficacy over ineffective 
controls. However, it was slightly less effective than Alcoholics Anonymous 
(AA) based treatment in outpatients in Project MATCH.  This may be due to 
the short course of treatment given.  It is suggested that MET form an 
important initial element in a course of psychosocial treatment but should not 
be the sole intervention. 
 
· Marital/relationship therapy has shown a beneficial effect. However, it is 
only usually feasible in those with relatives willing to invest substantial 
effort in the treatment and with the consent of the patient.  Thus it can only 
form an option for treatment of some patients.  An exception to this is the 
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Community Reinforcement Approach in which the  contractual element with 
non-family members has been tested. 
 
· Brief Interventions appear to be of unproven efficacy in alcohol dependent 
patients and the current evidence does not suggest that this is a promising 
approach.  The ‘Relapse Prevention’ model of treatment is also unproven. 
However, this model is quite loosely defined and some currently used 
implementations involve Coping Skills training, which is effective. 
 
· Lack of standardization of psychosocial treatments in clinical trials often 
leaves doubt as to how a treatment shown to be effective in a meta-analysis 
should be delivered in clinical practice.  A pragmatic approach is to adopt a 
protocol as detailed in a report from a trial included in the meta-analysis and 
with a larger than average effect size. 
 
· Encouragement to attend AA meetings has been shown to have benefit, but 
as noted in the patient issues section, patients should not be forced to attend.  
Explanation of the aims and philosophy of AA during treatment will allow 
patients to make an informed choice.  As with other psychosocial treatment 
approaches, agreement upon rather than pressure to enrol in AA treatment 
appears essential for benefit to be obtained. 
 
· Therapists will need to be able to give informed and dispassionate advice 
regarding AA and other non-NHS services. This ability may be facilitated by 
regular liaison between NHS staff and the other services. 
 
· Within a specialist unit, protocols should be available for all available 
treatment options to ensure standardized and consistent treatment.  These 
protocols should be closely based on methods that have been proven 
effective in clinical trials. 
 
· Practical help with problems such as housing, debt, and claiming benefits 
also appears likely to contribute to control of alcohol problems.  Thus close 
liaison with Social Work services and groups able to deliver such help is 
essential. 
 
 
The following points relate to pharmacological treatment. 
 
· Pharmacological treatments have been tested and licensed as additional to 
psychosocial treatment, not as alternative therapy. 
 
· Both acamprosate and naltrexone have extensive clinical trial data, which 
show that, used according to the clinical trial procedures, they can add value 
to a programme of psychosocial treatment. 
 
· Trials of both acamprosate and naltrexone show statistically significant 
unexplained heterogeneity in effect sizes.  Some large pragmatic trials have 
not shown an effect.  This suggests that differences in the method of use may 
-    -   61 
materially affect the effectiveness.  Further studies are needed to ensure that 
the full benefits of these treatments are achieved in practice.  
 
· The effect size estimated for naltrexone is smaller than that for acamprosate.  
There are major differences in the way these products were evaluated which 
make a direct comparison difficult but this fact, in combination with the 
unlicensed status of naltrexone, would suggest that acamprosate should be 
the current preferred choice between these two medicines. 
 
· No strong evidence exists for the use of unsupervised disulfiram.  
 
· Much of the evidence for supervised use of disulfiram arises from 
observational studies and is hence potentially biased.  Most of the evidence 
from randomised controlled trials confounds supervised disulfiram with 
other interventions.  However, one randomised unconfounded study has 
found a benefit and it seems likely that supervised disulfiram can contribute 
beneficially to a relapse prevention programme. 
 
The following points relate to delivery of treatment  
 
· Although a clear benefit for inpatient compared with outpatient treatment has 
not been demonstrated the literature suggests, and clinical opinion supports, 
the existence of groups of patients who require residential or inpatient 
treatment.  These include those with few social resources and/or 
environments that are serious impediments to recovery and those with 
serious medical/psychiatric conditions. 
 
· An increased rate of failure to attend associated with delay between referral 
and start of treatment has been demonstrated.  This underlines the 
importance of minimising such delays. 
 
 
5.2 Literature search 
 
A scoping search was undertaken to gauge the quantity and quality of the existing 
literature, with particular attention being paid to finding studies by other HTA 
organisations, systematic reviews and research in progress.  Following this, the 
decision was made to undertake a systematic literature review.  Given the large 
quantities of literature on this topic, this was restricted to material published after 
1990 and to randomised controlled trials.  The list of databases searched is given in 
Appendix 16.  No language restrictions were applied. 
 
To cover all aspects of the topic, the search was carried out in four parts.  The first 
two parts looked at the population in question, in combination with either 
pharmacological or psychosocial interventions.  A third part looked at the population 
again but this time in combination with general terms for the intervention, hence 
retrieving records concerning interventions which might not have been specified in 
the previous two parts of the search.  Finally a fourth part combined the population 
with the outcome of treatment, thereby retrieving records where the individual 
recovered without treatment and also relevant records not retrieved in the previous 
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three parts of the search.  The searches were performed using the available subject 
headings (e.g.  MeSH, EMTREE) and free text terms.  Members of the Topic Specific 
Group provided assistance in identifying interventions and their synonyms.  Use was 
also made of the National Institute on Alcohol Abuse and Alcoholism thesaurus.  
 
A copy of the strategy used to search the Medline database is given in Appendix 17  
This strategy was adapted to search the other databases.  A complete listing of all 
strategies can be obtained by contacting HTBS. Also contained with Appendix 17 is a 
flow chart showing the number of studies identified as potentially suitable for meta-
analysis and then included in each stage of the process. 
 
Additional studies, in particular grey literature, were identified by the TSG, or were 
submitted to HTBS as evidence.  
 
 
5.3 Issues related to assessment of relapse prevention interventions 
 
Therapists helping patients to overcome alcohol dependence have two quite different 
sets of clinical interventions open to them.  First there are the psychosocial methods 
and second the pharmacological treatments.  In addition to these measures, it may also 
be necessary or desirable to have purely social facilities available, such as 
accommodation or advice and practical help with other aspects of the client’s life 
which may have been disrupted by alcohol or contribute to continued use of alcohol.  
All these aspects of a comprehensive alcohol service have been tested in clinical 
trials. 
 
The psychosocial interventions present very special difficulties for health technology 
assessment.  The literature obtained from the searches described above contained 
randomised clinical trials of more than forty nominally distinguishable psychosocial 
methods each of which generally included several different components whose 
precise application would require a detailed written protocol.  This apparent diversity 
of interventions is handled by specialists through classification into broad categories 
based both on the underlying conceptual model of alcohol dependence and on 
familiarity with the practical details of the way interventions are delivered.  
Appropriate use of such classifications requires considerable in-depth knowledge and 
hence it is necessary to rely on expert judgments as exercised in published reviews of 
individual treatment models.  We have been guided in selecting which treatment trials 
to group by the decisions made in previous treatment specific reviews. Thus, this 
clinical effectiveness discussion is organised according to a hierarchy of evidence 
ordered by comprehensiveness.  First we review major extensive reviews then the 
reviews of specific treatment models, and lastly, when additional information is 
required, the individual clinical studies. 
 
Although we have chosen to rely on published expert reviews for decisions about 
grouping of clinical trials, we note that other approaches are possible. The conceptual 
models, whilst providing a useful framework for presentation of a treatment 
programme, may not be the best basis for systematic statistical analysis of 
psychosocial treatments.  The component parts of an intervention, for example ‘an 
analysis of factors which characterise high-risk situations for relapse’ or ‘practising 
responsible drinking skills’, may form elements in many different treatment 
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approaches and may cut across the boundaries between conceptual models.  
Furthermore, even treatments grouped within one conceptual model may contain 
some quite striking differences in terms of their component parts.  Thus analysis 
based on multiple regressions using such component parts as explanatory variables 
might prove informative.  However, this does assume that some independent effect is 
attributable to these parts – i.e. that primary effects due to components tend to 
outweigh those due to interactions between components.  To our knowledge, this 
approach has not been tried even within such dedicated alcohol research facilities as 
the Mesa Grande project. 
 
Clinical trials of some treatment attributes have been undertaken.  For instance there 
have been investigations of particular interventions delivered to groups or to 
individuals, as outpatient or as inpatient treatment, or with abstinence as a chosen 
objective compared to controlled drinking.   
 
In this Health Technology Assessment we have had to be selective.  Tested treatments 
for alcohol include many not judged likely to form part of a conventional NHS 
service.  Examples of these are LSD, electric shocks, acupuncture and intercessory 
prayer.  More conventional pharmacological interventions, such as antidepressants, 
have also been excluded since we considered only products aimed at reduction of 
alcohol intake, not at comorbid conditions, which may be associated with alcohol 
problems. 
 
The population to whom these results apply is difficult to define precisely.  Almost all 
trials of pharmacological treatment enrolled patients who had undergone 
detoxification.  Thus this corresponds with the population stated in our primary HTA 
questions, section 2.2.  However, trials of psychosocial treatments are generally less 
proscriptive.  Studies were selected when patients were described as dependent or 
“alcoholic”.  They were not selected if patients were described as problem drinkers 
only or were obtained through population screening.  It was hoped in this way to 
select trials of patients at the more severe end of the spectrum of alcohol problems.  
The setting of many of these studies within specialist centres for treatment of alcohol 
problems may itself add a pragmatic element to the patient selection.  The patients in 
these studies will be those who are referred to specialist centres and hence a fortiori 
appropriate to this assessment. 
 
A primary objective of some recent studies has been to investigate ‘matching’ in 
treating alcohol dependence.  In other words the intention was to evaluate differences 
in effectiveness of treatments between subgroup of patients.  Studies aimed at 
investigating such questions are still designed as randomised controlled trials but one 
or more patient characteristics are prespecified and the primary hypothesis is 
concerned with the interaction between the characteristics and treatment rather than 
with the difference in the effect of treatment between randomised groups.  In general 
the success of this approach has been questionable.  Review of recent studies suggests 
that it adds still another layer of complexity to an already labrynthine area and the 
methodological difficulties have not been adequately appreciated.  Several reports 
have not reported main effects and the interaction effects, which are the declared 
focus of the study, are presented purely as statistical measures of interaction without 
any clear clinical meaning.  A statistical point, which does not seem to have been 
generally understood by the designers of such studies, is that a trial aimed at 
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characterising an interaction will require at least twice as many patients as a trial 
investigating a main effect.  It is also likely that interactions may be smaller than main 
effects and obscured by misclassifications of patients, hence the sample size required 
may be even greater.  Matching hypotheses will not be addressed in this review and it 
may be doubted whether sufficient high quality research exists for a systematic review 
of the questions posed. 
 
By contrast with psychosocial interventions, the investigation of pharmacological 
interventions is relatively straightforward.  Acamprosate and naltrexone, have been 
extensively tested in conventional clinical trials over the last few years.  The clinical 
position regarding disulfiram is more complex.  This drug has been used for more 
than forty years and many of the effectiveness studies come from an earlier era of 
clinical research when a lower standard of proof of efficacy was required for 
pharmaceutical licensing.  Furthermore, the use of social contracts between the patient 
and a partner to reinforce taking of disulfiram has been incorporated as an element 
into several psychosocial treatment programmes.  Thus, studies that test disulfiram 
taken under conditions where treatment compliance is most likely tend to confound its 
effects with other components of a treatment programme.  
 
A major purpose of the clinical effectiveness analysis within a health technology 
assessment is to provide input to the cost-effectiveness analysis.  The most 
appropriate clinical outcome measure for assessing the impact of treatment on future 
health appears to be the success rates by patient in achieving lives free of alcohol 
problems, in other words in which drinking alcohol is either controlled and safe or 
avoided.  Not all studies and no reviews have presented this outcome in a manner, 
which allows estimates to be applied to economic models.  Thus, for this outcome 
only, it was necessary to extract data from studies and perform a meta-analysis.  
Rather than include this essentially separate analysis under reviews of specific 
interventions, it is included as a self-contained section. 
  
 
5.4 Previous Health Technology Assessments and Comprehensive Reviews  
 
5.4.1 The Mesa Grande Project 
 
The Mesa Grande project (Miller & Heather, 1998); (Miller & Wilbourne, 2002) is a 
long-term and ongoing systematic review of the randomized controlled trials in 
treatments for alcohol problems.  The results of ranking 87 alternative treatments on 
the basis of 361 separate studies have been presented.  Each study was given an 
overall score based on methodological quality and the number of studies supporting a 
beneficial effect compared with the number not doing so.  
 
A criticism of this method of ranking is that interventions are given weight on the 
basis of a positive benefit relative to a comparator irrespective of the nature of the 
comparator or the size of the benefit.  A more sophisticated model might give more 
weight to a positive result relative to a comparator which itself had been shown to be 
effective. 
 
The major strength of the Mesa Grande Project is the immense effort that has been put 
into identifying and interpreting randomised controlled trials in interventions for 
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alcohol problems.  Its methodology leads directly to a ranking of these interventions 
and hence it forms a natural starting point for any investigation of relative 
effectiveness.  It provides a good basis for differentiating promising interventions 
from unpromising ones and hence for focusing further research and reviews of 
specific comparisons.  It also reveals the wide range of interventions, which have 
been studied for alcohol problems.  Thus it is worth presenting the ranking of 
interventions on the basis of the Mesa Grande scoring system in full (see Appendix 
18).  
From the point of view of the present review there are some difficulties in interpreting 
the Mesa Grande results.  Notably, the database covers studies across a much wider 
range of patients and problems than is the remit of this assessment and the ranking 
table does not include information concerning the type of patient in each study. Hence 
studies in severely dependent patients may be ranked alongside those studying 
drinkers with less severe problems. A particular example of this is the primacy of 
place achieved by brief interventions in the ranking when others have found it 
ineffective in alcohol dependent patients (see section 5.5.1.3). The outcome measure 
is also not uniform across studies and thus the nature of the effect of each treatment is 
unclear. Hence for clinical applications targeting particular types of patient and with 
clinically relevant estimates of treatment effect it is necessary to seek more focused 
reviews. 
 
5.4.2 Raistrick and Heather 
 
A UK review of effectiveness of interventions in alcohol dependence has been 
produced by Duncan Raistrick and Nick Heather (Raistrick & Heather, 1998). Both 
authors were members of the Alcohol Commissioning Guidance Steering Group.  
 
Estimates of the extent of alcohol problems in England are presented.  Eight per cent 
of  English males and 4% of females are estimated to have definite problems and 
moderate dependence whilst 1.5% of the population may have definite problems and 
severe dependence.  
 
This report includes many recommendations for organisation of a comprehensive UK 
service for treatment of alcohol problems. Some of these are based on evidence and 
some are based on logistical or clinical considerations. A summary of those which are 
of particular relevance to this HTA is included in Appendix 18. 
 
Discussion is also made of initial assessment of the patient, training of therapists, 
dealing with psychiatric co-morbidity, measurement of outcomes in clinical practice, 
 
A chapter is devoted to intensive alcohol focused interventions. Social Skills 
Training, Community Reinforcement, Behaviour Contracting, Aversion Therapy, 
Cognitive-Behavioural Marital Therapy, and Behavioural Self-control Training are 
discussed on the grounds that all get good ratings in the Mesa Grande assessment. 
Relapse Prevention is also discussed. It is noted that two-thirds of clients will relapse 
within 6 months (Marlatt & Gordon, 1985). Aftercare is discussed and a number of 
reasons for it are listed. Some evidence for efficacy of aftercare is noted. 
 
The authors note that all the treatments, which, they found to be effective are based on 
a cognitive behavioural approach. They note that drinking is a learned response, 
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which can be modified by learning through rehearsal of new behaviours. There is also 
a social element to most of the interventions. 
 
The final chapter presents the authors’ view of a comprehensive service for treatment 
of alcohol problems. Much of the discussion is very general but specific suggestions 
are made (Raistrick & Heather, 1998), table 14.1) about the treatment programmes 
that a health district might need. A ‘stepped care’ model of treatment is discussed. 
The need for training is highlighted and general proposals made for research and 
development. 
 
5.4.3 Swedish (SBU) Health Technology Assessment 
 
In 2001 the Swedish national health technology assessment agency (SBU) published a 
two-volume report covering the treatment of alcohol and drug abuse (Andreasson et 
al., 2001). The full report has not yet been translated into English but the conclusions 
of the report have been reviewed. 
 
The report was compiled by a panel of 11 experts and it is noted that the Medline 
search found 23000 studies on alcohol problems from between 1950 and 2000. 641 
relevant studies, mostly RCTs, were selected (presumably this is alcohol and other 
drugs). 
 
The main questions addressed include assessment of both absolute (compared to no 
treatment) and relative efficacy. Subgroup effects, setting (inpatient or outpatient), 
and concomitant mental illness are mentioned. Cost-effectiveness is also an area of 
investigation. 
 
Three subjects relating to alcohol are covered: detection of hazardous drinking before 
dependence develops, treatment of alcohol dependence, and alcohol withdrawal. One 
hundred and thirty-nine (139) studies in psychosocial treatment of alcohol dependence 
were found 14 of which compared with no treatment. One hundred and twenty (120) 
randomised controlled trials in medications for alcohol dependence were found.  
 
This report covers a much wider area than this Health Technology assessment and it 
has not been able to review the evidence base as the report is in the process of 
translation but conclusions are listed in Appendix 18. 
 
 
5.5 Treatment specific reviews and clinical studies 
 
In addition to the ongoing work of the Mesa Grande project (Miller & Wilbourne, 
2002) the comprehensive review by Raistrick & Heather (1998) and the HTA by the 
Swedish agency (SBU), there have been a number of reviews focused on specific 
interventions for relapse prevention. These reviews generally cover a range of severity 
of alcohol problems. The approach in this HTA has been to review these sources of 
evidence and ask how well they apply to the group of alcohol dependent patients 
which is the concern of this assessment and also whether additional evidence can be 
added to the reviews or subsets abstracted appropriate to the primary HTA question. 
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5.5.1 Psychosocial treatments 
 
A fairly large number of treatment strategies exist which might be classed as 
psychosocial therapies. Most of these are based on conceptual models of addiction, 
which involve several components, each of which is addressed by a facet of the 
strategy. Different models frequently contain common themes and hence common 
elements to the treatment. Thus, a challenge in summarising the evidence for the 
effectiveness of these treatments is deciding when two treatments are substantially the 
same and should be combined, or have important differences and should not be 
combined. The following sections report reviews by other authors of a number of 
interventions commonly used in Scotland. 
 
 
5.5.1.1 Behavioural Self Control Training (BSCT) 
 
Walters (2000);(Walters, 2000) reviewed trials of behavioural self-control training for 
problem drinkers. The author investigated the subgroup of patients judged to be 
alcohol dependent. The inclusion of a trial in group required that three quarters of the 
study population met one of the criteria: DSM-III-R/IV diagnosis of dependence, 
traditional classification of gamma alcoholism (Jellinek, 1960), significant alcohol 
withdrawal symptoms, or hospitalisation for alcoholism.  
 
The technique of BSCT aims at controlled drinking rather than abstinence. This is 
achieved by teaching clients to drink more slowly and increase intervals between 
drinks and choose less alcoholic drinks. They are also taught to recognise high-risk 
situations and to set personal goals. 
 
The literature search identified English language studies from the PsycLIT database 
between 1984 and 1997 and was extended from reference sections of study reports. 
This found 17 randomised controlled trials. Seven studies were of alcohol dependent 
clients.  
 
Several comparisons were made. BSCT was compared with controls receiving no 
intervention, with alternative non-abstinent controls and with abstinent controls. 
 
A fixed effects meta-analysis was performed on standardised measures of outcome 
differences between groups in the studies.  This gave a highly significant positive 
treatment effect. However, these results combined trials in patients judged to be 
alcohol dependent with those classed as problem drinkers. Table 5-1 presents the 
results from this paper restricted to studies of alcohol dependent patients. 
 
A wide range of outcome measures were found in the studies and hence the analysis 
combined disparate effects. 
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Table 5 - 1  Randomized Control Studies on Behavioural Self-control Training for Dependent Drinking: Continuous Outcome 
Measures (Walters, 2000) 
 
    Mean Scores   Effect size  
Study Sample Outcome Measure  Length of 
Follow-Up 
BSCT Control    d          SE 
Sobell & Sobell 
(1976)  
20 Alcoholics receiving BSCT 
19 Alcoholics trained in abstinence 
% days functioning 
well 
24 mo 83.1 40.7 +1.28 .35 
Caddy et 
al.(1978) 
 13 Alcoholics receiving BSCT 
14 Alcoholics trained in abstinence 
% days functioning 
well 
36 mo 94.8 74.9 +0.32 .39 
 Baker et 
al.(1975) 
29 Alcoholics receiving BSCT 
9 Alcoholics receiving standard 
program 
% days sober 6mo 56.7 47.3 +0.48 .39 
Volger et al. 
(1975) 
23 Alcoholics receiving BSCT 
19 Alcoholics receiving standard 
program 
Monthly consumption 6 mo 37.0 78.9 +0.95 .34 
   12mo 38.7 68.8 +0.68 .33 
Stimmel et al. 
(1983) 
17 Alcoholics receiving BSCT 2 
16 Alcoholics trained in abstinence 2 
2- Day alcohol 
consumption 3 
2.5 yr -1.5 +1.6 +0.32 .35 
 17 Alcoholics receiving BSCT2 
36 Alcoholics receiving standards 
program 
2-Day alcohol 
consumption 3 
2.5 yr -1.5 -4.4 -0.30 .30 
 Foy et al. 
(1983) 
30 Alcohol receiving BSCT 
32 Alcoholics receiving standard 
program 
% days functioning 
well 
12mo 72.4 83.6 -0.51 .26 
 
When combined these results give a non-significant trend in favour of BSCT (effect size=0.21, p=0.09). The heterogeneity is highly significant 
X2(6)=22.6, p<0.001.  The major contributor to this is clearly the marginally significant adverse effect noted in the study by Foy. 
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Table 5 - 2  Randomized Control Studies on Behavioural Self-control Training for Dependent Drinking: Discrete Outcome Measures 
(Walters, 2000) 
   Length of        Mean Scores   Effect size  
Study Sample Outcome Measure  Follow-Up          BSCT Control    d         SE 
Sobell & Sobell 
(1976) 
20 Alcoholics receiving BSCT 
19 alcoholics trained in abstinence 
Rates improved by 
collateral 
24 mo 85.0 42.1 +1.13 .39 
Caddy et al. 
(1978) 
13 Alcoholics receiving BSCT 
14 alcoholics trained in abstinence 
Continuous drunk days 36 mo 38.5 71.4 +.76 .46 
 Volger (1975) 23 Alcoholics receiving BSCT 
19 Alcoholics receiving standard 
program 
Abstinent/control 
drinking 
12mo. 65.2 57.9 +.17 .24 
 
 Pomerleau et al. 
(1978) 
18 Alcoholics receiving BSCT 
14 Alcoholics trained in abstinence 
Abstinent/improved 12mo. 72.0 50.0 +.52 .41 
 
Stimmel (1983) 42 alcoholics receiving BSCT 42 
Alcoholics trained in abstinence 
Undesirable departure 2.5 yr 26.2 33.3 +.19 .26 
 42 Alcoholics receiving BSCT 
43 Alcoholics receiving standards 
program 
Undesirable departure 2.5 yr 26.2 37.2 +.28 .26 
 
When combined these results give a significant result in favour of BSCT (effect size=0.40, p<0.005). The heterogeneity is not significant. Note 
that the study by Foy, which was negative for the continuous outcomes in the preceding table, did not contribute to this analysis 
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It is worth commenting that the one trial which gave significant negative results for 
BSCT (Foy et al., 1984) tested simply those parts of the strategy aimed at controlled 
drinking; blood alcohol discrimination, responsible drinking skills and social drinking 
practice sessions.  Both arms received broad-spectrum behavioural treatment. 
Furthermore, there was a major imbalance between treatment arms with the pre-
treatment abusive days being 22% higher in the BSCT group (201.6) compared to the 
control group (164.6).  When corrected for this imbalance, the change in abusive days 
over 12 months was identical in the two treatment arms.  Thus it seems likely that this 
trial suggests that the three element listed above may add little to the overall 
programme but does not suggest that BSCT has a net negative effect. 
 
This review generally appears to support the effectiveness of the BSCT approach in 
promoting controlled drinking.  
 
5.5.1.2 Cognitive Behaviour Therapy in alcohol dependence  
 
Cognitive Behaviour Therapy provides a conceptual model, which has been widely 
adapted to treatment of drug and alcohol abuse.  Many of the interventions discussed 
in this report borrow ideas from it.  However, this very ubiquity makes it difficult to 
identify any clear set of therapies, which should contribute to a meta-analysis of CBT 
in alcohol therapy.  The Mesa Grande Project (Miller & Heather, 1998) a 
comprehensive assessment of alcohol interventions, does not allot a unique category 
to CBT. By contrast, Project MATCH, possibly the largest clinical trial of alcohol 
treatments, includes a treatment option labelled CBT.  
 
CBT in Project MATCH was designed to help patients understand their thoughts and 
feelings and how these trigger behaviours.  The goal was to provide clients with 
coping skills in high-risk situations that could contribute to relapse.  This included 
management of anger, depression and interpersonal difficulties.  A similar approach 
has been classified by others (Wolwer, 2001) as Coping Skills Training. 
 
Morgenstern & Longabaugh (2000) reviewed CBT for alcohol dependence with the 
specific objective of investigating its hypothesized mechanism of action.  CBT is 
described as care packages which use a standard set of skills that include 
identification of specific situations where coping inadequacies occur, and the use of 
instruction, modelling, role plays and behavioural rehearsal.  These authors 
considered CBT to be similar in nature to Social Skills Training.  They included 
interventions labelled as relapse prevention, social skills training or cognitive-
behavioural approaches. 
 
Interestingly, the authors of this study conclude that, although CBT clearly is 
effective, the studies provide no evidence to support its hypothesized mechanism. 
 
The conclusion we draw from the discussion on CBT in the studies mentioned above 
is that it does not, for the purposes of systematic review, constitute a single 
intervention.  Rather it is a model underlying many of the psychosocial interventions. 
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5.5.1.3 Brief Intervention 
 
Wilk et al. (1997) undertook a review of studies of brief intervention (BI) in heavy 
alcohol drinkers. These BIs were less than one hour in duration. 
 
The literature search of Medline and PsychLIT covered 1966 to 1995 and did not 
exclude dependence.  Thus studies relevant to this HTA should have been identified.  
However, most of the trials had ‘dependence’ as a specific exclusion criterion.  
 
The odds ratio for moderation of drinking with BI compared to no intervention was 
estimated to be 1.95 (1.66, 2.30).  However, the authors note that generalizability of 
our results must be limited to less severely affected drinkers who exhibit little or no 
alcohol dependence. 
 
A further meta-analysis of BI was carried out by Poikalainen (1999).  Two additional 
studies (Fleming et al., 1997); (Nilssen, 1991) were identified and three, included in 
Wilk, were excluded (Babor & Grant, 1992); (Chick et al., 1985); (Antti-Poika et al., 
1988) on the basis that they included some hospital patients.  
 
Oddly, since the excluded studies would seem likely to contain more severely affected 
patients, Poikolainen (1999) estimated smaller treatment effects than Wilk et al. 
(1997).  He noted only that BI decreased alcohol consumption in women.  
 
These studies seem to provide no evidence for or against the use of very brief 
interventions in dependent patients.  
 
Currently the most comprehensive review of brief interventions (Moyer et al., 2002) 
identified a total of 56 studies including all those in the Wilk et al. (1997) and 
Poikolainen (1999).  Thirty-four (34) studies were in non-treatment seeking and 22 in 
treatment-seeking patients.  Of the 22 studies in treatment-seeking subjects, 20 
compared to a more extensive intervention and 10 of these did not exclude alcohol 
dependent patients. 
 
The distinction between non-treatment-seeking and treatment-seeking patients is 
important because the latter group is likely to contain those with severe alcohol 
problems. 
 
The authors’ primary finding in respect of these groups is stated as Brief interventions 
were effective compared to control conditions in studies where more severely affected 
individuals were excluded; brief interventions were not more effective than control 
conditions in studies where more severely affected persons were not excluded. This 
finding suggests that, at least during this period in the post-treatment course (3-6 
months), such interventions – which usually consist of a single session of advice, often 
accompanied by feedback and delivered in a health-care setting – are useful only for 
patients with less severe drinking problems. 
 
Almost all studies in treatment seeking subjects compared brief interventions with the 
longer interventions.  Thus this is a more severe test than the no-treatment 
comparisons often made in less severely affected subjects.  However, there is a 
suggestion that brief interventions were less effective than these longer interventions.  
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The alcohol consumption was significantly higher in the brief intervention group after 
3-6 months of follow-up (p<0.01) and a composite drinking-related outcome showed 
an adverse trend (p=0.072).  These are the only outcomes reported. 
 
This study added appreciably to the previous reviews in that it showed not only that 
brief intervention is unsupported in treatment of alcohol dependent patients, but that it 
may be less effective than other measures. 
 
5.5.1.4 Motivational Interviewing (MI) 
 
Dunn et al. (2001) investigated the MI method described by Rollnick & Miller 
(1995).  This analysis was not restricted to alcohol dependence but 17 studies were in 
substance abuse and 7 of these included dependent patients and measured an alcohol 
related outcome.  Only four studies included only dependent patients.  Although very 
brief interventions were included, there appears to be no overlap with the studies in 
the reviews of BI by (Wilk et al., 1997) and (Poikolainen, 1999). 
 
The literature search used Medline, PsychInfo and Dissertation Abstracts International 
from 1983 to 1999 and looked for ‘motivational intervention’, ‘motivational 
interviewing’, ‘motivational counselling’, and ‘brief intervention’. 
 
The authors recorded both the time taken to deliver MI and, when available, the time 
taken to train staff to deliver MI. The latter averaged 15 hours. 
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Table 5 - 3  Drinking Related Outcomes in studies of Motivational Interviewing 
(Dunn et al., 2001) 
 
Study  Time Outcomes Control  Effect size (95% CI) 
ALL DEPENDENT  PATIENTS 
Drinks per week Inactive 0.72 (-0.07, 1.52) 
Percentage of days abstinent Inactive 0.30 (-0.47, 1.08) 
3 months 
Composite index Inactive 0.83 (0.03, 1.63) 
Drinks per week Inactive 0.35 (0.43, 1.12) 
Days abstinent (%) Inactive -0.20 (-0.97, 0.58) 
Bien (1993) 
N=31 
6 months 
Composite index Inactive 0.14 (-0.63, 0.91) 
Drinking consequences  CBT -0.09 (-0.28, 0.11) 9-month  
(o/p arm) Drinking consequences TSF -0.30 (-0.49, -0.12) 
Drinking consequences CBT -0.01 (-0.20, 0.19) 15-month 
 (o/p arm) Drinking consequences TSF -0.18 (-0.37, 0.01) 
Drinking consequences CBT -0.02 (-0.23, 0.20) 9-month 
(aftercare) Drinking consequences TSF -0.02 (-0.24, 0.19) 
Drinking consequences CBT 0.09 (-0.13, 0.31) 
Project  
MATCH 
(1997a) 
N=1726 
15-month 
(aftercare)  Drinking consequences TSF 0.16 (-0.05, 0.38) 
Days in treatment Inactive -0.08 (-0.68, 0.53) Wertz (1994) 
N=42 
1-Month 
Number standard drinks  Inactive 0.43 (-0.44, 1.30) 
SOME DEPENDENT PATIENTS 
6 month Drinks per week Inactive -0.08 (-0.26, 0.11) Gentilello 
(1999) N=762 12-month Drinks per week Inactive 0.09 (-0.12,0.31) 
2-month Total alcohol consumption Inactive 0.03 (-0.64, 0.71) Handmaker 
(1999)  N=42  Abstinent days Inactive 0.38 (-0.30, 1.05) 
6 month Drinks per week Inactive 0.16 (-0.29, 0.60) Heather (1996)  
N=174  Drinks per week SG 0.35 9-0.07, 0.76) 
3-month Alcohol Addiction Severity Index Inactive 0.24 (-0.17, 0.66) 
 Standard drinks past 30 days Inactive -0.09 (-0.51, 0.31) 
9-month Alc Addiction Sev. Ind Inactive 0.42 (0.00, 0.84) 
Schneider 
(1999) 
N=89 
 Standard drinks in 30 days Inactive -0.01 (-0.43, 0.41) 
Statistically significant results are in bold type 
 
The authors note that the best evidence for MI effectiveness found by this review was 
when it was used as an enhancement to more intensive substance abuse treatment. 
 
In the context of the present assessment, in which we are interested in the effects for 
alcohol dependent patients, it may be appropriate to be cautious.  Only two 
statistically significant effects were observed in trials that included a substantial 
majority of such patients.  A study of 42 patients found a benefit in terms of a 
composite drinking index (Bien et al., 1993) and Project MATCH found a significant 
adverse effect in outpatients  on ‘drinking consequences’ at 9 months relative to a 12 
steps approach.  The outpatient group in Project MATCH included 952 persons and 
the p value for differences between the treatment arms in drinking consequences at 9 
months was 0.006.   
 
This review and our own meta-analysis (see section 5.6) supports MI as an effective 
part of more extensive psychosocial treatment.  However the results of Project 
MATCH suggest that it should not be used as a short stand-alone treatment in the 
manner of that study (4 sessions).  
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5.5.1.5 Family Therapy 
 
O'Farrell (2001) reviewed trials with family involvement in the treatment of 
alcoholism.  
 
Twenty-two relevant studies were identified. The literature search methods are not 
reported but it is noted that studies were included if spouses and/or other family 
members were involved in the treatment of an alcoholic adult. This term appears to 
imply alcohol dependence. Trials were divided into those in which the alcoholic 
adults were unwilling to seek treatment and those in which they had sought help. In 
the former the outcome measures were either family coping or initiation of change, in 
the latter they were generally measures of reduction in drinking. All trials included a 
randomised control group, which was either ‘wait-list’, i.e. deferred treatment, or 
another intervention without family involvement. 
 
The review combines the results of the studies in a meta-analysis. Outcome measures, 
although differing in nature between studies, were grouped by underlying theme (see 
Table 5-4). Statistically significant benefits of family involvement compared with 
wait-list controls or individual therapy are reported in each outcome. 
 
Table 5 - 4  Effect of Family Involvement in Treatment (O'Farrell, 2001) 
Outcome No. Studies Subjects Median r p value  
Alcohol Use 16 692 0.30 2x10-10 
Treatment attendance 3 106 0.32 0.007 
Couple/family adjustment 11 413 0.17 0.035 
Patient adjustment 10 309 0.21 2x10-5 
Spouse/family member adj. 6 348 0.26 2x10-5 
The use of Pearson’s r as an outcome measure and the absence of data from individual 
studies tend to obscure the clinical meaning of these results. The authors give a rule of 
thumb (r=0.1 is small, r=0.3 medium, r=0.5 large) however this appears quite 
arbitrary. They also note that the effect size in the Physicians Health Study of aspirin 
was only r=0.03. 
 
A number of different interventions are included under the portmanteau term family 
therapy. The paper also examined the efficacy with respect to persuading reluctant 
patients to seek treatment. The authors note that the only form of family therapy that 
does not appear to increase engagement in treatment programmes is the Johnson 
Institute Intervention, which involves training family members to confront the patient. 
This may be because the family member will often decide against the planned 
confrontation. 
 
There are a number of difficulties with respect to O’Farrell’s analysis. Although 
overall results are presented, there is only a narrative discussion of the individual 
studies and the measures used as input for the meta-analysis are not presented. 
Furthermore, it is clear that the very wide inclusion criteria resulted in the 
combination of qualitatively different interventions varying from the highly intensive 
Community Reinforcement Approach to the simple addition of a disulfiram contract 
to individual therapy. 
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Whilst there appears to be some support for inclusion of family members in treatment 
the nature of their involvement and the clinical significance of any benefit is left 
unresolved. 
 
O’Farrell’s own study of couples relapse prevention is of particular interest because it 
studied long-term effects.  Couples were started on the treatment after an initial 5 
months of BCT.  The results suggested that useful treatment effects were sustained at 
18 months. Thus long-term treatment may be an important aspect of relapse 
prevention. 
 
5.5.1.6 Classical Relapse Prevention 
 
It is important to distinguish the general theme of ‘prevention of relapse’ from the 
conceptual model underlying a number of interventions – confusingly referred to as 
‘relapse prevention’. This section addresses interventions based on this conceptual 
model, which is founded on the belief (Marlatt & Gordon, 1985) that there is a 
common mechanism underlying the process of relapse – whether in alcohol 
dependence, smoking, gambling or any other dependence.  Thus therapy may target 
many areas not obviously related to alcohol intake.  In this model relapse is viewed as 
a natural part of a process of change rather than as a failure.  From a pragmatic point 
of view, many of the component parts of the interventions labelled as relapse 
prevention will be similar to other psychosocial methods, for example, identification 
of high risk situations and coping skills training.  However, the distinguishing mark of 
this approach is the emphasis on learning to respond to and learn from lapses.  
 
Irvin (1999) examined the efficacy of Relapse Prevention and undertook a meta-
analysis.  This meta-analysis examined the efficacy of relapse prevention in a range of 
addictive behaviours.  However, ten of the 26 studies examined the use of this 
technique in alcohol and hence are potentially relevant to the present HTA.  
 
All outcome measures were converted to weighted average correlation coefficients.  
The effect size estimated for alcohol treatment was r=0.37 (95% CI 0.28 to 0.45).  
This effect size represents a statistically significant benefit but is not easily 
interpretable in terms of clinical effects. 
 
The quality of this review is in some doubt.  For instance a positive effect of Relapse 
Prevention is attributed to one factorial trial of coping skills/relapse prevention 
against supportive therapy and naltrexone against placebo (O'Malley et al., 1992).  In 
fact there appears to be a trend for coping skills/RP to give worse results than 
supportive therapy in terms of the proportion without relapse and very similar results 
in other outcomes.  The test of significance from which the review result is derived 
appears to be a test of interaction between naltrexone and the psychosocial treatment 
for interviewer ratings of psychological problems.  
 
Two of the publications reviewed (Maisto et al., 1995); (O'Farrell et al., 1993) are 
different reports of the same study.  A subset of the patients is examined in Maisto et 
al.  Moreover, the subset is restricted to those patients who suffered a relapse, hence it 
no longer represents a randomised comparison. 
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On inspection it is clear that the majority of ‘treatment effects’ quoted in this report 
are not relative to no treatment or a control treatment but are assessed on the basis of 
pre and post intervention results or compared with ‘discussion controls’.  The authors 
state that they are ‘somewhat perplexed’ by the fact that the only study comparing 
relapse prevention with no-additional-treatment found only a weak effect.  A possible 
reason for this is that the majority of their results are confounded with placebo effects, 
which are known to be quite powerful in this therapeutic area. 
 
An article not included in the review is that by Allsop and Saunders (1997) that 
reports a study carried out in Scotland in which 60 patients with a diagnosis of alcohol 
dependence were ‘randomised’ to Relapse Prevention (RP) or to a relapse discussion 
treatment or to no additional treatment.  Allocation was in fact not random but 
alternated in pairs. 
 
The RP therapy consisted of eight 1-hour sessions intended to (1) develop, enhance 
and sustain commitment to change (2) identify individual relapse precipitants (3) 
develop coping skills (4) increase self-efficacy (5) encourage recognition that 
strategies are available to prevent relapse in case of lapse. 
 
The discussion group used the same exercises as RP for enhancing commitment but 
otherwise shared the patients’ personal strategies for avoiding relapse. 
 
Outcome was assessed immediately post treatment, at 6 months and at 1 year. 
Number of weeks abstinent, drinking moderately, drinking heavily or functioning 
poorly (> 1 day in prison or hospital) was assessed at 6 months and 1 year.  Time to 
first drink and time to first heavy drinking session (relapse) were also examined.  It 
was assumed that patients who could not be contacted had relapsed. 
 
The median times to relapse for the RP, discussion and no treatment groups were 189, 
51.5 and 26.5 days.  This was a statistically significant difference between survival 
curves (Log rank p<0.03). 
 
Table 5 - 5  Drinking Behaviour at 6-month Follow-up (Allsop & Saunders, 1997) 
 Relapse 
Prevention 
Discussion 
group 
Control 
group 
Contacted for Interview (n) 18 20 19 
Totally abstinent over follow-up (n) 8 1 1 
 Mean values 
Alcohol consumed in 7 days prior to interview 29.2 50.6 68.7 
Weeks abstinent (n) 16.0 9.8 8.4 
Weeks moderate drinking (n) 4.0 5.2 1.0 
Weeks heavy drinking (n) 5.6 10.6 13.4 
Weeks functioning well (n) 19.4 14.9 9.4 
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Table 5 - 6  Drinking Behaviour at 12-month Follow-up (Allsop & Saunders, 
1997) 
 Relapse 
Prevention 
Discussion 
group 
Control 
group 
Contacted for interview (n) 15 20 14 
Totally abstinent over follow-up (n) 4 1 0 
 Mean values 
Alcohol consumed in 7 days prior to interview 59.9 52.0 21.4 
Weeks abstinent (n) 10.1 8.2 9.0 
Weeks moderate drinking (n) 4.0 3.3 3.3 
Weeks heavy drinking (n) 7.8 14.2 11.2 
Weeks functioning well (n) 14.1 11.5 12.3 
 
Thirty six (90%) of 40 patients in the two control arms relapsed over 1 year.  This 
compares with 14 (70%) of 20 in the RP group.  This is not a statistically significant 
difference. 
 
5.5.1.7 Intensive case management 
 
Many interventions combine psychological interventions with practical help in other 
areas of the subjects lifestyle.  For instance the Community Reinforcement Approach 
may involve helping the client find a job, find a home and also to achieve a more 
rewarding social life.  The literature suggests that some interest surrounds the 
question of the extent to which alcohol dependence behaviour can be modified purely 
by altering the physical circumstances of the people affected . 
 
Cox et al. (1998) examined the effect of an ‘intensive case management (CM)’ 
strategy for people with an extensive history of alcohol abuse and treatment failures.  
This involved practical social support focused on improving welfare.  The aims were 
to stabilize the patients financial condition and housing status and to encourage 
reduction of substance use.  One hundred and fifty (150) subject were randomised to 
CM and 148 to control.  
 
Follow-up was at 6 month intervals for 2 years.  The primary analysis was based on 
repeated measures and required complete follow-up data.  This limited the analysable 
group to 193 (65%) out of the randomised 298. 
 
Statistically significant improvements between groups were noted in the three primary 
variables (Public income p=0.043, Own residence p=0.04, Days of drinking p=0.009).  
There were also changes over time in own residence and days of drinking which 
suggest a gradual improvement. 
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Table 5 - 7  Group Means for Dependent Variables for Subjects who had 6-, 12- 
and 18-month Follow-ups (Cox et al., 1998) 
 N Baseline  6-month 12-month 18-month 
  PRIMARY DEPENDENT VARIABLES 
Public Income in last 30 days (dollars) 
Control 84 218  198 262 269 
CM 105 238 343 303 358 
Difference  20 45 41 89 
Nights in own residence in last 60 days 
Control 83 7.1 10.3 17.8 21.7 
CM 108 9.5 19.4 24.0 25.4 
Difference  2.4 9.1 6.2 3.7 
Days of drinking (any alcohol use) in last 30 days 
Control 85 23.8 17.8 14.8 15.3 
CM 108 23.6 14.6 12.3 11.3 
Difference  -0.2 -3.2 -2.5 -4.0 
  SECONDARY DEPENDENT VARIABLES 
Days using alcohol since last interview 
Control 83 NA 123 97 99 
CM 105 NA 102 78 70 
Difference   -21 -19 -29 
Detox admissions in prior 6 months 
Control 85 8.1 11.5 5.7 5.1 
CM 107 8.8  9.1 3.6 2.4 
Difference  0.7 -2.4 -2.1 -2.7 
Days alcohol problems in last 30 days 
Control 80 22.6 15.8 16.3 16.3 
CM 105 22.4 15.3 14.8 12.7 
Difference  -0.2 -0.5 -1.5 -3.6 
Troubled or bothered by alcohol problems 
Control 85 2.9 2.4 2.1 2.1 
CM 107 2.7 2.2 2.0 1.6 
Difference  -0.2 -0.2 -0.1 -0.5 
 
The imbalance in numbers followed up is clear from Table 5 - 7  Group Means for 
Dependent Variables for Subjects who had 6-, 12- and 18-month Follow-ups (Cox et 
al., 1998). This is a weakness of the analysis. 
The authors note that their intervention is expensive – one case manager was assigned 
to each 15 patients – but also appears effective.  
 
Far simpler case management techniques have also been tested (Hilton et al., 2001). 
Stout et al. tested a low-cost, long-term procedure for maintaining contact with 
dependent people during periods when they are at elevated risk for relapse. The 
intervention involved telephone contacts on a tapering schedule for 2 years. Three 
hundred and forty two patients were randomised and the follow-up rate was 80%. 
Follow-up data and health cost data were collected for 3 years. There was a 
statistically significant (p < 0.05) treatment effect on percentage of days of heavy 
drinking during the third year. The frequency of heavy drinking was twice as high in 
the controls (mean = 24%) than the case-monitored subjects (mean = 12%).  
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Whilst these studies only constitute limited evidence, they suggest that practical social 
interventions, whether to keep clients housed and aid with appropriate use of the 
welfare system or simple contact over time, may have a beneficial effect on alcohol 
intake.  Some supporting evidence for this is supplied by the good performance of the 
Community Reinforcement Approach, ranked seventh in the Mesa Grande table of 
interventions (Section 5.4.1), which has substantial elements of social intervention. 
 
5.5.1.8 Conclusions on psychosocial imterventions 
 
In the preceeding sections a number of psychosocial interventions were found to be of 
value in preventing relapse in alcohol dependence.  These included Motivational 
Interviewing, Family/Relationship therapy, Behavioural Self Control Training and 
Coping/Communications Skills training. 
 
Many different outcomes are used in trials of these therapies and meta-analyses 
identified in the literature have used generalised outcome measures without clear 
clinical interpretation.  A meta-analysis of success rates – either abstinence or 
controlled drinking – at the end of study shows no clear differences in effect size 
between these treatments. See section 5.6.  
 
Even effective treatments will fail in around half the patients.  The total combined 
success rates, in terms of abstinence or controlled drinking at the trial end (varying 
between 6 months and beyond one year), in trials of those psychosocial treatments 
judged effective was 43% for treated patients and 28% for those receiving control 
treatments. 
 
No support was found for the efficacy of Brief interventions or classical Relapse 
Prevention therapy in dependent patients.  
 
The efficacy of purely social interventions has some support, which suggests that this 
may form an important component of a comprehensive service. 
 
5.5.2 Pharmacological Interventions 
 
The commonly accepted view of the role of pharmacological interventions in the 
prevention of relapse into alcohol dependence is that they are subsidiary to the 
psychosocial interventions.  Thus they should not be considered as alternative 
therapies and any treatment programme will contain a psychosocial element but may 
have an additional pharmacological component.  The question, which needs to be 
addressed in assessing the pharmacological intervention, is whether, for the targeted 
group of patients, additional net benefit is obtained above that from the psychosocial 
treatment. 
 
This HTA covers only those pharmacological products, which are currently in 
widespread use for the specific indication of ‘relapse prevention’.  This includes two 
products with UK Marketing Authorisations, acamprosate and disulfiram, but also 
naltrexone about which there is an extensive literature and which has marketing 
authorisations both in the US and in some EU member states. 
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Much of the work to demonstrate the effectiveness of pharmacological interventions 
comes from clinical trials aimed at providing information for Marketing Authorisation 
(licensing) applications and has been either designed or sponsored by manufacturers.  
Thus each manufacturer was given the opportunity to submit evidence regarding their 
products.   
 
5.5.2.1 Acamprosate 
 
Medication with acamprosate appears to decrease craving and counter the reinforcing 
properties of alcohol.  Although sometimes referred to as a GABA agonist, the 
mechanism by which it affects the use of alcohol is not known.  The manufacturer’s 
Summary of Product Characteristics is reproduced as Appendix 19. 
 
5.5.2.1.1 Information submitted by Merck Pharmaceuticals 
 
An expert report previously supplied to UK regulatory authorities and dated 1994 was 
supplied (Sass, 1994). The author, Professor Sass, was the principal investigator in a 
clinical trial of acamprosate, the PRAMA study. 
 
The expert report provided lists 2 phase II and 10 phase III double-blind, placebo 
controlled trials of acamprosate.  In these trials 1839 patients were allocated campral 
at the licensed dosage for treatment periods between 90 and 360 days. 1601 patients 
were allocated placebo.  All patients entering the studies had undergone a 
detoxification programme.  Patients in these studies generally received psychosocial 
interventions in addition to the randomised treatment.  It is not clear which 
psychosocial interventions were used.  
 
A number of measures of relapse were collected for assessment of efficacy.  These 
included total abstinence at each visit, time to irrevocable failure, and cumulative 
abstinence. In three studies (PRAMA, BENELUX, Pelc II) outcome data were 
confirmed by breathalyzer, urine analysis or evidence from relatives. 
 
High drop-out rates were a problem in all studies.  At 90 days 64% of the patients 
randomised to placebo were followed up and 67% of those randomised to 
acamprosate.  By 180 days the figures had fallen to 49% and 56%.  Intention to Treat 
(ITT) analyses, which assumed failure in non-attenders were carried out. 
 
Failure to attend for follow-up is a problem in most studies of alcohol dependent 
subjects.  If all patients who do not attend for assessment are taken as having relapsed 
it is impossible to tell the difference between a relapse preventing agent and one, 
which increases the probability of presenting.  Any treatment, which had a benefit – 
say an antidepressant effect – might increase the probability of presenting.  Thus it is 
important that analysis of attenders should agree qualitatively with the ITT analysis.  
The assumption that DNA (Did Not Attend) was equivalent to relapse should also be 
checked. 
 
In addition to the expert report some reports of individual studies were also supplied.  
A brief description is given below but results of these studies are presented in the 
HTBS analysis. 
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The PRAMA study (Schadlich & Brecht, 1998) enrolled 272 newly detoxified (14-28 
days) alcohol dependent patients in Germany.  They were randomized to 48 weeks of 
either acamprosate or placebo and then followed up for a further 48 weeks.  Patient 
with psychiatric problems were excluded.  All patients received weekly counselling or 
psychotherapy for a mean period of 18 weeks and then met in fortnightly contact 
groups.  Dosage was 1998mg/d (2x333mg t.i.d) with a 2/3 dose for those with body 
weight less than 60kg.  Assessment was every 4 weeks for 12 weeks and then every 
12 weeks.  Drinking status was checked by breath testing and GGT.  The primary 
outcome was abstinence.  Primary analysis was ITT but per-protocol (PP) was also 
done.  The drop-out rate was high, 134 (49.3%) of patients remained in the study at 1 
year.  The drop-outs were not balanced between treatments: 57 acamprosate, 81 
placebo.  
 
An uncontrolled study of 614 Belgian patients on acamprosate was also supplied to 
describe the demography and concomitant treatments used over 24 months (Ansoms 
et al., 2000).  Measures of outcome were also recorded and drinking episodes were 
classified as lapse, binge or relapse.  Patients included had no other major illness and 
were actively drinking within the 7 days before study inclusion.  Only 517/614 (84%) 
eventually fulfilled the study inclusion criteria.  A further 174 dropped out over the 
study period.  
 
It is difficult to extrapolate the data from this study.  Many patients in clinical practice 
would not satisfy the entry criteria.  However, rough estimates of drinking behaviour 
can be obtained from the paper. 
 
A brief digest of evidence concerning acamprosate from the British J of Clinical 
Governance (Earl-Slater, 1999) was also supplied.  Effectiveness data are based on 
three randomised controlled trials (Paille et al., 1995); (Whitworth & Fischer, 1996); 
(Sass, 1996).  This is not a meta-analysis but a checklist of issues related to the use of 
acamprosate in alcohol dependence. 
 
The Lancet report of a study by Whitworth et al was also supplied.  Data from this 
and PRAMA have been extracted and are included in the main effectiveness analysis 
for the economic model inputs.  
 
A review of the pharmacological treatment of alcohol dependence by Garbutt et al. 
(1999) covers acamprosate, naltrexone and disulfiram in addition to SSRIs, lithium, 
buspirone and ondansetron. Randomized controlled trials in alcohol dependent 
patients were included but so were other forms of controlled study and review articles.  
Nine studies of acamprosate, 9 of disulfiram (4 oral, 5 implanted), and 3 of naltrexone 
are assessed.  Meta-analysis or other modeling to combine trial results is not 
attempted.  The reviewers consider that acamprosate and naltrexone had consistent 
proof of efficacy compared to placebo from sufficient data.  Disulfiram had 
inconsistent evidence from sufficient data.  This was based on positive evidence that 
disulfiram reduced the number of drinking days but mixed results for other outcomes.  
The total drop-out rates in the trials are tabulated but the way that drop-outs are 
accounted in the analysis is not reported.  Relative drop-out rates are not reported.  
The time period for the naltrexone trials was only 12 weeks and longer-term evidence 
would have been desirable. 
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Another review by Mason & Ownby (2000) assesses only trials of acamprosate. It 
includes all the trials reviewed by Garbutt et al. (1999) with the exception of a small, 
four week study by Gerra (1992).  Six additional placebo controlled trials are included 
and a trial of acamprosate combined with disulfiram.  It is noted that a large US study 
was still to report and data could not be included.  The statement of interest notes that 
Dr Mason is a consultant to the manufacturer of acamprosate.  In these studies missed 
visits were counted as non-abstinence and biological markers and collateral reports 
were preferred to self-reports in the case of discrepancies.  A meta-analysis of 15 
European RCTs is referred to but not described or the results reported.  The summary 
notes that 14 of 16 placebo controlled RCTs found positive treatment effects for 
acamprosate. (exceptions were Roussaux et al. (1996); Chick et al. (2000)).  The 
authors suggest that delays in initiating treatment following detoxification in the study 
by Chick may have contributed to the lack of treatment effect.  
 
A further review by Mason was published in 2001.  This collated but did not meta-
analyse all the available European trials of acamprosate.  It is noted that only 2 of 15 
trials failed to show a significant effect on primary outcome (Roussaux et al., 1996); 
(Chick et al., 2000).  A new US study in which Dr Mason is involved is mentioned 
but not reported. 
 
A summary, an abstract and a report by Soyka describe an observational study 
(Integral) of various psychosocial interventions with acamprosate.  Patients given 
individual psychotherapy (242), group psychotherapy (183), CBT/coping strategy 
(122) and brief intervention (204) were found to have almost identical results for 
complete abstinence – about 55% at 24 weeks.  Per protocol cumulative abstinent 
days were also the same for each intervention – about 127 days.  ITT days to first 
relapse was 74.5.  Conflicting results for PP time to first relapse are provided, a graph 
shows about 128 days but the abstract gives 159 days.  
 
These data do not contain comparative information on acamprosate but provide 
estimates for effects under conditions closer to clinical practice than those in a clinical 
trial.  The quality of reporting was judged to be poor. 
 
5.5.2.1.2 Evidence from literature search 
 
There appear to be 18 controlled trials of acamprosate in alcohol dependence for 
which results are currently available.  The large US multicentre study of acamprosate 
has finished and some results were released in abstract form in 2001 but the 
manufacturers do not wish to release the detailed by-treatment results until 2003. 
 
HTBS effectiveness calculations are reported in section 5.6. 
 
5.5.2.2 Disulfiram 
 
Disulfiram is an antidipsotropic agent.  In other words it induces adverse reactions 
when alcohol is taken.  The manufacturer’s (Alpharma) Summary of Product 
Characteristics is included as Appendix 20. 
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5.5.2.2.1 Submission from Alpharma 
 
Alpharma has supplied some general commentary and literature on the efficacy of 
disulfiram.  They note that, in general, modern controlled trials are not available. 
 
A literature review by Brewer (1992) discusses several studies often of an 
uncontrolled nature. It is concluded that supervised disulfiram can be effective but 
that unsupervised disulfiram is of no proven benefit.  
 
One controlled study discussed by Brewer is that by Fuller et al. (1986)  This was a 
three arm study in which 605 men received either 250mg of disulfiram (202), 1mg of 
disulfiram (204), or no disulfiram (199) for one year.  The patients were unblinded to 
whether they received disulfiram but did not know that they might receive an 
ineffective dose.  Single patients were excluded, as social support was considered 
important for the trial. Follow-up was for one year.  No differences in total abstinence 
or time to first drink were found.  However, among those who did drink a reduced 
frequency of drinking was noted in the 250mg disulfiram group. 
 
A paper by Besson et al. (1998) reported a placebo controlled randomized trial of 
acamprosate in which the (unrandomised) use of disulfiram was also recorded.  It was 
concluded that the concomitant use of disulfiram improved the effectiveness of 
acamprosate.  Results from a single unrandomised study would not generally be 
considered sufficiently convincing to warrant arecommendation about clinical 
practice. 
 
5.5.2.2.2 Evidence from literature search 
 
A discussion of the use of disulfiram is given by O'Farrell et al. (1995).  These 
authors remark that various methods have been used to reinforce compliance with a 
disulfiram regimen.  They note that disulfiram implants have not been found to be 
effective because of inadequate levels of disulfiram release and adverse effects.  
Various incentives to persevere with disulfiram have also been tried and generally 
found, to some extent, to work.  However, the most common and extensively 
researched method has been a formally and publicly agreed contract, between the 
patient and a significant other – usual the wife or husband.  Such contracts have also 
been tried within the context of a Community Reinforcement Approach (CRA) (Hunt 
& Azrin, 1973).  This has been tested in Azrin (1976) and Azrin et al. (1982).  This 
latter study suggested that, for married subjects, the contract alone is as good as the 
contract with CRA.  However, CRA appeared to be important for single patients.  The 
authors conclude by noting that previous research has failed to differentiate the effect 
of recommending disulfiram from the effect of reinforcing compliance through 
contracts and they recommend further research which includes a double-blind 
factorial trial of disulfiram (clinical versus nominal dose) and compliance 
enhancement (present versus absent).  
 
It is difficult to see how compliance enhancement could be double-blind and it is not 
clear that blinded use of disulfiram is appropriate since the treatment effect appears to 
be due to fear of an adverse reaction from drinking.  This fear will still be present if 
the subjects think themselves to be taking disulfiram and hence the appropriate 
clinical effect can be measured only in an open treatment trial.  Any effect found in a 
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blinded trial can only be due to un-blinding caused by exposure to alcohol or some 
other uncontrolled effect of the drug. 
 
The HTBS analysis of effectiveness is reported in section 5.6 
 
5.5.2.3 Naltrexone 
 
Naltrexone is an opioid antagonist, which is administered to reduce drinking and 
craving.  It is not currently licensed in the UK for this indication but the 
manufacturer’s Summary of Product Characteristics for the Republic of Ireland is 
included as Appendix 21.  In the Republic of Ireland it is licensed for use within a 
comprehensive treatment programme for alcohol dependence to reduce risk of 
relapse, support abstinence and reduce alcohol craving. 
 
5.5.2.3.1 Submission from Dupont Pharma 
 
Naltrexone was initially developed for use in opioid addiction but then found to 
reduce alcohol craving.  As a consequence of its effect on opioid receptors current 
dependence on opioids must be ruled out before use in alcohol dependence.  
 
The product summary discusses two 12 week randomized placebo controlled trials 
(Volpicelli et al., 1992); (O'Malley et al., 1992).  A combined analysis of the two 
efficacy trials authored by O’Malley, Volpicelli and three employees of Dupont 
(O’Malley et al., 1995) is included in the submission.  The combined results showed 
statistically significant benefits in favour of naltrexone in time to first drink (p=0.002) 
and time to first episode of heavy drinking (p<0.001).  During 12 weeks 75% of 
naltrexone and 48% of placebo treated patients did not have an episode of heavy 
drinking.  Fifty-four percent (54%) of naltrexone and 31% of placebo treated patients 
were abstinent.  An interesting finding of these studies was that patients who were 
non-abstinent were at significantly lower risk of heavy drinking when on naltrexone.  
This was not a prespecified hypothesis of either study.  Both the percentage of 
drinking days and craving scores also showed significant benefit in favour of 
naltrexone. 
 
These were fairly small (combined n=186) and short-term studies.  However, they are 
well reported and appear well conducted. 
 
5.5.2.3.2 Evidence from literature 
 
There has been considerable recent interest in testing naltrexone for alcohol 
dependence and there appear to be 24 published and one unpublished clinical trial. 
 
Analysis of data from the trials is reported in section 5.6 
 
5.5.2.4 Comparison of acamprosate and naltrexone 
 
A meta-analysis by Kranzler and Van Kirk (2001) was motivated by the absence of 
direct comparative studies of naltrexone and acamprosate.  They thus attempted to 
collate and contrast the evidence from placebo-controlled trials of each treatment. 
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Nine naltrexone and 11 acamprosate studies were included.  All outcome measures 
were assessed in intention-to-treat analyses.  Two further acamprosate studies, 
Lhuintre et al. (1985) and Lhuintre et al. (1990), were omitted because of 
methodological concerns.  
 
The measures combined across studies were differences in proportions of successes 
between groups.  When continuous measures were reported the standardized mean 
difference was used.  
 
Comparisons were made of the percentage of patients abstinent at the end of the 
study, the cumulative abstinent days, and the percentage retention.  These 
comparisons did not show differences between the performance measured in the 
acamprosate studies and that measured in the naltrexone studies.  Both treatments had 
highly statistically significant benefits in these measures relative to placebo. 
 
Heterogeneity was noted in the estimates of the effect of naltrexone on the percentage 
of drinking days and the effect of acamprosate on cumulative abstinent days.  These 
effects were found to be significantly correlated with recency of study for naltrexone 
– effects fell with time - and proportion of males for acamprosate – the effect was 
greater in females. 
 
The authors conclude that both treatments have small but significant benefits in 
alcohol dependence.  
 
This study appears to be a systematic and comprehensive assessment of the published 
RCTs for acamprosate and naltrexone.  The comparison between acamprosate and 
naltrexone is, of course, not randomised.  Furthermore, absence of a statistically 
significant difference does not imply absence of a difference – confidence intervals 
would be useful rather than p values.  A difficulty, which is not addressed, is that the 
length of follow-up in each study is not reported and our own work (see Appendix 21) 
shows that it varies systematically between trials of acamprosate and of naltrexone.  
Thus differences in effectiveness are confounded with differences in trial procedures. 
 
Table 5 - 8  Outcome Measures and Mean Effect Sizes for Naltrexone and 
Acamprosate (Kranzler & Van Kirk, 2001) 
Measure  K N Effect size  
Rw (SD)  
Effect 
p-value 
Heterogeneity 
p-value 
Naltrexone outcomes 
% Subjects abstinent 8 781 0.122 (0.066) <0.001 0.88 
% Drinking days 8 650 -0.191 (0.195) <0.001 < 0.001 
Drinks/drinking day 5 439 -0.067, (0.126) 0.081 0.14 
% Relapse to heavy 
drinking 
7 549 -0.161 (0.107) <0.001 0.36 
Retention (%) 7 529 0.005 (0.132) 0.45 0.10 
Acamprosate outcomes 
% Subjects abstinent 11 3204 0.114 (0.073) <0.001 0.06 
Cumulative 
abstinent days 
10 3077 0.129 (0.088) 
 
<0.001 0.003) 
Retention (%) 10 3077 0.074 (0.071) <0.001 0.08 
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Positive effect sizes indicate higher means for active medication group; negative 
effects sizes indicate higher means for placebo group; 
K =  number of studies contributing effect sizes; 
N = total number of subjects contributing to Rw; 
 
5.5.2.5 Conclusions on pharmacological interventions 
 
Acamprosate and naltrexone were both found to be effective as treatments adjunctive 
to psychosocial interventions.  The combined success rates, in terms of abstinence or 
controlled drinking at the trial end (varying between 3 months and one year), in trials 
of these treatments was 36% for treated patients and 26% for those receiving placebo 
treatments. 
 
Use of unsupervised disulfiram was not supported by evidence but limited evidence 
suggests that supervised disulfiram may be an effective treatment for prevention of 
relapse. 
 
5.6 Calculation of effectiveness for input to economic analysis 
 
The economic model used in the cost-effectiveness section of this report compares 
costs of treatment with the long-term health consequences of any treatment-related 
changes in drinking behaviour.  Only limited information is available on the 
epidemiology of drinking related disease and, in particular, on the relationship 
between different patterns and quantities of alcohol consumption and risk of disease.  
Thus a very simple assumption is made that, following treatment, a subject will either 
be in a controlled (possibly abstinent) state in which disease risks are reduced to that 
of the general population or will be in an uncontrolled state with high risk of alcohol 
related disease.  
 
The nature of the model requires that information be available from clinical studies 
regarding the proportion of patients in each treatment group who are considered 
treatment successes – i.e. controlled – and those who are failures.  Unfortunately, 
many studies do not make this distinction on a patient by patient basis but report other 
drinking outcomes, for instance percentage of heavy drinking days.  In particular, 
none of the systematic reviews of psychosocial treatments have reported success rates 
in this fashion.  Consequently the individual studies have been reviewed and these 
data extracted when possible. 
 
Some difficulties are inherent in extracting this type of information.  Different points 
in time are chosen for outcome measurements in different studies.  The choice of 
success measure may also vary with some studies reporting only abstinence others 
only controlled drinking and with different definitions of controlled drinking.  Studies 
where subjects are given the choice of aiming for either an abstinent or controlled 
state may simply report a combined success rate.  In analysis we have generally tried 
to choose outcome measures around one year after treatment but, if these were not 
available, the closest time point was used.  Absolute success rates are likely to vary 
considerably with time, so analyses are carried out in terms of odds ratios for success 
between treated and untreated groups.  A further complication is the drop-out rate 
during follow-up in these studies.  We adhere to the view that the most reasonable 
assumption is that those lost to follow-up are likely to be treatment failures and 
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intention-to-treat calculations have been used when sufficient information is available.  
However, we also recognise that interventions of very different intensity or duration 
may induce different drop-out rates for reasons unrelated to treatment failure and that 
this methodological difficulty introduces an element of uncertainty into our 
calculations which will not be reflected in confidence intervals. 
 
The method of analysis used is the simple meta-analysis procedure of (DerSimonian 
& Laird, 1986).  Fixed effects estimates are used reflecting concerns about the quality 
of some smaller studies. 
 
The choice of interventions, which we have analysed, has been guided by the 
preceding effectiveness discussion.  In particular, interventions, which do not seem 
effective in dependent patients on the basis of more extensive reviews, have been 
excluded.  
 
A combination of coping skills training and communication skills training has been 
advocated by Monti and tested in three clinical trials.  No formal review of these was 
revealed by our literature search but they have been reviewed in the HTBS meta-
analysis as they form a well-defined group not covered by the other analyses.  In 
Table 5 - 9  Results of meta-analysis for rates of abstinence or controlled drinking 
(See Appendix 21) they are referred to as Coping Skills studies. 
 
The results of these calculations and further discussion are presented in the economic 
section of this report and more details of the calculations, including variations in 
follow-up period and treatment of missing data, are given in Appendix 21.  However, 
for ease of comparison with the other effectiveness results, the main results are 
reproduced in the following table.† 
 
Table 5 - 9  Results of meta-analysis for rates of abstinence or controlled 
drinking (See Appendix 21) 
Intervention Treated 
Total N 
Control 
Total N 
Odds Ratio 
(95%CI) 
Heterogeneity 
p-value 
Pharmacotherapy     
Acamprosate 2094 1925 1.82 (1.55,2.14) <0.005 
Naltrexone 1176 939 1.40 (1.16,1.69) <0.005 
Disulfiram 245 241 1.31 (0.81,2.10) NS 
Psychosocial     
Coping Skills 139 146 2.33 (1.44,3.76) NS 
Relapse Prevention* 159 174 1.14 (0.70,1.84) NS 
Behavioural Self Control 
Training 
141 135 1.86 (1.03,3.36) NS 
Motivational 
Interviewing 
78 118 2.19 (1.20,3.98) NS 
Marital/Family Therapy 360 380 1.81 (1.26,2.61) <0.01 
                                                 
† Note that there are small differences between these estimates and those presented in the economic 
section of this report at the consultation phase. These are due to (1) some late arriving data (2) 
changing from a one-step approximation to the odds ratio to the maximum likelihood estimate (3) an 
adjustment to the acamprosate effectiveness in the economic analysis to allow for the US study. They 
make no qualitative differences to any report conclusion. 
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* Following ‘classical’ or ‘Marlatt’ model.  
 
 
5.7 Safety of relapse prevention interventions 
 
There does not appear to be any literature on adverse effects associated with 
psychosocial interventions.  If any exist they are only reflected in this assessment in 
so far as they impinge on the effectiveness of treatment. 
 
Use of acamprosate, disulfiram and naltrexone carries some associated risk of adverse 
effects.  Those, which, have been observed in clinical trials or identified by national 
spontaneous reporting systems are documented in the SPCs for the products.  A 
clinically relevant discussion is given in the International Handbook of Alcohol 
Dependence and Problems (Heather et al., 2001). The commonest adverse effect of 
acamprosate (around 10%) is diarrhoea and abdominal discomfort.  Clinical trials of 
naltrexone have consistently revealed higher level of nausea when compared with 
placebo treated patients and headache, dizziness and weight loss may also be 
experienced.  Disulfiram may cause drowsiness, headache, bad breath or skin rashes.  
Very rare serious adverse reactions such as liver hypersensitivity (1/25,000) and 
psychosis have been reported. 
 
 
5.8 Other Issues 
 
5.8.1 Effectiveness of Alcoholics Anonymous 
 
AA is a self funding organisation outwith the NHS and, as such, not an easy treatment 
option to test in clinical trials.  However, the limited evidence which does exist has 
been reviewed by other researchers (Kownacki & Shadish, 1999). 
 
This review included both randomised and unrandomised studies comparing AA 
treatment with either active or inactive control treatments.  The nature of the active 
control treatments is unclear.  Treatments were compared in terms of a standardized 
mean difference to allow combination over different outcome measures.  All outcome 
measures were alcohol related. 
 
Ten randomised studies were identified which fell into three groups.  Three studies 
randomised to AA meetings, two examined inpatient treatment based on AA 
principles, and five examined only selected facets of the AA approach.  The 
comparisons in these groups gave different results.  The comparison of AA meetings 
with either active or inactive control treatments estimated a statistically significant 
adverse effect of AA meetings.  The comparison of AA based inpatient treatment with 
other inpatient treatments suggested no difference between the two.  However, the 
individual facets examined (Communication skills to do AA steps vs discussion, 
Recovered alcoholics as counsellors vs non-alcoholic counsellors, Senior abstinent 
patient-led group vs therapist-led group, Honest inventory milieu vs hypnotherapy) 
gave an overall significant benefit for the treatments based on AA principles.  
 
The authors note that the three studies, which gave the adverse estimate of AA 
meeting efficacy only enrolled subjects who were coerced into treatment.  They argue 
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that AA meetings, compared with other forms of treatment, may provoke more 
negative responses in those forced to attend them.  Thus the correct interpretation of 
these trials is that patients should not be coerced into attending AA. 
 
An argument is strongly put for more and better quality randomised trials of AA.  
 
The paucity of data concerning the actual effects of AA as an organisation does not 
extend to the effectiveness of the AA treatment philosophy.  This formed one of the 
three arms of the Project MATCH study (Project MATCH Research Group, 1993) 
and was, perhaps, the most successful of the treatment arms.  As already noted Project 
MATCH found a significant beneficial effect for the 12 Steps approach in outpatients 
on ‘drinking consequences’ at 9 months relative to motivational interviewing.  The 
outpatient group in Project MATCH included 952 persons and the p value for 
differences between the treatment arms in drinking consequences at 9 months was 
0.006.  The effects of the 12 Step approach were found to be similar to the CBT 
approach used in the third arm.  Although this was not a direct test of AA itself it is 
worth noting that the overall goal of the TSF programme in Project MATCH was to 
promote the active participation in ‘traditional fellowship activities of AA’.  To this 
end the intervention emphasised the beliefs of AA that alcoholism is a chronic and 
progressive illness without cure for which total abstinence is the only solution.  Hence 
the trial was a direct test of the acceptability and effectiveness of the AA model of 
alcohol dependence.  A further finding of Project MATCH was that TSF was more 
effective than CBT in patients ‘without support for abstinence in their environment’.  
 
5.8.2 Treating drug and alcohol dependent patients together 
 
Beidler (1991) randomised 450 people with either primary drug (206) or alcohol (244) 
problems to either be treated together or in segregated groups.  Subgroups of subjects 
were examined to try to find any in whom these strategies might be particularly good 
or particularly poor.  Treatment consisted of a number of coordinated psychosocial 
approaches.  Follow-up was for 8 months. 
 
Of those assigned to combined treatment (212) 53 (25%) had problems with both 
alcohol and drugs.  In the separate treatment group (238) only 29 (12.2%) had 
problems with both.  This is an odd and highly statistically significant (p<0.001) 
imbalance. 
 
No differences in changes in dependence levels, criminality, suicidal tendencies or 
employment levels were seen for either those with primary alcohol or primary drug 
problems between the two treatment options. 
 
This study is broadly supportive of combined treatment as an option.  However, the 
power to detect problems for particular subgroups is not discussed and the imbalance 
in multiple abuse may suggest problems with randomisation. 
 
5.8.3 Minimising pre-treatment drop-out. 
 
Stasiewicz & Stalker (1999) report a randomized controlled trial of measures to 
minimize failure to attend for first appointments at substance abuse clinics.  They 
compared a group given appointments within 48 hours with groups given 
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appointments after 48 hours but with (a) a reminder call 24 hours before the 
appointment or (b) an appointment card and clinic brochure in the post or (c) no 
additional reminder.  They found that those given appointments within 48 hours were 
substantially more likely to keep the appointment than those in the other groups.  
 
Table 5 - 10  Patients Attending for First Appointment 
Group  
Intake within 48 hours 23/32  (72%) 
Phone call 16/32  (50%) 
Appointment card/brochure 16/32  (50%) 
No contact 17/32  (53%) 
 
This suggests that a prompt response to requests for help with alcohol related 
problems is important.  Minimising the delay in obtaining treatment has also been 
picked out as a matter of concern to patients by the SIGN patient focus groups (SIGN, 
draft, 2002).  
 
5.8.4 Inpatient and outpatient care 
 
Rychtarik et al. (2000) randomised 192 individuals with a score of 9 or more on the 
Alcohol Use Disorders Identification Test (Babor et al.,1989) to (a) a residential, 
abstinence oriented, alcoholism treatment facility or (b) a specialist outpatient clinic 
with intensive treatment or (c) a specialist outpatient clinic with standard treatment.  
The intention of the study was to test treatment-matching hypotheses with respect to 
drinking problem severity and to social support for drinking.  Patients with high levels 
of either variable were expected to benefit from inpatient or intensive outpatient 
treatment. 
 
Drinking outcomes were obtained in each month following treatment by the timeline 
follow-back method, which reconstructs daily drinking via a calendar.  The primary 
outcomes were the percentage of voluntarily abstinent days and the number of drinks 
per drinking day. 
 
There was no overall difference between the groups in primary outcomes over 18 
months of follow-up.  However, a relationship was found between drinking problem 
severity and the treatment allocation.  This did not follow the hypothesized pattern in 
that, although highly involved patients benefited more from inpatient treatment, there 
seemed to be a negative association with intensive outpatient treatment and no 
significant association with standard outpatient treatment. 
 
Although this relationship was not as expected, and hence might be regarded as 
hypothesis generating, it suggests that inpatient care may be important for those with 
more severe alcohol problems. 
 
No interaction was found with social support for drinking. 
 
Several evaluations of the benefits of inpatient and outpatient care are reviewed by 
Finney & Moos (1998).  The evidence concerning effectiveness for all patients does 
not show clear superiority for either option.  However, the authors note that there is a 
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group of patients with few social resources and/or environments that are serious 
impediments to recovery for whom residential options should be available and that 
inpatient treatment options should be available for those with serious 
medical/psychiatric conditions. 
 
5.8.5 Matching of treatment to patient 
 
Litt et al.(1992) examined data from 79 male patients who had been previously 
allocated (randomized?) to either coping skills therapy or interactional group 
psychotherapy (Kadden et al., 1992).  The patients were divided into two subtypes (A 
and B) using methods of Babor et al. (1992)  Thirty-three female patients were not 
used in the study.   
 
It is unclear why a cluster analysis was used to sort patients into type A and type B.  
An algorithm for doing this should already have been available from the Babor study.  
Thus this study cannot be considered as a validation of the earlier work. 
 
A classification of the patients based on data, which appear to have been collected 
prior to starting treatment showed a significant interaction with treatment (p<0.05).  
In other words, the relative treatment effects for coping skills therapy and 
psychotherapy was different for type A and type B patients. 
 
A prospective classification of the patients would have been more convincing since it 
is difficult to be sure about the timing of assessments after the study has ended.  It is 
also unclear why the female patients were not used in the study – there does not seem 
to be any particular reason for supposing that the classification of males and females 
needed to be carried out separately. 
 
The most extensive and rigorous test of matching hypotheses was that provided by the 
clinical trial in Project MATCH (Project MATCH Research Group, 1993).  In this 
study 952 outpatients and 774 inpatients were randomised to, either, a cognitive-
behavioural treatment (CBT), a 12 steps approach (TSF) or motivational enhancement 
(MET).  A number of patient characteristics were measured at baseline and 10 a priori 
primary client-treatment matching hypotheses were pre-specified.  These failed to 
find any interaction effects that had an impact on drinking throughout the treatment 
phase.  Despite the size of this trial no convincing subgroup differences in treatment 
effects were discovered.  
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6 PATIENT ISSUES 
 
6.1 Summary 
 
The patient issues reported have been identified primarily by the early findings of a 
qualitative study commissioned by HTBS to explore patients’ treatment preferences, 
patient information leaflets, and a study entitled ‘Attitudes Towards Alcohol: Views of 
the General Public, Problem Drinkers, Alcohol Service Users and their Families and 
Friends’ (Lancaster B & Dudleston A, 2002). 
 
The qualitative study aims to collect data from 45 participants.  Data have, so far, 
been analysed from interviews with 32 people and this Interim Report presents the 
results of the preliminary analysis.  Of the 32 interviews analysed so far, twenty were 
with men and twelve with women.  Their ages range from thirty to seventy-two years.  
Four people were still drinking in a harmful way, and the longest period of abstinence 
at the time of interview was two years. 
 
Issues to emerge include: 
 
· Participation in residential or day case relapse services may currently depend on 
the way services are structured locally, rather than patient choice 
· Lack of understanding of terms such as cognitive behaviour therapy and 
motivational enhancement need to be recognised in patient literature 
· Participants valued activities such as anger management, stress/anxiety 
management and relaxation exercises, coping skills, assertiveness training and 
rehearsing difficult situations within a safe environment 
· Women who had experienced ‘women only’ group work had a preference for 
women only groups, but conversely men may have a preference for mixed sex 
group work 
· Individual therapy sessions may be valued for the depth of work they enable 
· Flexibility of times and venues was valued 
· All participants recognised that AA works well for many people, but most of 
them felt that it was not suitable for them. 
· Awareness of services other than Alcoholics Anonymous may be low and may 
require better promotion. 
 
 
6.2 Introduction 
 
Perhaps more than any other field of medicine, the treatment of addiction involves the 
risk of important differences between the goals of the patient and the aims perceived 
as desirable by the doctor.  Thus it is very important for both parties to understand and 
agree the purpose of treatment.  
 
The intention of the patient issues section of a Health Technology Assessment is to 
ensure that needs and preferences of patients are taken into consideration when 
developing treatment services and also to identify issues which may only affect a 
minority of patients but, in those few cases, may profoundly impinge on the benefit 
which an individual can derive from the service. 
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Obtaining accurate information about patient concerns regarding alcohol treatment 
services can present major difficulties.  Several methods have been used by HTBS.  A 
limited MedLine search has been carried out to identify published literature on patient 
preferences.  HTBS has commissioned a qualitative study focused on the patients 
within the Scottish relapse prevention services.  HTBS also contacted certain 
organizations that interact with subgroups of patients, in particular the criminal justice 
system.  
 
The Topic Specific Group included a representative from the Council on Alcohol and 
the organization of Alcoholic Anonymous in Glasgow generously gave time to 
explain its views on a number of issues.  
 
 
6.3 Literature search 
 
A search of Medline from 1990 to the present was undertaken to ascertain the 
usefulness of searching for general patient issues and concerns in relation to this topic.  
Approximately 500 abstracts were retrieved, the majority of which were found not to 
address the specific area of interest.  It was therefore decided not to continue 
searching in other databases.  Instead small-scale searches were carried out in 
response to specific issues that were identified. 
 
Part of the evidence presented in support of the Scottish Executive’s Plan for Action 
on Alcohol problems (Scottish Advisory Committee on Alcohol Misuse (SACAM), 
2002) was a study entitled ‘Attitudes Towards Alcohol: Views of the General Public, 
Problem Drinkers, Alcohol Service Users and their Families and Friends’ (Lancaster 
B & Dudleston A, 2002).  The study included an analysis of the perceptions of service 
provision by current and past problem drinkers of their needs and the extent to which 
they were being met.  As a consequence of recruitment problems, which were outwith 
the control of the researchers, the participants were mainly derived from urban areas.  
The report primarily focuses on alcohol misuse rather than dependence. 
 
 
6.4 Design and conduct of the qualitative patient issues study commissioned by 
HTBS 
 
The design of this study involved interviews with clients of the Scottish relapse 
prevention services in three Trusts.  This was not a formal questionnaire based 
interview but was intended to explore patients’ treatment preferences and to elicit 
factors, which prevent relapse to drinking.  The full protocol for this study is included 
as Appendix 22. 
 
This project seeks the experiences of individuals who have received treatment for 
alcohol dependence.  The study aimed to identify people’s preferences for 
psychosocial or pharmaceutical interventions, or a combination of both, according to 
their own particular experiences.  A qualitative approach was adopted using in-depth, 
one-to-one interviews with a sample of individuals from urban, rural and semi-urban 
areas in Scotland who have had relevant personal experience.  The study also sought 
to elicit factors, which, in the participants’ views, precipitated or prevented relapse to 
drinking. 
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6.5 Method and analysis 
 
Approval was granted by each of the three Local Research Ethics Committees, which 
govern research within the participating Trusts.  Consultants responsible for the care 
of the participating patients also gave approval for access.  On recruitment to the 
study all participants were assured that their confidentiality would be respected.  The 
conditions of the Data Protection Act (1998) are being observed.  
 
The sample was recruited and comprised individuals who had used the alcohol 
treatment services of three geographically distinct areas in Scotland within the past 
year.  Posters were displayed in prominent positions within treatment facilities and 
information about the study was made available to anyone who expressed interest in 
participating.  In addition, nurse managers wrote to a random sample of patients who 
had attended for treatment during the past year, seeking volunteers for the study and 
suggesting that those interested should contact the researcher.  In this way the 
anonymity of patients was protected until they agreed to volunteer.  Moreover, since 
the study involved an element of service evaluation, the process of randomising the 
sample recruited via the nurse managers ensured that bias in the selection was 
minimised.  
 
There were no exclusions with regard to gender, age, social class or employment 
status.  
 
The findings of this study are not representative of the entire population of Scottish 
drinkers in statistical terms.  Rather, as qualitative research, the results can be 
considered to be transferable if readers can judge, from the information given, that the 
findings are applicable to cases for whom, circumstances are similar (Guba and 
Lincoln 1985).  
 
One-to-one in-depth interviews were conducted during which the participants were 
asked to recount their experiences of treatment and their preferences for 
pharmacological and psychosocial interventions.  They were also asked to discuss the 
factors, which they perceived as contributing to the experience being either positive or 
negative, and to reflect on the reasons for their preferences.  The interview guide, 
which, was used to ensure that all relevant topics were addressed is appended.  
Prompts were used for clarification when necessary, and to encourage further 
disclosure.  The interviews were conducted at a variety of locations to meet the 
preferences of the participants and to minimise inconvenience incurred by them.  The 
venues included the researcher’s office, patients’ own homes, health service facilities 
and accommodation within the premises of one of the Councils on Alcohol. 
 
The duration of the interviews ranged from 30 minutes to one and three quarter hours.  
All except one were audio-tape recorded.  The reason for the exception was that the 
participant was reluctant to be recorded, so hand-written notes were taken instead. 
 
The interviews were transcribed prior to analysis.  Burnard’s framework for thematic 
analysis of qualitative data was used to search for themes and patterns in the data 
(Burnard 1991).  As a means of ensuring rigour in the process, a sample of the 
transcriptions are being analysed independently by a colleague of the researcher with 
experience of undertaking qualitative research.  Points of divergence are discussed 
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and agreement reached for the final analysis.  The participants will be invited to 
comment on a summary of the findings as part of the validation process for qualitative 
research (Sandalowski 1993, Whittemore et al 2001). 
 
 
6.6 Interim findings of patient issues study  
 
It is stressed that these are the interim findings of research, which is not yet complete. 
 
The gender distribution and age range of participants are shown in Table 6-1, and 
Table 6-2 shows the number of participants who had, at some time in their lives, 
experienced some form of psychosocial or pharmacological treatment for alcohol 
dependence. 
 
Table 6- 1  Gender distribution and age range of participants 
Gender  
Male Female 
Age range 
Trust 1 (n=15) 9 6 31 - 52 yrs 
Trust 2 (n=15) 10 5 30 - 71 yrs 
Trust 3 (n=2) 
(Data collection ongoing) 
1 1 56 - 72 yrs 
 
 
Table 6- 2  Treatment experiences 
 NHS 
individual 
therapy 
NHS group 
therapy 
Disulfiram Acamprosate Councils on 
Alcohol 
AA 
Trust 1 15 15 5 6 4 9 
Trust 2 15 15 5 4 8 11 
Trust 3 2 1 - - 1 1 
 
 
The following section summarises the views of the participants as regards their 
preferences for different treatment modalities for alcohol dependence and the 
prevention of relapse to drinking.  As a consequence of the recruitment process, 
which was through NHS alcohol services, all participants had been referred for 
treatment within the NHS.  Most had attended Alcoholics Anonymous for varying 
lengths of time.  A minority had experience of the Councils on Alcohol.  The sample 
included a small number of people who had defaulted from NHS treatment, and 
several had done so in the past but had returned to treatment.  
 
6.6.1 Organisation of care within the three participating areas 
 
6.6.1.1 Trust 1 
 
This Trust serves a rural and semi-urban area.  
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The participants’ descriptions of their treatment indicated services available to those 
attending one of the Trusts included a three week in-patient stay during which time 
detoxification was available, followed by a structured programme of group work, led 
by members of the nursing staff, and individual therapy.  After-care provision 
included the opportunity to attend a group on a weekly or twice-weekly basis.  The 
opportunity exists for these patients to attend as and when they feel necessary and 
appropriate, rather than as obligatory attendance on each occasion that the group 
meets.  This group is therefore open to some extent.  One of the options within this 
service is for a ‘women’s only’ group, which has led, by default, to the formation of a 
men’s group.  Some people in this area also talked of having been referred to an 
organisation, which offered aspects of community reinforcement in the form of 
training and support in seeking employment. 
 
6.6.1.2 Trust 2 
 
This Trust also serves a rural and semi-urban area.  
 
Those individuals who attended one of the other Trusts described an initial episode of 
4 weeks duration as an in-patient.  This stay comprised detoxification, a structured 
programme of group work, and individual therapy with members of the nursing team.  
Following completion of the programme a phased aftercare programme of one week’s 
in-patient stay was offered, with the interval between episodes lengthening over a 
two-year period.  Patients who live in one geographic area within this Trust’s 
catchment area are offered follow-up out-patient appointments in satellite clinics.  
Those who live within the same Trust area, but who live outwith the specified area, 
have no such opportunity.  The view was expressed that this represented unequal 
provision.  
 
6.6.1.3 Trust 3 
 
This Trust serves an urban area.  
 
Data are still currently being collected from patients in the third Trust.  The picture 
emerging is that different patterns of care are available to patients who live in 
different areas within the Trust’s catchment area.  For example, in one area a four-
week structured day programme is offered and, in another, an in-patient stay of 
approximately 2 weeks is available with periodic follow-up out-patient appointments 
arranged on discharge from hospital.  However, more data are required to verify the 
situation, and it may be that differences in service provision reflect differences in 
local need. 
 
6.6.2 Residential versus day-patient care 
 
For most patients there was no choice.  The decision about whether treatment would 
be offered on an in-patient, day-patient, or out-patient basis was generally made by 
the consultant and appeared to depend on the basis of how care delivery was 
organised.  An additional factor, in one area in particular, was that the geographic 
distance from the communities where the majority of patients lived made residential 
treatment essential. 
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Most patients valued the sense of asylum, which this brought.  However most 
recognised the fact that, as in-patients, they were protected from the environmental 
stressors, which they normally experienced.  They talked of feeling ‘cocooned’, and 
‘in a bubble’.  In one Trust they were required to return home from the unit at 
weekends and this was generally felt to be a useful time for preparing for discharge 
and practising new skills learned.  This sense of trepidation about leaving the relative 
safety of the hospital was also reported by Lancaster and Dudleston (2002), whose 
study of current and past drinkers’ perceptions of service provision in Scotland 
formed part of the evidence presented in support of the Scottish Executive’s Plan for 
Action on Alcohol problems (Scottish Advisory Committee on Alcohol Misuse 
(SACAM), 2002).  
 
Several participants, at the Trust where the residential programme seemed to be most 
structured, found the combined effect of group work, individual therapy, paper-and-
pencil exercised in the evenings and over the weekends, tiring, but the majority found 
it very worthwhile.  This level of activity contrasts with reports of residential care in 
which the users of the services complained of boredom and a lack of structured 
activity in another area in Scotland (Lancaster B & Dudleston A, 2002).  This could 
reflect variation in the philosophy of care in the two areas, or perhaps in the level of 
resources available. 
 
6.6.3 Psychosocial interventions 
 
All participants had experienced psychosocial interventions as both individual and 
group therapies.  None were able to identify what was meant by the terms ‘cognitive 
behaviour therapy’ or ‘motivational enhancement’, although one patient who had 
recently completed a psychology course was able to identify retrospectively different 
approaches, which he had experienced.  
 
“Now I’ve done the psychology course, I can recognise that the doctors take the 
biological approach, and the cognitive approach, and you can see the client-centred 
approach in the one-to-ones. I didn’t see it while I was there, obviously.” (Interview 
17, male, Trust 2) 
 
Others described the content of the psychosocial interventions as including the 
following range of activities: 
 
“… relapse prevention, talking about the cues and triggers, you know, as well as all 
the educational information. I don’t know if that would fit into what ye’re asking 
aboot [Motivational Enhancement, Cognitive Behavioural Therapy, Relapse 
Prevention]  You know it’s very informative. There was role play, and you know, a lot 
of group work”. (Interview 7, female, Trust 1) 
 
‘Like, you do the cost/benefits, and how to avoid risky situations, and the high risk 
situations. Well, we talk about voluntary work and other things to get you into, to try 
and pass your time. I mean, it’s not the cure all and be all, but it does give you the 
tools and the help to put you on the road and you can say well if this person can do it, 
then so can I. (Interview 2, female, Trust 1) 
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In general psychosocial interventions were described as being very helpful.  It was 
acknowledged that all such interventions could be delivered in either a group or an 
individual formats. 
 
6.6.3.1 Group work within NHS facilities 
 
Activities highlighted as beneficial by several participants included anger 
management, stress / anxiety management and relaxation exercises, coping skills, 
assertiveness training and rehearsing difficult situations within a safe environment. 
 
The majority of those who had experience of group work described it as being of 
value for some of the following reasons:  
 
“I would say that for me, coming here [to the open group] is the key.  It’s hard to say 
how they work, but they do work for me.  It’s good to come along and see the same 
people.  And you get benefit from other people, knowing that other people have been 
through the same thing.” (Interview 6, male, Trust 1) 
 
“How does it help?  Well I don’t know – but we’re a’ the same.  Emm, you can get 
things off yer chest, and if you relapse or whatever, and yer heed sterts [starts], and ye 
get things blown up out of all proportion, and at least coming to meetings you get a 
chance to air it, and you might not get an answer – often you don’t, but it does work, 
and ye go awa’ hame the calmer.” (Interview 7, female, Trust 1) 
 
“I don’t come every week, I used to, but I come about once a month now.  I come 
because they know what it’s like.  I’ve got other people I could speak to - I’ve got very 
good family, but they don’t understand – they can’t understand.  It’s not their fault, 
but they don’t understand.  Unless you’ve been there, you don’t ‘have the tee-shirt’, 
but here everyone does.  Even staff don’t know, despite all their qualifications, and all 
the training, unless you’ve been there, you don’t know.” (Interview 4, female, Trust 1) 
 
For one individual, attending groups was the preferred treatment of choice, although 
he did recognise the value of individual sessions too, but felt that the approach may 
become more directive within the individual situation. 
 
“I think the groups can be more empowering [than one-to-one sessions].  Probably if I 
think about it, Dr X did say “do this” or “don’t do that”, and cracks the whip!” 
(Interview 1, male, Trust 1) 
 
All but one of the minority of patients who were still drinking, found the groups 
difficult.  One described discharging himself from treatment because he said that he 
was on the brink of having a fight with one of the group members.  During another 
episode of care the same patient discharged himself again because he found the 
attitude of a staff member objectionable.  He described how, on this occasion, the 
staff member had instructed him to attend the group and then interrupted him as he 
was about to speak and told him to be quiet.  He could not give a reason for this.  Two 
of the other participants expressed resentment as they described incidents where they 
felt that the staff had treated them like children in the groups. 
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Several of the women who were interviewed made the point that one of the weekly 
groups, which they attended, was for women only.  The majority of the women who 
had experienced these groups valued this, expressing the view that they felt less 
inhibited in such an environment.  One person said that she could discuss issues, 
which seemed trivial but were sources of irritation, which could have developed into a 
trigger for drinking.  These findings echo those of Lancaster & Dudleston (2002) but 
are at odds with the recommendations of an expert seminar on women and alcohol, 
published by the Health Education Board for Scotland, which advocates the provision 
of ‘gender sensitive’, rather than ‘gender specific’ services on the grounds of current 
limited resources (Plant and Hawe 2000).  In the study reported here, those women 
who had no experience of women’s only groups had no strong feelings.  However, all 
of the men felt that mixed groups were preferable. 
 
6.6.3.2 Individual therapy sessions within NHS facilities 
 
This was also found to be helpful by most participants, and most people expressed the 
view that they enabled problem-solving approaches to be addressed at greater depth.  
They were also regarded as important for discussing issues which people felt were too 
personal to discuss within the groups. Other views included: 
 
“The one-to-ones are good, because there’s some things that, eh…, there can be so 
many people speaking at the one time in the groups, that you can’t explain, whereas 
in the one-to-one, although you have a set time for the one-to-one, they’ll always 
make time for you, day or night.” (Interview 17, male, Trust 2) 
 
 “And the one-to-ones, even though they were total strangers, you could just talk 
away to them no problem just as though you’d known them all your life.  You were a 
bit strange to begin with, but that might have been the alcohol still working, and all 
the lies you tell when you’re on heavy drinking, like.  But after the first couple and I’d 
done my detox and all that, it was just brilliant.  You could talk about everything, 
whatever troubles you’ve got, or if you’re doing well, even.  Just whatever you want 
to talk about.” (Interview 25, male, Trust 2) 
 
“It’s directed to your own individual circumstances, it only works if you are honest 
with them and you are honest with yourself.” (Interview 15, male, Trust 2) 
 
“The one-to-ones were more beneficial for me because I could let go more and I 
could tell more than I could in a group.  There’s a lot of underlying reasons that you 
wouldn’t share with a group but you need the one-to-ones to open up about them. 
(Interview 20, male, Trust 2) 
 
One participant felt that he could not cope with individual sessions since he was,  
“Too paranoid to benefit – not ready” (Interview 11, male, Trust 1) 
 
6.6.3.3 Couples therapy 
 
None of the participants had experienced formal couples therapy, although a few said 
that spouses/partners had attended joint consultations in the early stages of treatment. 
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6.6.4 Alcoholics Anonymous 
 
Most participants had attended at least one meeting of Alcoholics Anonymous (AA).  
All said that they recognised that AA works well for many people, but most of them 
felt that it was not suitable for them.  This may, however, have been an artefact of the 
recruitment strategy.  Those who found it beneficial, although in a minority, seemed 
to gain considerable support.  The flexibility of the times and venues of meetings was 
valued for a range of reasons, as illustrated by the following quotations:  
 
“It doesn’t matter how often you come and go, you’re always welcome – more than 
welcome.  People are rooting for you and they want you to do well.  There’s always a 
meeting while she’s [daughter] at school.” (Interview 7, female, Trust 1)  
 
Some participants found the experience intimidating. 
 
“I was really nervous at the AA because you had to stand up in front of people and it’s 
just the way it’s done.  I know it works for a lot of people you know, but I found when 
I went it wasn’t right for me at that time.  I’ll maybe give it another go some time….” 
(Interview 13, female, Trust 2) 
 
A few people expressed concern about the potential for confidentiality to be breached 
at AA meetings and were reluctant to disclose their own drinking experiences for this 
reason. In contrast they appeared to get a feeling of security from the professional 
code of practice of staff and commitment to confidentiality made by group members 
in the NHS facilities of which they had experience.  
 
Some people felt that members of AA tended to replace their dependence on alcohol 
with a dependence on involvement with AA, which they thought represented limited 
progress towards achieving a fulfilled life.  A few participants suggested that some 
AA members continued to drink while attending meetings.  Although they recognised 
that lapses can occur for people who attend NHS groups, AA appeared to be more 
tolerant of the latter.  
 
No-one had completed the 12-step programme, the closest reached was one person 
who had completed nine of the steps.  One participant had asked for a sponsor to work 
through the programme with her, but it had not been possible to find anyone who had 
completed the programme themselves.  However, another had made two attempts to 
work through the programme and had found both of his sponsors to be very good.  
However, he felt that it was a mistake to rely too much on the sponsor because, as he 
said, “It’s nothing to do with sponsorship, it’s all to do with me, you know.” 
(Interview 16, male, Trust 2) 
 
6.6.5 Councils on Alcohol 
 
Fewer of the participants had experienced the services offered by the Council on 
Alcohol.  Some valued the opportunity for one-to-one counselling and for 
complementary therapies, such as aromatherapy.  Others felt that the philosophy of 
the Councils was that controlled drinking was a feasible option, which many of the 
participants felt was inappropriate for their own situation. 
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Some participants said that they felt that they had attended the Council at an 
inappropriate time in their drinking careers.  For example: 
 
“I used to go and see, it was Mary [a pseudonym].  But I think when I first went to see 
her, I was still very resistant to change, you know. I was still a bit in denial.” 
(Interview 12, male, Trust 1) 
 
The availability of the service was important to one participant who described a recent 
incident when she felt close to drinking. 
 
“A couple of weeks ago I was really desperate for a drink, it was really severe 
craving, and I thought to myself, ‘I can go down to the shop and get a carry out,’ and 
then I thought, ‘No I’m going to talk to somebody’.  So I went down to the Council on 
Alcohol and spoke to somebody and stayed there for a couple of hours, and was 
speaking to other people that have been there and had the cravings, you know, that 
you’re going through, kind of thing and it really helped me.  I’ve found like even just 
going down to the Council on Alcohol and speaking to people, it was just an informal 
chat basically, you know, but that helped settle me down and you get a game of cards 
and stuff.” (Interview 13, female, Trust 2)) 
 
6.6.6 Pharmaceutical interventions 
 
Participants were asked about their experiences of taking pharmaceutical preparations 
as prevention of relapse to drinking.  The particular preparations of interest were 
disulfiram, acamprosate, and naltrexone.  
 
6.6.6.1 Disulfiram 
 
All participants had heard of disulfiram as Antabuse and approximately one third had 
experience of taking it.  One person had experienced a skin rash without having been 
drinking, and one said that she had experienced a reaction to perfume, which she was 
wearing.  This had precipitated a bout of drinking because her family accused her of 
drinking and she claimed that, having been falsely accused, decided that she might as 
well have a drink. 
 
A few people described the very unpleasant effects they had experienced as a result of 
drinking while taking disulfiram. 
 
“Yes , but I actually drank on it and was very ill, and even that didn’t deter me.  I 
even drank on it again, knowing how ill I’d be.” (Interview 7, female, Trust 1) 
 
Despite knowing about these effects, this person said he was unable to resist alcohol. 
Another explained his feelings at the time as follows,  
 
“I ended up in A&E one time. It was quite strange, because I’d got to the point where 
I’d got to the stage that I didn’t really care.  I knew I wasn’t safe to be taking drink 
but I had a whole bottle of single malt in the house, and I thought, well, it doesn’t 
really matter what happens. For a day there was really no reaction at all, and then, it 
just massively hit.  Apparently it must have been some sort of heart problem, because 
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when I was in the hospital I was on a heart monitor all the time.” (Interview 6, male, 
Trust 1) 
 
Of those who had no experience of taking disulfiram, most said that this was because 
they would not trust themselves not to drink while taking it.  
 
“I wouldn’t trust myself on Antabuse.  I’ve heard a lot of horror stories about 
antabuse.  I think there’s a good possibility that I would drink while I was on it and I 
wouldn’t like to risk it.” (Interview 20, male, Trust 2) 
 
Some of the participants said that they took disulfiram but were concerned that this 
should only provide support until they were able to manage without it, for example: 
 
“I wouldn’t be learning how to cope with it [abstinence].  You know I’d never feel the 
sense of accomplishing something if I kept on it.” (Interview 16, male, Trust 2) 
 
However, for some others taking disulfiram was an important supplement to other 
forms of treatment.  
 
“For me it is the backbone – it just strengthens my resolve.” (Interview 27, male, 
Trust 2) 
 
“I had seen these leaflets about Antabuse, so I said, ‘I want to go on it’, and he said, 
‘Well are you sure?’ And I said, ‘Yes it’s the only way, I cannot go back out there 
[home at Christmas and New Year] and say I won’t drink’.  So they started me on it 
and I haven’t had a drink since [December 2000] actually.” (Interview 21, female, 
Trust 2)  
 
Later this participant explained that she used disulfiram to reinforce the effects of the 
psychosocial support she had received while in hospital, in combination with ongoing 
support she received from a CPN.  Indeed, all who had found disulfiram of benefit felt 
that it was the combination of interventions, which was effective for them. 
 
6.6.6.2 Acamprosate  
 
Approximately half of the participants had taken acamprosate with reports of varying 
success.  Some people noticed no reduction in craving and felt that it was of no 
benefit, whereas others felt unable to discern whether a reduced sense of craving had 
resulted from their improved coping skills, the medication, or a combination of both.  
 
“I did try that once but it didn’t work for me. I’m not very good at taking tablets 
anyway, and that’s 3 times a day dose and they’re quite big tablets, and it didn’t seem 
to affect my desire to drink. I have to take a lot of tablets anyway because of other 
health problems.” (Interview 6, male, Trust 1) 
 
On the other hand, a minority of individuals did report that they were finding that 
taking acamprosate was effective in that, although they still experienced a craving for 
alcohol, that it was less severe and this they attributed to the drug. 
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“I’ve got my wee job noo and I’ve been doing alright since, and I’m back on the 
campral, so I’m quite okay.  The campral makes the craving go away, and with me 
working I’ve got no time on my hands.” (Interview 22, female, Trust 3) 
 
One participant, who had not been prescribed either disulfiram or acamprosate felt 
that NHS staff should provide more information about these drugs so that they could 
reach an informed choice about what treatments could be available to them.  
 
6.6.6.3 Naltrexone 
 
None of the participants had been prescribed naltrexone. 
 
6.6.7 Community reinforcement  
 
Only a few people had experience of attending organisations, which offered support 
regarding training and continuing education, or assistance with housing, but those 
who did valued the opportunities, which this afforded in terms of building self-esteem 
and life skills.  
 
“I’ve done my higher psychology and I’m going to do a computing course next year. 
I’ve thoroughly enjoyed the experience and I’ve met so many people. It’s opened so 
many doors I don’t have time to think about drink”. (Interview 17, male, Trust 2) 
 
“Once you have been sober for a while, they do a 3 month training programme to try 
and get you into work or a college” (Interview 3, male, Trust 1) 
 
“I’m with an organisation called Rehab Scotland.  It actually helps people with 
mental illness – with depression and all that, and I’m finding that a great deal of 
support, and they can pull all the strings for you for to get you back into 
employment.” (Interview 20, male, Trust 2) 
 
6.6.8 Relapse 
 
Participants reported a range of factors, which had contributed to their relapsing. 
These most often involved stressors.  Stressors included moving house, family 
problems, disappointment related to failed job applications and emotional 
anniversaries.  However, some could not explain why they had relapsed, and others 
described circumstances such as receiving relatively large sums of money, which was 
quickly spent on alcohol.  A few talked of continuing to use alcohol as a reward for 
periods of abstinence and described how it took several relapses to realise the irony of 
such actions.  High-risk precipitating factors therefore, for this sample, appear to 
include both interpersonal and intrapersonal determinants as described by Cummings 
et al. (1980) 
 
Those who were experiencing the longest periods of sobriety reflected that the ‘time 
had been right’.  When pressed to describe what was different about the ‘time’ and 
how they knew this, explanations were elusive.  Further analysis of the data pertaining 
to this aspect of the study has still to be undertaken and will be presented within the 
final report.  These preliminary findings are in keeping with those of Isenhart (1997) 
whose study of the relationship between pre-treatment stages of change and outcome 
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indicated that patients who experience less ambivalence about their drinking are more 
likely to acknowledge the existence of a problem and become more willing to take 
action to address the problem.  Similar findings were reported by Hu et al. (1997) 
 
Patients described several courses of action, which they had taken to prevent relapse. 
Several had used the Helpline, which the NHS service had made available, and some 
had contacted AA or the Council on Alcohol.  Others said that they rehearsed the 
exercises which they had learned, such as relaxation techniques, or found some 
meaningful way of occupying their time, such as tackling some chore or going for a 
walk, cycle run, or work-out. 
 
Others talked about continuing efforts to maintain sobriety so that relapse was less 
likely, as this person described: 
 
“Well what I’m doing now, going to xx [nurse therapist] every 2 weeks and coming 
here [NHS group] every Thursday and just making the effort to come.  Keeping it 
going and it’s far, far too easy to get lapsed and, you know and coming here 
especially is a great reminder that I can’t do it, can’t go down that road.” (Interview 
11, male, Trust 1) 
 
Some people talked about using AA meetings in this way, whereas others valued the 
chance to return for a week’s in-patient stay, for example: 
 
“I think that respite for me was terribly important. I think I could have fell off the rails 
if I hadn’t had that. I would say you learn something different every time.” (Interview 
17, male, Trust 2) 
 
However, after care, although available in the longer term, was not always timely, as 
described here: 
 
“You need follow-up. ‘I was in [as an in-patient in hospital] for 4 weeks, then waited 5 
weeks for an appointment with my follow-up worker.  That’s a long time, and you 
could undo all the good that’d been done”. (Interview 32, male, Trust 3) 
 
The view was also expressed that some facilities served too wide an area, and the 
suggestion was made that satellite resources should be available.  Some participants 
also felt that some GPs were unsympathetic and lacked understanding and knowledge 
of alcohol problems.  In discussing his experience of using acamprosate, one 
participant recounted the following: 
 
“It’s the GP I got it [acamprosate] from but it was part of my set up.  I actually went 
to see, actually because I had been sober for six weeks he said, ‘Well if you have 
managed six weeks I think eh. ….’ I said, ‘Well I managed six weeks, but the six weeks 
have been sheer hell, its been dragging minute by minute, I have heard of this 
[acamprosate] and I want to give it a try. ….  So he didn’t give me them but eventually 
after much persuasion I went to another doctor.  It was like dragging teeth to get them 
but at least I have got them now and I would say I have had a few lapses but I have 
managed nine weeks, lapsed for a week, then managed seven weeks and the drinking 
only lasted occasional days.  So I at least coming along here, I am on the right road 
now. They do help.” (Interview 3, male, Trust 1) 
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6.7 Range of treatment options 
 
It is clear from the clinical studies that all interventions are of limited effectiveness.  It 
is thus worth providing a range of options of proven efficacy.  Treatment should be 
individualised taking account of patients’ expectations, needs and wishes with the 
understanding that these needs may change and the treatment plan may need to adapt 
to this.  Flexibility is important in retaining engagement in the treatment system. 
 
Improving the engagement of the individual in the treatment process is likely to lead 
to better completion rates and outcomes and can be facilitated by involving 
individuals in planning their own treatment programme and making treatment plans 
clear and explicit.  Other factors such as engendering a positive relationship with the 
therapist and practical measures such as provision of transport to those who would 
otherwise not attend may improve engagement, although evidence is lacking in this 
area. 
 
 
6.8 Patient information 
 
In reply to the HTBS survey only 36% of NHS specialist services carrying out 
psychosocial interventions indicated that they had patient information sheets or 
leaflets for any of these interventions.  It is recommended that such information 
should be available for all interventions. 
 
Alcohol Focus Scotland publish a variety of information leaflets for people concerned 
about their drinking and their family and friends, as well as a drink diary and self help 
guide.  The leaflets are distributed through the Councils on Alcohol and do not 
discriminate between dependence and misuse.  They provide information to help 
people understand sensible drinking, identify if they have a problem or their drinking 
is harmful, and promote sources of support and advice.  Issues addressed include: 
women and alcohol; alcohol and older people; what children can do if they feel their 
parents drink too much; dual diagnosis; stress, and how alcohol affects behaviour and 
the body. Examples are included in Appendix 10. 
 
Alcoholics Anonymous also has numerous leaflets explaining their purpose and 
philosophy.  Some of these are aimed at specific subgroups such as young people, 
prisoners and armed forces.  
 
 
6.9 Awareness of alcohol-related services 
 
There may be a lack of awareness of the range of services for people with alcohol-
related problems in Scotland.  Lancaster & Dudleston (2002) found there were low 
levels of awareness of organisations that provide help or advice for people with 
alcohol-related problems and even lower awareness of services for the families and 
friends of drinkers.  They found that in most cases awareness and knowledge 
improved once contact had been made with the service. 
 
This lack of awareness resulted in the local GP being most commonly named as a 
source of help and advice, and referral to counselling and psychologists.  
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Additionally, they found most people were aware of Alcoholics Anonymous, although 
their knowledge of its aims and the type of service it provided was limited.  Only a 
few people were aware of other specific services. 
 
Lancaster and Dudleston also reported a perception among the public in Scotland that 
there were more services for drug misuse than services for alcohol problems and that 
the drug misuse services were better promoted. 
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7 ECONOMIC EVALUATION 
 
 
 
Summary 
 
· The cost effectiveness of eight therapies (three pharmacological and five 
psychosocial) to prevent relapse in people who are alcohol dependent has been 
modelled. 
 
· The economic evaluation compares the costs and consequences of each 
therapy in comparison to a standard care package.  The relevant outcomes are 
the disease endpoints which alcohol dependence affects the likelihood of 
developing: alcoholic psychosis (including organic brain damage), liver 
cirrhosis, epilepsy, chronic pancreatitis, cancer, stroke and death. 
 
· The economic evaluation for each therapy models a cohort of 1000 patients 
and involves: 
 
Ø defining and costing each therapy 
Ø applying the clinical effectiveness odds ratio of the therapy to the 
epidemiology for the cohort to calculate the number of patients likely 
to be in the various disease endpoints 
Ø calculating the costs to NHSScotland of the disease endpoints; and 
Ø calculating an incremental cost or saving per additional abstinent 
patient. 
 
· The results show that four of the five psychosocial therapies (Coping Skills, 
Behavioural Self Control Training, Motivational Interviewing and Marital and 
Family Therapy) have net savings per incremental abstinent patient.  This 
means that the cost of the treatment is less than the savings available to 
NHSScotland as a result of adopting the therapy.  These savings arise because 
the improved abstinence rate results in a lower incidence of diseases, thereby 
saving inpatient hospital stays and other disease related costs. 
 
· Acamprosate is less cost effective than these psychosocial therapies but 
dominates naltrexone and disulfiram.  Sensitivity analysis shows that the 
ranking of therapies is robust. 
 
· A serious limitation of the model is the absence of data on relapse rates 
beyond the period of the clinical trials (3-12 months).  There are also concerns 
about generalising from trials to treating patients in a Scottish setting.  Further 
research is needed to give more definitive estimates of the long term 
effectiveness of all the therapies in a Scottish setting. 
 
· The costing of the disease end points is limited because Scottish disease 
related costs are not available. 
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7.1 Framework for an economic evaluation 
 
Several guidelines for economic evaluations of health technologies are available, for 
example, ECHTA (2001), Drummond et al. (1997) and Gold et al. (1996).  HTBS has 
reviewed these and produced its own draft ‘Guidance to Manufacturers’ (Health 
Technology Board of Scotland, 2002) that highlights the main methodological issues 
to be addressed in the economic evaluations performed within the HTBS Health 
Technology Assessment (HTA) framework.  HTBS has consulted on the Guidance 
and will revise the draft shortly in light of comments received. 
 
Best practice recommends that economic evaluations adopt a societal perspective 
(Drummond & McGuire, 2001).  Adopting a societal perspective means all changes in 
resource use, that is all changes to costs and outcomes, should be included in the 
economic evaluation.  
 
In October 2001, Scottish Executive published a comprehensive report prepared by 
Catalyst Health Economics Consultants Ltd (Catalyst Health Economics Consultants 
Ltd, 2001) that estimated the total societal costs associated with alcohol misuse in 
Scotland to be £1071m, of which £96m are health-care costs.  These costs are 
discussed in section 7.4.1.  
 
The target population for this HTA is people with alcohol dependence who have 
undergone detoxification.  This group will give rise to some of the societal costs 
estimated in the Catalyst report.  However, HTBS cannot quantify the societal costs 
identified in that report attributable to this sub-group.  Rather, the economic 
evaluation will model future health care costs only, whilst noting that these costs are 
considerably lower than the costs to society. 
 
 
7.2 Objectives  
 
The objectives of the economic evaluation are to: 
 
· review the existing literature on economic evaluations of individual 
therapies, or combination of therapies, that have the aim of reducing relapse 
in alcohol dependent patients; 
· extract from the literature, data from studies that inform on possible 
economic models and the costs and outcomes of therapies; 
· develop a simple model that is valid for the Scottish population and 
healthcare system and to populate that model with Scottish cost and outcome 
data; 
· run the model to inform on the cost-effectiveness of different therapies;  
· make due allowance for uncertainty in the data variables and in the structure 
of the model by adopting sensitivity analysis; and 
· interpret the results, to include the outcomes from the sensitivity analysis in 
the context of answering the original HTA question. 
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7.3 Literature search 
 
7.3.1 Search strategy  
 
In 2001, the Centre for Reviews and Dissemination in York undertook a search of 
electronic databases for the period 1990 to 2000 for cost-effectiveness literature.  All 
economic evaluations were included and all identified studies were quality assessed 
using a standard checklist.  The literature search was used to inform the section on the 
cost-effectiveness of relapse prevention in ‘Cost-effective Measures to Reduce 
Alcohol Misuse in Scotland.’(Ludbrook et al., 2001)   
 
HTBS updated the CRD York database by searching the same range of databases and, 
where possible, starting from entries added to the databases from January 2000.  To 
date, only one additional paper has been identified, (Palmer et al., 2000) a modelling 
study reviewed below. 
 
The list of databases is shown in Appendix 23. It includes the NHS Economic 
Evaluation (NHS EED), Health Economic Evaluations Database (HEED) and the web 
sites of leading health economics units.  
 
A copy of the strategy used to search the Medline database is given in Appendix 24.  
This strategy was adapted to search the other databases.  A complete listing of all 
strategies can be obtained by contacting HTBS. 
 
7.3.2 Criteria for inclusion and exclusion of studies 
 
The following exclusion criteria were applied when reviewing the economic literature 
search results: 
 
· review articles not containing data on costs, outcomes nor models;  
· studies not carried out in a population that might be broadly relevant to 
Scotland; and 
· studies where it is not possible to disaggregate results of alcohol treatment 
from other addiction treatments. 
 
7.3.3 Data extraction 
 
Two main types of economic studies were identified in the review.  First, some 
studies have attempted to collect data on costs and effectiveness concurrently.  These 
studies have focussed on short-term economic consequences such as changes in health 
care costs before and after treatment.  In this first category most studies fail even a 
minimum quality criterion (Ludbrook et al., 2001) and are not considered further in 
this report.  The second type of economic study has used modelling techniques 
drawing data from a number of sources to estimate the longer term consequences of 
alcohol related problems, for example, the development of liver cirrhosis. 
 
The three key studies used in the economic modelling are of this second type and are 
described overleaf, with formal data extractions for each set out in Appendix 25.  
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7.4 Economic model of relapse prevention for alcohol patients  
 
7.4.1 Overview of the economics of relapse prevention 
 
There is substantial evidence that alcohol related ill-health gives rise to considerable 
costs to the NHS (Mckenna et al., 1996).  Moreover, considerably greater costs fall on 
society as a result of alcohol misuse. In October 2001, Catalyst Health Economics 
Consultants Ltd quantified the annual societal cost of alcohol misuse in Scotland to be 
over £1, 070m (Catalyst Health Economics Consultants Ltd, 2001). 
 
This sum comprised costs to NHSScotland (£96m), costs to the social work services 
and associated organisations (£86m), costs to the criminal justice system and 
emergency services (£268m), wider economic costs from absenteeism and premature 
mortality but not reduced productivity in the workplace (£404m) and premature 
mortality in the non-working population (£217m).  Thus healthcare costs are 
estimated to form only some 9 % of the costs to society arising from alcohol misuse. 
 
Table 7-1 reproduces the analysis of health service resource use in Scotland and is 
reproduced from the Catalyst document (Catalyst Health Economics Consultants Ltd, 
2001). 
 
Table 7 - 1  Annual NHSScotland costs of Alcohol Misuse at 2001/02 prices. 
(Catalyst Health Economics Consultants Limited) 
 
Health service resource use associated 
with: Annual resource use  
Annual cost 
(£ million) 
GP consultations 211,516   3.6 
GP-prescribed drugs 6% of drugs prescribed by GPs for 
substance dependence  
  0.2 
Consultations with practice & district nurses 
and health visitors  
No information currently recorded. 
Unable to quantify 
 
Laboratory tests 147,256   1.8 
Hospitalisation days 275,775 54.3 
Accident and emergency attendances  187,951  9.6 
Outpatient visits   93,999  8.1 
Day hospital attendances   44,800  3.1 
Community psychiatric team visits  8% of total community psychiatric 
team expenditure 
 4.0 
Ambulance journeys   64,382  9.1 
Health promotion/prevention by Health 
Education Board for Scotland (HEBS) 
HEBS, Drinkwise, Alcohol  
Development Officers  
 1.2 
Health board expenditure to alcohol-related 
voluntary organisations  
Funding to 25 organisations  0.6 
Total for NHSScotland        95.6 
 
In summary, the Catalyst report showed that 57% of the NHSScotland costs of 
alcohol misuse arise from the occupation of hospital beds to treat alcohol related 
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diseases, with a further 20% arising from ambulance journeys and attendance at 
accident and emergency units. 
 
A similar view of the cost of alcohol misuse for the health service is provided in the 
July 2000 Greater Glasgow Health Board consultation document on its alcohol 
strategy (Greater Glasgow Health Board, 2000).  This document noted that alcohol 
misuse accounts for probably 8 to 15% of attendances at accident and emergency 
units and about 13% of acute psychiatric admissions.  This document also noted that 
alcohol-related admission rates to general hospitals had risen by 278% between 1981 
and 1997. 
 
A study of the economic costs of alcohol misuse in the Lanarkshire Health Board area 
in 1999 (Brown et al., 2001) identified, measured and where possible valued the cost 
of alcohol misuse in Lanarkshire.  The results indicated that in 1999 between 128 and 
200 alcohol specific deaths occurred and that the total cost of alcohol misuse in 
Lanarkshire was between £31m and £49m.  This study concluded health costs formed 
some 16 to 20% of total societal costs, rather higher than the 9% reported in the 
Catalyst study.  Note about 11% of the Scottish population live in Lanarkshire.  
 
International studies have shown that other countries including Germany, Sweden and 
USA also face considerable costs to their societies from abuse of alcohol.  (National 
Institute on Drug Abuse & National Institute on Alcohol Abuse and Alcoholism, 
1998);(Brecht et al., 1996);(Andreasson et al., 2001).  For example the National 
Institute on Drug Abuse in the USA undertook a major review of the economic costs 
of alcohol and drug use in the States in 1992 (National Institute on Drug Abuse & 
National Institute on Alcohol Abuse and Alcoholism, 1998).  This study concluded 
that in 1992 the costs of treatment for health problems attributable to alcohol abuse 
were $13.2 billion, rising to $18.8 billion with the inclusion of treatment costs, some 
13% of the economic costs to society from alcohol abuse. 
 
These studies also show that the benefits in terms of future costs avoided from 
successful alcohol treatment extend beyond the initial improvements in health and 
quality of life for patients. 
 
Successfully treated patients have also been shown to reduce their utilisation of health 
care resources (Parthasarathy et al., 2001).  This study reviewed existing published 
studies and noted that these estimated a reduction in the use of health care resources, 
following treatment of patients with alcohol disorders, ranging from 26% to 69%, 
with a median of 40%.  The reduction in health care costs ranged from $0.41 to $1.10 
for every dollar spent on treatment.  The paper also noted that the research informing 
these results had several limitations, including that most research was conducted prior 
to the widespread change from inpatient to outpatient treatment.  
 
The Parthasarathy et al. (2001) study analysed the use that 1011 patients made of 
outpatient and inpatient health care services 18 months before and 18 months after 
entering the Chemical Dependency Recovery Programme at the Sacramento Kaiser 
Permanente facility.  Costs for the provision of the services were mainly from an 
internal accounting system. 
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The results of the analysis were that, following treatment, there was a 26% reduction 
in total medical costs, with a 35% and 39% reduction in inpatient and emergency unit 
costs respectively. 
 
Other older studies are summarised in Ludbrook et al. (2001). 
 
7.4.2 Economic evaluation technique 
 
Economic evaluation has been defined as ‘ the comparative analysis of alternative 
courses of action in terms of both their costs and consequences’ (Drummond & 
McGuire, 2001).  An economic evaluation thus requires the identification, 
measurement, valuation and comparison of the costs and outcomes of the alternatives 
being considered, from a stated perspective and over a relevant time horizon. In what 
follows, costs are evaluated from the perspective of the relevant health care system, 
while benefits are evaluated from the patient perspective.  
 
The outcome under review is relapse prevention, measured in terms of patients who 
are abstinent or have controlled drinking, consistent with the definition applied for 
clinical-effectiveness. 
 
The cost consequences of improving the effectiveness of relapse prevention which are 
within the perspective of our model are the immediate costs of treatment, coupled 
with any reduced demand for health interventions that are directly related to alcohol 
abuse (for example, alcoholic psychoses, alcoholic dependence syndrome, acute 
alcoholic hepatitis and liver cirrhosis). 
 
If satisfactory preference based, non-monetary units such as quality adjusted life years 
(QALYs) are available to use as outcomes before and after treatment for alcohol 
abuse then it may be possible to express the results of the analysis in terms of cost per 
QALY.  The resultant cost per QALY can then be compared to the cost per QALY of 
alternative health care treatments and be of assistance to health care decision makers 
when they are prioritising the use of scarce resources.  
 
7.4.3 Published and submitted economic models   
 
The literature search revealed that two forms of economic model have been used to 
model the cost effectiveness of alcohol relapse prevention strategies.  The first form is 
a static decision tree model as adopted by Schadlich & Brecht (1998).  This model is 
based on a cohort of patients entering treatment and then experiencing a range of 
endpoints with different probabilities.  Those who were successfully abstinent at the 
end of treatment were assumed to be free of alcohol related diseases.  Those 
unsuccessful at the end of treatment were assumed to have a fixed probability of 
various alcohol related disease endpoints.  
 
The second form of model is a dynamic Markov model, used by Annesmans et al. 
(2000).  In this model patients move between different alcohol related treatment 
regimes across time in a fashion determined by transition probabilities. 
 
The identified studies are reviewed below in terms of their model structure and the 
data employed. 
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7.4.4 Schadlich & Brecht Model  
 
The original Schadlich & Brecht model investigated the incremental costs per 
additional abstinent alcoholic from taking acamprosate compared to a standard care 
baseline.  The economic evaluation was a cost-effectiveness analysis from the 
perspective of the German healthcare system, concentrating on the disease costs 
incurred by the population based on major disease classifications.  Only direct costs 
were included, with accidents and productivity costs excluded.  
 
The clinical effectiveness data came from a randomised controlled trial, the 
Prevention of Relapse with Acamprosate in the Management of Alcoholism 
(PRAMA) study of patients at 12 outpatient centres in Germany.  All patients in the 
trial met at least five of the Diagnostic and Statistical Manual criteria for alcohol 
dependence and had to be completely abstinent from any alcohol consumption for 14 
to 28 days before entry into the trial.  In the trial patients received acamprosate or a 
placebo for 48 weeks in addition to routine counselling.  The patients were followed-
up for a further 48 weeks without medication. 
 
The measured health outcome was abstinence in the 48-week follow-up period but 
there was no reported definition of abstinence.  The analysis stated that at the end of 
the 48-week medication free period 39.9% of the 136 acamprosate-treated patients 
and 17.3% of the placebo patients had remained abstinent. 
  
The model included epidemiology data, to include frequency of disease events per 
person, obtained from records of the disease course of patients with alcohol 
dependence in West Germany and expert opinion.  The medical and rehabilitation 
inpatient days and associated costs were obtained from official sources.  
 
The model used a three-stage decision-tree analysis and is reproduced at Figure 7.1 
for a sample of 1,000 patients.  The first step was to model the relapse and abstinent 
rates for two cohorts of patients, one group having had acamprosate in conjunction 
with the standard care and the second group having the standard care only.  The 
second stage of the model was to calculate the disease events for patients in each of 
the two cohorts.  Five disease states were considered: alcoholic psychoses, alcoholic 
dependence syndrome, alcohol fatty liver, acute alcoholic hepatitis and liver cirrhosis.  
The third stage of the model was to cost the treatments for each cohort, to include the 
cost of acamprosate and to compare the costs of the two cohorts to derive the 
incremental costs avoided from using acamprosate. 
 
The results, based on 1,000 hypothetical patients are set out in Table 7-2. 
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Table 7 - 2  Cost savings of acamprosate (per 1,000 patients) 
 DM 000s £000s 
Treatment cost for acamprosate group*    7,333 2,317 
Treatment cost for placebo group 10,090 3,188 
Cost of acamprosate   2,170    685 
Cost saving of acamprosate      587    186 
Cost saving per marginal abstinent patient       2.6   0.823 
*Number of additional abstinent patients in acamprosate group = 226 
 
The total cost avoided per additional abstinent patient in the acamprosate group 
(obtained by dividing the cost savings from using acamprosate (£186,000) by the 
number of additional abstinent patients (226)) was £823. 
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P=0.827
P=0.173
P=1 
P=0.15 
103 cases
124 cases
4 years 
10 years
P=0.5 
3 years 
P=0.5 
5 years 
P=0.5 
10 years
301 cases
207 cases
827 cases
P=0.399
P=0.601
P=0.15 
P=1 
90 cases 
601 cases
10 years
4 years 
P=0.5 
3 years 
P=0.5 
5 years 
P=0.5 
10 years
301 cases 150 cases 75 cases 
414 cases
Adjuvant Acamprosate 
Therapy 
Figure 7 - 1   Decision tree for evaluation of acamprosate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard Care 
827 patients relapsed 
173 patients abstained 
ICD 303  
Alcohol-dependence 
Syndrome 
ICD 291  
Alcoholic Psychoses 
 
1,000 patients 
399 patients abstained 
601 patients relapsed 
ICD 291  
Alcoholic Psychoses 
ICD 303  
Alcohol-dependence 
Syndrome 
1,000 patients 
ICD 571.0 
Alcoholic fatty 
liver 
ICD 571.1 
Acute alcoholic 
hepatitis  
ICD 571.2 
Alcoholic liver 
cirrhosis  
ICD 571.0 
Alcoholic fatty 
liver 
ICD 571.1 
Acute alcoholic 
hepatitis  
ICD 571.2 
Alcoholic liver 
cirrhosis  
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7.4.5 Palmer Model  
 
Palmer et al. (2000) developed the Schadlich and Brecht model to include both a 
wider range of disease states and also mortality from these diseases.  The model 
consisted of a number of sub-models to model the disease costs and the mortality 
from the different diseases.  The model tested whether using acamprosate, in 
conjunction with standard counselling therapy, would reduce the incidence and 
progression of diseases arising from alcoholism and be cost-effective in comparison 
to the standard care treatment Palmer et al. (2000) 
 
The Palmer et al. (2000) model applied incremental cost-effectiveness analysis for a 
German male cohort with an average age of 41.  The model assumed that 80% of the 
cohort presented with fatty liver, 15% with cirrhosis, 22% with pancreatisis and 1% 
with liver cardiomyopathy when entering the model.  Disease progression was 
modelled using a Markov chain with probabilities of progression/regression between 
the states being derived from a literature search.  Only direct medical costs were 
considered. 
 
Palmer et al. developed a separate Markov model for each significant disease state 
(liver disease, gastrointestinal, alcoholic cardiomyopathy and other complications to 
include suicide and accidental death).  The results in Table 7.3 showed lifetime costs 
per patient of £15,244 for the acamprosate group, saving £524 per patient in 
comparison to the placebo group. 
 
Table 7 - 3  Lifetime costs per patient 
 DEM £ 
Group with 
acamprosate 
48,245 15,244 
Placebo group 49,907 15,768 
Difference 1,662 524 
 
From a baseline of 41 years, life expectancy increased from 14.70 to 15.90 years with 
acamprosate, a life year gain of 1.2 years, equivalent to a gain of 0.52 years when 
discounted at 5% per annum.  
 
7.4.6 Annemans et al. model 
 
Annemans et al. (2000) used a Markov model to investigate flows of patients through 
different alcohol related treatments, and compared the cost-effectiveness of 
acamprosate in preventing alcohol relapse, in comparison to no pharmacological 
treatment, over a 24-month period and from the Belgian health care perspective.  Only 
direct medical costs were used and these were sourced from official statistics and a 
survey of GPs. 
 
A Markov model was developed to model the movement of patients between six 
different health states. The six states were: 
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· Community follow-up after detoxification  
· Community detoxification 
· Hospital detoxification 
· Hospital follow-up after detoxification 
· Lost to follow-up 
· Death. 
 
Relapse rates were taken from a placebo controlled prospective trial of 448 patients in 
Belgium, whilst details of treatment following relapse were taken from an 
unpublished Belgian study.  Effectiveness of inpatient and outpatient detoxification 
was taken from Hayashida (1989) who compared 87 outpatient and 77 inpatient 
detoxifications, which showed a 66% success rate for outpatients compared with 81% 
for inpatients. 
 
The data were entered into the Markov model and the costs of treatment and future 
health care costs applied.  The model then predicted how the average patient would 
progress through the time window of 24 months. 
 
In the Annemans model the expected cost of the acamprosate strategy, to include drug 
costs, was 211,986 BEF (£3,193) compared to 233,287 BEF (£3,514) for the placebo.  
Although the cost of acamprosate treatment over the 24 month period was 34,712 
BEF (£522) compared to no cost for the placebo population, cost savings through a 
lower rate of acute hospitalisation, lower long term hospitalisation and fewer liver 
complications resulted in a net cost saving from treatment of around 213,100 BEF 
(£320) per patient. 
 
The sensitivity analysis included adjusting several of the unit costs.  The authors 
reported that the cost of acute hospitalisation would need to be 50% lower than in the 
model before the acamprosate treatment ceased to be cost saving. 
 
The authors conclude that if 30% of patients reporting to their GPs with an alcohol 
problem were to be detoxified and started on acamprosate the total net saving would 
be 220 m BEF (£3,314,139) over two years. 
 
7.4.7 Merck model 
 
PH Consulting developed a hybrid of the Schadlich & Brecht and Annemans et al. 
models to investigate the effectiveness of managing alcohol abuse through 
acamprosate.  Dr A Walker added Scottish cost data to the PH Consulting model.  The 
new model, ‘the Merck model’ and its results formed the main submission by Merck 
Lipha to HTBS as part of the HTA process (Walker, 2001). 
 
The Merck model (Walker, 2001)adapted some of the data inputs applied in the 
Schadlich & Brecht model for Scottish conditions.  For example, Scottish hospital bed 
costs were applied to German hospital bed stay days for the four diseases of alcoholic 
psychoses, alcoholic dependence syndrome, acute alcoholic hepatitis and liver 
cirrhosis.  The Merck model removed any resource costs for in-patient rehabilitation 
because, according to the author, a Scottish patient care pathway seldom makes 
provision for such care.  The author also noted that he used German epidemiological 
data because no Scottish epidemiological data were available. 
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The Merck model applied abstinence rate data from one German and one Austrian 
study (Sass, 1996);(Whitworth & Fischer, 1996). The abstinence rates applied are set 
out in Table 7-4. 
 
Table 7 - 4  Abstinence rates after 24 months 
 
The Merck model did not include data from the UK trial on acamprosate undertaken 
by Chick et al. (2000).  The Merck report stated that this study was not included 
because the trial placed patients on acamprosate with some delay following 
detoxification, which is inconsistent with the protocol.  The latter specifies that the 
drug should be used as soon as possible after detoxification.  The Chick et al. trial did 
not find any difference in abstinence rates following the use of acamprosate in 
comparison to the standard baseline treatment.  
 
The Merck model allowed for short-term savings from reduced community and 
hospital follow-up and reduced detoxification costs adapting the different care 
pathways from the Annemans et al. study of a Belgian trial of 448 patients 
(Annemans et al., 2000).  
 
The results of the Merck model are set out in Table 7-5. 
 
Table 7 - 5  Mean cost-effectiveness of acamprosate (1,000 patients) 
 
 £000 
Cost of acamprosate 373.7 
Short-term savings from reduced detoxification (186.6) 
Long-term savings from avoided disease conditions (537.0) 
Net cost saving (349.9) 
Cost saving per marginal abstinent patient*          1.841 
*Number of additional abstinent patients = 190 
 
The Merck model concluded that, under the base case assumptions, to include the 
clinical effectiveness of acamprosate, there would be cost savings to the NHS of using 
the drug.  These cost savings, resulting from avoided repeat detoxifications and fewer 
incidences of liver and mental health diseases exceeded the initial cost of prescribing 
the drug.  
 
 
 
 
                                                 
‡ This study is also used by Schadlich and Brecht in their model 
 Acamprosate Placebo 
Sass ( n=104)‡ 39% 17% 
Whitworth  (n=148)     11.9%      4.9% 
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7.5 Summary of Results 
 
The results of the four models are summarised in Table 7-6 below. 
Table 7 - 6  Summary of results from economic models 
Study  Cost saving per patient from acamprosate £ 
Schadlich & Brecht     823 
Merck     1,841 
Annemans      320 
Palmer       524 
 
The Merck model realised the greatest savings because it aggregated the effects found 
by Schadlich & Brecht and Annemans and assumed all the benefits could be 
attributed to one application of the drug. 
 
 
7.6 Model Limitations 
 
Models can be validated by considering how well each model performs in respect of 
three major groups of attributes; these being structure, data and validation (ISPOR, 
2001).  ISPOR set out 13 attributes concerning model structure, 17 concerning data 
identification, data modelling and data incorporation and six validation attributes.  
This economic evaluation has not rigorously examined each model for each key 
attribute.  Rather the limitations notified by the original authors and by others 
critiquing the studies, for example in the Scottish Executive report on alcohol misuse 
(Ludbrook et al., 2001), have been noted.  
 
The limitations that apply to all the above models include: 
 
· The assumption that abstinence rates are maintained at the value observed at 
the end of the trial period 
· Lack of clarity about the definition of the abstinence outcome  
· The exclusion of benefits relating to an end point of controlled drinking 
(which itself will reduce morbidity and mortality) 
· The model specification of  ‘lost to follow-up’ and incomplete disease states 
· The use of average costs determined for insurance or administration 
purposes  
· The absence of opportunity costs and non-medical costs relating to crime, 
accidents, productivity etc. 
· The absence of good incidence data for disease states and death 
· The application of data from different sources and often different countries 
into the same model with no correction for these differences  
· The absence of observed probability distributions around costs and 
epidemiology data 
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· The exclusion of trial data that shows no significant difference in the 
abstinence rates following the adoption of  acamprosate (Chick et al., 2000) 
and Roussaux (1996) and 
· The absence of any revealed preference data. 
 
More research is needed in particular to provide: 
· more definitive estimates of the long-term effectiveness of the acamprosate 
therapies; 
· on the incidence and prevalence of alcohol related diseases and 
· on the relevant Scottish costs of these diseases.  
 
 
7.7 Proposed Economic Model 
 
This economic evaluation adopts the Schadlich & Brecht model, which provides a 
simple but useful approach to structure the evidence on clinical and economic 
outcomes.  
 
Currently the Schadlich & Brecht model only seeks to measure the marginal costs and 
outcomes of adopting acamprosate as an adjunct to conventional psychosocial therapy 
in comparison to adopting only the conventional therapy.  This economic evaluation 
will extend the analysis to consider the changes to costs and outcomes following the 
adoption of other pharmacological and psychosocial therapies including: 
 
· Naltrexone 
· Disulfiram 
· Coping Skills 
· Classical Relapse Prevention 
· Behavioural Self Control Training 
· Motivational Interviewing 
· Marital/family therapy 
 
The proposed model will have many of the limitations identified above.  The 
implications of these limitations are addressed in the Discussion section of this 
chapter. 
 
In particular the costings will be from an NHSScotland viewpoint rather than a 
societal perspective.  This limitation has, in part, been addressed by the quantification 
of the societal costs from the Catalyst Economics report for the Scottish Executive 
(Catalyst Health Economics Consultants Ltd, 2001).  However the assumption will 
result in an understatement of costs, omitting to capture costs incurred in private 
sector hospitals and rehabilitation services. 
 
Most costs in the economic model are average costs collected for administrative 
purposes and thus include non-marginal components such as overheads.  However, 
given the long-term perspective of the economic evaluation, this may be a reasonable 
approximation to long run marginal costs (see next section). 
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No revealed preference data is available to enable the model to be enhanced to 
measure outcomes in terms of QALYs.  A study by Patience et al. (1997) did report 
data from a study of  212 patients who had contacted an alcohol problem clinic at the 
Royal Edinburgh Hospital 12 months previously.  The report explained that the results 
of an Alcohol Related Problem Questionnaire could be used to map drinking 
behaviour onto a quality of life score (SF-36) and act as an indicator of resource costs. 
(In essence, the lower the score, the higher the resource cost and the lower the quality 
of life.)  The study concluded that the questionnaire could be used in a clinical setting 
to predict future costs and act as a marker for quality of life. 
  
The Merck submission noted that a literature search found no utility or QALY 
measurements for alcohol related health states (Walker, 2001).  The author used the 
SF-36 data obtained from the study by Patience et al. and used the SF-36 scores as 
utility scores.  This approach has significant shortcomings including the fact that the 
SF-36 measures do not explicitly incorporate preferences.  
 
One report of a potential technique to move from observed SF-36 scores to utility 
scores has recently been published. Brazier et al. (2002) simplified the SF-36 scoring 
system into 249 health states and then asked 836 members of the public to rank and 
value states.  The resultant preferences were incorporated into a least squares 
regression model and various data transformations applied.  The results indicated that 
the approach adopted by Brazier et al. may offer a method of analysing existing 
quality of life scores, for example SF-36 scores, to generate QALYs.  However, as the 
paper notes, this research is at a very early stage.  
 
The research by Brazier (2002) offers a potentially promising methodology to 
estimate preference weights from health related outcomes.  However, the 
methodology is not proven and further work is needed before it may be possible to 
transform SF-36 scores to a preference based utility measure.  Thus, in the absence of 
observed or estimated data on utilities, it will not be possible to include utility 
measures or QALYs within this economic evaluation. 
 
 
7.8 Costings for the economic model  
 
Costing for economic evaluations should identify, measure and value all resource 
changes that occur as a certain health intervention is carried out.  The categories of 
costs identified by Brouwer, Rutten and Koomanschap in Chapter 4 of the book by 
Drummond & McGuire, (2001) are: 
 
Due to the perspective adopted, a subset of the cost groups identified in Brouwer, 
Rutten and Koomanschap in Chapter 4 of the book by Drummond and McGuire 2001 
need to be quantified: 
 
· Medical resources directly needed for the intervention 
· Future medical costs that are a consequence of the intervention 
 
Brouwer et al. explain that the decision on whether to use marginal or average cost 
depends on the research question.  They note that when longer-term cost 
consequences are being considered then average costs may be more appropriate 
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because many cost items that are fixed in the short-term may become variable in the 
long term.  The authors also state that, in general, the resources used should be valued 
at their opportunity costs, being the value of their best alternative use.  This will 
usually be the observed price where there are competitive markets but in health care 
there is often no market price that reflects the opportunity cost. 
 
This economic model requires two major categories of costs, namely the costs of the 
alcohol relapse prevention therapies and the disease related costs.  This section 
explains the method used to estimate each category. 
 
7.8.1 Cost of pharmacological therapies  
 
Patient pathways for the treatment programmes of acamprosate and disulfiram are set 
out in Figure 7-2 and Figure 7-3 were provided by a TSG member (Ms C Keogh, 
Consultant Clinical Psychologist, Personal communication, 17 April 2002).  No 
naltrexone patient pathway has been found.  Following discussions with Board 
Members (Board Meeting, 27 May 2002) it is assumed to be the same as Disulfiram 
but excluding supervisory requirements. 
 
The resource units, unit costs and total costs of the three drug treatment programmes 
are contained in Tables 7-7 and Table 7-8 and summarised in Table 7-9.  The 
resources used are derived from the patient pathways.  All patients receiving 
acamprosate are assumed to have a 30 minute consultation with a consultant level 
alcohol counsellor.  This assumption may not fit in with some parts of the Scottish 
service pattern where initial visits are not with a consultant level counsellor.  
Sensitivity tests assume a lower grade staff member conducts the initial interview.  
 
 
Table 7 - 7  Resource uses and costs: Acamprosate 12 months treatment per 
patient May 2002 prices 
Resource Unit cost 
£ 
Total costs 
 £ 
Source of costings 
15 min GP consultation 15.33 15.33 NHSScotland  
30 min consultant alcohol 
counsellor 
  8.72   8.72  Keyworker £25.59k + 20% & 
1760 hours p.a (NHSScotland) 
1st appointment 52.50 52.50 NHSScotland  
2nd & 3rd appointment 15.33 76.65 As above 
Monthly appts CPU then Dr    
90% at 6 tablets per day 
10% at 4 tablets a day 
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Table 7 - 8   Resource uses and costs: Disulfiram and Naltrexone 6 months 
treatment per patient  May 2002 prices 
Resource Unit cost 
£ 
Total costs 
 £ 
Source of costings 
15 min GP consultation 15.33 15.33 NHSScotland  
30 min keyworker    8.72   8.72  Keyworker £25.59k + 20% & 
1760 hours p.a (NHSScotland) 
Medical & bloods 52.50 52.50 NHSScotland  
5 monthly GP visits 15.33 76.65 As above 
Week 1 visits to APTU  4.36 30.52 As above 
6*15min per month keyworker  4.36 26.17 As above 
Blood test +check-up month 1 30+14.6 46.83 NHSScotland  
25 weeks @ 3 per week 10 min 
supervision§  
 1.36 per 
dose 
107.39  
Disulfiram tablets 
25 weeks @ 6 tablets per week + 1 
week at 8 tablets 
18.38 for 
50 
55.53 BNF 43* March 2002 + 5% 
dispensing on-costs 
Naltrexone tablets 
Naltrexone daily dose 50 mg 42.51 for 
28 
290.14 BNF 43* March 2002 + 5% 
dispensing on-costs 
 
 
Table 7 - 9  Total costs for three drug treatments per patient 
Total Costs £  
Mean Low High 
Acamprosate  12 month treatment period 538 419 645 
Disulfiram       6 month treatment period 337(a) 315 425 
Naltrexone      6 month treatment period 547 525 630 
 
The high and low costs are used in the sensitivity analysis.
                                                 
§ Assume supervision at home or at APTU has same cost based on opportunity cost of £12,000 pa 
*(British Medical Association (BMA) & Royal Pharmaceutical Society of Great Britian (RPSGB), 
2002) 
(a) if 80% supervision at home with nil cost 
Resource Unit cost 
£ 
Total costs 
£ 
Source of costings 
 
15 min GP consultation 15.33 15.33 NHSScotland  
30 min consultant alcohol 
counsellor  
22.96 22.96 Av salary £67.34k +20% payroll 
costs:1760 hrs (NHSScotland) 
1st  appointment  19.69 19.69 Keyworker £25.59k + 20% & 
1760 hours p.a (NHSScotland) 
2nd & 3rd appointment 14.58 29.16 As above 
Monthly appts CPU then Dr 4.36:15.33 67.80 As above 
90% at 6 tablets per day 
10 % at 4 tablets a day  
£28.92  
for 168 
382.65 BNF 43  March 2002 + 5% 
dispensing on-costs 
Total Costs Acamprosate  537.59  
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1 month script 
1 month script 
1 month script 
Monthly scripts 
 
Figure 7 - 2  Patient Pathway: Acamprosate - 12 month Treatment Programme 
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Figure 7 - 3  Patient Pathway: Disulfiram - 6 month Treatment Programme 
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+In addition to the NHSScotland costs, there may be patient costs to include travel 
and incidental costs of supervision for disulfiram users.  Such costs have been 
excluded in the base case but are modelled in the sensitivity analysis. 
 
7.8.2 Cost of psychosocial therapies 
 
Following discussions with a TSG member (Ms C Keogh, Consultant Clinical 
Psychologist, Personal communication, 17 April 2002) and Ms M O’Sullivan, (Day 
Hospital Manager, Alcohol and Drug Directorate, Parkhead Hospital, Personal 
communication, 13 May 2002) it was decided that the costs of delivering a training 
programme for psychosocial therapies vary with the structure and duration of the 
course, rather than course content.  
 
Costings for psychosocial therapies have thus been developed for three different, but 
commonly used, training courses being: 
(a) a six week course of 1 two-hour session per week, with follow up at 3 and 6 
months;  
(b)  a daily course for four weeks with each session of one and a half hours 
duration; and  
(c)  ten hourly one-to-one sessions.  
 
An allowance for supervision is included in the costings for all the courses since such 
a function is regarded as essential to ensure standards are maintained and the course 
complies with ‘best practice’ as defined for that location.   
 
The first course format is used in several parts of Scotland and is based on a 
programme devised by Annis et al. (1996).  This course is delivered at weekly two-
hour sessions (one and a half hour’s group work + 30 minutes for one to one work), 
for groups of 8-12, for some six weeks, with three month and six month follow up. 
Initially invitations go to some 16 potential participants. 
 
The costed staff input is: one psychologist (although other parts of Scotland use 
different levels of professional input), one CPN and one trainee/student for three 
hours on a weekly basis.  The costs assume 1 hour for set up, travel time, 
administration and a supervisory element per session.  The accommodation costs are 
assumed to be £15 per session to hire a community hall for 3 hours plus £5 
administration costs. 
 
The second course costed is over  4 weeks, providing one and a half hours group work 
plus a half-hour set-up, admin and supervision time (ie two hours) per day, five days a 
week, with two further follow-ups of the same duration.  This course is delivered to 
groups of 8-12 by a mix of staff to include F and E grade nurses, a senior occupational 
therapist, together with consultant level support.  It is assumed initial invitations are 
issued to 16 with some 12 attending the first session.  The accommodation costs of 
£550 per course are calculated by applying the relevant rates from ‘Scottish Health 
Service Costs’ to an area of 100 m2. 
 
The third option costed is one-to-one training for ten hours, (15 hours if including 
preparation, administration time and some supervisory element) with a grade G nurse.  
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No marginal accommodation costs are included for this option because it is assumed 
accommodation provided for other purposes will be usable at nil additional cost. 
 
All course materials are assumed to cost £10,000 to produce and to be used for 5 
years.  This has been annualised using the 6% financial discount rate, to yield a cost 
per person is £5.  Admin costs are assumed to be £10 per invited attendee.  
 
The costs per course for the three models are summarised in Table 7-10. 
 
Table 7 - 10  Costs of psychosocial courses 
 Model a 
£ 
Model b 
£ 
Model c 
£ 
Staff 1,778 1,688 262 
Accommodation  
(non-residential) 
   160    550     0 
Admin & manual    303    305   15 
Total 2,241 2,543 277 
Cost per attendee  £187 to £280 
(8 or 12 attendees) 
£212 to £318 
(8 or 12 attendees) 
277 
 
These costs are all reasonably similar with the main determinant being number of 
attendees and the drop out rate.  To avoid spurious accuracy all the psychosocial 
courses have been assumed to have a mean cost of £250 per person, with sensitivity 
analysis assuming a high and low cost of £150 and £350 per person. 
 
7.8.3 Costs of disease 
 
The epidemiology of alcohol dependent patients and the resultant incremental disease 
cases, in comparison to the general population, has been discussed in Section 3.20.  
This section predicted disease cases over 20 years in a base case of 45-year-old men 
and women who are alcohol dependent, in comparison to the general male and female 
population.  The results are tabulated in tables 7.11 (a) and (b). 
 
Table 7 - 11 (a)  Estimated Disease Cases - Men 
 Alcohol Dependent Non-alcohol dependent 
Death to include suicide               936               318 
Stroke 43  (26) 33  (18) 
Cancer 88  (53) 97  (50) 
Cirrhosis 102  (72) 10   (6) 
Alcoholic psychoses  571  (403)                  - 
Chronic pancreatitis 44  (31)                  - 
Epilepsy 41  (29)                  - 
Alcohol dependence 
syndrome 
814  (575)                  - 
(discounted at 6% p.a.) 
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Table 7 - 11 (b)  Estimated Disease Cases 2 
 Alcohol Dependent Non-alcohol dependent 
Death                785 268 
Stroke  53  (31)                      33  (18) 
Cancer 146  (93)                    125  (73) 
Cirrhosis  52  (35)                        4  (3) 
Alcoholic psychoses 160  (107)                        - 
Chronic pancreatitis 32  (22)                        - 
Epilepsy 50  (34)                        - 
Alcohol dependence 
syndrome  
260  (175)                        - 
(discounted at 6% p.a.) 
 
The economic evaluation uses these diseases as end points for the economic model.  
The model attributes costs to each of the end points except death.  However it is 
important to note that avoidance of death is the major benefit from preventing relapse.  
 
The cost of each disease other than stroke has been estimated using data extracted 
from the Scottish medical records held by ISD.  This Division provided: 
 
· mean treatment inpatient days in Scottish non-psychiatric hospitals, mental 
illness hospitals and psychiatric units for each relevant disease 
· mean cost per inpatient day in the following speciality groups: 
Ø general psychiatry 
Ø medical 
Ø general practice 
Ø radiotherapy. 
 
Each disease other than stroke was mapped to a speciality for costing purposes; for 
example all liver related diseases were mapped to the medical group.  The ISD data 
showed that some patients with diseases such as alcohol dependence had episodes in 
general psychiatric and non-psychiatric units.  The costings used a weighted average 
of the costs for these units with the weights being relevant in-patient episodes.  All 
patients were assumed to have six GP appointments, thereby adding some £90 to the 
disease costs. 
 
No rehabilitation costs are included in the disease costs.  The same assumption was 
used in the Merck model because in Scotland there is little provision for such 
rehabilitation services (Dr PJ Jauhar, Clinical Director, Greater Glasgow Primary 
Care Trust. Personal communication). 
 
The cost of stroke was obtained from a study of Scottish Borders stroke patients 
(Syme et al., 2002).  The mean value of £5,000 is some 3% lower than the average 
number of inpatient days costed at a medical unit mean cost of £257 per day.  The 
lower figure may be more appropriate since some of the stay will be in rehabilitation 
wards at a lower unit cost.   
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The uncertainty around the costs is expressed in a sensitivity analysis.  High and low 
costs for each disease were obtained using semi-interquartile values of the hospital 
related costs.   
 
Table 7-12 gives the average inpatient days and mean, high and low cost per hospital 
day for each relevant disease group. 
 
Table 7 - 12  Average in-patient days and costs by disease 
Costs £  
Disease 
In-
patient 
days 
Low Mean High 
 
Alcoholic dependence 
syndrome 
 
16.31 
 
2,571 
 
2,897 
 
3,219 
 
Alcoholic psychosis 
 
44.37 
 
7,216 
 
8,131 
 
8,893 
 
Liver cirrhosis 
 
11.97 
 
2,807 
 
3,165 
 
3,517 
 
Epilepsy 
 
3.70 
 
651 
 
726 
 
798 
 
Chronic pancreatitis 
 
5.00 
 
1,223 
 
1,373 
 
1,520 
Cancer weighted average; 
Men 
 
8.56 
 
2,819 
 
3,301 
 
3,696 
Cancer weighted average; 
Women 
 
7.32 
 
2,425 
 
2,836 
 
3,172 
 
Stroke 
 
20.90 
 
4,500 
 
5,000 
 
7,000 
 
 
The cohort used in the modelling assumes a ratio of four males to every one female in 
the population.  This ratio was observed in the Copenhagen City Heart Study 
discussed in section 3.20.9.3.  
 
As explained in section 3.20.7, alcoholic psychosis aggregates several separate 
conditions to include withdrawal, psychotic disorder and amnesic syndrome due to the 
use of alcohol (ICD codes F103 to F107).  Two codes, F106 alcoholic amnesic 
syndrome, to include Korsakov’s syndrome and F107 residual and late onset 
psychotic disorder, to include alcoholic dementia and chronic alcoholic brain 
syndrome, account for just over one third of the number of patients discharged  
in this group but some 90% of the related inpatient stays. 
 
Indeed in 2000/01 the mean stay for patients coded to F106 as a primary diagnosis 
was over 572 days.  Assuming a cost per inpatient week for general psychiatry care of 
£1,210, (the 2000/01 level updated by 5 % ){Scottish Health Service Costs 2000/01} 
then the cost per inpatient with such a disorder is almost £100,000. 
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7.9 Discounting  
 
Individuals and society exhibit behaviour that indicates they have a positive rate of 
time preference (Drummond et al., 1997).  Thus most people prefer to have benefits 
today rather than at a later date and to defer costs for as long as possible.  It is 
important in economic evaluation to adjust the cash flows associated with costs and 
benefits over time to take account of this time preference effect.  This enables 
decision makers to compare alternative treatments over any time horizon.  
 
In line with HTBS’s Guidance to Manufacturers (Health Technology Board of 
Scotland, 2002) costs will be discounted according to the UK Treasury discount rate 
(currently 6.0%).  
 
 
7.10 Effectiveness  
 
Analysis of the cost-effectiveness of therapies for prevention of relapse in alcohol 
requires estimates of the proportion of patients in whom treatments will be effective.  
The estimates of the effectiveness of the therapies are taken from sections 5.5 to 5.6 
of this report.  That section explained that the effectiveness of the pharmacological 
treatments are based on placebo controlled or no-treatment controlled trials but the 
evaluations of psychosocial therapies are based on a more heterogeneous selection of 
trials.  Most of these included a treatment arm in which the therapy was thought likely 
to have little or no effect and this is used as the comparator arm when available.  
However, other trials included therapies thought likely to be less effective but not 
necessarily ineffective.  These have also been included and thus it may be that 
psychosocial therapies effects will be somewhat underestimated.  Psychosocial 
therapies are also poorly standardized in content and duration and cannot be blinded 
which allows the possibility of many other sources of heterogeneity and bias. 
 
The proportion of patients in whom treatment is successful may be expressed either as 
those in a controlled drinking state or as those totally abstinent.  Furthermore, these 
figures are reported at different time points in different studies.  Thus combining these 
outcomes can be difficult.  The strategy used has been to extract figures for controlled 
drinking where presented and figures for abstinence otherwise.  The analysis used 
works in terms of odds ratios – in the hope that these will vary less than absolute 
values over time – and chooses times of follow-up as close to 1 year as possible.  
However, due to limited duration of many trials, follow-up may often be only three 
months. 
 
In order to make valid comparisons of treatments it is necessary to choose a single 
baseline value of the probability of success when no treatment is given and refer all 
the treatment effects to this value.  The observed proportions of successes in placebo 
or no-treatment arms varied widely over the therapies examined.  Figures between 
15.5% and 37% were found.  The following figures are referred to an intermediate 
figure of 25%. 
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Table 7 - 13  Effectiveness estimates using odds ratios 
 
Therapies  Odds Ratio Success 
per 
1000 
Failed  
per  
1000 
 
Success  per 1000 
    (low 
estimate) 
(high 
estimate) 
Standard treatment 1.0 250 750   
Pharmacotherapy       
Acamprosate 1.74 (1.48,2.04) 367 633 331 405 
Naltrexone 1.41 (1.18,1.69) 320 680 283 361 
Disulfiram 1.31 (0.82,2.09) 304 696 215 411 
Psychosocial      
Coping Skills 2.29 (1.44,3.64) 433 567 325 548 
Classical Relapse 
Prevention 
1.10 (0.69,1.76) 268 732 188 370 
Behavioural self 
control training 
1.84 (1.04,3.25) 380 620 258 520 
Motivational 
Interviewing 
2.16 (1.20,3.88) 419 581 286 564 
Marital/family 
therapy 
1.87 (1.33,2.64) 384 616 307 468 
 
The low and high estimates are obtained from the upper and lower limits of the 95% 
confidence interval.  
 
Various other therapies were considered in the clinical effectiveness analysis but 
treatment effects were not included. These include: 
 
Brief Therapies. Strong evidence suggests that brief therapies do not work in the 
class of alcohol dependent patients considered in this HTA.  This contrasts strongly 
with the results in alcohol abusing patients where such measures appear effective. 
 
Cognitive Behavioural Therapy. This does not appear to be a single well defined 
therapy in treatment of alcohol problems. 
 
Anxiety Management. Some evidence suggests that this is a useful therapy in 
alcohol dependent patients with anxiety.  However, its effect is to reduce anxiety and 
appears unrelated to reduction of alcohol intake. 
 
Alcoholics Anonymous.  Section 5.8.1 explains that there is some evidence to 
suggest that the treatment philosophy of the AA is successful but that more high 
quality randomised trials are required.  For an economic evaluation conducted from 
the NHSScotland perspective, the use of AA should be encouraged.  Such therapies 
are costless to NHSScotland at point of delivery and could be cost saving in the 
longer term through the associated reduction in the incidence of diseases.  
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Some points that should be borne in mind in applying the effectiveness figures are: 
 
1. The figures for disulfiram are obtained from studies of oral disulfiram only.  
2. It has been noted that the effectiveness of disulfiram may depend strongly on 
the degree of supervision exercised over those taking it. This has not been 
incorporated into the analysis. 
3. In most studies of pharmacotherapy, patients in both arms of the trial received 
some psychosocial therapy.  
4. Psychosocial and pharmacological therapies should not be treated as 
competing.  The design of the trials of pharmacotherapy gives every reason to 
believe that some additional effect can be obtained by adding pharmacy to 
psychotherapy. 
5. Family/Marital therapy is only occasionally feasible as the consent of the 
patient and the availability and cooperation of family are required.  Thus it 
should not be regarded as a competitor treatment to the other psychosocial 
therapies but as an occasional addition. 
6. ‘Classical Relapse Prevention’ is included despite rather poor performance in 
trials as it is an option that many experts consider viable and hence should be 
evaluated.  It may be that the available trials underestimate its effectiveness as 
many use comparators, which may themselves be effective.  However, 
experimental justification of its use appears somewhat lacking at present. 
7. The effectiveness of acamprosate currently requires review as a large US trial, 
as yet unpublished, has recently reported disappointing results.  Some 
adjustment for this fact has been made in the estimates in this report.  It is 
hoped exact results will be available before the final report is published. 
 
 
7.11 Economic model  
 
The economic model is a simple treatment model constructed in Microsoft Excel. A 
cohort of 1000 patients is assumed to enter each of the eight therapies: three 
pharmacological therapies and five psychosocial programmes.  Figure 7-4  shows how 
the range of treatments is compared to the standard care package, with costs and 
consequences associated with each. 
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Figure 7 - 4  A basic economic evaluation 
 
 
The results are presented as an incremental cost effectiveness analysis of the treatment 
over and above the ‘standard treatment’ scenario.  The pharmacological therapies 
used in the model are provided as an adjunct to the standard treatment, for example 
acamprosate is provided in addition to a standard care package.   
 
The incremental cost effectiveness ratio is calculated as follows: 
 
Costs A -  Costs B         ICER       = 
Consequences A -  Consequences B 
 
Patients are assumed to enter one of two arms of a basic decision tree following 
compliance with the treatment programme.  The ‘successes’ become non-alcohol 
dependent whilst the ‘failures’ continue as alcohol dependent.  This is shown in 
Figure 7.5. 
 
Figure 7 - 5  Alcohol dependent and non-dependent outcomes in the model 
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Patients then experience a range of disease endpoints being death, stroke, cancer, 
cirrhosis, alcoholic psychoses, chronic pancreatitis, epilepsy and alcohol dependence 
syndrome.   
 
 
7.12 Results 
 
The effectiveness of standard treatment is taken as 250 successes and 750 failures per 
1000 patients, and therefore the effectiveness of each therapy is calculated by 
examining the number of successes over and above that of standard treatment.   
 
For each therapy, the number of disease endpoints is multiplied through by the disease 
costs per case for both the therapy and the standard treatment package.  The change in 
disease costs over and above standard care are calculated and presented both 
discounted at 6% and also undiscounted for a range of therapies in Table 7.14.  The 
Table also presents the net change in health care costs when the cost of the therapy is 
deducted. 
 
An estimate of the additional patients abstinent when each treatment is assessed in 
comparison to standard care is combined with these estimated costs to calculate the 
cost per additional abstinent patient.  Estimates of the number of deaths averted are 
presented in addition to the cost per change.  It should be noted from the Table that a 
negative cost represents a cost saving. 
 
When discounted at 6%, four of the five psychosocial therapies (Coping 
Skills, Behavioural Self Control Training, Motivational Interviewing and Marital and 
Family Therapy) demonstrate net health care cost savings ranging from £584,824 
(coping skills) to £343,044 (Behavioural Self Control Training).  
 
 For the pharmacological therapies there is a net economic cost associated with a 
cohort using acamprosate of £4,260 rising to  £227,668 for naltrexone. Acamprosate 
is the most cost-effective of the pharmacological therapies.  
 
Also presented are the net health care costs per death averted.  Using the discounted 
results, the range is from -£5635 (a net saving per death averted) for Coping Skills to 
£15,262 for Relapse Prevention.  Assuming that each death averted only saved one 
life year (a very conservative assumption) these costs per life year saved are lower 
than the equivalent rates for many of the recent products approved by NICE.  Indeed 
four of the psychosocial therapies actually show a net saving per life year gained. 
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Table 7 - 14  Results summary for 1,000 patients 
  Acamprosate  Disulfiram  Naltrexone
Coping
Skills
Relapse 
prevention
BSCT  Motivational 
interviewing
Family 
Therapy
Total Therapy Cost £538,000 £337,000 £547,000 £250,000 £250,000 £250,000 £250,000 £250,000
Change in Health Care costs (discounted) -£533,740 -£246,341 -£319,332 -£834,824 -£82,114 -£593,044 -£770,958
-
£611,292
Change in Health Care costs (undiscounted) -£752,054 -£347,102 -£449,947 -£1,176,290 -£115,701 -£835,616 -£1,086,301
-
£861,327
Net Health care cost over and above standard treatment 
(discounted) £4,260 £90,659 £227,668 -£584,824 £167,886 -£343,044 -£520,958
-
£361,292
Net Health care cost over and above standard treatment 
(undiscounted) -£214,054 -£10,102 £97,053 -£926,290 £134,299 -£585,616 -£836,301
-
£611,327
Additional patients abstinent over and above standard 117 54 70 183 18 130 169 134
Reduction in deaths over and above standard 70 32 42 109 11 78 101 80
Net Health care cost per death averted (discounted)  £61 £2,833 £5,421 -£5,365 £15,262 -£4,398 -£5,158 -£4,516
Net Health care cost per death averted (undiscounted) -£3,058 -£316 £2,311 -£8,498 £12,209 -£7,508 -£8,280 -£7,642
Cost per additional abstinent patient (discounted) £36 £1,679 £3,252 -£3,196 £9,327 -£2,639 -£3,083 -£2,696
Cost per additional abstinent patient (undiscounted) -£1,830 -£187 £1,386 -£5,062 £7,461 -£4,505 -£4,949 -£4,562
 
 
Note: Discount rate = 6% 
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7.13 Sensitivity Analysis 
 
The impact of uncertainty in any kind of economic analysis should always be explored to 
assess how the results change when different values for the input parameters are 
observed.  For the individual cost variables, measures of dispersion around the central 
case value are not available and hence it is not possible to provide probability 
distributio ns.  The cost variables have been expressed as mean, high and low values only.  
 
The following analysis is based on incremental discounted cost per additional abstinent 
patient, with the increment being the costs and consequences over and above standard 
care.  The model used consists of three main variables: the cost of treatment, the 
effectiveness of treatment and the disease cost consequences.  
 
Table 7.15 shows two extreme scenarios.  Scenario 1 is a ‘worst case’ scenario based 
upon the highest therapy cost, lowest therapy effectiveness and the lowest costs for 
averted diseases.  The incremental discounted cost per additional abstinent patient ranges 
from £617 for Coping Skills to £39,700 for Behavioural Self Control Training.  The 
disulfiram and Classical Relapse Prevention programmes are ‘dominated’, whereby the 
lower effectiveness estimate is below that of standard case, whilst the cost exceeds the 
standard care option.   
 
Scenario 2 represents a ‘best case’ scenario with the lowest treatment cost, highest 
treatment effectiveness and also highest cost of averted diseases.  In this case the range is 
-£303 (naltrexone) to -£4,236 (Motivational Interviewing) and there is a net health care 
cost saving from all of the therapies. 
 
Note that the scenario of delivery treatments in an inpatient setting in a dedicated ATU 
has not been explored.  This may be developed in a later draft.     
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Table 7 - 15  Incremental cost per additional abstinent patient (extreme scenarios) 
 Incremental cost per additional abstinent patient (discounted) 
Therapies Scenario 1:  Based on high 
therapy cost, lowest 
effectiveness and lowest 
disease costs. 
Scenario 2:  Based on 
low therapy cost, 
highest effectiveness 
and highest disease 
costs. 
Pharmacotherapy   
Acamprosate £3,913 -£2,329 
Naltrexone £15,041 -£303 
Disulfiram Standard treatment 
dominates 
-£3,076 
Psychosocial   
Coping Skills £617 -£4,194 
Classical Relapse 
Prevention 
Standard treatment 
dominates 
-£2,949 
Behavioural Self Control 
Training 
£39,700 -£4,107 
Motivational Interviewing £5,672 -£4,236 
Marital/family therapy £2,091 -£3,886 
 
7.13.1 Pair-wise sensitivity analysis 
 
Further sensitivity analysis was performed using a pair-wise approach using the 
incremental cost per additional abstinent patient over standard treatment (discounted at 
6%).  The three main variables of treatment cost, disease costs and treatment 
effectiveness are examined, holding two of the variables constant at the average values 
and using the extreme values of the third.  Negative estimates demonstrate net cost 
savings for the relevant therapy under the high/low conditions at the top of the column.  
 
The sensitivity analysis results show that under each of the different assumptions, the cost 
per additional abstinent patient is less than or equal to £2,080 for acamprosate, whilst 
naltrexone costs range from £366 to £12,014 per additional abstinent patient.   
 
Of the psychosocial therapies both Coping Skills and Marital/Family therapy result in net 
health care cost savings per additional abstinent patient for all of the possible pair-wise 
comparisons, indicating these results to be fairly robust.  Coping Skills is consistently 
more cost-effective than Marital/Family therapy.  The results for Behavioural Self 
Control Training show the therapies to be generally cost saving although the results are 
sensitive to the effectiveness estimates at the lower bound.  This is very close to the 
effectiveness of the standard care treatment.  Relapse Prevention shows the most 
variation in results by both effectiveness and treatment cost, although the high and low 
estimates of disease cost yield similar figures. 
 
Acamprosate is the most cost-effective of the pharmacological treatments except under 
the high treatment effectiveness assumption whereby disulfiram yields a greater saving 
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per abstinent patient.  However, under no assumptions were any of the pharmacological 
therapies more cost-effective than Coping Skills.  Naltrexone is generally found to have 
the lowest cost-effectiveness of the three pharmacological therapies except under the 
lowest treatment effectiveness assumption where disulfiram is the dominated alternative.   
 
It should be noted that the range of odds ratios for naltrexone and Relapse Prevention 
include 1.0, and therefore the effectiveness evidence may indicate that these programmes 
do not have a significant outcome when compared to standard treatment. 
 
The full results of the pair-wise sensitivity analysis are presented in Appendix 26. 
 
 
7.14 Comparison with alternative approaches to estimating cost-effectiveness 
 
The incremental cost per abstinent patient was also estimated using a decision tree model 
based on the Schadlich and Brecht study of acamprosate therapy in Germany .  The costs 
of treatment and local disease costs for Scotland, together with treatment efficacy, were 
substituted into the model.  In this case costs were discounted by assuming the German 
observed latent periods for a range of diseases (alcoholic psychoses, alcohol dependence 
syndrome, cirrhosis and hepatitis) and again the incremental cost-effectiveness over and 
above standard care was computed.  These estimates ranged from a saving of £1,643 
(Coping Skills versus standard care) to a cost of £13,991 (Relapse Prevention versus 
standard care).  The full results are shown in Table 7-16. 
 
These compare with a saving of £3,196 (Coping Skills) to a cost of £9,327 (Relapse 
Prevention) for the methodology described earlier.  The higher savings for the most 
effective therapies and lower costs for the less effective under the previous methodology 
can be explained by the inclusion of several more disease categories in the estimates. 
 
The figures follow a very similar ranking in terms of cost-effectiveness and also the 
estimated disease costs are similar despite being calculated by two very different models. 
 
Table 7 - 16  Results based on German decision tree model 
Therapies Incremental cost per additional 
abstinent patient (discounted at 6%) 
Pharmacotherapy  
Acamprosate £1,288 
Naltrexone £6,819 
Disulfiram £5,715 
Psychosocial  
Coping Skills -£1,643 
Classical Relapse Prevention £13,991 
Behavioural Self Control Training -£923 
Motivational Interviewing -£1,472 
Marital/family therapy -£960 
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7.15 Discussion 
 
The economic evaluation raises some interesting issues in two main areas being: 
 
i. the epidemiological and effectiveness assumptions; and 
ii. the resources used and the costs applied to each resource. 
 
This section will consider each of these areas and briefly discuss the interpretation of the 
results. 
 
7.15.1 Epidemiology and effectiveness  
 
Section 3.20 raises several methodological issues concerning the calculation of the health 
benefits from reducing alcohol relapse in a cohort of people who are alcohol dependent.  
A significant issue for the economic evaluation is the assumption that a person who does 
not relapse reverts to having the same health condition as a member of the general public.  
For example, there may be underlying psychological co-morbidities that would cause this 
assumption to overstate the beneficial effect of abstinence on a cohort of people with 
mental disorders and alcohol dependence.  Also, if the health of a person recovering from 
alcohol dependence is adversely affected by a history of heavy drinking then the health 
benefits used in the economic evaluation will be overstated.  However, no evidence or 
discussion of such aspects has been found from the literature search.  
 
The epidemiology does not provide evidence on how the recurrence of alcoholic 
episodes, after a period of abstinence following detoxification, affects disease incidence.  
Such data would enable the economic evaluation to model the cost-effectiveness of 
therapies for a cohort of patients who are in a cycle of abstinent periods for several years 
followed by an episode of alcohol dependence.  Such modelling may be more 
representative of observed events in the community than the model presented above.  
 
The economic evaluation has assumed that people who relapse are similar to those who 
do not relapse other than in respect of this one factor.  However, there may be inherited or 
environmental factors that give rise to alcohol dependence in the first place and these 
may also affect the effectiveness of the therapies.  If so, and the occurrence of these 
inherited or environmental factors is different in Scotland from their occurrence in the 
populations from whom the clinical effectiveness evidence in Chapter 5 is derived, then 
the results may not generalise to the Scottish setting.  
 
The odds ratio for each therapy is the parameter that has the greatest impact on cost 
effectiveness and the ranking of therapies.  The evidence used to calculate the odds ratios 
has been explained in section 5.6 and is primarily from reported randomised controlled 
trials.  However, the trial setting may differ significantly from the Scottish community 
setting.  For example, the entry criteria to trials could result in a sample that is atypical of 
the alcohol dependent population in Scotland.  Such a bias could affect the effectiveness 
recorded for the placebo group and the therapies under examination. If so, then the 
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absolute level of benefits used in the model may be overstated since all the odds ratios 
will be too high.   
 
The trials may also have a higher treatment compliance rate than is observed in the 
treated population because trial settings provide incentives to comply that do not exist in 
the community. This would result in an inflated odds ratio.  
 
Trials may also have fewer ‘lost to follow up’ than is seen in the community setting 
where the number of dropouts tends to be high.  Again, HTBS would welcome data on 
compliance and dropout rates in Scotland in order to refine the economic model. 
 
A further problem with trial data is that follow-up stops at 48 weeks or earlier for the 
pharmacological treatments and six month or earlier for the psychosocial treatments.  The 
effectiveness ratios assume the last observed effectiveness rate is maintained over time.  
This assumption is likely to overstate the benefits from the therapies since experience 
suggests that people do relapse after years of not drinking.  This is related to the earlier 
point that patients may cycle between abstinence and dependence and this is a key area 
where further research is required.   
 
Section 5.6 has explained that different trials have used different definitions of 
abstinence.  Thus it may be that there are some health related benefits from patients 
moving to controlled drinking but not abstinence that have not been adequately captured 
in the simple economic model.  
 
7.15.2 Resource uses and costs  
 
The costs of the psychosocial therapies are about £250 when costed on a short-run 
marginal cost basis.  However, if significantly more trained staff require to be recruited to 
meet the demand for alcohol relapse prevention services then there could be a step 
change in the level of fixed costs.  
 
The disease costs are calculated using inpatient length of stay in NHSScotland hospitals 
as the only measure of resource use.  This is likely to understate resource use.  For 
example, it does not capture outpatient use, rehabilitation provided in the community, or 
the use of long stay private homes by psychiatrically damaged patients who are 
discharged there and paid for by NHSScotland.  
 
The underlying assumption of the economic evaluatio n that patients do not cycle between 
abstinence and relapse means the resource use and costs of repeated detoxifications and 
interventions for relapse prevention are omitted from the economic model.  Thus the 
present model only captures longer-term effects.  It would be helpful to have estimates of 
the short-term benefits of preventing alcohol relapse, as measured by avoided community 
and hospital costs.  The data set required is the number of events such as community or 
inpatient detoxifications and other treatments per patient avoided as a result of permanent 
prevention of relapse.  This could be the next stage of the economic evaluation if data on 
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the events avoided became available.  The cost of detoxification in the community has 
been estimated as £290.  
 
The inpatient hospital costs used are from ISD who collate and publish cost information 
by speciality group (for example, by medical, general practice, general psychiatry).  
There are some 38 codes in total but these do not map easily to diseases.  However, the 
economic evaluation requires cost to treat of diseases.  Decision-making would be 
enhanced if Scottish costs were available by disease group, possibly using the ICD code 
that is currently used by ISD to record hospital and general practice events,  
 
The costings are also limited to the NHSScotland perspective.  They do not capture the 
patient or societal costs that could be avoided by preventing relapse.  The Catalyst report 
indicated that health care costs are less than 10% of the costs that alcohol imposes on 
society.  Whilst the ratio may be different for this sub-group of people with established 
alcohol dependence, taking the narrow health care perspective will undoubtedly lead to 
an understatement of the benefits from reducing relapse.  
 
The model has not sought to value death although the epidemiology indicates that 
reducing the death rate would be the biggest benefit from reducing alcohol relapse.  Other 
Government Departments, in particular the Department of the Environment and Transport 
have developed a methodology that values a life at about £800,000.  The economic model 
could be extended to include an annual saving per death avoided based on this capital 
sum.  However, this approach would be inconsistent with adopting the NHSScotland 
perspective and would raise issues of employment participation rates and the 
appropriateness of applying such a value to this cohort of the population. 
 
7.15.3 Interpretation of Results 
 
The economic evaluation has ranked therapies in terms of the incremental cost per 
abstinent patient.  This approach assumes the psychosocial therapies can be neatly 
categorised using the definitions applied within the HTA, which may not always be 
possible.  This approach could also be misinterpreted since it fails to recognise that 
different people will respond better to different therapies and it is thus important that a 
range of therapies are offered.  For example, not all patients, and possibly very few, can 
take advantage of a Marital/Family therapy.  
 
The costings did not indicate a systematic difference in the cost per person of providing 
group or individual training and the effectiveness is assumed to be the same under either 
approach.  However, this should not be interpreted as suggesting the courses are identical 
in terms of outcomes for individual patients; rather individual preferences will still be 
important when deciding whether a course should be on a one-to-one basis or in a group 
setting. 
 
Similarly the costings did not indicate a systematic difference in the cost per person of 
providing intervention in the community rather than a hospital setting, or as an in-patient 
rather than an out-patient or day-patient.  This is probably not true for all service 
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provision in Scotland and it will thus be important to review the costs for the decision 
maker’s own circumstances.  
 
 
7.16  Draft Recommendations 
 
The economic evaluation shows that Coping Skills, Motivational Interviewing, Marital 
and Family therapy and Behavioural Self Control training all result in positive net 
economic benefits.  That is the cost of treatment is more than offset by the savings in 
alcohol related disease treatment costs following the programme.  In these simulations, 
these four psychosocial therapies therefore dominate the pharmacological therapies and 
classical Relapse Prevention (i.e. the four therapies are cheaper and more effective). 
 
Of these four dominant therapies, Coping Skills generates the greatest cost savings per 
abstinent patient, whilst Behavioural Self Control Training has the lowest cost saving.  
However, the results for the four therapies are similar.  Of the pharmacological therapies, 
acamprosate is provided at the lowest economic cost of £36 per abstinent patient, whilst 
the most costly is naltrexone at £3,252 per abstinent patient.   
 
The Discussion section suggests that the effectiveness observed from the trials may not 
be appropriate for adoption in a community setting but no evidence is available to 
indicate the effect of the change in setting.  The Discussion also indicates that the 
potential savings may be understated.  Neither effect alters the ranking of the therapies, 
only their absolute cost-effectiveness.  
 
Under the worst-case scenario the incremental costs of acamprosate, Coping Skills, 
Motivational Interviewing and Marital/Family Therapy all have an incremental cost per 
additional abstinent patients of under £6,000.  This indicates that these therapies are 
likely to be cost effective unless new evidence emerges indicating the effectiveness in a 
community setting is considerably less than that reported under trials, or new trials report 
lower rates of effectiveness.  
 
 
7.17 Potential resource impact for NHSScotland 
 
At present, the analysis does not include costings of the potential resource impact for 
NHSScotland of implementing the draft recommendations.  This section summarises how 
we may take forward this aspect. 
 
HTBS will seek to establish a baseline of the present Scottish costs incurred to prevent 
alcohol relapse.  For example, ISD records show that the present annual costs for 
acamprosate and disulfiram are £318,021 and £162,208 respectively.  We are seeking 
data on the costs of psychosocial therapies across Scotland and the short-term costs of 
detoxification.  If obtained, these will form the baseline and the cost of implementing the 
draft recommendations will be compared to this baseline.  
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Using the epidemiology, we can estimate the number of people with acute alcohol 
dependence in Scotland.  So far, no evidence has emerged of the number of these who 
would accept treatment, although there is German evidence to indicate one third of 
patients with alcohol dependence may accept treatment (Schadlich & Brecht, 1998). 
 
Applying this rate will give the number of people who may be suitable for treatment in 
Scotland.  We will cost providing treatment to this sub-group for a range of therapies.  
 
The clinical effectiveness assumptions will be used to estimate the number of additional 
abstinent patients following the adoption of the therapy.  The epidemiological and cost of 
disease assumptions will be used to determine the number and cost of disease endpoints 
avoided.  The cost and savings will be presented as a cash flow over time.   
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8 ORGANISATIONAL ISSUES 
 
8.1 Summary 
 
The following points arise from consideration of the service structure and the 
requirements for effective service delivery.  They are primarily based on expert opinion. 
 
· Alcohol services are highly suited to ‘joint working’, as recommended by the 
Joint Futures Group, involving specialist mental health and social work 
addiction services and non statutory agencies with joint resourcing and 
management of community care services. 
 
· Certain subgroups such as young people, the homeless, those with co-morbid 
mental health problems, have special services needs and providers should ensure 
that the service is accessible to all. 
 
· Specialist services must make themselves aware of mutual help (AA) and non-
statutory agencies operating in their area and co-ordinate their approach making 
this information available to individuals under their care.  Introduction to AA 
and non-statutory agencies should be part of the overall relapse prevention 
strategy. 
 
· Controlled use of alcohol may be an appropriate treatment goal for those with 
less severe alcohol problems.  However, abstinence should be the goal for severe 
dependence, where controlled use is rarely sustainable and especially when there 
is evidence of alcohol related organ damage.  If controlled use / harm 
minimisation is the considered preferred goal of the individual there must still be 
options for intervention e.g. referral to a voluntary agency or outpatient 
motivational sessions. 
 
· An improved information collection system is required. (ISD are currently 
changing the way in which information is collected, for instance from GP 
contacts). 
 
· A regularly updated comprehensive directory of alcohol services would be 
beneficial.  This should be useable by all participating agencies and provide 
accurate outcome data (as recorded and analysed) as well as a greater 
understanding of progress through the treatment system. 
 
· More research and evidence are needed regarding the benefits of different 
settings for psychosocial interventions e.g. group vs. individual, inpatient vs. 
outpatient vs. day unit, intensity and length and frequency of sessions etc. 
 
 
 
-    -   145 
8.2 Introduction 
 
Providers of healthcare services require the clearest evidence available to provide cost-
effective specialist alcohol services, equitable with other services throughout Scotland 
and concentrating resources on improving delivery of treatments of proven efficacy.  In 
providing this service account must be taken of the particular problems involved in 
treating patients with alcohol dependence and of making best use of the available 
resources.  The main aims of relapse prevention are to support, motivate and encourage 
effective coping skills – medication is an adjunct to this.  
 
The complex and varied nature of the problems faced by alcohol dependent patients 
means that many agencies might be involved in their care.  A high level of coordinated 
integration must exist between statutory physical health, mental health and social care 
services and the voluntary agencies with local collaboration and implementation required 
to promote development of a logical and effective ‘treatment system’.  Attempt should be 
made to avoid overlap in treatment provision (and therefore waste and duplication) as 
much as possible.  Development of clear lines of referral from one service to another will 
be required. 
 
Bearing this in mind, individuals accessing the ‘treatment system’ note a desire for 
continuity in terms of those managing their care and therefore transition through the 
treatment system should ideally be managed retaining such continuity as far as possible.  
This may also encourage the avoidance of overlap in information gathering and 
interventions offered. 
 
In this respect alcohol services are highly suited to ‘joint working’, as recommended by 
the Joint Futures Group, involving specialist mental health and social work addiction 
services and non statutory agencies with joint resourcing and management of community 
care services. 
 
Shared care guidelines, based on national policy but locally determined, can be developed 
between specialists and GPs and Social Work teams.  These require sufficient flexibility 
to allow for the needs of a diverse range of patients. 
 
Certain subgroups such as young people, the homeless, those with co-morbid mental 
health problems, have special services needs and providers should ensure that the service 
is accessible to all. 
 
NHS specialist alcohol services should ideally be multidisciplinary community (and day 
hospital) based services with the opportunity of access to specialist inpatient care.  They 
should be made up of a highly skilled team that sees the most severe end of the spectrum 
of alcohol problems.  They should also provide supervision and training to all 
professionals in less specialised tiers of service. 
 
These specialist services should have the core principals of: confidentiality; accessibility; 
ongoing contact rather than time limited; holistic care; a supportive / non-judgemental 
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approach; the ability to tailor this approach to the individual; co-ordination with different 
agencies involved in helping those with alcohol problems (mental health, general 
medical, social, forensic); addressing the needs of other family members.  The specialist 
service should create the opportunity for individuals to engage in social and occupational 
activities.  
 
Services should be able to offer a comprehensive package of help whether through their 
own actions or integration with other agencies, which deal with employment issues, 
housing issues etc.  (Early liaison with Social Work services, housing services and debt 
counselling services may help in capitalising on the gains achieved through 
detoxification). 
 
Services from area to area need to show consistency and equity in the content of 
treatment offered, with interventions being given to centrally accredited standards and 
protocols, with equity of accessibility to the heterogeneous group which makes up 
alcohol users, with training of staff locally to agreed national standards (centrally 
accredited) and with the use of common assessment tools and outcome measures.  Staff 
should be well trained and closely supervised.  
 
Use of screening tools such as FAST (abbreviated version of AUDIT) in Primary Care 
settings (as per SIGN guidelines) may not be as appropriate to the specialist setting.  
Standardised assessment tools may none the less be drawn up for use between agencies. 
 
Outcome measures such as biological markers (e.g.  gamma GT and MCV) may be 
useful, if elevated initially, to use as markers of progress.  (However, in 20% of patients 
there will be no such marker to monitor (Scottish Intercollegiate Guidelines Network 
(SIGN), 2002).  Self-report (e.g. of cumulative abstinence days, CADs) is an acceptable 
measure of outcome when abstinence is not the goal, then self-reported days when 
drinking is less than e.g. 8 units may be an appropriate measure, supplemented if possible 
by corroborative reporting. 
 
Long-term (up to 3 years) monitoring following treatment and discharge back to GP care 
is useful in reducing the severity of relapses and may facilitate early referral back to 
specialist services. 
 
Alcohol dependence should be viewed as a relapsing condition and the need for ongoing 
treatment even after a number of unsuccessful interventions should be recognised.  
Recurrent relapse should not be a barrier to re-referral (and the HTBS survey of specialist 
services suggest that this is generally accepted).  The condition should be approached like 
other relapsing medical conditions with long term monitoring and intermittent or 
continuous treatment (Chick). 
 
Relapse prevention should not be seen as a treatment to be implemented at a specific 
point in the treatment system but rather as a component part of all stages of treatment 
with time given to motivational work throughout the individual’s transition through the 
care pathway and with recognition that levels of motivation will fluctuate. 
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Non-specialist NHS services need to remain aware that detoxification or treating the 
presenting alcohol related physical disease is only one part of the process of treating 
alcohol dependence and they should have a clear understanding of how to access the care 
pathway / treatment system.  This awareness can be stimulated by improved liaison 
between general hospitals and specialist services.  Acute hospital staff, identified for 
developing a special interest in alcohol problems, (.e.g.’alcohol liason nurses’) may be 
able to counsel patients as a preparatory step to specialist care, develop knowledge about 
locally available non-statutory agencies and link up with liaison psychiatry and specialist 
alcohol services.  Such acute hospital staff with this special interest may be able to 
educate and increase the knowledge of their co-workers. 
 
Specialist services must make themselves aware of mutual help (AA) and non-statutory 
agencies operating in their area and co-ordinate their approach making this information 
available to individuals under their care.  Introduction to AA and non-statutory agencies 
should be part of the overall relapse prevention strategy. 
 
The funded non-statutory agencies, which carry out ‘counselling’ should be expected to 
deliver interventions of known efficacy.  As it stands, our survey of these services 
suggests that much of the non-NHS sector appears to offer well-validated and probably 
efficacious interventions (albeit therapist factors and standardisation of interventions are 
not accounted for).  For instance AA is the origin of the now validated process called 
Twelve Step Facilitation, the Councils on Alcohol are trained in a CBT / Motivational 
Interviewing approach through the Alcohol Focus Scotland training scheme which is 
accredited at Edinburgh University, Social Work services appear to be carrying out Social 
Skills Therapy, CBT and Motivational Interviewing. 
 
Over 50 % of the homeless facilities that we contacted did not provide psychosocial 
interventions despite a large proportion of their clientele having alcohol problems.  There 
may be opportunity for training the staff in these facilities in community reinforcement 
therapy, which has been shown to be effective in this population.  
 
Rural communities may have different needs from the urban population.  There may be 
greater need for inpatient detoxification and relapse prevention due to geographical 
factors, which prevent effective community interventions.  The non-statutory agencies are 
noted to be a valuable resource in the rural setting. 
 
Controlled use of alcohol may be an appropriate treatment goal for those with less severe 
alcohol problems.  However, as will usually be the case in the specialist setting, 
abstinence should be the goal for severe dependence, where controlled use is rarely 
sustainable and especially when there is evidence of alcohol related organ damage.  If 
controlled use / harm minimisation is the considered preferred goal of the individual there 
must still be options for intervention e.g. referral to a voluntary agency or outpatient 
motivational sessions. 
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8.3 Implications of cost effectiveness analysis for service provision for prevention of 
relapse in alcohol dependence 
 
8.3.1 Psychosocial interventions 
 
An evidence based assessment of the efficacy of psychosocial interventions is included in 
section 5 of this report. Further discussion of these, including comments on cost-
effectiveness, is given in section Table 7 - 10  Costs of psychosocial courses.  With 
respect to the implementation of these methods a number of recommendations are widely 
accepted on the basis of clinical considerations or hypothesis generating studies. 
 
· Shorter less intensive interventions should be offered first, bearing in minds the 
principles of ‘tiered’, or ‘stepped’ care. 
 
· When the patient has not responded to less intense intervention, increasing the 
intensity is appropriate. 
 
· Disengaged individuals and/or those showing a high degree of anger are 
probably more likely to benefit from the Motivational Interviewing / 
Motivational Enhancement Therapy than from other approaches. 
 
· There are common therapist factors and characteristics which appear to be 
important whatever the intervention used, including; the ability to form a 
therapeutic alliance; taking a non-judgemental empathic approach; using 
reflective listening.  These factors may be crucial to the successful completion 
of treatment.  Therapist empathy and expertise is as important as experience and 
in this respect adequate training and audit of therapist competencies is 
recommended. 
 
· Clear and acceptable guidelines should be used locally, if possible to agreed 
national standards, for each psychosocial intervention employed. 
 
· Monitoring of adherence to protocols, ensuring that what is delivered under the 
name of a specific intervention is the intervention as more widely recognised, 
will be an important factor in auditing the effectiveness of these approaches.  
 
· Another important factor in ensuring that the treatment delivered corresponds to 
that which has been demonstrated to be effective is continuing clinical 
supervision of therapists, which will be accompanied by continuing 
opportunities for skill enhancement. 
 
8.3.2 Pharmacological interventions 
 
Discussion of the clinical effectiveness and cost effectiveness of pharmacological 
interventions is included in section 5 and section9.2.2.  The following points relate to the 
use of these therapies and are widely accepted. 
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· Pharmacotherapy should only be used as an adjunct to psychosocial intervention 
but whether this is structured or relatively non-intensive is not yet established,. 
 
· In using pharmacotherapy note should be taken of individual needs and 
expectations as well as contraindications, cautions and interactions. 
 
· Shared care protocols (examples of which are provided within Appendix 12) 
should be drawn up for the use of both acamprosate and disulfiram. 
 
· Acamprosate should be commenced immediately after or shortly before 
successful completion of alcohol detoxification. 
 
· Compliance with acamprosate should be monitored in the first month and the 
medication should be discontinued if compliance is poor and/or the clinical 
result is poor. 
 
· Review of the medication (acamprosate) should take place at 2 weeks, 4 weeks, 
8 weeks and 12 weeks at which stage transfer of prescribing to the GP would be 
appropriate.  Ongoing monitoring in shared care with the GP should continue 
thereafter.  Monitoring ideally should include information from the family or 
other closely involved party, and/or lGGT, MCV, as well as assessment of 
CADs. 
 
· At present acamprosate is advised to be used for one year, with little evidence 
available for continued prescription beyond this time period.  However, there is 
no evidence to show that continuing the prescription for 12 months is superior to 
discontinuing it after, say, 6 months. 
 
· For disulfiram, patients should be told of the nature and dangers of the alcohol 
reaction prior to prescription of the drug and should carry a card warning of the 
danger of administration of alcohol. 
 
· Daily, supervised administration of disulfiram is recommended.  Twice or thrice 
weekly administration may be more logistically practical if supervision is by a 
day hospital, CPN, a practice nurse, or an occupational health worker or deputy.  
 
· Information sheets for the nominated supervising agent (e.g. spouse, family 
member, Practice Nurse, Workplace Nurse) should be available (an example of 
such an information sheet can be found in the Appendix 14). 
 
· It is recommended that adherence to disulfiram and ongoing benefit from its use 
be reviewed on a monthly basis by the specialist service for the first 3 months, 
and thereafter 2 monthly by a physician alert to rare adverse effects of the drug 
such as neuropathy, or potential drug interactions. 
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· Naltrexone is not authorised for treatment of alcohol dependence in the UK and 
so is not recommended for use. 
 
· Acamprosate and disulfiram have not been studied in combination and so should 
not be used in this manner. 
 
 
8.4 High risk groups 
 
Homeless people may have particular problems in accessing specialist services for 
alcohol dependence.  It is thus important to maintain liaison between these services and 
groups specifically dealing with problems of homelessness in order that referrals can be 
made when appropriate.  As noted in section 3.6.3 the Scottish Prison Service provides a 
treatment and care plan to those identified as in need of help.  However, many of these 
prisoners might benefit from referral to NHS services during the period of renewed 
exposure to alcohol immediately after release.  Thus agreed procedures for routine 
referrals between the SPS and NHS services convenient to the prisoner might provide 
significant benefits. 
 
 
8.5 Aftercare 
 
Specialist services should make special arrangements for aftercare for each individual.  
 
There has been a dearth of clinical trials comparing different intensities of long-term 
contact but some evidence suggests that even low-intensity contact may have a beneficial 
effect (Hilton et al., 2001), see section 5.5.1.7.  
 
If, during aftercare, other psychiatric problems persist e.g. anxiety, depression at 3 weeks 
post detoxification, these should be treated appropriately e.g. with psychological therapy 
(CBT) or antidepressant medication (Scottish Intercollegiate Guidelines Network (SIGN), 
2002), but without drawing the patient’s attention away from the primacy of the drinking 
goal. 
 
 
8.6 Data Recording 
 
Greater Glasgow Alcohol and Drug Directorate have developed and are currently piloting 
a computerised information system specifically developed to enable useful clinical 
information to be recorded on patients throughout their contact with the directorate.  In 
addition Greater Glasgow Social Work Addiction Services already have an outcome 
monitoring system for recording information on the progress of clients through their 
contact with relevant services.  However, the information on individuals once they have 
left these services, through default or completion of a programme, is not collected.  
Consequently no information can be obtained about the longer-term impact of contact 
with these services.  Such information systems help gain greater understanding of the 
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demands on and effective organisation of services.  Nonetheless, the difficulty in 
estimating the true prevalence of alcohol problems in Scotland, as noted above, may 
suggest that further alterations are required in the way that contacts with individuals 
presenting with alcohol problems are recorded. 
 
 
8.7 Audit and research 
 
The difficulty highlighted in estimating the prevalence of alcohol dependence suggests 
that it is important to change the way in which contact with those with alcohol problems 
is recorded.  
 
An improved information collection system is required. (ISD are currently changing the 
way in which information is collected, for instance from GP contacts). 
 
ISD and the Scottish Executive are looking at the feasibility of setting up a National 
Alcohol Information Resource to benefit those who plan and provide services. 
 
A regularly updated comprehensive directory of alcohol services and accommodation 
would be beneficial.  This should be useable by all participating agencies and provide 
accurate outcome data (as recorded and analysed) as well as a greater understanding of 
progress through the treatment system. 
 
Attempt should be made to standardise outcome measures so that greater comparison of 
outcome between services is possible.  There is need for ongoing debate about which 
outcome measures should be used. 
 
There is also the need to collect information routinely on what happens to individuals 
once they have left the service through default or completion of a programme.   
It is essential to have a longer-term measurement of quality and effectiveness.  Future 
measurements of outcome should cover longer periods post intervention e.g. up to 5 
years. 
 
There is need for the ongoing monitoring of the performance of the ‘treatment system’ 
locally, with the facility to modify the system as the need to change is highlighted. 
 
There should be scope for incorporating any new treatment, with evidence to support its 
use, into the current system and monitoring its success against current accepted standard 
treatment. 
 
Local services should liase with ISD regarding methods of recording and collecting 
information for audit so that local information systems can be co-ordinated with the 
national information system. 
Our survey showed that the current use of audit of psychosocial and pharmacological 
interventions is minimal, in some areas not occurring at all. 
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Audit of interventions should include: locally (and nationally) agreed outcome 
measurements (e.g. % of completed sessions, blood tests, patient self-report, CADs); 
checking that interventions delivered are done so according to recognised methodology; 
audit of therapist accreditation and supervision; checking that local protocols are being 
adhered to etc. 
 
This improvement in recording contact and progress through the service and the long-
term outcomes is essential for the longer-term impact of interventions and the 
organisation of services in the treatment system to be accurately evaluated.   
 
Research and Development is an essential component of any improvement in the current 
system of care. 
 
More research and evidence are needed regarding the benefits of different settings for 
psychosocial interventions e.g. group vs. individual, inpatient vs. outpatient vs. day unit, 
intensity and length and frequency of sessions etc. 
 
National evaluation should be co-ordinated to avoid the ‘evaluation overkill’ noted by 
workers in both statutory and non-statutory agencies. 
 
Other published quality standards such as Quality in Alcohol and Drugs Services 
(QUADS) should be consulted. 
 
 
8.8 Staff training 
 
Relapse prevention training in Scotland appears to have started with the establishment of 
the University of Paisley’s, Centre for Alcohol and Drug Studies, Scottish Alcohol 
School training weeks held at Herriot Watt University in the early 1980’s.  A week-long 
residential programme allowed a wide range of attendees to review psychosocial 
interventions for alcohol misusers and in particular relapse prevention techniques.  The 
Centre for Alcohol and Drug Studies maintained these programmes until 1990 when the 
Scottish Council on Alcohol took over their running.   
 
A research programme to evaluate relapse prevention was undertaken in 1982 (Saunders 
& Allsop, 1991); (Allsop & Saunders, 1991).  The research was conducted in 
Ravenscraig Hospital, Inverclyde, and the techniques were adopted by the hospital staff 
as ‘standard clinical practice’.  The work on relapse prevention and management 
techniques influenced the residential programme.   
 
In 1998 the Scottish Council on Alcohol changed the residential programme to specific 
training sessions.  The Introduction to Relapse Prevention module is run twice a year and 
has had 40 attendees.  
The Centre for Alcohol and Drug Studies was established in 1979 and provides 6 
postgraduate qualifications ranging from a Postgraduate Certificate in Alcohol and Drug 
Studies to an MSc in Alcohol and Drug Studies with practice.  300 Students have 
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completed these courses each of which contains educational and skills based sessions on 
relapse prevention.   
 
The Centre for Alcohol and Drug Studies employed two external National Trainers one 
for Health and one for Social Care from 1987 to 2001.  The educational focus of these 
trainers posts were brief intervention awareness training for generic and specialist staff.  
A total of 1,500 staff was trained per year over the 14-year period of the Trainers 
employment.  
 
Alcohol Focus Scotland, (previously the Scottish Council on Alcohol) runs a national 
training scheme for volunteer counsellors.  This training scheme is run in conjunction 
with supervision from accredited counsellors.  The training scheme has 36 educational 
units of which two focus on relapse and strategies for relapse prevention.  Since 1979 
2039 people have completed this training, 356 are still practicing within a Council on 
Alcohol in Scotland.   
 
STRADA, aims to improve the skills of professional staff addressing drug and alcohol 
misuse throughout Scotland and will provide training on interventions that are evidence 
based.  The training will consists of: 1 & 2 day Module courses, Certificate in Addictions, 
Certificate in the Management of Alcohol and Drug Services and a Leadership 
Programme. Relapse prevention techniques will be a core content of each course.   
 
There are short, undergraduate and postgraduate training courses available that offer the 
therapeutic concept of relapse prevention techniques to health, social care and voluntary 
staff in Scotland.  There is no evidence of a consistent Scotland wide application of a 
standardised treatment approach as suggested by the Project Match Manuals, 1995**. The 
suggestions from Project Match to select, train and supervise therapists to ensure 
standardised application of therapeutic technique are similarly not presently in evidence.   
 
 
8.9 Current services 
 
The HTBS survey of NHS specialist services highlighted that availability of treatment is 
currently unevenly distributed throughout Scotland leaving some without access to what 
should be minimum core services. 
 
Some areas may appear to be comparatively well serviced but nonetheless are unable to 
meet the health care needs of their population.   
The core minimum services required for one individual with alcohol dependence to be 
offered a flexible and comprehensive package of care would appear to be:  
 
                                                
** There are eight manuals which were published between 1994 and 2001.'They are the result of 
the collaborative efforts of the Project MATCH investigators and were used as guides by the 
therapists in the trial.  
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1. The facility of inpatient / residential detoxification if necessary. 
2. At least some members of staff covering this inpatient facility should have a 
special interest / additional training in alcohol misuse. 
3. The facility for outpatient / day patient detoxification (which may be solely a 
specialist CPN in liaison with the GP who is taking responsibility for the 
prescription of replacement medication). 
4. The GP in liaison with the CPN needs to be able to carry out assessment of need / 
risk and refer as necessary for inpatient or outpatient detox. 
5. The CPN should be able to carry out relapse prevention work including MET, 
Social Skills Training or another efficacious intervention, and be able to offer 
ongoing follow-up. Relapse prevention should be available in outpatient, 
daypatient and inpatient settings. 
6. Voluntary agencies should also be able to offer psychosocial interventions of this 
nature and may take on the bulk of relapse prevention work when the specialist 
service is small. 
7. The voluntary agency may also take on the bulk of individuals seeking controlled 
drinking. 
8. GPs may require to be able to assess for the suitability of prescribing 
Acamprosate or Disulfiram (supervised e.g. by Practice Nurse, CPN, relative, 
community pharmacy). 
9. The GP will be required, on prescription of such medication, to monitor 
outcomes, arrange appropriate counselling, and carry out appropriate blood 
testing etc. The GP might have counselling arranged through his/her  Practice, or 
via a non-statutory agency , or with the locality CPN, if available. 
10. A consultant psychiatrist should be accessible for patients with psychiatric 
symptoms 
 
Areas without core minimum services are therefore: 
 
1. Those with no inpatient facility (unless these routinely go to general medical 
beds) – Grampian, Shetland. 
2. Those without specialist CPNs – Shetland. 
3. Those with very minimal community / CPN staffing and a very small voluntary 
sector – Orkney, Borders, Western Isles (although the Western Isles inpatient unit 
appears to offer a fairly comprehensive treatment package). 
 
Those areas with a disproportionately small number of beds given morbidity and 
mortality figures are Grampian and Lothian (and to a lesser extent Greater Glasgow, 
Forth Valley, Fife and Highland).  Fife has no dedicated specialist beds. 
 
Certain areas, Borders and Shetland, might consider offering psychosocial therapies such 
as motivational interviewing and coping skills training.  Many services could add 
relationship therapies such as the Community Reinforcement Approach (CRA) and 
Behavioural Marital / Couples Therapy (BMCT) to their repertoire. 
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Many services would benefit from audit of pharmacological and psychosocial 
interventions. 
 
In terms of staff complement relative to morbidity and mortality figures, Grampian and 
Fife are understaffed, as to a lesser extent are Lothian, Argyll and Clyde and Forth 
Valley. 
 
Fife has no dedicated specialist beds. 
 
Non-NHS facilities appear to be evenly spread generally (purely in terms of numbers in 
relation to levels of morbidity and mortality) but Fife and Forth Valley probably have less 
than their share, as do Lanarkshire and Ayrshire & Arran (although notably this area has 
a proportionately high specialist staffing level).  Lothian and Grampian have 
proportionately slightly fewer non-NHS services and this is compounded by lower staff 
and bed numbers, taking account of mortality and morbidity figures. 
 
Overall, areas needing services are Lothian, Grampian, Forth Valley, Fife, Greater 
Glasgow (beds) and Highland (beds). 
 
 
8.10 The Care Pathway 
 
A number of care pathways are described in the Scottish specialist care services.  The 
following diagram is a synthesis of these and may provide a useful template for the 
structure of a local care service. 
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Figure 8 - 1  Example Care Pathway 
 
                          GP (or general psychiatrist/CPN/SW/non-statutory agency) 
                            Problem identified – follow SIGN guidelines  
 
                               Refer if multiple relapse/Concurrent psychiatric illness/ 
                              Potential need for residential rehabilitation  
 
                          NHS Specialist Alcohol Service  
 
 Emergency (assess level of 
risk/withdrawal 
 
non-urgent 
allocation meeting 
HOME DETOX/DAY HOSPITAL 
DETOX/IP  DETOX 
CPN      ADU      OP (medical/nursing)  
2 SEE  BELOW 
assessment  Specialist help not 
required 
help required not accepted 
(provide info./BRIEF  INT.) 
Accepted (identify 
(goal of treatment) 
Abstinence controlled drinking 
dependent Non-dependent Voluntary agency (e.g. COA) 
 
assess risk – detox. waiting list 
(MOTIVATIONAL  INTERVIEWING)
HOME DETOX      DAY HOSP. DETOX     IP DETOX 
1.2  
1.3 ADU/CPN 
Psychosocial interventions (MET/SS/CRA/BMCT or RP 
group/individual) 
(+/-ACAMPROSATE/supervised DISULFIRAM) 
PROGRAMME  COMPLETE (review continuing needs)  
Purchased services   medical/  general psychiatry general medical                      
e.g. residential rehab.       Nursing             OP                      
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9 DISCUSSION 
 
9.1 Nature and scope of this health technology assessment 
 
Inappropriate use of alcohol is a cause of many important problems in Scottish society.  
A broad picture of these has been given in the Plan for Action on alcohol problems 
(Scottish Advisory Committee on Alcohol Misuse (SACAM), 2002).  The adverse 
consequences of alcohol are apparent in health, criminal justice, road traffic, employment 
and productivity.  In a substantial part, however, these problems arise through drinking in 
individuals who are not dependent upon alcohol and may not be considered either by 
themselves or most others to have an alcohol-related problem. 
 
This report addresses the problems of the relatively small but significant subgroup of 
people who find themselves, at some stage, unable to control their drinking.  This group 
is qualitatively different from others in the continuity of their exposure to alcohol and the 
consequent effects it may have on all aspects of their lives and in particular on their 
health.  The profound adverse influence, which high levels of alcohol have on many 
aspects of morbidity and also on life expectancy, has been investigated in numerous 
epidemiological studies some of which are reviewed in this report.  From these studies 
HTBS has attempted to construct a profile of the health and life expectations of an 
untreated alcohol dependent person and contrast it with the expectations of the general 
population.  Such calculations are fraught with difficulties, some of which are described 
below.  However, the general message appeared to be that, whilst the burden of ill health 
is high in alcohol dependence, the biggest impact of heavy drinking is in raising 
mortality.  Two studies, one in Taiwan (Chen et al., 2001) and the other in Sweden 
(Denison et al., 1995), observed death rates which were around 12 times that of the 
Scottish population.  This effect could not be explained by national differences in 
mortality; the life expectancy at birth in Sweden being slightly higher than in Scotland 
based on 1997 figures from Statistics Sweden.  Furthermore, the majority of the excess 
mortality did not arise from somatic diseases generally linked with alcohol.  Thus it 
would be unwise to concentrate on too narrow a group of alcohol-associated illnesses and 
disregard the general message that alcohol dependence should itself be seen as a life-
threatening condition.  
 
In this report we have examined four discrete aspects of relapse prevention in alcohol 
dependence.  These are the clinical effectiveness of the interventions, the cost-
effectiveness, the patient perspective on treatment and a number of issues related to 
organisation of treatment services.  The intention has been to produce an account which 
will be useful to those planning and running specialist services for relapse prevention 
and, with this in mind, it is clear that some interpretive discussion of the report findings is 
necessary. 
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9.2 Clinical effectiveness 
 
9.2.1 Psychosocial Interventions 
 
Use of the results of either clinical trials or reviews of research as the basis of a practical 
effective clinical service is not a trivial undertaking.  This is so even with conceptually 
simple interventions such as medicines that will have been tested according to carefully 
specified protocols, which should be reflected in the SPC in a way which makes it 
reasonable to suppose that the efficacy measured in trials will be similar to the 
effectiveness achieved in clinical practice.  For psychosocial interventions the difficulties 
are much greater.  There is rarely a single agreed protocol for delivery of these treatments 
and the setting, duration and personal qualities of the therapist may all play a part in 
determining the effectiveness.  In addition to this, trials of nominally similar treatments 
may have involved substantively different procedures.  It is generally the responsibility of 
each service provider to be acquainted with the practical details of what has been proven 
effective in research and to decide how it can be delivered locally.  A pragmatic approach 
to this problem is to choose treatments which have been shown to perform well in meta-
analyses and then to select trials from these meta-analyses of interventions which had 
estimated treatment effects towards the higher end of the distribution of results – 
preferably statistically significant in their own right – and examine the nature of the 
intervention in more detail by consulting original research reports.  A good example of 
this procedure is provided by Finney and Moos (1998) who pick out social skills training, 
community reinforcement and behavioural marital therapy as examples of effective 
therapies and discuss the possible elements of a service based on these interventions.  The 
results of the meta-analyses in this report would agree with Finney’s general approach. 
 
The results of our analysis also suggest that the combination of Coping Skills Training 
and Motivational Enhancement Therapy offered by many Scottish specialist care units 
provides a good foundation for treatment.  However, very few of these interventions are 
delivered according to standardized protocols.  This makes it difficult to be certain that 
the treatments correspond to those proven effective in clinical trials. 
 
There is also common use of Brief Interventions (BI), which is not supported by evidence 
in alcohol dependent patients.  Note that this contrasts strongly with problem drinking 
among non-dependent people where it has been shown effective.  This conclusion may at 
first seem at odds with much perceived wisdom but the predominance of non-dependent 
patients in studies of BI and the substantively different nature of the problems faced by 
dependent drinkers provides a background against which this conclusion appears more 
compelling.  Finney & Moos, (1998) has some comments on the way that BI has been 
assessed which shed further light on this issue. 
 
The apparent failure of the intervention (confusingly) named classical Relapse Prevention 
in clinical trials is also worth commenting upon.  It is a surprising result because RP 
includes many of the cognitive-behavioural elements found in effective interventions.  It 
is worth asking whether the failure to show an effect may be explicable in terms of the 
nature of the clinical trials. O’Farrell(O'Farrell et al., 1993) tested RP with involvement 
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of a spouse or partner but only following a course of behavioural marital therapy.  The 
intention was to ‘develop and cognitively rehearse a relapse prevention plan’ and, in 
addition, to maintain the gains of BMT and deal with emerging marital issues.  Thus the 
only new element was the development of the relapse prevention plan.  In a similar way, 
McCrady (McCrady BS et al., 1999) compared Alcohol Behavioral Couples Therapy 
with Relapse Prevention plus ABCT.  Thus only the specific additional element of RP 
was assessed. Sandahl (Sandahl C et al., 1998) compared RP with psychodynamically 
oriented group treatment which appears to have been the primary focus of the study and 
was not considered by the authors to be an inactive control.  Thus a significant result in 
these three trials would have required RP to show additional benefit over active 
treatments.  The only trial in our meta-analysis to show a marginally significant positive 
effect was Allsop (Allsop & Saunders, 1997) in which the comparator was inactive.  
However, the comparator was also inactive in the study by O’Malley(O'Malley et al., 
1992)†† in which no effect was shown.  The overall conclusion from these considerations 
is that no convincing evidence of the efficacy of RP is available.  However, from the two 
trials, which tested the specific relapse prevention paradigm of RP it seems reasonable to 
draw the stronger conclusion that this particular element has little to add to a cognitive-
behavioural based treatment programme.  
 
The psychosocial interventions, which our analysis shows to have empirical support are 
coping skills training, behavioural self-control training, marital/relationship therapy and 
motivational enhancement therapy.  However, there are some practical limitations in the 
use of any of these methods and any one treatment is unlikely to suit every situation. 
These limitations are discussed below. 
 
All the clinical trials of coping skills included in our analysis are based on the work of 
Monti (2001) who investigated a combination of cue exposure with urge-specific coping 
skills training (CET), and communication skills training (CST) and compared them with 
educational discussions and relaxation training.  These interventions were delivered as 
adjuncts to an intensive two-week partial hospital programme involving 6 hours per day 
of group, individual and marital treatment based on learning principles and 12-step 
philosophy.  This comparison was not randomised, patients being allocated according to 
month of admission.  Each CET/CST session took 90 minutes a day and a total of 5 
coping strategies and 8 communication skills were taught.  Burtscheidt (2001) used 
Monti’s treatment techniques in an outpatient treatment programme with 26 group 
sessions of 100 minutes over six months.  There were six or less patients per group.  The 
comparator was a standard outpatient programme, also with weekly meetings.  The two 
very different patterns of delivery in these studies do not provide a clear guide to 
therapists wishing to use these techniques.  The greatest estimated treatment effect was in 
Monti (2001) when CET/CST was used as an adjunct to another therapy. 
 
Behavioural self-control therapy is a complete treatment package.  It may be aimed either 
at controlled drinking or at abstinence.  However, the review by Walters (2000) and most 
of the studies included in it investigate controlled drinking.  Some components of the 
                                                
†† Note the possibly confusing reference to the psychosocial treatment in this trial as ‘coping skills’. It 
appears to follow the Marlatt model and has thus been classed as Relapse Prevention. 
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technique, for instance drinking rate control, are only applicable to this aim but other 
aspects such as goal setting and identification of high-risk situations are applicable to 
either aim.  The meta-analysis we have presented of success rates is based on Walter’s 
selection of studies and restricted to those whom he judged as ‘alcoholic’ rather than 
problem drinkers.  Consequently it is also restricted to subjects seeking a controlled 
drinking outcome.  It may thus be appropriate to use it in this fashion in clinical practice. 
 
It has already been noted that the brief form of MET used in Project MATCH did not 
perform as well as the more intensive 12 Steps Approach.  This suggests the qualification 
that it may not be a sufficient stand-alone therapy but should be a precursor to other 
treatments or, possibly, an early component of a stepped care programme.  It is notable 
that Sellman (Sellman et al., 2001) excluded patients for whom abstinence might be 
advised or with ‘severe dependence’ from his study.  However, it is not clear whether he 
considered four sessions of MET inappropriate for such patients or just the ‘no further 
counselling’ option. Bien (Bien et al., 1993) used only a single session of MET but as a 
precursor to standard outpatient treatment, much in the manner recommended in this 
report. 
 
Many therapies involving spouses, partners or contracts with other individuals have been 
tested and the twelve trials, which, provided appropriate outcome data for the HTBS 
analysis are rather diverse.  Finney and Moos (Finney JW & Moos RH, 1998) picked out 
the studies of the Community Reinforcement Approach as figuring prominently in several 
league tables of effective treatments, and the contribution of CRA (Hunt & Azrin, 1973); 
(Smith et al., 1998) to increasing the estimated treatment effect of relationship therapies 
is clear (Appendix 21).  It is notable that the trial reported by Smith enrolled homeless 
patients and, for the most part, the relationship involved a contract with the project nurse 
for supervision of disulfiram.  Other standard elements of CRA such as a job club and 
social club reinforcing non-drinking recreational activities were also used.  Non-CRA 
relationship interventions generally tended to show positive, if less impressive, results but 
the only study in which a statistically significant effect was estimated on treatment 
success rates was that by Corder (Corder et al., 1972).  This study involved the wives of 
patients in an intensive 4-day workshop at the end of a 3-week daily treatment 
programme.  The control group received a four-week daily programme without 
involvement of wives.  Although the intervention appears to have been a successful the 
result should be regarded with some caution as allocation was unrandomised and 
confounded by time period – all the control group were recruited first.  Combined with 
the general positive trend in other marital therapies this suggests that involvement of 
spouses in treatment, when acceptable to both patient and partner, is an option to be 
considered.  However, this acceptability may prove a limiting factor in practice.  
 
A concern with regard to the CRA treatment may be that the social elements involve 
substantial organisation and time.  However, these elements could be run by staff without 
clinical expertise and the good clinical trial results suggest that such a strategy might be 
worth serious consideration. 
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9.2.2 Pharmacological Interventions 
 
Both acamprosate and naltrexone appear to be effective additions to psychosocial 
treatments.  Although the meta-analysis results suggest a slightly larger effect for 
acamprosate, the confidence intervals overlap by a substantial margin and no firm 
conclusion can be drawn about the relative efficacy of the treatments.  A concern is that 
there is appreciable heterogeneity between trial results for both acamprosate and 
naltrexone.  This suggests that there are genuine differences in efficacy possibly 
associated with trial procedures or types of patient.  Two large pragmatic studies of 
acamprosate (Chick et al., 2000) (Mason BJ, 2001) have now produced negative results 
and this must raise the possibility that the effectiveness may be low in clinical practice.  
Post-hoc rationalisations of these negative results cannot provide satisfactory guidance on 
which to base clinical procedures.  Hence a large phase IV study using acamprosate 
according to procedures achievable in clinical practice – which should be recommended 
by the manufacturer – would do much to strengthen confidence in the treatment.  This 
comment also applies to naltrexone in so much as a very large recent study (Krystal et al., 
2001) produced rather disappointing results and a truly pragmatic study with a positive 
result would do much to increase confidence in the treatment generally.  
 
With regard to Scottish usage of acamprosate and naltrexone it is stressed that only 
acamprosate currently holds a UK marketing authorisation.  A licence to market 
naltrexone in the UK for prevention of relapse has previously been applied for but 
refused by the licensing authority on the advice of the Committee on Safety of Medicines.  
The CSM reviewed full evidence for the efficacy, safety and quality of the product at the 
time of application.  Medicines can be given outwith the provisions of their UK licence 
but the responsibility for this action lies solely with the prescribing physician.  The 
manufacturers, Dupont, are currently deciding whether to make a further application. 
Naltrexone is currently marketed in the U.K for the treatment of opioid addiction.  It has 
licences for use as an adjunct treatment in preventing alcohol relapse in a number of 
countries including the Republic of Ireland and the U.S.A. 
 
The evidence reviewed in this report does not support the unsupervised administration of 
disulfiram.  However, one well-designed clinical trial (Chick et al., 1992) and diverse 
supporting evidence have suggested that disulfiram is effective when it is appropriately 
supervised.  The single trial did not report long-term success rates in terms of abstinence 
or controlled drinking and hence it is not possible to express this effect in a manner 
comparable to the effects for the other treatments we have reviewed. 
 
The studies of pharmacotherapy reviewed in this report have considered the use of 
acamprosate, naltrexone and disulfiram used in conjunction with psychosocial therapies 
in centres of expertise.  The important issue of how or whether these treatments should be 
used in other settings has not been addressed.  
 
The prescription of two or more of these medicines for simultaneous use does not appear 
to have any supporting evidence of effectiveness or safety.  However, the HTBS survey 
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shows that acamprosate and disulfiram are used together in 57% of Scottish services and 
this is clearly an area for reflection and further study.  
 
9.2.3 Non NHS services 
 
Non-NHS services treating alcohol dependent patients use a wide range of psychosocial 
techniques.  Some of these are not adequately supported by clinical trial evidence.  
Concentration on a few techniques closely based on those with proven benefits would be 
likely to increase the effectiveness of these services.  Other approaches should be tested 
in formal randomised trials before being adopted as standard procedures. 
 
 
9.3 Patient issues 
 
A study involving in-depth one-to-one interviews of 45 alcohol dependent patients 
attending three NHS Specialist Centres is underway. Interim results show that most 
patients valued group therapy, which provided an opportunity to share experience with 
other patients who really understood the situation.  Women prefer single sex groups, 
whereas men did not express a preference.  Those still drinking found the group work 
more difficult.  Those coerced into attending AA meetings did not continue with them, 
but others were positive about AA meetings and valued the flexibility of times and 
venues available.  Most patients also found one-to-one therapy helpful to discuss a wide 
range of issues in-depth and in a manner direct to meet the individuals’ needs.  Some 
interviewees had attended a Council on Alcohol, mainly after being referred by an 
employer.  Some valued the counselling and alternative therapies, but others felt that the 
‘controlled drinking’ philosophy of the Councils was not a feasible approach for them.  
The availability of the service from the Councils at times of crisis was appreciated. 
 
 
9.4 Cost effectiveness 
 
Section 7.17 has set out many of the issues emerging from the economic evaluation. 
These primarily relate to the quality of evidence on the clinical effectives of each therapy 
and whether it can be generalised to a Scottish setting.  These issues have been taken 
forward in section 9.2 above. 
 
The other issues emerging from the discussion on the economic evaluation included 
whether the assumptions underlying the epidemiology are robust.  Section 3.20 of this 
document explained that the economic evaluation has included illnesses associated with 
chronic drinking which may understate the potential benefit to NHSScotland of treating 
alcohol dependence.  
 
The disease incidences used in the economic evaluation combine probabilities extracted 
from various international studies with incidences from the Scottish population taken 
from the Scottish Health Statistics and other sources.  These sources are combined to 
provide a forecast number of disease case for a cohort of alcohol dependent and non-
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alcohol dependent men and women.  The model is particularly sensitive to the incidence 
of alcoholic dependence syndrome and alcoholic psychosis, two diseases that were not 
well covered in the literature.  Moreover the model assumes that abstinent patients have 
the same health as non-alcohol dependents.  Evidence on both these points would be 
beneficial. 
 
The remaining major issue for the economic evaluation is the absence of Scottish disease 
related costs.  These have been approximated by obtaining data from ISD on length of 
stay by disease and applying the average inpatient cost for a general function.  For 
example, in the case of cirrhosis, ISD advised that the average length of inpatient stay 
was almost 12 days and we applied a daily cost based on published cost for a ‘medical’ 
inpatient day.  It is not possible to say whether this average cost overstates or under the 
costs of managing patients with cirrhosis.  
 
 
9.5 Current gaps in knowledge 
 
A Health Technology Assessment requires collection of data relating to clinical 
effectiveness and safety of interventions; a full description of the long-term prognosis for 
patients and the variation in prognosis with different treatments; and also detailed 
knowledge of costs of treatments and of disease states.  These data come from a variety 
of sources and it is frequently necessary to combine these sources using a model 
employing many assumptions.  In the process of collecting the data it is often clear that 
they could be more complete and more directly informative.  Thus one of the outputs of 
an HTA is a set of recommendations concerning how better data might be obtained. 
 
The epidemiology input to the cost effectiveness calculations has relied on many diverse 
observational studies of disease and mortality among alcohol dependent people.  It would 
be very desirable for this, and many other HTAs, to have access to complete clinical life-
event histories collected on a patient-by-patient basis for the Scottish population.  This 
would permit the direct assessment of the interactions between different disease states 
associated with alcohol and the effects, which current alcohol treatments have on these 
states.  In recent years the linkage of different clinical dataset has allowed the first moves 
towards making such information available.  Access to such data would both speed up 
and increase the accuracy of HTA assessments. 
 
Data collection in order to assess the long-term clinical course of alcohol dependence 
following treatment in Scotland is needed.  Measurement of simple outcomes such as 
further detoxification over a period such as five years would provide useful long-term 
outcome data.  Demonstration that a high quality of clinical service is being provided is 
strongly dependent on the availability of such measures and they also provide a way of 
assessing potential improvements to the service. 
 
As noted above, large scale pragmatic clinical trials of pharmacological interventions for 
relapse preventions would increase confidence in the effectiveness of these treatments. 
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Long-term treatment success rates in terms of abstinence or controlled drinking should be 
reported. 
 
The quality of trials of psychosocial treatments is generally not high.  In this assessment 
studies which were not randomised have occasionally been included if the treatment 
allocation appeared to have no element of discretion.  However, there is no good reason 
for not including an element of randomisation – either at the individual or group level – 
in any clinical trial.  Complete blinding is not possible in studies of psychosocial 
treatments and hence biases due to clinician or patient enthusiasms for particular 
treatments may be difficult to avoid.  Consideration should be given to ensuring 
treatments are delivered in an unbiased fashion and that outcomes are assessed by 
clinicians blinded to treatment.  The results of Project MATCH may have lessened 
enthusiasm for performing studies with primary hypotheses expressed in terms of 
matching patients to treatments.  Whether this is so or not, the sample size calculations 
for such studies should be appropriate to the nature of the hypothesis. In addition the trial 
results by randomised group (ignoring the matching variables) should be clearly 
presented. 
 
Finally the availability of Scottish disease related costs would inform the forecast 
savings to NHSScotland of avoiding relapse in people who are alcohol dependent.  
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Appendix 2 SIGN Guideline: Key Questions on Alcohol Dependence 
 
 
 S I G N 
  Key Questions    June 2002 
 
 
Detection and assessment 
1. What evidence is there on the use of CAGE, AUDIT, history taking, liver function tests, and 
aspects of the physical examination in the detection of harmful drinking and alcohol 
dependence in A & E and the primary care setting? 
2. What evidence is there on the sensitivity and specificity of the above methods? 
3. What evidence is there on detection rates of harmful drinking and alcohol dependence by 
the courts, A & E, schools, homeless services, antenatal services, services for the elderly, 
police, social workers, new employee assessment, new patient assessment? 
4. What evidence is there that training general practitioners, practice nurses, community 
nurses, social workers, and A & E staff in the detection of harmful drinking or alcohol 
dependence improves detection rates? 
 
Early Intervention for hazardous and harmful alcoholism 
Interventions by general practitioners, practice nurses, community nurses, social workers, and 
health visitors 
 
5. What evidence is there that advice and information on safe levels of alcohol consumption 
on one or two occasions (minimum intervention) will (a) reduce hazardous drinking (b) 
reduce harmful drinking or (c) prevent harmful or hazardous drinking progressing to alcohol 
dependence? 
6. What evidence is there on assessing a patient’s readiness to change his or her drinking 
habits? 
7. What evidence is there on how the subject of alcohol consumption should be discussed 
with patients? 
8. What evidence is there on the accuracy of self-assessment of alcohol consumption by 
counting units of alcohol? 
9. What evidence is there on who should be given counselling or who should be referred to 
specialist addiction wards, or general psychiatric wards, or specialised alcohol services? 
 
Detoxification 
10. What evidence is there on the criteria (gender, age, alcohol consumption, associated 
morbidity such as cardiovascular disease, liver disease, or mental illness) that should be 
used when considering where detoxification should be carried out (i.e. in-patient versus 
community, specialist versus primary care)?  
11. What evidence is there on the criteria (gender, pregnancy status, age, alcohol 
consumption, alcohol dependence symptoms, associated morbidity such as cardiovascular 
disease, liver disease, or mental illness) that should be used when considering whether 
pharmacological detoxification is required and if so which drugs and with which dosing 
schedules are appropriate (e.g. chlordiazepoxide, diazepam, variable vs fixed dosage, 
amount, length of drug treatment)?  
12. What evidence is there on how different treatment settings (general psychiatric wards, 
specialist addiction wards, medical wards, general practice, nurse prescribing, home 
detoxification services, day units, alcohol clinics, and prisons) affect detoxification 
outcome?  
Alcohol Dependence Guideline Development Group 
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outcome?  
13. What evidence is there on the role of vitamin supplements in detoxification? 
14. What evidence is there on which is the preferred setting to which the general practitioner 
should refer (medical ward, psychiatric ward, detoxification unit) a patient with delirium 
tremens?  
 
Specialist care and relapse prevention in primary care (including treatment for comorbidity) 
15. What evidence is there that the AA reduces alcohol dependence or harmful drinking, and 
how should health care facilitate the patient’s utilisation of the AA? 
16. What evidence is there that other lay services reduce alcohol dependence, harmful or 
hazardous drinking, and how should primary care facilitate the patient’s utilisation of these 
services 
17. What evidence is there regarding the effectiveness of antidepressants/anxiolytics in alcohol 
dependence, in relieving depression and anxiety disorders and/or preventing relapse? 
18. What evidence is there that alternative therapies help prevent relapse/maintain abstinence? 
(shaitsu, aromatherapy, relexology, massage)? 
19. What evidence is there that involving family members (family therapy, couples therapy, Al-
Anon) improves quality of life, drinking habit, and compliance to treatment regime? (Primary 
care aspects of this question are to be covered by SIGN) 
20. What evidence is there on how schizophrenia, learning disability, bipolar disorder and 
substance abuse affect the management of harmful drinking and alcohol dependence? 
 
 
 
 
Appendix 3 HTBS planning questions 
 
HTBS ASSESSMENT OF  
PREVENTION OF RELAPSE IN ALCOHOL DEPENDENCE 
 
 
The HTA questions 
 
1. Which approach or combination of approaches will yield the maximum 
maintenance of recovery amongst the population of those with alcohol 
dependence who have undergone detoxification? 
 
2. What is the most clinically and cost effective approach to delivering the 
individual interventions, or combination of interventions, taking into account 
the different risk groups, locations, duration of treatment, concomitant 
medications, etc? 
 
HTBS Evidence Questions  
 
1. Relapse 
 
Q1a. What definitions of relapse are in current use?  
Q1b. Are different definitions appropriate to different individuals?  
Q1c. Are different definitions comparable? 
 
2. Population 
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Q2a. How are individuals identified for alcohol relapse prevention? 
 
3. Service capacity and demand 
 
Q3a. What is the current service capacity for inpatient and outpatient care? 
Q3b. What is the current service demand for inpatient and outpatient care, as 
indicated by those presenting for treatment? 
Q3c. How is healthcare use distributed between primary vs specialist care? 
 
4. Effectiveness and Delivery of psychosocial interventions – current practice 
 
Q4a. What psychosocial interventions are in current use for relapse prevention? 
Q4b.  Who is delivering psychosocial therapies? 
Q4c. Where are psychosocial therapies being provided? 
Q4d For what time period are psychosocial therapies being provided (no. of 
sessions and length of treatment period). 
Q4e. For which of the psychosocial interventions are there protocols/manuals? 
Q4f. If a psychosocial intervention has no manual/protocol can it be sufficiently 
well characterised for an HTA to be performed? 
Q4g. Are pharmacological interventions used as a standard adjunct to psychosocial 
therapies? 
 
 
 
5.  Effectiveness and Delivery of psychosocial interventions – evidence base 
 
Q5a. What is the evidence base for the effectiveness of each psychosocial method 
(including objective evaluations of relapse using blood, breath or other formal 
test)? 
Q5b. Who should deliver psychosocial therapy? 
Q5c. What evidence exists on the effectiveness of inpatient versus outpatient 
delivery of treatment? 
Q5d. What evidence exists on the optimal duration for the provision of psychosocial 
therapies? 
Q5e. What are the training, competency, accreditation and supervision requirements 
for the therapists? 
Q5f. Are there groups of individuals at whom psychosocial therapies are best 
targeted (e.g. treatment matching)? 
Q5g. Should pharmacological interventions be given with psychosocial therapies? 
Q5h. What evidence is there that the AA helps to reduce relapse and how should 
healthcare services facilitate access of individuals to the AA? 
 
6. Effectiveness and delivery of pharmacological interventions – current 
practice 
 
Q6a.  What pharmacological interventions are in current use for relapse prevention? 
Q6b.  Who is prescribing and administering these therapies? 
Q6c. Where are pharmacological therapies being provided? 
Q6d. For what time period are pharmacological therapies being prescribed? 
Q6e. Do established protocols exist for delivery of these interventions? 
Q6f. What are the safety issues with these pharmacological interventions –
particularly interaction issues with Antabuse? 
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Q6g. What adjunct psychosocial therapies are being given with pharmacological 
interventions? 
 
7. Effectiveness of pharmacological interventions – evidence base 
 
Q7a. What is the evidence base for the effectiveness of each medication (including 
objective evaluations of relapse using blood, breath or other formal test)? 
Q7b. Who should deliver pharmacological therapy? 
Q7c. What evidence exists on the optimal location for the commencement and 
subsequent provision of pharmacological therapies? 
Q7d. What evidence exists on the optimal duration of treatment with 
pharmacological therapies? 
Q7e. Should pharmacological therapies be targeted at groups of individuals? 
Q7f. Should adjunct psychosocial therapies be given with pharmacological 
interventions? 
 
8. Important concomitant substances 
 
Q8a. What other medications do individuals use for the treatment of alcohol or 
alcohol related problems in addition to those prescribed for relapse 
prevention? 
Q8b. Is the success of either psychosocial or pharmaceutical interventions in relapse 
prevention affected by the use of other medications? 
Q8c. Does the presence of concomitant disease or substance abuse affect the choice 
of interventions for relapse prevention? 
9. Combining treatment 
 
Q9a. Are combinations of psychosocial and pharmacological interventions more 
effective in relapse prevention than either approach given alone? 
 
10. Patient Issues 
 
Q10a. What are the best methods to support and encourage individuals through the 
treatment programme? 
Q10b. What are the patient preferences for treatment? 
Q10c. What are the issues involved in relapse prevention in alcohol dependent 
individuals who have been involved in the criminal justice system? 
 
11. Healthcare system use 
 
Q11a. Following relapse, what proportion of individuals leave the healthcare system 
and what proportion remain undergoing further detoxification and relapse 
prevention?  
Q11b. What are the current courses of action when a patient relapses? 
Q11c. Is there any evidence for continued repetitions of the detoxification and 
relapse prevention treatment programme, following failure? 
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Appendix 4 Definitions of dependence 
 
DSM-IV Criteria for Substance Dependence 
 
The Diagnostic and Statistical Manual (DSM-IV) of the American Psychiatric 
Association defines substance dependence as: 
 
A maladaptive pattern of substance use, leading to clinically significant impairment or 
distress, as manifested by three (or more) of the following, occurring at any time in 
the same 12-month period: 
 
(1) Tolerance, as defined by either of the following: 
 
(a) a need for markedly increased amounts of the substance to achieve 
intoxication or desired effect. 
(b) Markedly diminished effect with continued use of the same amount of 
the substance. 
 
(2) Withdrawal, as manifested by either of the following: 
 
(a) The characteristic withdrawal syndrome, for the substance (refer to 
Criteria A and B of the criteria sets for Withdrawal from the specific 
substances). 
(b) The same (or a closely related) substance is taken to relieve or avoid 
withdrawal symptoms. 
 
(3) The substance is often taken in large amounts or over a longer period than was 
intended. 
 
(4) There is a persistent desire or unsuccessful efforts to cut down or control 
substance use. 
 
(5) A great deal of time is spent in activities necessary to obtain the substance 
(e.g. visiting multiple doctors or driving long distances) use the substance (e.g. 
chain-smoking), or recover from its effects. 
 
(6) Important social, occupational, or recreational activities are given up or 
reduced because of substance use. 
 
(7) The substance use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have caused or 
exacerbated by the substance (e.g. current cocaine use despite recognition of 
cocaine-induced depression, or continued drinking despite recognition that an 
ulcer was made worse by alcohol consumption. 
 
Specify if: 
With Physiological Dependence: evidence of tolerance or withdrawal (i.e. 
either Item 1 or 2 is present). 
Without Physiological Dependence: no evidence of tolerance or withdrawal 
(i.e. neither Item 1 nor 2 is present). 
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Course specifiers (See text for definitions): 
 
Early Full Remission 
Early Partial Remission 
Sustained Full Remission 
Sustained Partial Remission 
On Agonist Therapy 
In a Controlled Environment 
 
 
Table 4 ICD-10 criteria for substance dependence 
 
 
A diagnosis of dependence should usually be made only if three or more of the 
following have been experienced or exhibited at some time during the previous year. 
 
( a ) A strong desire or sense of compulsion to take the substance. 
( b ) Difficulties in controlling substance-taking behaviour in terms of its onset, 
termination, or levels of use. 
( c ) A physiological withdrawal state when substance use has ceased or been 
reduced, as evidenced by the characteristic withdrawal syndrome for the substance, or 
use of the same (or a closely related) substance with the intention of relieving or 
avoiding withdrawal symptoms. 
( d ) Evidence of tolerance such that increased doses of the psychoactive substance 
are required in order to achieve effects originally produced by lower doses. 
( e ) Progressive neglect of alternative pleasures or interests because of 
psychoactive substance use, increased amount of time necessary to obtain or take the 
substance or to recover from its effects. 
( f ) Persisting with substance use despite clear evidence of overtly harmful 
consequences, such as harm to the liver through excessive drinking, depressive mood 
states consequent to periods of heavy substance use, or drug-related impairment of 
cognitive functioning; efforts should be made to determine that the user was actually, 
or could be expected to be, aware of the nature and extent of the harm.  
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Appendix 5 HTBS survey of NHS secondary care in Scotland - Questionnaire 
 
Health Technology Board for Scotland     
           
           
           
       
The Current Provision of Services for Alcohol Relapse Prevention 
In Secondary Care 
 
 
Name of Respondent: ____________________________________________ 
 
Occupational Title and Grade: _____________________________ 
 
Work Address: ___________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
 
Name and Address of Employer: ________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
 
Name / Title of the Service Covered in this Questionnaire: 
____________________________________________________________________ 
____________________________________________________________________ 
 
 
Geographical Area / Sector Covered by the Service: 
____________________________________________________________________ 
____________________________________________________________________ 
 
Name of the Consultant / Other (Please give designation) in Charge of the Service: 
__________________________________________________________ 
 
 
 
Date of Completion of Questionnaire: _______________________ 
 
 
 
May we contact you to clarify details regarding your response to this questionnaire? YES / NO 
Telephone no. ___________________________ 
E-mail address ___________________________ 
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A INVENTORY OF ALCOHOL SERVICES 
                                                                                  Delete As Appropriate 
1. Do you have any specialist alcohol workers / services?         YES  /  NO 
                                                                                    Go to     go to 
                                                                                   Q.A2    Section B 
 
2. Is the service: 
                              Please ‘X’ all that apply  
community based          ___ 
outpatient based           ___ 
day hospital based          ___ 
inpatient based            ___ 
other (please specify)       _______________________________________ 
 
 
 
3.With respect to inpatient alcohol services: 
                             
                                                                            Delete As Appropriate       No. of beds 
                                                                                                    (If applicable) 
do you have dedicated beds for alcohol patients?            YES  /  NO       ___ 
 
 
if yes, are the nursing staff covering these beds dedicated to      Delete As Appropriate 
or specifically trained in alcohol / substance misuse nursing?      YES  /  NO 
 
 
                                                                                                Please give an estimate of 
                                                                         Delete As Appropriate     no. in use at any onetime 
do you use general adult psychiatric acute admission beds?   YES  /  NO             ___ 
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4. Please complete details of the specialist alcohol workers in the community / 
outpatient / day hospital based service as well as inpatient staff solely dedicated to 
alcohol/substance misuse services. 
 
 Please ‘X’ all that 
     Apply 
Permanent Whole Time 
     Equivalent Posts 
Temporary Whole Time 
      Equivalent Posts 
(Example-staff grade psych.)         X               0      1 x 0.6 
Consultant psychiatrist    
Staff grade psychiatrist    
Senior house officer    
Other medical-please specify 
______________________ 
   
Other medical-please specify 
______________________ 
   
Community / staff nurse (I)  * * 
Community / staff nurse (H)  * * 
Community / staff nurse (G)  * * 
Community / staff nurse (F)  * * 
Community / staff nurse (E)  * * 
Community / staff nurse (D)  * * 
Community / staff nurse (C)  * * 
Nursing assistant    
Other nursing staff-please 
specify_________________ 
   
Other nursing staff-please 
specify_________________ 
   
Consultant clinical 
psychologist 
   
Clinical psychologist    
Trainee psychologist    
Assistant psychologist    
Occupational therapist    
Other-please specify 
_______________________
   
Other-please specify 
_______________________
   
*Please indicate whether nursing staff are RGN or RMN 
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B ALCOHOL RELAPSE PREVENTION – PSYCHOSOCIAL INTERVENTIONS 
 
1. Does your service offer psychosocial interventions for alcohol relapse prevention? 
Yes ¨ No ¨ (If No go to section C)  
 
 
2. Which psychosocial intervention does your service provide for relapse prevention?  
 
  Please ‘X’ 
A Motivational interviewing  
B Cognitive Behaviour Therapy  
C Brief intervention  
D Twelve step facilitation therapy  
E Behavioural marital/couples therapy  
F Couples therapy  
G Family therapy  
H Community reinforcement approach/therapy  
I Social skills training  
J Coping skills training  
K Stress management  
L Non-specific counselling (please give details below*)  
M Other (please specify below*)  
*____________________________________________________________________
_____________________________________________________________________ 
_____________________________________________________________________ 
 
 
3. Please give codes (A-M above) of those interventions with written protocols in place.  
 
_____________________________________________________________________ 
   (It would be helpful if copies of protocols could be enclosed with the questionnaire) 
 
 
4. Please give codes (A-M above) of those interventions with patient information 
leaflets. 
 
_____________________________________________________________________ 
(It would be helpful if copies of patient information leaflets could be enclosed)
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5. For each of the interventions marked in question 1 above please give the following details  
Note: If there are more than 4 interventions used please photocopy this page and attach to the completed questionnaire. 
Code (A-M above)     
Individual/group 
(If applicable)  
    
Residential (Y/N)     
Proposed duration/ number 
of sessions 
    
Aim of intervention 
e.g. abstinence, increase in CAD 
    
Outcome measures used? 
e.g. timeline follow back, 
collateral info, diary, laboratory 
investigations (specify) 
    
Process audited? (If known 
give no. seen/year) 
    
Accredited staff 
e.g. discipline, grade, no.  
 
    
Non-accredited staff 
carrying out therapy. 
e.g. discipline, grade, no. 
 
 
    
What training does staff 
receive? e.g. internal or external 
and from which body/organisation 
etc 
 
    
Does this result in 
accreditation? 
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C ALCOHOL RELAPSE PREVENTION – PHARMACOLOGICAL INTERVENTIONS 
 
1. Please complete details of the pharmacological interventions offered for relapse prevention 
 Acamprosate Naltrexone Disulfiram Other (*specify) 
Please ‘X’ if used     
Start as in/outpatient/both?      
Which staff prescribe this 
medication? 
    
Frequency of review?     
Initial proposed duration?     
Are psychological interventions 
usually used in combination? 
(Please specify) 
    
Are special conditions of 
administration employed? e.g. 
CPN supervision (Please specify) 
    
What outcome measures are 
used? e.g. timeline follow back, 
collateral info, diaries, lab. 
Investigations (Please Specify 
    
What is the goal / aim of the treatment?
e.g. abstinence inc. in CAD 
    
Is the process audited? (If 
possible enter no. seen / yr) 
    
*___________________________________________________________________________________________________________ 
 
2. Are combinations of pharmacological interventions regularly used for relapse prevention? Please specify. 
_________________________________________________________________________________________________________ 
 
3. For which of the pharmacological interventions are there protocols in place? 
_________________________________________________________________________________________________________  
(It would be helpful if copies of protocols could be enclosed with the questionnaire) 
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D APPROACH TO TREATMENT ADHERENCE, DEFAULT, RECURRENT RELAPSE 
 
1. What is your approach to non-adherence / default from psychosocial intervention? ____________________________________________________ 
_________________________________________________________________________________________________________________________ 
_________________________________________________________________________________________________________________________ 
2. What is your approach to non-adherence / default from pharmacological intervention? _________________________________________________ 
_________________________________________________________________________________________________________________________ 
_________________________________________________________________________________________________________________________ 
3. What measures would you continue to offer in the case of recurrent relapse if each of the aforementioned interventions has already been used? 
_________________________________________________________________________________________________________________________ 
_________________________________________________________________________________________________________________________ 
 
E USE OF OTHER AGENCIES 
 
1. Which agencies do you ‘make use of’ / integrate in the aftercare of patients? 
      NEVER    RARELY OCCASIONALLY   REGULARLY 
Social work     
Alcoholics Anonymous     
Alanon (carer / family support)     
Council on Alcohol     
Voluntary hostels     
Private care e.g. Priory, Castle Craig     
Non-statutory rehabilitation units e.g. Church of Scotland     
Other secondary care (e.g. GI clinic – please specify) 
___________________________________________ 
    
Other primary care (e.g. practice nurse – please specify) 
___________________________________________ 
    
Other (please specify) ________________________ 
__________________________________________ 
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          F OTHER ASPECTS OF CURRENT SERVICE 
 
1. With respect to your service, what is the standard minimum aftercare package offered 
to most individuals on discharge from hospital care following alcohol detoxification? 
(Please only answer if relevant to your service) 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
 
 
2. Are there other features of your service which are important in relation to relapse  
prevention which are not covered in this questionnaire? If so please comment. 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________   
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Appendix 6 HTBS survey of other providers in Scotland - Questionnaire 
 
Health Technology Board for Scotland 
 
SERVICES FOR PREVENTION OF RELAPSE 
IN ALCOHOL DEPENDENCE IN SCOTLAND 
 
Name of Respondent_______________________________________________________________ 
 
Designation (Occupational title and grade) _____________________________________________ 
 
Name of Service / Unit _____________________________________________________________ 
 
Address of Service / Unit ___________________________________________________________ 
________________________________________________________________________________ 
 
Parent Body _____________________________________________________________________ 
 
 
Date of Questionnaire Completion___________________________ 
 
 
A.1 Please give the approximate no. of staff in your service. ____ 
                                                                                                              
B.1 Do you have dedicated beds for individuals with        Delete as appropriate     no. of beds 
alcohol dependence/problems?                         YES / NO          ____ 
 
Please add any additional explanatory comments if required __________________________ 
___________________________________________________________________________ 
 
B.2 Please describe on what basis these beds are allocated to individuals and the length  
of time individuals would be expected to occupy these beds. __________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________  
 
C.1 Does your service offer psychosocial interventions / counselling            Delete as appropriate 
for alcohol dependency / alcohol relapse prevention?    YES / NO 
 
C2 Please describe what forms of psychosocial intervention are offered (e.g. CBT,  
social skills training, non-specific counselling) ______________________________________ 
____________________________________________________________________________ 
 
C.3 Please describe the training that staff receive to carry out these interventions.  
____________________________________________________________________________ 
____________________________________________________________________________ 
                                                          Delete as appropriate 
C.4 Does the training result in accreditation?                       YES / NO 
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D.1 Please estimate how many individuals with alcohol problems are newly engaged or re-engaged (e.g. in treatment 
programs, counselling etc.) with your service in an average month. _______ 
 
D.2 On average, what would be the usual proposed length of treatment / ongoing contact with individuals engaged 
with your service? (Please add any additional comment if required). _______                          
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Appendix 7 Narrative summary of results of surveys by NHS Board 
NHS SPECIALIST SERVICES QUESTIONNAIRE 
(A specimen questionnaire can be found in Appendix 5) 
 
 · 27 survey questionnaires were sent to identified individuals who were either known to be leading 
NHS specialist alcohol teams or, in the case of NHS Board areas without such teams, individuals 
who would have information regarding specialist services for the treatment of alcohol problems in 
their area.  
 
· The questionnaires covered all NHS Board areas. 
 
· Telephone enquiry prior to sending the questionnaires could not identify any further NHS 
specialist service specifically involved in the treatment of alcohol problems which may have been 
overlooked. 
 
· After the questionnaires had been sent out, it was clarified that Lanarkshire NHS Board had 3 
main centres with base hospitals at Hairmyres, Hartwood and Monklands. 5 questionnaires had 
been sent to Lanarkshire with a resultant overlap in the services covered. In addition both Lothian 
Health Board and Western Isles Health Board were sent 2 questionnaires each with only 1 
respondent answering for the whole area. The number of questionnaires expected to be returned 
was therefore reduced to 23. 
 
· Only 1 questionnaire out of the 23 remaining questionnaires was not returned. Additional 
information was obtained on telephone enquiry from that particular service covering basic staffing 
and service data. 
 
· The returned questionnaires were almost universally completed to a high standard in terms of 
quality and detail of information. 
 
· Additional protocols for psychosocial interventions, pharmacological interventions and other 
aspects of aftercare were submitted by respondents from Orkney, Lothian, East Glasgow, South 
Glasgow, Lomond and Argyll, Dumfries and Galloway and Renfrewshire & Inverclyde. 
 
· The collated information has been checked for accuracy using written follow-up contact with all 
respondents.  
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NON NHS SERVICES QUESTIONNAIRE 
(A sample questionnaire can be found in Appendix 6) 
 
· Survey questionnaires were sent out to all voluntary facilities / Social Work facilities that we 
could identify as having some role in helping individuals with alcohol related problems.  We did 
not send out questionnaires to the AA who have already submitted information to the HTBS. 
Neither did we send questionnaires to private facilities such as Castle Craig or The Priory who 
were asked to submit comments during the earlier information gathering process.  
 
· 114 questionnaires were sent to various groups and organisations based throughout Scotland.  Of 
these 2 questionnaires had erroneously been sent to facilities already surveyed. In addition 1 
questionnaire was sent to an NHS service, again by mistake. The number of active questionnaires 
was therefore 111. 
 
· The organizations, which were sent the questionnaire included all identified Councils on Alcohol 
(31), although the sub offices of the various Councils were not surveyed.  The Council on Alcohol 
appears to have services in all NHS Boards except Western Isles and Shetland.  Other non NHS 
facilities surveyed included the day services of various voluntary, independent, Church of Scotland 
and Social Work organisations.  Residential rehabilitation facilities and residential homeless 
facilities, again run by various voluntary, independent, Church of Scotland or Social Work 
organisations were also surveyed. 
 
· 39 (35%) of the questionnaires were returned (44% of which were from Councils on Alcohol). 
 
· 61% of questionnaires returned were from day services (this was 24 out of 62 (39%) of the day 
services surveyed). 
 
· 8% of questionnaires returned were from residential rehabilitation services (this was 3 out of 13 
(23%) of the residential rehabilitation services surveyed)  
 
· 31% of questionnaires returned were from residential homeless services (this was 12 out of 37 
(32%) of the residential homeless services surveyed). 
 
· The questionnaires returned represent a reasonably broad distribution of the non-NHS services 
identified for the survey as can be seen in Table 4 (returned surveys in bold italics). 
 
· 17 Social Work facilities were not identified until after the questionnaires had been returned.  
Information from these services was available from the SACAM survey of alcohol services carried 
out for the preparation of the Plan for Action on Alcohol Problems. 
 
· Of non-statutory services, 32 Council on Alcohol sub-offices and 10 other facilities identified 
post-survey from SACAM information were not surveyed. 
 
· The total number of non-statutory facilities (i.e. not including the Social Work services) identified 
in Scotland as dealing in some way with people with alcohol related problems was therefore139 (of 
which 97 were surveyed, 36 (37%) of whom returned completed questionnaires).  This figure does 
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not include the very large number of AA meetings, which take place on a daily basis throughout 
Scotland. 
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SERVICES SUMMARY IN BRIEF PER NHS BOARD 
 
ARGYLL & CLYDE 
(Population: 426 046) 
 
LOMOND & ARGYLL 
 
(Population: 136 046) 
 
NHS STATUTORY SECONDARY CARE 
 
1 inpatient and outpatient based secondary care service but no community or day hospital service. 
(Community Addiction Team, CAT, in Dumbarton area) 
14 dedicated inpatient beds, no use of general adult psychiatry beds (total: 14 beds)  
Staffing compliment includes Consultant Psychiatrist, other medical staff and RMN trained nursing 
staff. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include Motivational Interviewing (MI), Cognitive Behavioural 
Therapy (CBT), Community Reinforcement Approach (CRA), Social Skills Training (SS), Coping 
Skills Training (CS), Stress Management (SM), Non-specific Counselling (NSC), Residential 
Relapse Prevention Programme and Respite Admissions. 
 
NON NHS SERVICES 
 
In addition to Alcoholics Anonymous (AA), the area has 9 of the non-NHS facilities identified, 
about 8 of which are day facilities (7 Council on Alcohol and 1 social work facility) and 1 service 
which is a Church of Scotland residential rehabilitation facility. 
 
REFREWSHIRE & INVERCLYDE 
 
(Population: 290 000) 
 
NHS STATUTORY SECONDARY CARE 
 
2 outpatient and day hospital based services. 
11 dedicated inpatient beds and about 4 other general adult psychiatry beds in use for alcohol 
problems at any one time (total: 15 beds). 
Staffing compliment includes Consultant Psychiatrists, other medical staff, RMN trained nursing 
staff and Clinical Psychology staff. 
Uses Acamprosate, Disulfiram and Naltrexone (1 of services). 
Psychosocial interventions include MI, CBT, Brief Intervention (BI), SS, CS, SM, Alcohol 
Education Groups, Solution Focussed Relapse Prevention Groups, Anxiety Management, Anger 
Management, Relaxation and Exercise Groups, outpatient women’s group ‘self help’. 
 
 
 
 198
NON NHS SERVICES 
 
In addition to AA, the area has 16 of the non nhs facilities identified, about 12 of which are day 
facilities (mostly Councils on Alcohol and social work facilities), 3 of which are residential 
homeless facilities (Jericho Society) and 1 facility which is a Salvation Army residential 
rehabilitation facility. 
 
AYRSHIRE & ARRAN 
(Population: 374 545 ) 
 
NHS STATUTORY SECONDARY CARE 
 
A comprehensive community, outpatient, day hospital and inpatient based service. 
6 dedicated alcohol beds and 12 beds for residential dual diagnosis service, which at any time are 
used by approximately 50% alcohol users (total: 12 beds). 
Staffing compliment includes Consultant Psychiatrist, other medical staff, nursing staff (both RGN 
and RMN trained) and Occupational therapy staff. 
Uses Acamprosate, Disulfiram and Naltrexone. 
Psychosocial interventions include MI, CBT, BI, Behavioural Marital/ Couples Therapy (BMCT), 
Couples Therapy, Family Therapy, CRA, SS, CS, SM, NSC, Anger Management, Relapse 
Management. 
 
NON NHS SERVICES 
 
In addition to AA the area has 8 of the non NHS facilities identified, all of which are day facilities, 
spread between the Council on Alcohol, social work, Church of Scotland and an independent 
voluntary facility. 
 
BORDERS 
(Population: 106 389) 
 
NHS STATUTORY SECONDARY CARE 
 
A solely community based service. 
1.5 dedicated alcohol beds and 0.8 general psychiatry beds in use for alcohol problems at any one 
time (total: 2.3 beds) 
Staffing compliment without a Consultant Psychiatrist or any medical staff, but does have 
dedicated social work staff as well as nursing staff. 
Uses Acamprosate and Disulfiram. 
No psychosocial interventions offered. 
 
NON NHS SERVICES 
 
In addition to AA, the area has 2 of the non nhs facilities identified, both of which are day facilities 
(Council on Alcohol and independent voluntary). 
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DUMFRIES & GALLOWAY 
(Population: 147 280) 
 
NHS STATUTORY SECONDARY CARE 
 
A community, outpatient and inpatient based service with no day hospital service. 
4 beds dedicated to either alcohol or substance use disorders and 2 general psychiatry beds in use 
for alcohol problems (total: 6 beds). 
Staffing compliment includes a Consultant Psychiatrist, other medical staff, RMN and RGN trained 
nursing staff and Occupational Therapy staff. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include MI, CBT, BI, Couples, SS, CS, SM. 
 
NON NHS SERVICES 
 
In addition to AA the area has 2 of the non nhs facilities identified (Councils on Alcohol) 
 
FIFE 
(Population: 348 214) 
 
NHS STATUTORY SECONDARY CARE 
 
2 services, a very small outpatient and day hospital based service in West Fife and one solely 
community based service in Kirkcaldy and related areas. 
No dedicated alcohol and up to about 4 general adult psychiatry beds in use at any one time (total: 
up to 4 beds). 
Staffing compliment with no Consultant Psychiatrist or other medical staff.  
Uses Acamprosate and Disulfiram. 
Only 1 of the 2 services offers psychosocial interventions, which include MI, CBT, BI, Couples, 
Family, SS, CS, SM. 
 
NON NHS SERVICES 
 
In addition to AA the area has 4 of the non nhs facilities identified, all of which are day facilities 
equally spread between Council on Alcohol, social work, Church of Scotland and another 
independent voluntary facility. 
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FORTH VALLEY 
(Population: 275 806) 
 
NHS STATUTORY SECONDARY CARE 
 
A community and outpatient service with no day hospital or specialist inpatient provision. 
No dedicated alcohol beds and 2 general adult psychiatry beds in use for alcohol problems (total: 2 
beds). 
Staffing compliment includes Consultant Psychiatrist and RMN nursing staff. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include MI, CBT, BI, SS, CS, SM. 
 
NON NHS SERVICES 
 
In addition to AA the area has 4 of the non nhs facilities identified (Councils on Alcohol). 
 
GRAMPIAN 
(Population: 532 110) 
 
NHS STATUTORY SECONDARY CARE 
 
A community and outpatient service with no day hospital or specialist inpatient provision. 
No acknowledged use of beds for alcohol problems, either dedicated or general adult psychiatry 
(total: 0 beds). 
Staffing compliment includes Consultant Psychiatrist, other medical staff and RMN nursing staff. 
Uses Acamprosate, Disulfiram and Naltrexone. 
Psychosocial interventions include MI, CBT, BI, Twelve Step Facilitation (TSF), CS, SM. 
 
NON NHS SERVICES 
 
In addition to AA the area has 14 of the non nhs facilities identified, 9 of which are day 
facilities (spread across Councils on Alcohol, social work, Salvation Army, Cyrenians etc.), 2 
of which are residential homeless facilities (Cyrenians and independent voluntary) and 3 
residential rehabilitation facilities (1 Church of Scotland and 2 independent voluntary 
facilities). Albyn House Association Ltd. has 14 hostel beds for respite / rehabilitation and 4 
designated place beds for sobering up of ‘drunk and incapable’ persons arrested by 
Grampian Police.
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GREATER GLASGOW 
(Population: 897 053) 
 
NHS STATUTORY SECONDARY CARE 
 
4 centres, 3 of which have comprehensive community, outpatient, day hospital and inpatient 
services, 1 of which has no day hospital service. 
19-21 dedicated alcohol beds and 6 general adult psychiatry beds in use at any one time (total: 25-
27 beds). Future planning to reorganize as 2x15 bedded units. 
Staffing compliment includes Consultant Psychiatrists, other medical staff, nursing staff, 
Consultant Clinical Psychologists and other clinical psychology staff and Occupational Therapy 
staff. 
Uses Acamprosate, Disulfiram and Naltrexone (1 service). 
Psychosocial interventions include MI, CBT, BI, SS, CS, SM, BMCT, Couples, CRA, Anger 
Management, Relapse Prevention Groups/Programme. 
 
NON NHS SERVICES 
 
In addition to very large AA presence, the area has 47 of the non NHS facilities identified, 28 of 
which are day facilities (9 Councils on Alcohol, 12 social work, others include Church of Scotland, 
independent voluntary and City Council facilities), 15 of which are residential homeless facilities 
(6 Talbot Association, 4 City Council, 3 Simon Community (SW and HB funded), and independent 
voluntary facilities), 4 of which are residential rehabilitation facilities (1 Church of Scotland, 1 
Salvation Army, 1 Turning Point, 1 ind. vol. facilities). 
 
HIGHLAND 
(Population: 210 418) 
 
NHS STATUTORY SECONDARY CARE 
 
A comprehensive community, outpatient, day hospital and inpatient based service (also employing 
a prison liaison nurse and providing liaison to general hospital receiving ward and maternity ward) 
6 dedicated alcohol beds and no general adult psychiatry beds used (total: 6 beds). 
Staffing compliment includes Consultant Psychiatrist, other medical staff, nursing staff and social 
work staff. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include MI, CBT, BI, BMCT, SS, CS, SM, Solution Focussed Therapy, 
Assertiveness Training. 
 
NON NHS SERVICES 
 
In addition to AA the area has 13 of the non NHS facilities identified, 12 of which are Councils on 
Alcohol with 1 Church of Scotland residential rehabilitatio n facility. 
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LANARKSHIRE 
(Population: 559 150) 
 
NHS STATUTORY SECONDARY CARE 
 
3 services with base hospitals at Monklands, Hairmyres and Hartwood.  All are community, 
outpatient and inpatient services with no day hospital service. 
7 dedicated alcohol beds and 8 general adult psychiatry beds in use at any one time (total: 15 beds). 
Staffing complement includes Consultant Psychiatrists, RMN trained nursing staff, Consultant 
Clinical Psychology and other Clinical Psychology staff and Occupational Therapy staff. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include MI, BI, CS, SS, Couples. 
 
NON NHS SERVICES 
 
In addition to AA the area has 6 of the non nhs facilities identified, 5 of which are day facilities (3 
social work,2 Councils on Alcohol) with 1 facility which is a social work residential rehabilitation 
facility. 
 
LOTHIAN 
(Population: 774 528) 
 
NHS STATUTORY SECONDARY CARE 
 
A community, outpatient and inpatient based service. 
12 dedicated alcohol beds and no use of general adult psychiatric beds (total: 12 Beds). 
Staffing compliment includes Consultant Psychiatrists, other medical staff, nursing staff, 
occupational therapists and a clinical psychologist.. 
Uses Acamprosate, Disulfiram and Naltrexone. 
Psychosocial interventions include MI, CBT, BI, TSF, BMCT, SS, CS, SM, Supportive 
Counselling, Group Therapy (support and relapse prevention groups). 
 
NON NHS SERVICES 
 
In addition to a large AA presence, the area has 27 of the non nhs facilities identified, 15 of which 
are day facilities (9 Councils on Alcohol with 1 social work and 1 Church of Scotland facility, the 
rest being other ind. vol. facilities), 9 of which are residential homeless facilities (3 Cyrenians, 2 
City Council, 1 Church of Scotland, 1 Salvation Army, 2 independent vol.) and 3 of which are 
residential rehabilitation facilities (1 Church of Scotland and 2 independent vol. facilities). 
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ORKNEY 
(Population: 19 794) 
 
NHS STATUTORY SECONDARY CARE 
 
A solely community based service. 
1 bed allocated for use in Balfour NHS Hospital (total: 1 bed). 
Staffing compliment with nursing staff only. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include MI, CBT, BI, SS, CS, SM, Relapse Prevention. 
 
NON NHS SERVICES 
 
In addition to AA the area has only 1 of the non nhs facilities identified (Council on Alcohol). 
 
SHETLAND 
(Population: 22 855) 
 
NHS STATUTORY SECONDARY CARE 
 
No specialist service (total: 0 beds). 
 
NON NHS SERVICES 
 
In addition to AA the area has 2 of the non nhs facilities identified (independent voluntary day 
facilities). 
 
TAYSIDE 
(Population: 391 397) 
 
NHS STATUTORY SECONDARY CARE 
 
A community, outpatient and inpatient service with no day hospital service. 
12 dedicated alcohol beds as well as general adult psychiatry beds in use (total: 12 beds). 
Staffing compliment includes Consultant Psychiatrist, other medical staff and RMN trained nursing 
staff. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include MI, CBT, BI, CS, SM, womens’ groups,jointly staffed relapse 
prevention groups (TAPS and OT Dept. in Montrose, and NHS and SW Dept in Angus. 
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NON NHS SERVICES 
 
In addition to AA the area has 13 of the non nhs facilities identified, 6 of which are day facilities (3 
SW, 2 Councils on Alcohol, and 1 independent vol.) and 7 of which are residential homeless 
facilities (3 Cyrenians, 1 Jericho Society, 3 other independent vol.). 
 
WESTERN ISLES 
(Population: 28 476) 
 
NHS STATUTORY SECONDARY CARE 
 
A small but comprehensive community, outpatient, day hospital and inpatient based service. 
No dedicated alcohol beds and up to 1 –2 general adult psychiatry beds in use at any one time 
(total: 1-2 beds). 
Staffing compliment includes Consultant Psychiatrist and nursing staff. 
Uses Acamprosate and Disulfiram. 
Psychosocial interventions include MI, CBT, BI, BMCT, Couples, Family CRA, SS, CS, SM. 
 
NON NHS SERVICES 
 
In addition to AA the area has 2 of the non nhs facilities identified (Church of Scotland day facility 
and independent vol. day facility) 
 
 
 
 
 
 
 
Additional notes 
 
 
 
1) Residential homeless facilities may not have any specific remit for dealing with alcohol 
problems. This was the case in about 50% of questionnaires returned. 
 
2) Community Addiction Teams (CATs) may not have been included in all cases due to the 
newness of the service and the fact that they may not have been picked up as NHS statutory 
facilities, coming under a social work umbrella instead.  
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Appendix 8 Tabulated summary of results of survey of services 
 
Table 1: Pharmacological and Psychosocial Interventions in NHS Secondary Care  
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Lomond & Argyll · ·  · ·    · · · ·   · · 
Renfrewshire & Inverclyde · · · · · ·    · · ·    · 
Ayrshire & Arran.  · · · · · ·  · · · · · · · ·  
Borders. · ·               
Dumfries & Galloway · ·  · · ·    · · · ·    
Fife · ·  · · ·    · · · · ·   
Forth Valley · ·  · · ·    · · ·     
Grampian · · · · · · ·    · ·     
Greater Glasgow · · · · · ·  · · · · · ·   · 
Highland · ·  · · ·  · · · · · · · · · 
Lanarkshire  · ·  ·  ·    · ·  ·    
Lothian · · · · · · · ·  · · ·    · 
Orkney · ·  · · ·    · · ·   ·  
Shetland*                 
Tayside · ·  · · ·     · ·    · 
Western Isles · ·  · · ·  · · · · · · ·   
* No specialist services 
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Table 2: Break down of NHS bed usage per health board 
 
NHS 
BOARD 
 
DEDICATED 
ALCOHOL  
BEDS 
GEN. ADULT 
PSYCH. BEDS 
(in use at one 
time) 
TOTAL BEDS 
(in use at one 
time) 
POPULATION BEDS per 
100 000 
Borders 1.5 0.8 2.3 106,389 2.16 
Dumfries & Galloway 4* 2 6 147,280 4.07 
Lothian 12 0 12 774,528 1.55 
Ayrshire & Arran 6(+6)** 0 18 374,545 4.81 
G. Glasgow 19-21 6 25-27 897,053 2.90 
Renfrewshire & 
Inverclyde 
11*** 4 15*** 290,000 5.17(some 
beds daytime 
only) 
Lomond & Argyll 14 0 14 136,046 10.30 
Lanarkshire 7 8 15 559,150 2.68 
Forth Valley 0 2 2 275,806 0.76 
Tayside 12? 0**** 12 391,397 3.07 
Fife 0 4.4 4.4 348,214 1.26 
Grampian 0 0 0 532,110 0 
Highlands 6 0 6 210,418 2.85 
W. Isles 0 1-2 (probably) 1-2 28,476 3.51(only used 
for alc. problems 
if needed) 
Orkney 0 1 1 19,794 5.05(as above) 
Shetland 0 0 0 22,855 0 
 
General Adult Psychiatry (GAP) beds recorded are those used specifically by the Specialist team for their patients for 
treatment of alcohol problems  
 
* Dumfries and Galloway has 4 dedicated beds for either alcohol or substance misuse 
** Ayrshire and Arran has ‘6 beds for alcohol detoxification and 12 beds for residential dual diagnosis services which 
at any one time are used by approximately 50% alcohol users (and also drug users)’ (C.Lind,Consultant 
Psychiatrist,13/3/02, Personal Communication) 
*** Renfrewshire and Inverclyde have 11 dedicated beds but those in Inverclyde (7 beds) are in daytime use only with 
severely unwell patients, including those at risk of seizures, being admitted to general adult psychiatric beds 
**** Tayside has General Adult Psychiatry beds not exclusively for alcohol use but used by general adult psychiatry 
for patients whose primary problem is related to alcohol. About 300 alcohol related admissions/year (assuming a stay 
of 12 days this would be 10 GAP beds in use at any one time) (P.Rice, Consultant Psychiatrist, 16/03/02, Personal 
Communication) 
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Table 3: Psychosocial Interventions as used in NHS Secondary Care Alcohol Services 
intervention % of those 
services 
which 
provide 
psychosocial 
interventions 
written 
protocols 
patient 
info.  
leaflets 
individual 
/group 
residential 
/ non res. 
proposed 
duration 
audited % using 
accredited 
staff  
external 
training 
MI 100 few few mostly 
individual, 
some 
group 
mostly 
non res., 
some res. 
up to 6 
sessions, 
rarely 
longer 
few 53 - 83.%  some 
CBT 84 few several mostly 
individual, 
some 
group 
mostly 
non res., 
some res. 
variable very few 63 – 91% Most 
BI 90 1/3rd few mostly 
individual, 
some 
group 
non res. variable/ 
1-2 
sessions 
1 service 53 - 82% Some 
BM/CT  25 none none couples non.res. ? (1-2 
sessions 
in 1 
response) 
no 20 -100% some 
CRA 33 few few individual mostly 
non res., 
some res. 
variable no 43 -100% some 
SS 79 few few mostly 
individual, 
some 
group 
mostly 
non res., 
some res. 
variable 
(up to 10 
sessions 
specified 
by 25%) 
1 service 60 -100% some 
CS 100 few few both 
individual 
and group 
mostly 
non res., 
some res. 
variable 
(up to 10 
sessions 
specified 
by 25 %) 
few 53 -100% some 
SM 95 very few 1/3rd both 
individual 
and group 
mostly 
non res., 
some res. 
variable 
(up to 10 
sessions 
specified 
by 25%) 
very few 56 -100% some 
couples 33 none none couples mostly 
non res. 
variable no 0% ? 
Rel.prev. 
groups 
?25-33 ?all none group mostly 
non res., 
some res. 
variable 
(6-8 
sessions 
specified 
in some 
services)  
routinely 
done 
20-100% ? 
 
Key to table: acmp = Acamprosate ; dislf = Disulfiram ; naltx = Naltrexone ; MI = motivational interviewing ; CBT = cognitive behavioural therapy ; 
BI = brief intervention ; TSF = twelve step facilitation ; BM/CT = behavioural marital / couples therapy ; CRA = community reinforcement approach 
; SS = social skills training ; CS = coping skills training ; SM = stress management ; couple = couples therapy ; RP.gp. = relapse prevention group
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Table 4: Staff Numbers per Health Board Area – WHOLE TIME EQUIVALENT posts  
 
AREA CONSULTANT 
PSYCHIATRISTS 
OTHER 
MEDICAL 
STAFF 
NURSING 
STAFF 
PSYCHOLOGY 
STAFF 
OCCUPATIONAL 
THERAPY 
STAFF 
SOCIAL 
WORK 
STAFF 
Lomond & 
Argyll 
0.2 0.4 9.25 0 0 0 
Renfrewshire. 
& 
Inverclyde 
 0.5  1.3 8.2 0.1 0 0 
Ayrshire & 
Arran 
1.2 1.0 27.0 0 1.0 0 
Borders 0 0 2.0 0 0 0.5 
Dumfries& 
Galloway 
1.0 1.0 9.0 0 1.0 0 
Fife 0 0 3.0 0 0 0 
Forth 
Valley 
0.2 0 6.0 0 0 0 
Grampian 0.5 1.0 2.5 0 0 0 
G.Glasgow 4.4 7.6 53.3 2.4 4.0  
Highland  0.2 1.6 36.2 0 0 1.0 
Lanarkshire 2.0 2.2 22.0 1.7 2.0 0 
Lothian 1.6 1.66 21.5  0.5  1.5  0.5 
Orkney 0 0 1 0 0 0 
Shetland 0 0 0 0 0 0 
Tayside 1.0 2.0 18.5 0 0 0 
W.Isles 0.0 0 2.0 0 0 0 
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Table 5: Non-NHS Services Distribution (and returned survey numbers in bold) 
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Day facilities * 
Council 
On Alcohol 
7 
(3) 
6 
(2) 
5 
(1) 
1 
(1) 
2 
(1) 
1 4 
(1) 
2 9 
(1) 
12 
(4) 
2 
(1) 
9 
(1) 
1 
(1) 
 2  
Social 
Work 
1 5 1   1  2 12 
(2) 
 3 
(1) 
1   3  
Other LA/ 
City 
Council 
  1   1  1 1        
Church of 
Scotland 
        1 
(1) 
  1    1 
Salvation 
Army  
       1         
Other 
Voluntary 
 1 1 1  1  3 5 
(1) 
  4 
(1) 
 2 
(1) 
1 1 
Residential Rehabilitation Facilities 
Social 
Work 
          1      
Other 
LA/City 
Council 
                
Church of 
Scotland 
1       1 
(1) 
1 1  1     
Salvation 
Army  
 1       1        
Other 
Voluntary 
       2 2 
(1) 
  2 
(1) 
    
Residential homelessness facilities 
Social 
Work 
        1        
Other LA/ 
City 
Council 
        4   2     
Church of 
Scotland 
           1 
(1) 
    
Salvation 
Army  
           1 
(1) 
    
Other 
Voluntary 
 3 
(2) 
     2 
(2) 
10 
(3) 
  5 
(1) 
  7 
(2) 
 
TOTAL 9 16 8 2 2 4 4 14 47 13 6 27 1 2 13 2 
Number 
per 105  
7 6 2 2 1 1 2 3 5 6 1 4 5 9 3 7 
* day facilities include all non-residential facilities irrespective of hours of functioning and intensity / time period of 
intervention 
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Appendix 9 Definitions of psychosocial interventions 
 
Psychosocial interventions  
 
Psychotherapy: The term frequently used to talking treatment based upon psychodynamic or 
psychoanalytic principles.  In practice, the term is also used to refer to a wide range of 
psychological interventions. 
 
Psychotherapeutic techniques: A term used to describe the process/skill involved in carrying out 
the particular psychotherapy or treatment. 
 
Behaviour therapy/modification: A branch of psychotherapy narrowly conceived of as the 
application of classical and operant conditioning to the amelioration of clinical problems.  It is 
more broadly conceived of as applied experimental psychology. 
 
Behaviour contracting: A procedure involving the client signing a contract that he/she will attend 
a specified number of continuing care meetings; this is combined with active follow-up if the client 
fails to meet the conditions of the contract. 
 
Cognitive therapy: Therapy aimed at examining and change cognitions and their underlying 
assumptions.  This involves identifying and challenging negative thoughts, developing alternative 
more accurate and adaptive thought and promoting cognitive and behavioural responses based on 
these adaptive thoughts.  It is an active, structured and directive therapy. 
 
Cognitive behavioural therapy: This involves the use of behavioural techniques to modify 
maladaptive cognitions.  There are a range of behavioural, activity—oriented interventions or 
homework exercises that are used e.g. graded task assignments, activity scheduling, and 
behavioural experiments.  
 
Motivational interviewing/enhancement: A client-centred counselling approach for initiating 
behaviour change by helping clients to resolve ambivalence about engaging in treatment and 
stopping alcohol use. This approach uses strategies to evoke rapid and internally motivated change 
in the client. 
 
Twelve-Step model/Alcoholics Anonymous: A self-help or mutual support group with explicitly 
religious/spiritual aspects.  The philosophy is that alcoholics drink because of a compulsion to do 
so and that they have lost control over their drinking whether or not they are aware of this. 
 
Psychosocial intervention: Cognitive behavioural therapy, motivational 
interviewing/enhancement and the twelve-step/Alcoholics Anonymous comprise the three main 
forms of psychosocial intervention.  The best evidence of effectiveness was found in Project 
March. 
 
Group Therapy: Commonly used procedure but often poorly defined.  Groups can be run 
according to strict psychoanalytical principles, as problem solving groups, experimental groups, 
support groups, discussion groups and, in some cases, according to no clear principles at all. 
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Aversion therapy: A behavioural therapy based on the principle of counter-conditioning.  This 
involves pairing incompatible or aversive consequences with specific stimuli associated with the 
use of alcohol or drugs. 
 
Cover Sensitisation: A form of aversion therapy which uses imagined scenes as aversive events. 
 
Counselling: The task of counselling is to draw out the client and enable him or her to reach a 
greater level of understanding, or a greater commitment to take action.  The process involves 
enabling clients to realize that alternatives exist, and helping the, to clarify what some of those 
choices might be. 
 
Relapse Prevention: A treatment package involving a range of strategies to prevent relapse in the 
field of addictive behaviours.  The aim of this approach, within the field of alcohol treatment, is to 
help the problem drinker develop confidence or self-efficacy in his or her ability to cope with high-
risk for drinking situations. The focus of the treatment is to teach the individual coping-skills so 
that he/she can avoid relapse in the future.  Avoidance of high-risk for drinking situations would be 
encouraged as an early coping strategy, however, during the course of treatment, gradual exposure 
to progressively more risky situations is encourage. 
 
Techniques such as:  Stress management 
   Relaxation  
   Anger management 
   Assertiveness training 
 
can be delivered as individual treatments but are also incorporated within the relapse prevention 
treatment package. 
 
Coping skills: as described above, this treatment approach involves teaching clients coping skills 
for successful living and relationships (such as communications and assertion skills). 
 
Social skills: the focus of social skills training is to help clients increase social support and 
improve their ability to establish rewarding interpersonal relationships.  The content of training will 
focus on a range of areas including body language, listening skills, assertiveness etc. 
 
Couples/marital/family therapy: behavioural marital or family therapy emphasis the teaching of 
skills to improve communication and behaviour change negotiation.  Other marital and family 
therapy approaches draw on systems theory in both formulating the hypotheses about distress and 
planning interventions.  Systemic therapists invariably construct a map defining the organisation, 
roles and rules of the family and couples they treat. 
 
Community reinforcement: in this approach, partners, family and friends are viewed as crucial 
collaborators in the treatment process.  Their roles have included supervising disulfiram, being 
partners in marital counselling, active agents in re-socialisation and reinforcement programmes, 
and relapsed or problem detectors. 
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Brief intervention: this is time-limited intervention focusing on changing an individual’s 
behaviour with respect to alcohol consumption.  The precise content of brief interventions vary.  
They are mainly used to reduce alcohol consumption in people drinking above recommended levels 
but who are not dependent. 
 
Supportive-expressive psychotherapy: is a time limited, focused psychotherapy.  (This approach 
has been adapted for heroin and cocaine use) 
 
The therapy has two main components: 
· Supportive techniques to help patients feel comfortable in discussing their personal 
experiences. 
· Expressive techniques to help patients feel comfortable in discussing their personal 
experiences. 
 
Special attention is paid to the role of drugs in relation to problem, feelings and behaviours, and 
how problems may be solved without recourse to drugs. 
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Appendix 10 Patient Information 
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Appendix 11 12 steps of Alcoholics Anonymous 
 
TWELVE SUGGESTED STEPS OF ALCOHOLICS ANONYM OUS 
 
1. We admitted we were powerless over alcohol – that our lives had become unmanageable. 
 
2. Came to believe that a Power greater than ourselves could restore us to sanity. 
 
3. Made a decision to turn our will and our lives over to the care of God as we understood Him. 
 
4. Made a searching and fearless moral inventory of ourselves. 
 
5. Admitted to God, to ourselves and to another human being the exact nature of our wrongs. 
 
6. Were entirely ready to have God remove all these defects of character. 
 
7. Humbly asked Him to remove our short-comings. 
 
8. Made a list of all persons we had harmed, and became willing to make amends to them all.  
 
9. Made direct amends to such people wherever possible, except when to do so would injure them 
or others. 
 
10. Continued to take person inventory and when we were wrong, promptly admitted it. 
 
11. Sought through prayer and meditation to improve our conscious contact with God as we 
understood Him, praying only for knowledge of His will for us and the power to carry that out. 
 
12. Having had a spiritual awakening as the result of these steps, we tried to carry this message to 
alcoholics and practice these principles in all our affairs. 
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Appendix 12 Greater Glasgow shared care protocols for acamprosate 
    DRAFT FOR APPROVAL 
 
ACAMPROSATE SHARED CARE PROTOCOL 
 
The Area Drug and Therapeutics Committee has approved the use of Acamprosate in the treatment 
of Alcohol Dependence Syndrome on a shared care basis with Primary Care. 
 
Acamprosate 
Acamprosate is indicated for maintenance of abstinence in patients with Alcohol Dependence.  
 
The mechanism of action is believed to be by stimulating GAB ergic inhibitory transmission and 
by antagonising excitatory amino acids, particularly glutamic acid.  It may surpress cravings for 
alcohol triggered by conditioned response. 
 
A meta analysis of randomised controlled trials demonstrated that six months to one year treatment 
with Acamprosate doubles abstinence rates in alcoholics. 
 
An evaluation of treatment with Acamprosate over a one year period in Glasgow showed that two 
thirds of patients assessed suitable for treatment were compliant after one month and they achieved 
83% of potential Cumulative Abstinent Days. 
 
Acamprosate does not interact with alcohol or Benzodiazepines.  Acamprosate does not impair an 
individuals ability to drive or operate machinery. 
 
The main side effects are gastrointestinal as well purites and fluctuation in libido. 
 
Inclusion Criteria 
Moderate to severe Alcohol Dependence with abstinence goal in conjunction with psychosocial 
treatments and counselling. 
 
Tendency to anxiety symptoms in post withdrawal phase, not amounting to Generalised Anxiety 
Disorder or Panic Disorder. 
 
Reported cravings for alcohol, prompting relapse. 
 
Exclusion Criteria 
Patients with a history of repeated self harm, Anti-Social Personality Disorder or minimal brain 
damage. 
 
Patients with significant social problems and lack of support. 
 
Dosage 
Acamprosate should be initiated soon after detoxification.  
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Acamprosate 333 mg tablets. 
 
For adults over 60 kilograms 2 tablets in the morning, one at noon and one at night with meals. 
 
For adults below 60 kilograms 2 tablets in the morning, one at noon and one at night with meals. 
 
Shared Care 
Acamprosate will be initiated by Specialist Alcohol Services, as part of therapeutic plan including 
counselling, relapse prevention or psycho-social support. 
 
Patients would be monitored at least monthly by Specialist Alcohol Services for a three month 
period.  Acamprosate will be dispensed by Hospital Pharmacy during this period. 
 
Specialist Alcohol Services would liase with general practitioners regarding continued prescribing, 
for a further nine months (total treatment one year). 
 
Continued monitoring by specialist services, while Acamprosate is prescribed by general 
practitioner. 
 
Treatment Discontinuation and Outcome 
Acamprosate should be discontinued following repeated or protracted relapse (relapse is defined as 
more than five drinks for a five day period) or non compliance. 
 
Outcome will be evaluated by measuring Cumulative Abstinence Days (CADs). 
 
Contact 
For further information please contact your local specialist service:- 
 
___________________________ Tel No: __________________________________ 
 
Dr P Jauhar 
Clinical Director 
December 2001 
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Appendix 13 Lothian protocol for use on naltrexone 
  Alcohol Problems Service, Lothian Primary Care NHS Trust 
 
PROTOCOL FOR THE USE OF ORAL NALTREXONE 
 
Naltrexone given to detoxified patients, or non-dependent patients who commence taking 
Naltrexone when sober, reduces the frequency and severity of relapses into “heavy drinking” 
(over 8 units a day) (references attached).  There is one study where Naltrexone was started in 
patients of mild severity of dependence who continued to drink; overall drinking in the coming 
year reduced. 
 
Contraindications 
 
Established liver disease (bilirubin currently about 25 mmols/l, history of varices or ascites); 
current use of opiates or any opiate-like analgesic. 
 
Indications  
 
Either Has achieved abstinence but has repeatedly relapsed to problem drinking despite 
previous attempts with Disulfiram, Acamprosate, individual or group therapy or, 
refusal to consider these therapies. 
 
Or Repeated failure to succeed with an abstinence goal and patient and therapist feel 
that goal of limited drinking is clinically appropriate. 
 
And History of impaired control within sessions of drinking. 
 
Relative Indications  
 
Theoretically, Naltrexone is most likely to help those for whom drinking has positive rewards 
e.g. euphoria, rather than for reduction of negative feelings e.g. to reduce anxiety or depression. 
 
Procedure 
 
1. Baseline liver function is checked, and a biological marker, sensitive in that patient (GGT, 
MCV and /or CDT) is chosen so that outcome can be objectively monitored in the coming 
months. 
 
2. Patient signs Consent Form having read the information Sheet. 
 
3. Initial prescription for one week at a time. 
 
4. Initial prescription 25 mg (half tablet) for first 2 days, to continue at half a tablet until 
nausea (if present ) diminished, when full tablet 50 mg is taken (with breakfast). 
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5. Our prescription should be via REH Pharmacy (only if patient unable to attend Pharmacy is 
the GP asked to prescribe, when he is given full background). 
 
6. Renewed prescriptions only if evidence of reduction of problematic/heavy session drinking 
e.g. improving blood tests.  The patient is breathalysed at each appointment. 
 
7. After 3 months the prescription is changed to “targeted” use only on days when risk of 
drinking is anticipated and one day before e.g. only taken on Thursday, Friday and 
Saturday. 
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LOTHIAN PRIMARY CARE NHS TRUST 
ALCOHOL PROBLEMS CLINIC 
SUMMARY OF INTERVENTIONS DURING TREATMENT PROGRAMME 
 
 
Assessment 
 
Brief Interventions used to increase awareness of alcohol and motivation. 
 
 
Detoxification over two weeks 
 
Day patient detoxification and four motivational sessions on individual basis: 
 
1. Exploring lifestyle issues. 
2. Awareness – the good things and less good things. 
3. Decisional balance pros/cons of changing and staying the same. 
4. Exploring ambivalence and supporting self-efficacy 
 
 
Education groups 
 
Six sessions over two weeks: 
 
1. Alcohol dependence – withdrawal, importance of detox. – consequences of dependence. 
2. What is alcohol, factor affecting consumption, effects of alcohol, how body gets rid of 
alcohol. 
3. Tolerance cravings – domains of dependence. 
4. Aids to abstinence Antabuse, Campral and other agencies – AA, RCA. 
5. Introduction to cycle of change, process of change, where are we now? 
6. Weekend planning / daily planning. 
 Structuring time. 
 Evaluation questionnaire. 
 
These groups are audited. 
 
 
Relapse Prevention – solution focused 
 
Six sessions over two weeks: 
 
1. Introduction to principles of solution focused therapy. Exploring confidence/importance of 
change. 
 “The miracle question” 
 Lifestyle changes 
2. Cycle of change -  
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 Predicting relapse – ABC model – antecedents – behaviour-consequences. 
 Slips/lapse/relapse. 
3. High risk situations. 
 High success situations 
 Seemingly irrelevant decisions. 
4. Craving – Cognitive and behavioural -  
 Stop, refocus, breathe technique 
5. Decision making – how we make decisions and influences on decision-making. 
 Problem solving and success finding. 
 Goal setting. 
6. Drink refusal skills/re-evaluating importance/confidence. 
 Assertiveness – support and follow up. 
 Post group questionnaire. 
 
These groups are audited. 
 
 
Anxiety Management 
 
Six sessions over three weeks –  
 
Individually as required. 
Cognitive/behavioural approach. 
 
 
Anger Management – 
 
Six sessions over six weeks –  
 
Individually cognitive / behavioural approach 
 
 
Longer term support group 
 
One session per week –  
 
Ongoing support for clients remaining abstinent. 
Support of clients using Antabuse and Acamprosate. 
 
 
Input from other services as required – 
 
Physiotherapy – eight week (16 sessions) fitness/exercise programme. 
 
3 sessions relaxation. 
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O.T. – one session per week – women’s group. 
We currently audit all referrals to the Unit as a way to provide statistical data of referrals and 
treatment outcomes. 
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Appendix 14 Information on supervised administration of disulfiram 
      LOTHIAN PRIMARY CARE NHS TRUST 
 
ALCOHOL PROBLEMS SERVICE 
 
 
ANTABUSE (DISULFIRAM): THE PARTNERSHIP APPROACH 
 
1. A partner is a person who is asked by the patient to observe them taking the Antabuse 
tablets. 
 
2. So that other tablets cannot be substituted, the genuine Antabuse tablets are marked 
DUMEX 110 L (Dumex is the manufacturer). 
 
3. To ensure they are not placed under the tongue and removed later, Antabuse tablets 
should be dissolved in half a glass of water (the tablets break up and disperse and the 
mixture is tasteless). 
 
4. It does not matter what time of the day the tablet is given.  If it is more convenient, it 
can be given on 3 days per week – instead of one tablet daily it can be taken: 2 on a 
Monday, 2 on a Wednesday and 3 on a Friday. 
 
5. If it is suspected that the patient has decided to vomit after taking the tablet, the partner 
can stay with the patient for up to 30 minutes after the tablets are taken (this is rarely 
necessary). 
 
6. If the patient decides to stop taking the tablets, the patient or the partner should 
telephone the treating Doctor or a member of nursing staff so that the reason for this 
may be discussed. 
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Appendix 15 Examples of care pathways  
LOTHIAN PRIMARY CARE NHS TRUST 
ALCOHOL PROBLEMS CLINIC 
Care Pathway 
 
 
 Assessment 
Date……………………….. 
Risk Assess………………... 
Discharge proforma……….. 
GP Letter…………………... 
Controlled Drinking 
Abstinence 
Refer to Council 
on Alcohol 
Dependent Drinker 
Non-Dependent Drinker 
In-patient 
Detox 
Day Patient 
Detox 
WAITING LIST 
Date…………….. 
ADMITTED  
Date…………….. 
DISCHARGED 
Date……………. 
DETOX COMMENCED 
Date…………… Bloods……………. 
Physical……….SUCES…………….. 
Front Sheet……….. DVLA leaflet…… 
Care Plan…………..Info leaflets…….. 
Orientation to Unit …………………….. 
Abstinence Policy Explained…………… 
INDIVIDUAL MOTIVATIONAL SESSIONS 
SESSION 1 ….…….. SESSION 2…………. 
SESSION 3 ….……. SESSION 4 ……….… 
EDUCATION GROUP 
1……………. 2 …………… 3 ……………… 
4 …………… 5 …………… 6 ……………… 
RELAPSE PREVENTION GROUP 
1…………… 2 …………… 3 ………………. 
4 ……………5…………… 6 ……………….. 
SUPERVISED 
ANTABUSE/  
ACAMPROSATE 
IF APPROPRIATE 
PROGRAMME COMPLETE 
Discharge Proforma ………….. 
Letter GP ……………………….. 
OTHER SERVICES 
Physiotherapy 
Social Work 
Occupational Therapy 
Dietician 
 
GP Follow up MEDICAL OUT 
PATIENT 
ABSTINENCE 
SUPPORT GROUP 
Nursing Out 
patient 
Council 
on 
Alcohol 
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Appendix 16 Databases searched for clinical effectiveness studies 
 
Databases searched for clinical effectiveness studies 
 
High Level Literature Search - Sources 
An initial search was undertaken in August 2001 to identify HTA reports, systematic reviews and 
other evidence reports, using the following sources: 
· Health Technology Assessment Database 
Via the Cochrane Library (CD-ROM, 2001 Issue 2) 
· NICE (National Centre for Clinical Effectiveness) 
http://www.nice.org.uk/ 
· NCCHTA (National Coordinating Centre for Health Technology Assessment) 
http://www.ncchta.org/ 
· NHS Centre for Reviews and Dissemination, University of York 
http://www.york.ac.uk/inst/crd/ 
· Birmingham Technology Assessment Group, Department of Public Health and 
Epidemiology, University of Birmingham 
http://www.publichealth.bham.ac.uk/wmhtag/ 
· ScHARR, University of Sheffield 
http://www.shef.ac.uk/~scharr/publications.htm 
· South and West R&D Directorate, DEC reports 
http://www.doh.gov.uk/research/swro/rd/publicat/dec/  
· British Columbia Office of Health Technology Assessment (BCOHTA) 
http://www.chspr.ubc.ca/bcohta/ 
· Health Services Utilization and Research Commission (HSURC Saskatchewan) 
http://www.hsurc.sk.ca/ 
· Institute for Clinical and Evaluative Sciences (ICES) 
http://www.ices.on.ca/ 
· Manitoba Centre for Health Policy (MCHP) 
http://www.umanitoba.ca/centres/mchp/ 
· ISTAHC (International Society of Technology Assessment in Health Care) 
http://www.istahc.org/ 
· ECRI 
http://www.ecri.org/ 
· HSTAT 
http://text.nlm.nih.gov/ 
· Cochrane Database of Systematic Reviews (CDSR) 
Cochrane Library (CD-ROM, 2001 Issue 2) 
· Database of Abstracts of Reviews of Effectiveness (DARE) 
Cochrane Library (CD-ROM, 2001 Issue 2) 
· Ongoing Reviews database 
http://www.update-software.com/National/ 
· SIGN (Scottish Intercollegiate Guidelines Network) 
http://www.sign.ac.uk/ 
· ARIF (Aggressive Research Intelligence Facility) 
http://www.bham.ac.uk/arif/ 
· Health Evidence Bulletins Wales  
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http://hebw.uwcm.ac.uk/ 
· Centre for Clinical Effectiveness, Monash Institute of Public Health  
http://www.med.monash.edu.au/healthservices/cce/ 
· TRiP 
http://www.tripdatabase.com/ 
· Bandolier 
http://www.jr2.ox.ac.uk/bandolier/ 
 
Randomised Controlled Trials – Sources  
The following sources were searched during December 2001 to identify randomized controlled 
trials 
· Medline (Ovid) 
· Premedline (Ovid) 
· Embase (Ovid) 
· Cochrane Controlled Trials Register (Ovid) 
· Psychinfo (Ovid) 
· EtOH  
http://etoh.niaaa.nih.gov/ 
· MRC Funded Research 
http://fundedresearch.cos.com/MRC/ 
· Current Controlled Trials  
http://www.controlled-trials.com/ 
· Clinical trials.gov  
http://clinicaltrials.gov/ 
· NRR 
http://www.update-software.com/National/ 
· CRISP (Computer Retrieval of Information on Scientific Projects) 
https://www-commons.cit.nih.gov/crisp/ 
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Appendix 17 Search strategy for clinical effectiveness studies 
 
Search Strategy for clinical effectiveness randomized controlled trials in Medline 
Database: MEDLINE  
Coverage: <1966 to October Week 5 2001> 
Host: Ovid 
Date searched: 1/12/01 
-------------------------------------------------------------------------------- 
1   alcoholism/  
2   alcohol drinking/  
3   alcoholic?.tw.  
4   alcoholism.tw.  
5   (harmful$ adj1 drinking).tw.  
6   dipsomania$.tw.  
7   (alcohol adj2 (dependen$ or addict$ or abus$ or misus$)).tw.  
8   or/1-7  
9   intervention studies/  
10   intervention$.tw.  
11   (relaps$ adj1 prevent$).tw.  
12   or/9-11  
13   alcohol deterrents/  
14   behavior addictive/dt  
15   (alcohol adj2 deter$).tw.  
16   (alcohol adj1 sensiti$).tw.  
17   (alcohol adj2 aversi$).tw.  
18   (alcohol adj2 anti?craving).tw.  
19   (pharmacolog$ adj1 (intervention$ or treatment$)).tw.  
20   taurine/  
21   disulfiram/  
22   naltrexone/  
23   acamprosate.tw.  
24   campral.tw.  
25   disulfiram.tw.  
26   antabuse.tw.  
27   naltrexone.tw.  
28   trexan.tw. 
29   or/13-28  
30   psychotherapy/  
31   exp behavior therapy/  
32   exp psychoanalytic therapy/  
33   exp socioenvironmental therapy/  
34   exp self concept/  
35   psychotherapy brief/  
36   alcoholics anonymous/ 
37   social support/  
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38   behavior addictive/px  
39   psychotherap$.tw.  
40   (psychosocial adj2 (care or therap$ or intervention$ or technique$ or treatment$)).tw.  
41   (behavio?r$ adj2 (therap$ or treatment$ or modification or contracting)).tw.  
42   (assertive$ adj2 (skill$ or training or technique$)).tw.  
43   (aversi$ adj2 (therap$ or treatment$)).tw.  
44   (cognitive adj2 (therap$ or treatment$)).tw.  
45   cbt.tw.  
46   (relaxation adj2 (skill$ or training or technique$)).tw.  
47   sociotherapy.tw.  
48   psychoanaly$.tw.  
49   (socioenvironmental adj2 (therap$ or treatment$)).tw.  
50   therapeutic community.tw.  
51   ((group or marital or couple$ or famil$) adj2 (therap$ or intervention$or technique$ or 
treatment$)).tw.  
52   (community adj2 reinforc$).tw.  
53   (motivational adj (interview$ or enhancement)).tw.  
54   supportive expressive therap$.tw.  
55   counsel?ing.tw.  
56   counsel?or?.tw.  
57   (cue$ adj1 (therap$ or exposure)).tw.  
58   covert sensitization.tw.  
59   (self adj1 concept).tw.  
60   (self adj (efficacy or esteem or control or care)).tw.  
61   (social$ adj1 support).tw.  
62   ((coping or life) adj1 skills).tw.  
63   social skill$.tw.  
64   ((stress or anger) adj2 manag$).tw. 
65   supportive treatment$.tw.  
66   ((brief or short or minimal) adj2 intervention$).tw.  
67   coping behavio?r.tw.  
68   stepped care.tw.  
69   alcoholics anonymous.tw. 
70   aa.tw.  
71   twelve step.tw.  
72   "12 step".tw.  
73   or/30-72  
74   temperance/  
75   temperance.tw.  
76   sobriety.tw.  
77   (alcohol adj2 (consum$ or intake) adj2 (reduc$ or control$ or moderat$ or attenuat$ or 
restrict$ or restrain$)).tw.  
78   (abstinence or abstain$).tw.  
79   ((control$ or moderat$ or attenuat$ or reduc$ or restrain$ or restrict$) adj2 drinking).tw.  
80   (self adj (change or help)).tw.  
81   maturing out.tw.  
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82   or/74-81  
83   randomized controlled trial.pt.  
84   randomized controlled trials/  
85   (random$ adj2 (trial$ or stud$)).tw.  
86   random allocation/  
87   double blind method/  
88   single blind method/  
89   or/83-88  
90   animal/ not (human/ and animal/)  
91   89 not 90  
92   8 and 12 and 91  
93   limit 92 to yr=1990-2002  
94   8 and 29 and 91  
95   limit 94 to yr=1990-2002  
96   8 and 73 and 91  
97   limit 96 to yr=1990-2002  
98   8 and 82 and 91  
99limit 98 to yr=1990-2002  
 
 
This search strategy was reviewed by Gill Ritchie, Information Officer, at CRD, University of 
York.  Suggested changes will be incorporated when the strategy is updated during the 
Consultation period. 
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Flow chart of literature selection process for meta-analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
All references identified 
by literature search 
n=3065 
Reading title and abstract 
(with selection criteria) 
Section ? 
Not relevant  
n=2737 
 
Potentially relevant for HTA 
n=328 
(exc. duplicates) 
Order literature 
Not available 
n=12 
Available  
Systematic search n=316 
Submissions m=68 
 Evaluation of full 
manuscript (with selection 
and quality criteria) 
Section ? 
Excluded or used as 
subsidiary evidence n=290 
Considered for meta-
analysis n=A* 
Non quantitative synthesis, 
exploration of heterogeneity 
Section ? 
Non-suitable for meta-analysis  
n=C* 
Suitable for meta-analysis  
n=B* 
Submissions 
 
Search strategy 
Appendix ? 
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Numbers of studies for each meta-analysis (see preceeding figure) 
 
 A B C 
Acamprosate 19 17 2 
Naltrexone 21 16 5 
Disulfiram 3 2 1 
Motivational enhancement 8 3 5 
Relapse Prevention 11 5 6 
Behavioural self-control training 7 5 2 
Coping Skills 3 3 0 
Marital/Relationship therapy 22 12 10 
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Appendix 18 Conclusions from comprehensive reviews of alcohol treatment 
 
In this appendix we present: 
 
1. The ordering of all interventions derived using the Mesa Grande methodology  
2. Some recommendations for a comprehensive UK alcohol problems treatment service from 
the report by Raistrick and Heather 
3. Some conclusions from the Swedish health technology agency (SBU) report on 
management of drug and alcohol problems. 
 
Table 18-1 Mesa Grande Project – Rankings of interventions derived from controlled 
trials in patients with alcohol problems of any severity 
Rank Treatment modality N Rank Treatment modality N 
1 Brief intervention 31 45 Family therapy 3 
2 Motivational enhancement 17 46 ‘Moral reconation’ therapy 1 
3 GABA agonist 5 47 Community reinforcement – buddy  1 
4 Anti-depressant, non-SSRI 6 48 Recreational therapy 1 
5 Opiate antagonist 6 49 Job finding 1 
6 Social skills training 25 50 Legally sanctioned 
probation/rehab.  
2 
7 Community reinforcement 4 51 Medical monitoring 1 
8 Behaviour contracting 5 52 BAC surveillance 1 
9 Behavioural marital therapy 8 53 Occupational therapy 1 
10 Dopamine antagonist 2 54 Tobacco cessation with nicotine 
gum 
1 
11 Sensory deprivation 2 55 Tobacco cessation with exercise 1 
12 Biofeedback 2 56 Aversion therapy, electric  20 
13 Case management 6 57 Twelve-Step facilitation 3 
14 Cue exposure 2 58 Antidepressant, SSRI 15 
15 Developmental counselling 1 59 Dopamine agonist 1 
16 Anti-convulsant medication 1 60 Dopamine precursor 1 
17 Detoxification as treatment 1 61 Serotonin precursor 1 
18 Significant other as treatment support  1 62 BAC discrimination training 2 
19 Self-monitoring 6 63 Beta blocker  1 
20 Transcendal meditation 1 64 Client choice among options 1 
21 Assessment as intervention 1 65 Psychotherapy, group process 2 
22 Aversion therapy, negative emotion 1 66 Lithium 7 
23 Feedback 1 67 Marital therapy, other 8 
24 Hypnotic medication 1 68 Electrical stimulation of the head 2 
25 Cognitive therapy 10 69 Functional analysis 3 
26 Client-centred counselling 7 70 Anti-psychotic mediation 2 
27 Disulfiram 24 71 Hypnosis  4 
28 Unilateral family therapy 1 72 Psychedelic medication 8 
29 Aversion therapy, apnoeic 3 73 Placebo (non-blinded to provider) 2 
30 Covert sensitization 8 74 Calcium carbimide 3 
31 ‘Affective contra-attribution’ therapy 1 75 Serotonin antagonist 3 
32 Problem solving 2 76 Anti-anxiety medication 14 
33 Acupuncture 3 77 Relapse prevention 20 
34 Aversion therapy, nausea 5 78 Metronidazole 9 
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35 Tobacco cessation 2 79 Milieu therapy 12 
36 Systematic desensitisation 2 80 Alcoholic anonymous 7 
37 Self-help 5 81 Video self-confrontation 8 
38 ‘Reminiscence’ therapy 1 82 Standard Treatment 15 
39 Self-control training 35 83 Relaxation training 18 
40 Other medications (3 types) 3 84 Confrontational counselling 11 
41 Minnesota model 3 85 Psychotherapy 18 
42 Exercise 3 86 General alcoholism counselling 20 
43 Stress management 3 87 Educational lectures, films, groups 23 
44 Therapeutic community 1    
 
N denotes the number of studies on which each intervention is ranked.  It should be noted that the 
project authors have concerns about ordering an intervention on the basis of less than three studies 
and hence split the above list into two section for those with three or more and those with two or 
less studies. 
 
 
Summary of recommendations by Raistrick and Heather 
 
1. In-patient and supported residential units might be shared between several health districts. 
 
2. Arrangements should be in place to deal with mentally ill, violent or aggressive patients and 
those with acute stress reaction. 
 
3. An argument is put for Motivational Enhancement Therapy as a standard of treatment.  It 
may be a self contained treatment or a preparation for more intensive treatment (Brown & 
Miller, 1993) 
 
4. Pharmacotherapies should be integrated into the treatment model. 
 
5. ‘Relapse prevention should not be seen as a treatment in itself but should be a component 
part of all treatment programmes’. 
 
6. Information on local mutual aid groups should be available through staff. 
 
7. There is a marked diversity of clients and, although Project MATCH did not support the 
systematic matching of therapies to clients (see section 5.6.4) it is clear that different 
facilities will be necessary: for instance for homeless or very young people. 
 
8. Disulfiram is considered to have some effect as a sensitising agent.  The importance of 
monitoring compliance is noted.  
 
9. Naltrexone and acamprosate are both considered to have a role in treatment of alcohol 
problems.  Four uses are suggested (1) when sensitizing agents are contraindicated (2) 
enhancement of abstinence oriented programmes when clients are in the pre-contemplation 
or contemplations stages of change (3) an enhancement to controlled drinking programmes 
(for some subgroups not yet determined) (4) an aid to containing relapse. 
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Conclusions from SBU report 
 
Amongst the conclusions are: 
 
1. The effectiveness of certain ‘mini interventions’ that are possibly not used as much as they 
might be. 
 
2. That certain other psychosocial treatments have beneficial effects, which are similar to each 
other.  These include types of CBT (e.g. 12 steps) and motivational programmes.  
Structured interactional therapy and structured modern therapy with psychodynamic 
reference frameworks seem similar in effect to CBT.  Partner therapy and family 
intervention show positive effects. 
 
3. Only weak evidence exists on subgroup effects. Inpatient and outpatient results are similar.  
Important to address problems of mental illness and lifestyle problems concurrently with 
abuse. 
 
4. Acamprosate, naltrexone and disulfiram are noted to have confirmed effect. Disulfiram only 
when given under supervision. 
 
Certain areas for research are noted. Of particular interest for the current assessment are: 
 
5. Integration of psychosocial and pharmacological interventions 
6. Optimal intensity and duration of different treatment interventions 
7. The cost-effectiveness of different treatment methods 
 
SBU Economic analysis 
 
A search of several literature databases found 1200 articles of which 24 studies were economic 
analyses and 8 were based on RCTs.  These included alcohol and drug studies.  About half the 
studies were of poor quality and the remainder covered diverse areas.  It was concluded that 
evidence was weak and contradictory.  No conclusions on cost-effectiveness could be drawn. 
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Appendix 19 Summary of Product Characteristics for Acamprosate 
 
Appendix 20 Summary of Product Characteristics  for Naltrexone (Ireland) 
 
Awaiting permission to reprint from Manufacturers 
 
 240
 
Appendix 21 Meta-analyses of treatment effectiveness for economic model 
 
In this section we present the data extracted from individual studies concerning the numbers of 
patients in each treatment arm who were considered to have achieved a controlled drinking state at 
the end of the study follow-up period. 
 
These data are combined using meta-analytic methods in order to give estimates of effectiveness, 
which can be used as inputs to the cost-effectiveness model. 
 
Trials of pharmacotherapy 
 
The clinical trials of acamprosate and naltrexone generally compare the active drug with a placebo 
allocated in a random fashion and both the patients and the clinical investigators are unaware of the 
nature of the intervention received.  These are aspects of study design, which are considered 
important in reducing the likelihood of biased results and, in these respects these trials are of good 
quality.  The major difficulty with these, and indeed almost all, trials of treatments for alcohol 
dependent subjects is the high incidence of patients being lost to follow-up before the designated 
end of the trial.  Good practice in analysis requires consideration of the influence which such drop-
out might have on inferences drawn from the trial and one method of doing this is to analyse all 
randomized patients using various strategies to estimate what outcomes might have been observed 
in drop-outs (an Intention To Treat analysis).  We have attempted to do this wherever possible 
using the assumption that drop-outs have relapsed.  This is the strategy used in most of the original 
analyses of acamprosate but not so frequently in analyses of naltrexone where ‘last observation 
carried forward’ seems to have been preferred.  This means that the state of the patient at the end of 
the study is assumed to be the same as that at the last actual observation. 
 
A successful outcome may either involve complete abstinence on the part of the patient or drinking 
at a moderate level, which does not cause acute crises, have a deleterious effect on their lifestyle, or 
unacceptably increase risk of longer term clinical harm.  Either abstinence or controlled drinking 
may be nominated as the treatment goal and different treatments may be aimed more to one than 
the other.  For instance, acamprosate is licenced for the promotion of abstinence.  We have 
combined trials aimed at abstinence with those aimed at controlled drinking but have identified the 
outcomes for each trial in the tables. 
 
A further difficulty in making valid comparisons between acamprosate and naltrexone is that the 
trials tended to report outcomes at very different times.  Many acamprosate studies reported after a 
year of follow-up whilst naltrexone studies often had only 3 months.  The time at which our results 
are extracted is shown in the table.  Differences are also present in the time duration over which the 
outcome was assessed.  For instance a twelve-month outcome might only consider abstinence or 
control over the previous 6 months.  
 
There are fewer trials of disulfiram and they are generally of lower quality.  Some of this 
deficiency is unavoidable, for instance the only intended clinical effect of disulfiram is the 
unpleasant reaction when alcohol is drunk.  Hence an important part of the true effect of disulfiram 
is the fear of what might happen after drinking.  A blinded placebo controlled trial would not 
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measure this effect since the placebo should cause the similar fear.  Hence simple blinded trials are 
inappropriate – possibly also unethical since the knowledge that they might be receiving a placebo 
could encourage the patient to take an unnecessary risk.  
 
It has been suggested that the use of disulfiram is only likely to have an effect when it is coupled 
with some method of increasing compliance.  This could involve either a contract with a family 
member or directly observed administration by clinic staff.  Whilst this suggestion appears very 
reasonable, the evidence to support it is limited.  Only one study (Chick et al., 1992) appears to 
have examined supervised disulfiram in a randomized controlled trial against an inactive 
comparator without any additional confounding treatment.  This study found a statistically 
significant increase in the number of abstinent days and a reduction in the number of units 
consumed over six months as assessed by a blinded assessor.  The results are not given in terms of 
abstinence or controlled drinking by patient and hence cannot be used in the economic model. 
 
Trials of psychosocial treatments 
 
The evaluations of psychosocial interventions are based on a fairly heterogeneous selection of 
trials.  Most of these included a treatment arm in which the intervention was thought likely to have 
little or no effect and this is used as the comparator arm when available.  However, other trials 
included interventions thought likely to be less effective but not necessarily ineffective.  These 
have also been included and thus it may be that psychosocial intervention effects will be somewhat 
underestimated.  Psychosocial interventions are also poorly standardized in content and duration 
and cannot be blinded which allows the possibility of many other sources of heterogeneity and bias.  
The difficulties with respect to length of follow-up, high numbers of drop-outs and variety of 
outcome measures which have already been discussed for trials of pharmacological agents are 
present in the trials of psychosocial treatments. 
 
The following tables show the calculations performed to combine results across different studies.  
The methods used are those of DerSimonian and Laird (1986).  The dependent variable Y which is 
combined across studies is the estimated Log(odds ratio) for a successful outcome given the 
intervention of interest compared with the control intervention.  The weight given to each study is 
the inverse variance estimate for the Log(odds ratio). 
 
Key 
N Number of studies combined 
Y Dependent variable 
W Weight for study 
C1 W x Y 
C2 (Y - ?WY/?W ) 2 
C3 W x (Y - ?WY/?W ) 2 
Q SC3 
C4 W x W 
SW2 (SW2 – (SW)2/N)/(N – 1)  
U (SW/N – SW2/SW) x (N – 1) 
D (Q – N + 1)/U 
Wc* 1/(D + 1/W) Weight for random effects model 
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C6 Y x Wc* 
Y* SC6/SWc* Random effects estimate 
LCB Y* - 1.96 / Ö(SWc*) 
UCB Y* + 1.96 / Ö(SWc*) 
 
It should be noted that the random effects estimate is not used unless Q is greater than the degrees 
of freedom (N –1). When this is not the case the fixed effect – the weighted mean of Y – is used 
and is written in bold to indicate this. 
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META-ANALYSIS OF TRIALS OF NALTREXONE 
 
Name of trial NT NC XT XC Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
O’MALLEY 1992/6 
(S) 
29 25 6 5 1.0435 ( 0.28,3.89) 9 C 
O’MALLEY 1992/6 
(C) 
23 27 12 4 6.2727 ( 
1.65,17.51) 
9 C 
VOLPICELLI 1997 48 49 31 23 2.0614 ( 0.91,4.50) 3 C 
KRYSTAL 2001 418 209 235 104 1.2965 ( 0.93,1.81) 3 C 
MORRIS 2001 55 56 19 7 3.6944 ( 1.41,8.11) 3 C 
VOLPICELLI 1992 35 35 27 16 4.0078 ( 1.42,9.61) 3 C 
LEE 2001 35 18 16 7 1.3233 ( 0.42,4.09) 3 A 
CHICK 2000 90 85 32 30 1.0115 ( 0.55,1.88) 3 C 
KNOX 1999 31 32 3 5 0.5786 ( 0.14,2.57) 6 A 
OSLIN 1997 21 23 18 15 3.2000 (0.75,11.23) 3 C 
LANDABASO 1999 15 15 11 3 11.0000 (1.94,32.52) 12 C 
ANTON 2001 68 63 38 28 1.5833 ( 0.80,3.12) 6 C 
KRANZLER 2000 61 63 35 32 1.3041 ( 0.64,2.63) 3 C 
MONTI 2001 64 64 32 34 0.8824 ( 0.44,1.76) 12 C 
DUPONT-MERCK 
393-1032 
84 87 46 49 1.0652 ( 0.58,1.94)   
HERSH 1998 31 33 16 18 1.1250 ( 0.42,2.98)   
JURD 2000 TOTAL PATIENTS=105 NO OUTCOMES REPORTED 
MONTERESSO 2001 121 62 SUCCESS RATES NOT REPORTED 
BALLDIN 1998         
GALARZA 1997         
HEINALA 2001         
1 Outcomes – C = controlled drinking, A = abstinence 
2 Data from Streeton & Whelan 2001 
 
TREATED TOTAL 1176 CONTROL TOTAL  939 
TREATED EVENTS 605 CONTROL EVENTS 398 
OVERALL ODDS RATIO= 1.41  95% CONFIDENCE INTERVAL= ( 1.16, 1.69) 
CHISQUARE FOR HETEROGENEITY=  40.5  DEGREES OF FREEDOM=  16 
 244 
 
 N1 N2 X1 X2      
O’MALLEY 1992/6 
(S) 
29 25 6 5 
     
O’MALLEY 1992/6 
(C) 
23 27 12 4 
     
VOLPICELLI 1997 48 49 31 23      
KRYSTAL 2001 418 209 235 104      
MORRIS 2001 55 56 19 7      
VOLPICELLI 1992 35 35 27 16      
LEE 2001 35 18 16 7      
CHICK 2000 90 85 32 30      
KNOX 1999 31 32 3 5      
OSLIN 1997 21 23 18 15      
LANDABASO 1999 15 15 11 3      
ANTON 2001 68 63 38 28      
KRANZLER 2000 61 63 35 32      
MONTI 2001 64 64 32 34      
DUPONT-MERCK 393-
103* 
84 87 46 49 
     
HERSH 1998 31 33 16 18      
   n= 16      
 Y W C1 C2 C3 C4 Wc* C6  
 0.04256 2.173228 0.092492 0.08603 0.186962 4.7229 1.3581 0.057801  
 1.836211 2.138028 3.925871 2.25103 4.812766 4.5711 1.3442 2.46841  
 0.723376 5.779632 4.180848 0.150163 0.867885 33.404 2.2262 1.610419  
 0.259669 34.65124 8.997847 0.005806 0.201196 1200.7 3.2784 0.85131  
 1.30683 4.103832 5.363012 1.344074 5.515853 16.841 1.9236 2.513917  
 1.388246 3.607912 5.008668 0.746493 2.69328 13.017 1.8072 2.508882  
 0.280135 2.866169 0.802914 0.078476 0.224924 8.2149 1.5998 0.448172  
 0.011429 9.999347 0.114279 1.316736 13.1665 99.986 2.6583 0.030382  
 -0.54719 1.649935 -0.90283 0.29942 0.494024 2.7222 1.1334 -0.62023  
 1.163151 1.722488 2.003513 1.35292 2.330388 2.9669 1.1672 1.35768  
 2.397895 1.32 3.165222 5.749902 7.58987 1.7424 0.9673 2.319632  
 0.459532 8.068756 3.707854 0.21117 1.703879 65.104 2.4993 1.148548  
 0.265503 7.660427 2.033865 0.070492 0.539997 58.682 2.4587 0.652815  
 -0.12516 7.984344 -0.99935 0.015666 0.125081 63.749 2.4912 -0.31181  
 -0.06318 10.55087 -0.66659 0.003992 0.042115 111.32 2.6958 -0.17032  
 -0.11778 3.977901 -0.46853 0.013873 0.055185 15.823 1.8955 -0.22326  
          
Totals 9.281218 108.2541 36.35909 Q= 40.5499 1703.5 31.505 14.64235 Random 
         effects 
 Mean= 6.765882 0.335868  SW2= 64.743 Y*= 0.464761 1.59 
 ASE= 0.096112 0.147488  U= 92.517 LCB= 0.115568 1.12 
   0.524248  D= 0.2761 UCB= 0.813954 2.26 
          
 Fixed= 1.41 1.16 1.69      
 245 
 
META-ANALYSIS OF TRIALS OF ACAMPROSATE 
 
 
Name of trial NT NC XT XC  Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
LADEWIG 19933 29 32 12 7  2.5210  ( 0.83, 7.18) 3-6  A 
PAILLE 1995 361 177 67 20  1.7889  ( 1.05, 2.78) 12 A 
ROUSSAUX 19963 63 64 18 21  0.8190  ( 0.39, 1.74) 3 A 
SASS 1996 136 136 58 29  2.7436  ( 1.60, 4.42) 11 A 
WHITWORTH 1996 224 224 41 16  2.9126  ( 1.58, 5.37) 12 A 
GEERLINGS 1997 128 134 14 7  2.2281  ( 0.89, 5.27) 12 A 
PELC 1997 63 62 32 16  2.9677  ( 1.39, 5.85) 3 A 
POLDRUGO 1997 122 124 53 37  1.8061  ( 1.07, 3.01) 12 A 
NAMKOONG 72 70 27 25  1.0800  ( 0.55, 2.13) 2 C 
TEMPESTA 2000 164 166 62 48  1.4943  ( 0.94, 2.35) 9 A 
BESSON 1998 55 55 14 3  5.9187  ( 1.63,12.76) 12 A 
GUAL 2001 141 147 49 38  1.5277  ( 0.92, 2.52) 6 A 
CHICK 2000 289 292 19 23  0.8230  ( 0.44, 1.54) 6 C 
LHUINTRE 19852 42 43 26 14  3.366  ( 1.25, 9.07) 3  
BARRIAS 1997 150 152 59 39  1.879  ( 1.15, 3.07) 9-12 A 
PELC 19922 55 47 13 2  6.964  ( 1.48,32.71) 12  
LHUINTRE 1990 279 290 Not Reported 3  
MASON 2001 TOTAL N=601 N/A    
1 Outcomes – C = controlled drinking, A = abstinence 
2 Data from Mason 2001 
3 Data from AHCP report (West et al., 2000) 
 
TREATED TOTAL 2094 CONTROL TOTAL 1925 
TREATED EVENTS 564 CONTROL EVENTS 345 
OVERALL ODDS RATIO= 1.82  95% CONFIDENCE INTERVAL= ( 1.55, 2.14) 
CHISQUARE FOR HETEROGENEITY=  64.4  DEGREES OF FREEDOM=  15 
 
The US multicentre trial (Mason) has not yet published results and the manufacturers 
report that it will not do so until 2003, however, it is known to be negative. Despite 
the size of this trial a negative result would not qualitatively change the results of 
the meta-analysis. Insertion of a trial with no treatment effect and size N=600 into 
this analysis would reduce the fixed effects OR ratio to 1.68 (1.45, 1.96) 
 246 
 
 N1 N2 X1 X2 N1-X1 N2-X2 Log OR W  
LADEWIG 1993T 29 32 12 7 17 25 0.924659 3.07679  
PAILLE 1995 361 177 67 20 294 157 0.581626 13.38757  
ROUSSAUX 1996T 63 64 18 21 45 43 -0.19961 6.727092  
SASS 1996 136 136 58 29 78 107 1.009267 13.53355  
WHITWORTH 1996 224 224 41 16 183 208 1.069035 10.29205  
GEERLINGS 1997 128 134 14 7 114 127 0.801136 4.330285  
PELC 1997 63 62 32 16 31 46 1.087801 6.768318  
POLDRUGO 1997 122 124 53 37 69 87 0.591176 13.9117  
NAMKOONG 72 70 27 25 45 45 0.076961 8.231707  
TEMPESTA 2000 164 166 62 48 102 118 0.401645 18.10254  
BESSON 1998 55 55 14 3 41 52 1.778117 2.230237  
GUAL 2001 141 147 49 38 92 109 0.423793 14.97727  
CHICK 2000 289 292 19 23 270 269 -0.19477 9.658941  
LHUINTRE 1985* 42 43 26 14 16 29 1.213746 4.833887  
BARRIAS 1997 150 152 59 39 91 113 0.630504 16.01826  
PELC 1992* 55 47 13 2 42 45 1.940795 1.605253  
          
          
   n= 16      
 Y Weight WeightxY (Y-Ym)2 xWeight Weight2 Wc* Wc*xY  
 0.924659 3.07679 2.844982 0.106227 0.326837 9.46664 1.450983 1.341664  
 0.581626 13.38757 7.786563 0.000293 0.003918 179.227 2.278578 1.325281  
 -0.19961 6.727092 -1.34282 0.637359 4.287572 45.25377 1.949977 -0.38924  
 1.009267 13.53355 13.65897 0.168537 2.280904 183.157 2.282769 2.303924  
 1.069035 10.29205 11.00256 0.398897 4.105469 105.9262 2.167616 2.317258  
 0.801136 4.330285 3.469147 0.001691 0.007321 18.75137 1.680374 1.346208  
 1.087801 6.768318 7.362586 1.183312 8.009031 45.81013 1.953426 2.124939  
 0.591176 13.9117 8.224256 0.91696 12.75647 193.5353 2.293284 1.355733  
 0.076961 8.231707 0.633521 0.005923 0.048756 67.76101 2.059073 0.158468  
 0.401645 18.10254 7.270798 0.161319 2.920281 327.702 2.384274 0.957632  
 1.778117 2.230237 3.965621 3.161699 7.051337 4.973955 1.230683 2.188298  
 0.423793 14.97727 6.34727 0.179601 2.689931 224.3187 2.320499 0.983412  
 -0.19477 9.658941 -1.88123 0.037934 0.3664 93.29515 2.1381 -0.41643  
 1.213746 4.833887 5.867112 1.47318 7.121186 23.36646 1.75117 2.125476  
 0.630504 16.01826 10.09958 0.397535 6.367827 256.5847 2.344101 1.477966  
 1.940795 1.605253 3.115467 3.766685 6.046482 2.576837 1.013039 1.966101  
          
          
          
Totals 12.13588 147.6854 88.42438 Q= 64.38973 1781.706 31.29795 21.16669 Random
         effects 
 Mean=  9.23034 0.598735  SW2=  27.90128 Y*= 0.676297 1.966581
 ASE= 0.082287 0.437452  U= 135.6213 LCB= 0.32595 1.385346
   0.760017  D= 0.364174 UCB= 1.026643 2.791679
          
 Fixed=  1.819814 1.548756 2.138313      
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META-ANALYSIS OF TRIALS OF DISULFIRAM 
 
Name of trial NT NC XT XC  Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
FULLER 1979 43 42 9 5 1.9588 (0.61, 5.98) 12 A 
FULLER 1986 202 199 38 32 1.2092 (0.72, 2.02) 12 A 
1 Outcomes – C = controlled drinking, A = abstinence 
 
TREATED TOTAL  245 CONTROL TOTAL  241 
TREATED EVENTS  47 CONTROL EVENTS  37 
OVERALL ODDS RATIO= 1.31  95% CONFIDENCE INTERVAL= ( 0.81, 2.10) 
CHISQUARE FOR HETEROGENEITY=   0.532  DEGREES OF FREEDOM=  1 
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 N1 N2 X1 X2 N1-X1 N2-X2 Log OR W  
FULLER 1979 43 42 9 5 34 37 0.672344 2.720719  
FULLER 1986 202 199 38 32 164 167 0.189978 14.35722  
          
          
   n= 2      
 Y W C1 C2 C3 C4 Wc* C6  
 0.672344 2.720719 1.829259 0.164446 0.447412 7.402312 3.769489 2.534394  
 0.189978 14.35722 2.727551 0.005905 0.084785 206.1297 -30.6649 -5.82564  
          
          
Totals 0.862322 17.07794 4.55681 Q= 0.532197 213.532 -26.8954 -3.29125 Random 
         effects 
 Mean= 8.538969 0.266824  SW2= 67.70406 Y*= 0.122372 1.13
 ASE= 0.241982 -0.20746  U= 4.574552 LCB= #NUM! #NUM! 
   0.741108  D= -0.10226 UCB= #NUM! #NUM! 
          
 Fixed= 1.31 0.81 2.10      
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META-ANALYSIS OF TRIALS OF BEHAVIORAL SELF-CONTROL TRAINING 
 
Name of trial NT NC XT XC  Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
Sobell 1995(?) 35 35 5 2 2.7500 ( 0.54, 12.05) 12 C 
Volger 1975 23 19 15 11 1.3636 ( 0.39, 4.66) 12 C 
Caddy 1978 35 35 10 5 2.4000 ( 0.74, 7.17) 36 C 
Pomerleau 1978 18 14 13 7 2.6000 ( 0.61, 10.37) 12 C 
Foy 1984 30 32 8 7 1.2987 ( 0.41, 4.10) 12 C 
1 Outcomes – C = controlled drinking, A = abstinence 
 
TREATED TOTAL  141 CONTROL TOTAL  135 
TREATED EVENTS  51 CONTROL EVENTS  32 
OVERALL ODDS RATIO= 1.86  95% CONFIDENCE INTERVAL= ( 1.03, 3.36) 
CHISQUARE FOR HETEROGENEITY=   0.96  DEGREES OF FREEDOM=  4 
 
 
All trials other than Foy et al. (1984) used a control arm with a dissimilar 
and possibly ineffective treatment. Foy used the same Broad Spectrum Behavioral 
approach in both groups which differed only in the addition of blood alcohol 
discrimination, responsible drinking skills training and social drinking 
practice to thr BSCT treatment. 
 
An additional study, Harris & Miller (1990), was carried out in problem 
drinkers rather than dependent drinkers. It is of interest, however, because of 
some suggestion that the BSCT method can be self administered for a few weeks 
when specialists are unavailable and may prove a useful interim measure. 
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 N1 N2 X1 X2 N1-X1 N2-X2 Log OR W  
 35 35 5 2 30 33 1.011601 1.309524  
 23 19 15 11 8 8 0.310155 2.453532  
 35 35 10 5 25 30 0.875469 2.678571  
 18 14 13 7 5 7 0.955511 1.777344  
 30 32 8 7 22 25 0.261365 2.830362  
          
   n= 5      
 Y W C1 C2 C3 C4 Wc* C6  
 1.011601 1.309524 1.324715 0.152068 0.199137 1.714853 2.418957 2.447019  
 0.310155 2.453532 0.760975 0.097024 0.238051 6.019817 17.43962 5.408983  
 0.875469 2.678571 2.345006 0.064428 0.172576 7.174745 43.29325 37.90189  
 0.955511 1.777344 1.698272 0.111469 0.198119 3.158951 4.708047 4.498592  
 0.261365 2.830362 0.739757 0.052608 0.1489 8.010949 325.0296 84.95128  
          
Totals 3.414101 11.04933 6.868725 Q= 0.956783 26.07932 392.8894 135.2078 Random 
         effects 
 Mean= 2.209867 0.621642  SW2= 0.415441 Y*= 0.344137 1.41
 ASE= 0.300838 0.032  U= 8.689071 LCB= 0.245254 1.28
   1.211283  D= -0.35024 UCB= 0.44302 1.56
          
 Fixed= 1.86 1.03 3.36      
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META-ANALYSIS OF TRIALS OF FAMILY/MARITAL THERAPY 
 
 
Name of trial NT NC XT XC  Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
Hunt 1973 8 8 7 1 49.0000 ( 2.50,**.**)  C 
Hedburg 19742 15 30 11 16 2.4063 ( 0.65, 7.89) 6 C 
O'Farrel 1996 10 12 6 6 1.5000 ( 0.28, 7.63) 12 A 
O'Farrel 1993 30 29 14 10 1.6625 ( 0.59, 4.60) 12 A 
McCrady 1991 31 14 9 4 1.0227 ( 0.26, 4.05) 18 A 
Zweben 1988 79 139 8 13 1.0921 ( 0.43, 2.78) 18 C 
Bowers 1990 8 8 6 4 3.0000 ( 0.38,19.30) 12 C 
McCrady 1982 26 7 16 4 1.2000 ( 0.22, 6.43) 6 C 
Corder 19723 20 20 11 3 6.9259 ( 1.54,20.03) 6 C 
Cadogan 19732 20 20 13 7 3.4490 ( 0.95,10.96) 6 C 
Fichter 1993 49 51 14 16 0.8750 ( 0.37, 2.05) 18 A 
Smith 1998 64 42 22 6 3.1429 ( 1.16, 6.70) 9 A 
1 Outcomes – C = controlled drinking, A = abstinence 
2 No clear statement about randomisation 
3 Systematic allocation 
 
TREATED TOTAL  360 CONTROL TOTAL  380 
TREATED EVENTS 137 CONTROL EVENTS  90 
OVERALL ODDS RATIO= 1.81  95% CONFIDENCE INTERVAL= ( 1.26, 2.61) 
CHISQUARE FOR HETEROGENEITY=  25.9  DEGREES OF FREEDOM=  11 
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 N1 N2 X1 X2 N1-X1 N2-X2 Log OR W  
 8 8 7 1 1 7 3.89182 0.4375  
 15 30 11 16 4 14 0.87807 2.105983  
 10 12 6 6 4 6 0.405465 1.333333  
 30 29 14 10 16 19 0.508322 3.489669  
 31 14 9 4 22 10 0.022473 1.974078  
 79 139 8 13 71 126 0.088094 4.4654  
 8 8 6 4 2 4 1.098612 0.857143  
 26 7 16 4 10 3 0.182322 1.340782  
 20 20 11 3 9 17 1.935272 1.683  
 20 20 13 7 7 13 1.238078 2.275  
 49 51 14 16 35 35 -0.13353 5.233645  
 64 42 22 6 42 36 1.145132 3.792066  
          
   n= 12      
 Y W C1 C2 C3 C4 Wc* C6  
 3.89182 0.4375 1.702671 10.87816 4.759194 0.191406 0.349008 1.358275  
 0.87807 2.105983 1.849199 0.080914 0.170404 4.435164 0.948415 0.832774  
 0.405465 1.333333 0.54062 0.0354 0.047201 1.777778 0.752133 0.304964  
 0.508322 3.489669 1.773877 0.007275 0.025387 12.17779 1.154584 0.586901  
 0.022473 1.974078 0.044363 0.042891 0.08467 3.896983 0.92071 0.020691  
 0.088094 4.4654 0.393376 0.756138 3.376457 19.9398 1.24456 0.109639  
 1.098612 0.857143 0.941668 1.206949 1.034528 0.734694 0.572666 0.629138  
 0.182322 1.340782 0.244453 1.157223 1.551584 1.797697 0.754497 0.137561  
 1.935272 1.683 3.257062 3.745277 6.303301 2.832489 0.851985 1.648822  
 1.238078 2.275 2.816628 1.532838 3.487207 5.175625 0.981245 1.214858  
 -0.13353 5.233645 -0.69886 0.017831 0.093319 27.39104 1.297649 -0.17328  
 1.145132 3.792066 4.342417 1.311328 4.972642 14.37976 1.185872 1.35798  
Totals 11.26013 28.9876 17.20748 Q= 25.90589 94.73022 11.01332 8.028325 Random 
         effects 
 Mean= 2.415633 0.593615  SW2= 2.246074 Y*= 0.728965 2.07
 ASE= 0.185735 0.229575  U= 25.71964 LCB= 0.13836 1.15
   0.957656  D= 0.579553 UCB= 1.31957 3.74
 Fixed= 1.81 1.26 2.61      
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META-ANALYSIS OF TRIALS OF RELAPSE PREVENTION 
 
Name of trial NT NC XT XC  Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
O'Farrell 1993 30 29 14 10  1.6625  ( 0.59, 4.60) 12 A 
O'Malley 1992 54 50 19 17  1.0538  ( 0.47, 2.35) 12 C 
Sandahl 1998 24 25 3 10  0.2143  ( 0.07, 0.88) 15 C 
McCrady 1999 31 30 12 11  1.0909  ( 0.39, 3.04) 6 C 
Allsop 1997 20 40 6 4  3.8571  ( 0.99,17.19) 12 C 
1 Outcomes – C = controlled drinking, A = abstinence 
 
TREATED TOTAL  159 CONTROL TOTAL  174 
TREATED EVENTS  54 CONTROL EVENTS  52 
OVERALL ODDS RATIO= 1.14  95% CONFIDENCE INTERVAL= ( 0.71, 1.84) 
CHISQUARE FOR HETEROGENEITY=   7.37  DEGREES OF FREEDOM=  4 
 
The effect found by Allsop & Saunders (1997) is larger than that in the other 
trials and marginally statistically significant. This may be because Allsop 
used No Treatment and Discussion Only control groups – interventions very 
likely to be ineffective. Other trials may have used effective controls. 
McCrady et al. (1999), for instance, added only four sessions of RP to 15 
session of behavioral couples therapy. However, the absence of any effect 
suggests that no additional effect is attributable to the distinctive features 
of RP. 
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 N1 N2 X1 X2 N1-X1 N2-X2 Log OR W  
 30 29 14 10 16 19 0.508322 3.489669  
 54 50 19 17 35 33 0.052385 5.870971  
 24 25 3 10 21 15 -1.54045 1.826087  
 31 30 12 11 19 19 0.087011 3.577746  
 20 40 6 4 14 36 1.349927 1.938462  
          
          
   n= 5      
 Y W C1 C2 C3 C4 Wc* C6  
 0.508322 3.489669 1.773877 0.141991 0.495502 12.17779 1.812583 0.921377  
 0.052385 5.870971 0.307552 0.00626 0.036752 34.4683 2.296378 0.120296  
 -1.54045 1.826087 -2.81299 2.795419 5.104677 3.334594 1.230379 -1.89533  
 0.087011 3.577746 0.311305 0.189298 0.677262 12.80027 1.83606 0.159758  
 1.349927 1.938462 2.616781 0.545889 1.058184 3.757633 1.28039 1.728433  
          
Totals 0.457201 16.70293 2.196528 Q= 7.372377 66.53859 8.45579 1.034533 Random 
         effects 
 Mean= 3.340587 0.131506  SW2= 2.685245 Y*= 0.122346 1.13
 ASE= 0.244683 -0.34807  U= 12.71929 LCB= -0.55168 0.58
   0.611084  D= 0.265139 UCB= 0.796376 2.22
          
 Fixed= 1.14 0.71 1.84      
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META-ANALYSIS OF TRIALS OF MOTIVATIONAL ENHANCEMENT 
 
Name of trial NT NC XT XC  Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
Bien 16 16 9 5  2.8286  ( 0.68,10.58) 6  
Handmaker 20 22 7 6  1.4359  ( 0.39, 5.19)   
Sellman 42 80 24 29  2.3448  ( 1.10, 4.92) 6  
1 Outcomes – C = controlled drinking, A = abstinence 
 
TREATED TOTAL  78 CONTROL TOTAL  118 
TREATED EVENTS  40 CONTROL EVENTS  40 
OVERALL ODDS RATIO= 2.18  95% CONFIDENCE INTERVAL= ( 1.20, 3.98) 
CHISQUARE FOR HETEROGENEITY=   0.55  DEGREES OF FREEDOM=  2 
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 N1 N2 X1 X2 N1-X1 N2-X2 Log OR W  
 16 16 9 5 7 11 1.039772 1.835275  
 20 22 7 6 13 16 0.36179 2.227435  
 42 80 24 29 18 51 0.852212 6.608825  
          
          
   n= 3      
 Y W C1 C2 C3 C4 Wc* C6  
 1.039772 1.835275 1.908268 0.066393 0.121849 3.368236 3.396441 3.531523  
 0.36179 2.227435 0.805864 0.176664 0.393507 4.961467 5.0379 1.822662  
 0.852212 6.608825 5.632119 0.004915 0.032483 43.67657 -10.0869 -8.59616  
          
          
Totals 2.253774 10.67154 8.346251 Q= 0.547839 52.00627 -1.65254 -3.24197 Random 
         effects 
 Mean= 3.557179 0.782104  SW2= 7.022858 Y*= 1.961813 7.11
 ASE= 0.306116 0.182116  U= 5.798172 LCB= #NUM! #NUM! 
   1.382092  D= -0.25045 UCB= #NUM! #NUM! 
          
 Fixed= 2.18 1.20 3.98      
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META-ANALYSIS OF TRIALS OF COPING SKILLS TRAINING 
 
Name of trial NT NC XT XC  Odds 
ratio 
95% CI Months 
of fu 
Outcome1 
Monti 20012 77 88 48 32 2.8966 (1.53,5.17) 12 C 
Burtscheidt 
2001 
40 40 21 15 1.8421 (0.76,4.37) 6 C 
Monti 1993 22 18 11 7 1.5714 (0.45,5.33) 6 C 
1 Outcomes – C = controlled drinking, A = abstinence 
2 Systematic allocation 
 
TREATED TOTAL  139 CONTROL TOTAL  146 
TREATED EVENTS  80 CONTROL EVENTS  54 
OVERALL ODDS RATIO= 2.33  95% CONFIDENCE INTERVAL= ( 1.44, 3.76) 
CHISQUARE FOR HETEROGENEITY=   1.09  DEGREES OF FREEDOM=  2 
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 N1 N2 X1 X2 N1-X1 N2-X2 Log OR W  
Monti 2001* 77 88 48 32
29 56 1.063521 9.576413  
Burtscheidt 2001 40 40 21 15
19 25 0.610909 4.832849  
Monti 1993 22 18 11 7
11 11 0.451985 2.40625  
          
          
   n= 3     
 Y W C1 C2 C3 C4 Wc* C6  
 1.063521 9.576413 10.18472 0.047346 0.453406 91.70768 97.05058 103.2153  
 0.610909 4.832849 2.952431 0.055235 0.26694 23.35643 8.865408 5.415958  
 0.451985 2.40625 1.087589 0.155192 0.373431 5.790039 3.110758 1.406016  
          
          
Totals 2.126415 16.81551 14.22474Q= 1.093777 120.8541 109.0267 110.0373 Random 
         effects 
 Mean= 5.605171 0.845929 SW2= 13.30017 Y*= 1.009269 2.74
 ASE= 0.243862 0.367959 U= 9.628448 LCB= 0.821558 2.27
   1.3239 D= -0.09412 UCB= 1.19698 3.31
          
 Fixed= 2.33 1.44 3.76     
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Appendix 22 Protocol for patient preference study 
 
 
Project title 
A study of the relapse prevention treatment preferences of individuals1 who have experienced 
alcohol dependence. 
 
 
Names and contact details of investigator 
Professor Hazel Watson MN PhD RGN RMN RNT 
Department of Nursing and Community Health 
Glasgow Caledonian University 
70 Cowcaddens Road 
Glasgow G4 0BA 
Tel 0141 331 3457;  Fax 0141 331 8312 
Email h.e.watson@gcal.ac.uk 
 
 
Brief summary of project 
The project aims to describe the experiences and preferences of individuals for pharmaceutical or 
psychosocial interventions, or a combination of both, for the treatment for alcohol dependence.  A 
qualitative approach will be adopted whereby data will be collected using in-depth, one-to-one 
interviews with a purposive sample of people who have relevant personal experience.  The focus of 
the study will be to explore patients’ treatment preferences and also to elicit factors which prevent 
relapse to drinking.  
 
1. Background to project 
 
The International Classification of Diseases (ICD), describes alcohol dependence syndrome as a 
cluster of symptoms which include a subjective compulsion to drink, physiological dependence 
(tolerance and withdrawal) and rapid reinstatement of symptoms after a period of abstinence.  
There may be a loss of control over drinking, an increased urgency to drink, and increased priority 
of alcohol over the person’s previous interests and activities.  The individual persists with drinking 
despite evidence of its harmful effects (ICD-10, WHO 1992). 
 
The goals of treatment are to reduce alcohol-related harm.  This may be achieved at differing 
levels, and by a variety of means (Heather 2001).  Such goals may range from achievement of 
controlled drinking at a negotiated level to the achievement and indefinite maintenance of total 
abstinence.  Decisions concerning goals may depend on therapists’ philosophies, and patients’ 
preferences are likely to impinge on the treatment approach adopted. 
 
Relapse prevention aims to reduce the impact of cues which precipitate relapse to alcohol (Brown 
2001).  Because the goals of treatment are so variable, the concept of relapse can be interpreted in a 
                                                
1 This term is used to denote a person who has experienced treatment for alcohol dependence syndrome. It 
encompasses the terms ‘patient’ and ‘client’. Where either of these latter terms is used, the intention is to refer to such 
an individual.  
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range of ways.  For the purposes of the Health Technology Board for Scotland’s (HTBS) Health 
Technology Assessment (HTA) of alcohol dependence relapse prevention strategies, the following 
definition was agreed: “Failure to achieve a pre-determined goal (e.g. complete abstinence, < 5 
drinks on one occasion, total number of drinks over a certain time period, or cumulative number of 
days of complete abstinence)” see Minutes of Topic Specific Group meeting, 31 May 2001).  
 
People’s preferences are closely bound to motivation and, in terms of treatment for an alcohol 
problem, with adherence with treatment (Donovan 1998).  Given that more than two-thirds of 
clients of alcohol treatment programmes may relapse within six months of treatment (Marlatt and 
Gordon 1985), it is important to consider the preferences of such clients in order to find ways of 
improving patient outcomes through corresponding improvements in compliance rates. 
 
In order to develop services, which meet the needs of local populations it is crucial that the views 
of users are sought (WHO 1996, Coulter 1999).  As highlighted in the Plan for Action for the NHS 
(Scottish Executive 2000), this is particularly true for individuals and groups who are marginalised 
and whose voices may not be heard for a range of reasons.  Those who misuse alcohol constitute 
just such a group. 
 
A literature search has revealed some case study work on potential causes of relapse but no 
comparable wide-ranging study exists which attempts to identify and explore patient attitudes to 
relapse.  It is therefore timely that such a study be conducted.  This study aims to explore and 
describe the relapse prevention treatment options from the perspective of individuals who have 
themselves experienced alcohol dependence. 
 
2. Aim  
 
The project aims to describe the experiences and preferences of individuals with regards 
pharmaceutical and/or psychosocial interventions for the treatment for alcohol dependence.  
Furthermore, the study will attempt to elicit factors that prevent relapse to drinking. 
 
3. Methods 
 
A phenomenological approach is the methodology of choice as this can facilitate an understanding 
of the social world from the standpoint of the of individuals (Wilkes 1991).  As a qualitative 
research method it provid es a rigorous, critical and systematic means of investigating complex 
phenomena which are enmeshed in the life experience of people (Streubert and Carpenter 1995). 
 
Sample 
The sample will comprise individuals who have used the alcohol treatment services of three 
geographically distinct areas in Scotland within the past year.  Individuals who have experienced 
treatment for alcohol dependence from one of three NHS Primary Care Trust, two of which provide 
services within rural and semi-urban areas, and one whose catchment area is urban, will be invited 
to participate in the study.  
 
The sample will be recruited in two ways.  Firstly, posters will be displayed in prominent positions 
within treatment facilities and information about the study was made available to anyone who 
expressed interest in participating.  In addition, the nurse managers will write to a random sample 
of patients who have attended for treatment during the past year, seeking volunteers for the study 
and suggesting that those interested should contact the researcher. In this way the anonymity of 
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patients will be protected until they agree to volunteer.  Moreover, since the study involves an 
element of service evaluation, the random process of sample recruitment via the nurse managers 
will ensure that bias in the selection is minimised.  
 
There will be no exclusions with regard to gender, age, social class or employment status.  
 
In keeping with the tenets of qualitative research, data collection will continue until saturation is 
reached, (i.e. until no new themes emerge).  It is therefore not possible to determine the exact 
sample size necessary to achieve this at the outset of the study (Polit and Hungler 1997).  However, 
it is anticipated that it will be necessary to undertake approximately forty interviews. 
 
Procedures 
One-to-one in-depth interviews will be conducted during which the participants will be asked to 
recount their experiences of treatment and their preferences of pharmacological and psychosocial 
interventions (e.g. disulfiram, acamprosate, motivational enhancement therapy, cognitive-
behavioural therapy, supportive psychotherapy, group work, counselling, the 12-steps approach).  
They will be invited to discuss the factors which they perceived as contributing to the experience 
being either positive or negative, and to reflect on the reasons for their preferences.  An interview 
guide will be used to ensure that all relevant topics are addressed (Appendix 1).  Prompts will be 
used for clarification if necessary, and to encourage further disclosure.  Interviews will be 
conducted at the location of the participants’ choice and, with permission, audio-tape recorded.  It 
is anticipated that each interview will last for approximately 1 hour. 
 
Analysis 
All tape-recorded interviews will be transcribed verbatim.  Burnard’s framework for thematic 
analysis of qualitative data will be used to search for themes and patterns in the data (Burnard 
1991).  As a means of ensuring rigour in the process, a sample of the transcriptions will be 
independently analysed by a colleague of the researcher with experience of phenomenology.  
Points of divergence will be discussed and agreement reached for the final analysis.  The 
participants will be invited to comment on a summary of the findings as part of the validation 
process for qualitative research (Sandalowski 1993, Whittemore et al 2001). 
 
Plans for ethical approval and access negotiation 
Approval of each of the Local Research Ethics Committees of the participating Trusts has been 
granted. Verbal permission for access has been agreed from the consultant psychiatrists with 
responsibility for all participating patients. 
 
Full informed consent will be sought in writing from all individuals who are invited to participate.  
Permission to tape-record the interviews will be sought, and participants will be assured that they 
may request that recordings cease at any point.  All participants will be informed that they can 
withdraw without penalty at any stage in the project.  Those who agree to participate will be 
guaranteed confidentiality.  However, since their identity will need to be known if they are to be 
contacted to provide verification of the findings full anonymity cannot be assured.  If they do not 
wish to be contacted again their full anonymity can and indeed will be afforded. 
 
The conditions of the Data Protection Act (1998) will be observed. 
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Existing facilities 
The study will be based in the Caledonian Nursing and Midwifery Research Centre.  This is located 
within the Department of Nursing and Community Health and has all the advantages of the modern 
facilities of the new Faculty of Health building.  The researcher has access to a wide range of 
support systems, such as library and computing advice.  Equipment for tape-recording and 
transcribing the interviews are available, as are computing hardware and the necessary software. 
 
Justification of requirements 
Given the sensitivity of the interviews it is important that the data are collected by an individual 
who has experience both of the research methods and of working with people with problems of 
alcohol dependence.  Since the participants’ views of their treatment are being explored, it is 
preferable that the researcher is not be regarded by the participants as being part of the NHS 
culture.  It is therefore proposed that the data be collected by a member of the academic fraternity 
whose Curriculum Vitae is appended (Appendix 2).  A secretary will be employed on a part-time 
basis to transcribe the tape-recorded interviews.  
 
4. Dissemination plans  
 
The following strategies will be adopted to disseminate the study findings: 
 
1. Copies of the research report will be sent to the Health Technology Board for Scotland from 
which it will be available to all interested parties. 
2. The report will be lodged in the libraries of the participating voluntary organisations and NHS 
Trusts, and Glasgow Caledonian University. 
3. Results will be presented at relevant medical, social science and nursing conferences. 
4. Manuscripts will be submitted for publication in appropriate specialist and generic professional 
journals, such as Addiction, Addiction Research, the Health Bulletin. 
 
5. Research expertise / practice experience 
 
The applicant has research experience in the management of problem drinkers and has investigated 
aspects of the nurse’s role in relation to working with problem drinkers in acute care settings, 
having undertaken a PhD and published widely in this area.  
 
Key references  
 
Brown JM (2001) The effectiveness of treatment. In Heather N, Peters TJ, and Stockwell T (Eds), 
International Handbook of Alcohol Dependence and Problems, Ch 24, p500. Wiley and Sons, 
Chichester. 
 
Burnard P (1991) A method of analysing interview transcripts in qualitative research. Nurse 
Education Today 11 461-466. 
 
Coulter (1999) Seeking the views of citizens Health Expectations 2 219-221. 
 
Donovan DM (1998) Contiuing care: promoting the maintenance of change. In Miller WR and  
Heather N (Eds), Treating Addictive behaviours, 2nd ed., pp317-336). Plenum, New York. 
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Wilkes L (1991) Pheneomenology: a window to the nursing world. In Gray G and Pratt R (Eds) 
Towards a discipline of nursing. Melbourne: Churchill Livingstone. 
 
World Health Organisation (1992) The Lubljana Charter on reforming health care, Geneva, World 
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World Health Organisation (1996) The ISD-10Classification of mental and behavioural Disorders: 
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ADDENDUM 
 
A study of the relapse prevention treatment preferences of individuals 
who have experienced alcohol dependence. 
 
Interview guide 
 
 
1. Introduction, reiteration of the purpose of the study, and explanation of the processes for data 
collection, including the use of the tape recorder. 
 
2. Discuss drinking history and treatment history. 
 
3. Explore the form(s) of treatment the patient has experienced, and his/her views of its 
effectiveness and acceptability. (using layman’s terms, cover disulfirum, acamprosate, 
psychosocial interventions including individual, group and 12-step). 
 
4. If relevant, depending on the answer to item 3, explore patient’s preferences for treatments, and 
reasons for answers. 
 
5. Explore whether some treatments may be more appropriate at different times in one’s 
life/drinking history, and what these might be. 
 
6. If appropriate, ask how important it is that the person’s wife/husband/partner is involved in the 
treatment to help him/her to continue. 
 
7. Ascertain whether the person has relapsed.  If so, explore the circumstances; duration of period 
of abstinence/controlled drinking; the extent of the relapse, and the pattern of relapses. 
 
8. Ask what might have prevented the relapse(s). 
 
9. What aspects of the service does the person perceive to be good, and what is felt to be less 
good/bad (if not already discussed). 
 
10. To what extent was the person involved in decision-making about the choice of treatment?  
Does s/he see this as this relevant to relapse prevention? 
 
11. If the patient has defaulted from an appointment, what action did s/he take? 
 
12. How proactive should the service provider be in trying to re-establish contact? 
 
 
 
Ask if the patient feels I should know anything else; thank the patient for his/her time; end 
recording. 
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Appendix 23 Databases searched for cost effectiveness studies 
 
Databases searched for cost effectiveness studies 
 
Cost Effectiveness Literature Search – sources 
The following sources were searched during February 2002 to update the search undertaken by 
CRD, York during 2000: 
· Medline (Ovid) 
· Premedline (Ovid) 
· Embase (Ovid) 
· DARE  
Cochrane Library (CD-ROM, 2001 Issue 4) 
· NHS EED 
Cochrane Library (CD-ROM, 2001 Issue 4) 
· HTA 
Cochrane Library (CD-ROM, 2001 Issue 4) 
· Ongoing Reviews 
http://www.update-software.com/National/ 
· National Research Register 
http://www.update-software.com/National/ 
· HEED (CD-ROM, Feb, 2002) 
· Econlit (OCLC) 
· Social Science Citation Index (Web of Science) 
· Science Citation Index (Web of Science) 
· Cinahl (Ovid) 
· British Nursing Index (SilverPlatter) 
· Psychinfo (Ovid) 
· AMED (Allied and Complementary Medicine Database) (Ovid) 
· PAIS (Public Affairs Information Service) (CSA) 
· HMIC (SilverPlatter) 
· SIGLE (SilverPlatter) 
· ASSIA Plus (Applied Social Sciences Index and Abstracts) (CSA) 
· EconBase 
http://www.elsevier.nl/homepage/sae/econworld/menu.htm 
· HDA Evidencebase 
http://213.121.184.60/hda/docs/evidence/eb2000/corehtml/intro.htm 
 
In addition, the following web-sites were searched: 
· EtOH  
http://etoh.niaaa.nih.gov/ 
· Health Economics Research Unit, Aberdeen 
www.abdn.ac.uk/heru 
· Centre for Health Economics, York 
www.york.ac.uk/inst/che/ 
· Health Economics Research Centre, Oxford 
www.ihs.ox.ac.uk/herc/ 
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· Health Economics Research Group, Brunel 
http://http1.brunel.ac.uk:8080/departments/herg/home.html 
· Health Economics Group (HEG), Newcastle 
www.ncl.ac.uk/deph/hegroup.html 
· SCHARR School of Health and Related Research, Sheffield  
www.shef.ac.uk/uni/academic/R-Z/scharr/ 
· Health Economics Group, East Anglia  
www.uea.ac.uk/menu/acad_depts/hsw/hpp/hegwelc.htm 
· Institute of Health Economics IHE, Alberta, Canada 
www.ihe.ab.ca 
· LSE London School of Economics and Political Science 
www.lse.ac.uk/ 
· Southampton University Economics Department 
www.soton.ac.uk/~econweb/ 
· Centre for Health Economics Research and Development CHERE, University of Sydney 
and Central Sydney Area Health Service 
www.chere.usyd.edu.au 
· Institute of Health Economics (IHE), Alberta, Canada 
www.ihe.ab.ca/ 
· International Health Economics Association iHEA 
www.healtheconomics.org/cgi-bin/WebObjects/ihea 
· Centre for Health Economics and Policy Analysis (CHEPA), McMaster University 
www.chepa.org/ 
· Centre for Health Program Evaluation (CHPE), University of Melbourne and Monash 
University, Australia 
chpe.buseco.monash.edu.au/ 
· NetEc 
http://netec.mcc.ac.uk/NetEc.html 
· IDEAS Internet Documents in Economics Access Service 
http://ideas.uqam.ca/ 
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Appendix 24 Search strategy for cost effectiveness studies 
 
Search Strategy for cost effectiveness studies in Medline  
 
Database: Medline  
Coverage: <January 2000-January 2002 Week 3> 
Host: Ovid 
Date Searched: 11/02/02 
 
 
1. alcoholism/ 
2. alcohol drinking/ 
3. alcoholic?.tw. 
4. alcoholism.tw. 
5. (harmful$ adj1 drinking).tw. 
6. dipsomania$.tw. 
7. (alcohol adj2 (dependen$ or addict$ or abus$ or misus$)).tw. 
8. or/1-7 
9. intervention studies/ 
10. intervention$.tw. 
11. (relaps$ adj1 prevent$).tw. 
12. or/9-11 
13. alcohol deterrents/ 
14. behavior addictive/dt 
15. (alcohol adj2 deter$).tw. 
16. (alcohol adj1 sensiti$).tw. 
17. (alcohol adj2 aversi$).tw. 
18. (alcohol adj2 anti?craving).tw. 
19. (pharmacolog$ adj1 (intervention$ or treatment$)).tw. 
20. taurine/ 
21. disulfiram/ 
22. naltrexone/ 
23. acamprosate.tw. 
24. campral.tw. 
25. disulfiram.tw. 
26. antabuse.tw. 
27. naltrexone.tw. 
28. trexan.tw. 
29. or/13-28 
30. psychotherapy/ 
31. exp behavior therapy/ 
32. exp psychoanalytic therapy/ 
33. exp socioenvironmental therapy/ 
34. exp self concept/ 
35. psychotherapy brief/ 
36. alcoholics anonymous/ 
37. social support/ 
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38. behavior addictive/px 
39. psychotherap$.tw. 
40. (psychosocial adj2 (care or therap$ or intervention$ or technique$ or treatment$)).tw. 
41. (behavio?r$ adj2 (therap$ or treatment$ or modification or contracting)).tw. 
42. (assertive$ adj2 (skill$ or training or technique$)).tw. 
43. (aversi$ adj2 (therap$ or treatment$)).tw. 
44. (cognitive adj2 (therap$ or treatment$)).tw. 
45. cbt.tw. 
46. (relaxation adj2 (skill$ or training or technique$)).tw. 
47. sociotherapy.tw. 
48. psychoanaly$.tw. 
49. (socioenvironmental adj2 (therap$ or treatment$)).tw. 
50. therapeutic community.tw. 
51. ((group or marital or couple$ or famil$) adj2 (therap$ or intervention$ or technique$ or 
treatment$)).tw. 
52. (community adj2 reinforc$).tw. 
53. (motivational adj (interview$ or enhancement)).tw. 
54. supportive expressive therap$.tw. 
55. counsel?ing.tw. 
56. counsel?or?.tw. 
57. (cue$ adj1 (therap$ or exposure)).tw. 
58. covert sensitization.tw. 
59. (self adj1 concept).tw. 
60. (self adj (efficacy or esteem or control or care)).tw. 
61. (social$ adj1 support).tw. 
62. ((coping or life) adj1 skills).tw. 
63. social skill$.tw. 
64. ((stress or anger) adj2 manag$).tw. 
65. supportive treatment$.tw. 
66. ((brief or short or minimal) adj2 intervention$).tw. 
67. coping behavio?r.tw. 
68. stepped care.tw. 
69. alcoholics anonymous.tw. 
70. aa.tw. 
71. twelve step.tw. 
72. "12 step".tw. 
73. or/30-72 
74. temperance/ 
75. temperance.tw. 
76. sobriety.tw. 
77. (alcohol adj2 (consum$ or intake) adj2 (reduc$ or control$ or moderat$ or attenuat$ or 
restrict$ or restrain$)).tw. 
78. (abstinence or abstain$).tw. 
79. ((control$ or moderat$ or attenuat$ or reduc$ or restrain$ or restrict$) adj2 drinking).tw. 
80. (self adj (change or help)).tw. 
81. maturing out.tw. 
82. or/74-81 
83. exp economics/ 
84. exp "quality of life"/ 
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85. (economic$ or cost$).tw. 
86. "quality of life".tw. 
87. qol$.tw. 
88. quality adjusted life year$.tw. 
89. qaly$.tw. 
90. or/83-89 
91. 200$.em. 
92. 8 and 12 and 90 and 91 
93. 8 and 29 and 90 and 91 
94. 8 and 73 and 90 and 91 
95. 8 and 82 and 90 and 91 
96. or/92-95 
 
This search strategy was reviewed by Gill Ritchie, Information Officer, at CRD, University of 
York.  Suggested changes will be incorporated when the strategy is updated during the 
Consultation period.  
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Appendix 25 Economic data extraction 
Study Paper Economic Evaluation of Campral (Acamprosate)  Compared 
to Placebo in Maintaining Abstinence in Alcohol-Dependent 
Patients  
 
Study Authors Annemans L., Vanoverbeke N., Tecco J., D’Hooghe D. 
  
Study Perspective Health care payers in Belgium  
 
Clinical Data 
Sources 
Survey of 129 GPs informed frequency of somatic, psychic 
and other problems related to alcohol use  
 
Diagnostic 
Technology 
Acamprosate is an anti-craving neuromodulator  
Study Population RCT (n = 448) for relapse rates; RCT (n=582) unpublished 
trial for type of relapse in second line management and 
Belgian registry data 
 
Data Sources for 
Resource Use 
Resource savings from sample of GP records.  Success of 
detox from RCT (N = 164). Resource costs and resource use, 
from official statistics from Ministry of Health  
 
Outcome Measures Net cost savings per incremental abstinent patient 
 
Method of Analysis Monte Carlo Markov model  
 
Discounting No discounting applied; study period 2 years  
 
Assumptions  
 
 
· % of patients remaining abstinent after 2 years 11.9% for 
acamprosate and 4.9% for placebo 
· saving from institutional and ambulatory detoxification, 
acute and long term hospitalisation and liver 
complications.  
 
Results Average net saving per patient over the two year period of 
21,301 BEF (528 Euro) 
 
Comments  High lost to follow up and unclear of treatment of this group.  
· Rate of abstinence under acamprosate has greatest impact 
on net savings 
· The model assumes that the abstinence rate after 48 weeks 
is continued, with no further relapses.  
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Study Paper The Cost Effectiveness of Acamprosate in the Treatment of 
Alcoholism in Germany  
 
Study Authors Schadlich PK., Brecht JG 
 
Study Perspective The German healthcare system 
 
Clinical Data 
Sources 
Retrospective analysis of clinical data on the effects of acute 
alcohol dependency on the incidence of 
· alcoholic psychosis 
· alcoholic dependency syndrome 
· fatty liver 
· hepatitis and 
· cirrhosis  
 
Drug Technology Acamprosate was registered in Germany in 1996 and is an 
anti-craving neuromodulator  
 
Study Population Abstinent clients in 12 German psychiatric outpatient clinics 
 
Data Sources for 
Resource Use 
Effectiveness data from a RCT: health resources savings from 
retrospective German registry data; health savings per 
resource from insurance and administration sources and expert 
knowledge  
 
Outcome Measures Net cost savings per incremental abstinent patient from 
treatment avoided 
 
Method of Analysis Decision tree analysis using Monte Carlo simulation 
 
Discounting 5% discount rate  
 
Assumptions  
 
Key assumptions are: 
· 39.9% of acamprosate treated clients remain abstinent 
after 48 weeks in comparison to 17.3% of the placebo; and  
· health care savings from avoiding alcoholic psychosis, 
alcohol depending syndrome, fatty liver, hepatitis and 
liver cirrhosis 
 
Results Net savings in direct medical costs of DEM2600 per 
additional abstinent alcoholic 
  
Comments  · The rate of abstinence under acamprosate has the greatest 
impact on the net savings.  
· The model assumes that the abstinence rate after 48 weeks 
is continued, with no further relapses.  
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Study Paper The Long-Term Cost-Effectiveness of Improving Alcohol 
Abstinence with Adjuvant Acamprosate  
 
Study Authors  Palmer AJ., Neeser K., Weiss C., Brandt A., Comte S., Fox M 
 
Study Perspective German health insurance perspective  
 
Clinical Data 
Sources 
Probabilities for clinical events were retrieved from published 
literature  
 
Drug Technology Acamprosate was registered in Germany in 1996 and is an 
anti-craving neuromodulator except registered in Gemany 
1996 
 
Study Population  A typical male cohort aged 41, 80% with fatty liver, 15% with 
cirrhosis, 22% with pancreatitis and 1% with alcoholic 
cardiomyopathy  
 
Data Sources for 
Resource Use 
· disease incidences and transitional probabilities from 
literature 
· disease costs from literature and an expert German health 
economics company 
 
Outcome Measures Incremental savings in mean total lifetime costs with 
acamprosate compared to standard therapy 
 
Method of Analysis Meta-analysis to inform a series of Markov sub-models 
 
Discounting 5% per annum  
 
Assumptions · key assumption is description of disease in cohort (see 
above) 
· acamprosate assumed to prevent relapse in 40% of the 
cohort in comparison to 20% for the placebo 
 
Results Mean expected total lifetime discounted savings per patient of 
1662 DEM  
 
Comments All assumptions are from meta-analysis and no validation of 
the model and its assumptions  
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Appendix 26 Sensitivity analysis on economic model 
 
 
This appendix contains the full results of the pair-wise sensitivity analysis referred to in Chapter 7. 
 
 
Table A26-1 Acamprosate 
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
£2,080 -£1,091 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
£549 -£434 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
-£981 £951 
 
 
Table A26-2 Naltrexone  
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
£12,014 £366 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
£3,765 £2,782 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
£2,938 £4,438 
 
 
Table A26-3 Disulfiram 
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
Standard 
treatment 
dominates 
-£2,469 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
£2,191 £1,208 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
£1,271 £3,308 
 
 
Table A26-4 Coping Skills 
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
-£1,229 -£3,723 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
-£2,684 -£3,666 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
-£3,742 -£2,649 
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Table A26-5 Relapse prevention 
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
Standard 
treatment 
dominates 
-£2479 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
£9,839 £8,856 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
£3,771 £14,883 
 
 
Table A26-6 Behavioural self control training 
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
£26,688 -£3,636 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
-£2,127 -£3,109 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
-£3408 -£1870 
 
 
Table A26-7 Motivational interviewing 
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
£2,383 -£3,766 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
-£2,570 -£3,553 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
-£3,674 -£2,491 
 
 
Table A26-8 Marital and Family Therapy 
 Low estimate High estimate 
Average treatment cost, average disease cost, 
varying intervention effectiveness 
-£176 -£3,415 
Average treatment cost, average intervention 
effectiveness, varying disease cost 
-£2,184 -£3,167 
Average intervention effectiveness, average 
disease cost, varying treatment cost 
-£3,442 -£1,950 
 
 
 
 
 
 276 
GLOSSARY AND ABBREVIATIONS 
 
A&E Accident and Emergency 
AA Alcoholics Anonymous 
ABCT Alcohol Behavioural Couples Therapy 
Acamprosate A drug that in combination with counselling may be 
helpful in maintaining abstinence in alcohol dependent 
patients.  
Accreditation A process, based on a system of external peer review 
using written standards, designed to ensure the quality 
of an individual, activity, service or organisation. 
ADU Alcohol Day Unit  
AFS Alcohol Focus Scotland 
Alcohol Development Officers Government-appointed personnel who co-ordinate 
action programmes to tackle alcohol misuse at a local 
level in Scotland.  
Alcohol Support Groups Self help groups offering support and advice to people 
with alcohol problems and their families. 
Anger Management Relapse prevention technique which offers training and 
support for learning to recognise and manage angry 
emotions. 
Antabuse Manufacturers’ name for disulfiram. 
APTU Alcohol Problems Treatment Unit 
Arrhythmias  A condition in which the heart beats with an irregular 
or abnormal rhythm.  
Assertiveness Training A relapse prevention technique which teaches the 
individual to express thoughts and emotions in a direct, 
honest, and appropriate way.  
AUDIT Alcohol Use Disorders Identification Test 
Audit The process of setting or adopting standards and 
measuring performance against those standards with the 
aim of identifying both good and bad practice and 
implementing changes to achieve unmet standards. 
Aversion Therapy A behavioural therapy based on the principle of 
counter-conditioning.  This involves pairing 
incompatible or aversive consequences with specific 
stimuli with the use of alcohol or drugs. 
BEF Belgian Francs 
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Behaviour Contracting A procedure involving the client signing a contract that 
he/she will attend a specified number of continuing care 
meetings; this is combined with active follow-up if the 
client fails to meet the conditions of the contract. 
Behaviour Therapy A branch of psychotherapy narrowly conceived of as 
the application of classical and operant conditioning to 
the amelioration of clinical problems.  It is more 
broadly conceived of as applied experimental 
psychology. 
BENELUX Belgium, The Netherlands and Luxembourg 
BI Brief Intervention 
This is a time-limited intervention focusing on 
changing an individual’s behaviour with respect to 
alcohol consumption.  The precise content of brief 
interventions vary.  They are mainly used to reduce 
alcohol consumption in people drinking above 
recommended levels but who are not dependent. 
Blinding 
 
 
Concealment of intervention in a controlled trial to 
ensure the absence of subjective bias in evaluation of 
intervention effects.  
BNF British National Formulary 
BSCT Behavioural Self Control Training 
Aims at controlled drinking rather than abstinence. This 
is achieved by teaching clients to drink more slowly 
and increase intervals between drinks and choose less 
alcoholic drinks. They are also taught to recognise 
high-risk situations and to set personal goals. 
CAART Common Addictions Assessment Tool 
CAD Cumulative Abstinence Duration/Days 
Campral Trade name for acamprosate. 
Capital costs The cost of investment in items which remain useful 
beyond the period when costs are incurred. 
Carer A person, paid or unpaid, who regularly helps another 
person, often a relative or friend with all forms of care 
as a result of illness or disability.  This term 
incorporates spouses, partners, parents, guardians, paid 
carers, other relatives, and voluntary carers who are not 
health professionals. 
CAT Community Addiction Team 
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Treatment and rehabilitation – referrals are usually 
through the family doctor but referrals will be accepted 
from users and their families. 
CBT Cognitive Behavioural Therapy 
This involves the use of behavioural techniques to 
modify maladaptive cognitions.  There are a  range of 
behavioural, activity-oriented interventions or 
homework exercises that are used e.g. graded task 
assignments activity scheduling, behavioural 
experiments. 
CENAPS A biopsychosocial approach to recovery and relapse 
prevention.  
CET Coping Skills Training 
This treatment approach involves teaching clients 
coping skills for successful living and relationships, 
such as communication and assertion skills. 
Chronic Present over a long period of time. 
CI Confidence Interval. 
Clinical Effectiveness The evaluation of benefit: risk in a standard clinical 
setting using outcomes of importance to the patient. 
Clinical Governance A framework through which NHS organisations are 
accountable for continuously improving the quality of 
their services and safeguarding high standards of care 
by creating an environment in which excellence in 
clinical care will flourish. 
Source: DEPARTMENT OF HEALTH – NHS WHITE 
PAPER: A FIRST-CLASS SERVICE (1998). 
Clinical Trial Research study conducted with patients, usually to 
evaluate a new treatment or drug.  Each trial is 
designed to answer scientific questions and to find 
better ways to treat individuals with a specific disease. 
CM Case Management 
COA Councils on Alcohol 
Committee on Safety of Medicines 
(CSM) 
An independent advisory committee established under 
the Medicines Act (Section 4). The CSM advises the 
UK Licensing Authority (Government Health 
Ministers) on the quality, efficacy and safety of 
medicines. 
Co-morbidity The presence of co-existing or additional diseases with 
reference to either an initial diagnosis or the index 
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conditions that is the subject of study.  Co-morbidity 
may affect the ability of affected individuals to function 
and also their survival; it may be used as a prognostic 
indicator for length of hospital stay, cost factors, and 
outcome or survival. 
Complementary Therapy Treatments such as acupuncture and hypnosis. 
Contraindication Any factors related to the patient’s condition, medical 
history or other current treatments which generally or 
absolutely preclude the use of the treatment in question.  
Control Standard of comparison in a clinical trial or an 
experiment. 
Corroborative Supported with evidence or authority.  
Cost effectiveness  Cost effectiveness is used in its broadest form to 
encompass all forms of economic analysis. 
Cost effectiveness analysis A form of economic analysis which compares two 
interventions in terms of both their costs and their 
effect upon patients, to ascertain whether the additional 
cost of the more expensive intervention gives rise to 
sufficient additional patient benefits to warrant the 
additional cost. 
Cost effectiveness ratio The additional cost of the more expensive intervention 
as compared with the less expensive intervention 
divided by the difference in effect or patient outcome 
between the interventions. This gives a cost per effect, 
such as the additional cost per true positive from a 
screening test, or a cost per patient outcomes, such as 
the cost per QALY. 
Counselling The task of counselling is to draw out the client and 
enable him or her to reach a greater level of 
understanding, or a greater commitment to take action.  
The process involves enabling clients to realise that 
alternatives exist, and helping them to clarify what 
some of those choices may be. 
Couples/Marital/Family Therapy Behavioural, marital or family therapy emphasises the 
teaching of skills to improve communications and 
behavioural change negotiation.  Other marital and 
family therapy approaches draw on systems theory in 
both formulating the hypotheses about distress and 
planning interventions.  Systemic therapists invariably 
construct a map defining the organisation, roles and 
rules of the family and the couples that they treat.  
CPN Community Psychiatric Nurse 
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CPU  
CRA Community Reinforcement Approach 
In this approach, partners, family and friends are 
viewed as crucial collaborators in the treatment process. 
Their roles have included supervising disulfiram, being 
partners in marital counselling, active agents in re-
socialisation and reinforcement programmes and 
relapse or problems detectors. 
CRD Centre for Reviews and Dissemination 
CS Coping Skills  
CSA Common Services Agency. 
CST Communication Skills  Training 
Day Facilities Non-residential facilities. Opening hours and type of 
intervention may differ. 
DEM/DM Deutchmark 
Detoxification Treatment designed to free an addict from his drug 
habit. 
Discounting A means of converting the value of future events to 
their value in the present period. Future costs are 
converted using a financial discount rate similar to the 
interest rate, while patient benefits are converted using 
the reported time preference for health benefits. This 
reflects society’s preference for immediate benefits 
compared to benefits occurring in the future.  
DNA Did Not Attend 
DoH Department of Health (England). 
Drinkwise A campaign to promote the reappraisal of personal 
drinking behaviour. 
DSM American Psychiatric Association's Diagnostic and 
Statistical Manual of Mental Disorders 
EC European Community 
ECHTA The European Collaboration for Health Technology 
Assessment 
Economic model This simplifies the patient pathway to a level that 
describes the essential choices and consequences within 
treatment options. Linking patient outcomes to resource 
usage enable different courses of action to be compared 
from an economic viewpoint. Modeling may also be 
used to extrapolate from existing data into the longer 
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term. 
Effect sizes A measure of the magnitude of a treatment effect 
commonly used in meta-analyses. 
EMTREE Embase (literature searching database) Subject 
Headings. 
Epidemiology The medical and scientific study of epidemic diseases. 
EU European Union 
Evidence-based The process of systematically finding, appraising, and 
using contemporary research findings as the basis for 
clinical decisions. 
FAST Family Addiction Screening Tool 
GABA ?-aminobutyric acid 
Gamma GT/GGT Gamma glutamyltransferase 
GGHB Greater Glasgow Health Board  
GP General Practitioner 
Grey Literature That which is produced on all levels of government, 
academics, business and industry in print and electronic 
formats, not controlled by commercial publishers. 
Group Therapy/Work Commonly used procedure but often poorly defined.  
Groups can be run accordingly to strict 
psychoanalytical principles, as problem solving groups, 
and, in some cases, according to no clear principles at 
all. 
HDL Health Department Letters 
Health Board In Scotland there are 15 area health boards, responsible 
for commissioning and delivering local health care. 
Health Education Educational strategy designed to improve health 
knowledge and promote informed decisions conducive 
to health. 
Healthcare Professional 
 
A person qualified in a health discipline. 
HEBS Health Education Board for Scotland 
HEED Health Economics Evaluation Database 
HQ Headquarters 
HTA Health Technology Assessment is a multi-disciplinary 
field of policy analysis which studies the medical, 
social, ethical and economic implications of 
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development, diffusion and use of health technology. 
HTBS Health Technology Board for Scotland 
ICD International Coding Dictionary 
ICER Incremental Cost Effectiveness Ratio 
INAHTA International Network of Agencies for Health 
Technology Assessment 
Incidence How often a disease occurs; the number of new cases of 
a disease among a certain group of people during a 
specific period of time. 
Indication (therapeutic) The diseases or conditions which a medicine has been 
authorised (licensed) to treat. 
Intervention (health) An item or service delivered or undertaken primarily to 
prevent, diagnose or treat a medical condition or to 
maintain or restore functional ability. 
IP In Patient 
ISD Information and Statistics Division 
ISPOR International Society for Pharmacoeconomics and 
Outcomes Research 
ITT Intention to treat 
LFT Liver Function Test 
LHCC In Scotland, Local Healthcare Co-operatives are 
voluntary groupings of GPs and other local health care 
professionals intended to strengthen and support the 
primary health care team in delivering local care. 
Life Tables Tabulated mathematical models presenting, for 
example, the number of individuals who have 
experienced a certain event by a specified time. 
LSD Lysergic acid diethylamide 
Managed Clinical Networks Linked groups of health professional and organisations 
from primary, secondary and tertiary care, working in a 
co-ordinated manner, unconstrained by existing 
professional and NHS Board boundaries, to ensure 
equitable provision of high quality clinically effective 
services throughout Scotland. 
MATCH Matching Alcoholism Treatments to Client 
Heterogeneity 
MCV Mean Cell Volume 
Medication Drugs prescribed to treat a condition. 
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MeSH Medical Subject Headings 
MET Motivational Enhancement Therapy 
*A client-centred counselling approach for initiating 
behaviour change by helping clients to resolve 
ambivalence about engaging in treatment and stopping 
alcohol use.  This approach uses strategies to evoke 
rapid and internally motivated change in the client. 
Meta-analysis Statistical method to combine the outcomes of more 
than one randomised clinical trial. 
MI Motivational Interviewing  
As * 
Morbidity The frequency (incidence and/or prevalence) of a 
particular disease or group of diseases. 
Mortality rate The number of deaths in a given population during a 
specified period of time. 
Multidisciplinary A multidisciplinary team is a group of people from 
different disciplines (both healthcare and non-
healthcare) who work together to provide care for 
patients with a particular condition.  The composition 
of multi-disciplinary teams will vary according to many 
factors.  These include: the specific condition, the scale 
of the service being provided and geographical/socio-
economic factors in the local area. 
NAIP National Alcohol Indicators Project 
Naltrexone An opioid antagonist, blocks the action of opioids and 
precipitates withdrawal symptoms in opioid-dependent 
subjects.  
NHS National Health Service 
 
NHS Boards  The role of the NHS Boards is to ensure the efficient, 
effective and accountable governance of the local NHS 
system. There 15 NHS Boards in Scotland. 
NHS EED NHS Economic Evaluation Database 
NHS24 NHS24 is a special Health Board of NHSScotland that 
aims to give people across Scotland equal access to 
health advice, information and help, when they need it 
and as far as possible in one phone call. 
NHSScotland National Health Service in Scotland 
NICE National Institute for Clinical Excellence. 
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NMDA N-methyl-D-aspartate 
Odds ratio The association between a random event, E, and some 
condition, A, expressed as the odds that E occurs when 
A is true divided by the odds that E occurs when A is 
not true. 
OP Out Patient 
Opportunity cost The opportunity cost of selecting a particular health 
technology is the amount of alternative health 
technologies that could have been obtained had that 
selection not been made. 
OT Occupational Therapist 
Outcome The end result of care and treatment.  In other words, 
the change in health, functional ability, symptoms or 
situation of a person, which can be used to measure the 
effectiveness of care and treatment.  Also referred to as 
patient impact or patient benefit. 
p.a Per anum 
Patient A person who is receiving medical treatment 
(especially in a hospital).  Also, a person who is 
registered with a doctor, dentist, etc and is treated by 
him/her when necessary. 
Sometimes referred to as a user. 
PCT Primary Care Trust 
Person-centred counselling  Counselling which focuses on the individual. 
Pharmacological Deals directly with the effectiveness and safety of drugs 
in humans. 
Placebo Dummy treatment which is given to some of the 
volunteers participating in a clinical trial.  Patients can 
feel better even when the treatment they are given is a 
‘sugar pill’ or placebo. 
Plan for Action Refers to the SACAM document “The Plan for Action 
on Alcohol Problems”. 
Positive Modelling  
PP Per protocol 
PRAMA Prevention of Relapse with acamprosate in the 
Management of Alcoholism 
Prevalence The number of existing cases of a disease among a 
certain group of people, usually at a specified point in 
time. 
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Problem Solving (Skills Training) A systematic method used to approach problems in 
general. 
Prognosis An assessment of the expected future course and 
outcome of a person’s disease. 
Psychosocial Intervention Cognitive behavioural therapy, motivational 
interviewing/ enhancement and the twelve-
step/Alcoholics Anonymous comprise the three main 
forms of psychosocial intervention.  The best evidence 
of effectiveness was found in project Match. 
Psychotherapeutic Techniques A term used to describe the process/skill involved in 
carrying out the particular psychotherapy or treatment. 
Psychotherapy This term is frequently used to refer to talking 
treatment based upon psychodynamic or psychoanalytic 
principles. In practice the term is also used to refer to a 
wide range of psychological interventions. 
PYLL Potential Years of Life Lost 
QA Quality Assurance 
Improving performance and preventing problems 
through planned and systematic activities including 
documentation, training and review. 
QALY Quality adjusted life year. A means of adjusting the 
benefits accruing to patients that takes into account the 
quality of life of each year. 
QUADS Quality in Alcohol and Drugs Services 
r Pearson’s r  
An estimate of the association between two variables. 
Randomised Randomly allocated to one or more than one different 
choices of treatment. 
RCT Randomised, controlled trial 
Risk Factor A clearly defined occurrence or characteristic that 
increases the possibility that a person will get a disease. 
RP Relapse Prevention 
A treatment package involving a range of strategies to 
prevent relapse in the field of addictive behaviours.  
The aim of this approach within the field of alcohol 
treatment, is to help the problem drinker develop 
confidence or self-efficacy in his or her ability to cope 
with high-risk for drinking situations.  The Focus of 
treatment is to teach the individual coping-skills so that 
he/she can avoid relapse in the future.  Avoidance of 
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high-risk for drinking situations would be encouraged 
as an early coping strategy, however, during the course 
of treatment, gradual exposure to progressively more 
risky situations is encouraged. 
Techniques such as:             Stress management 
                                             Relaxation 
                                             Anger management 
                                             Assertiveness training  
Can be delivered as individual treatments but are also 
incorporated within the relapse prevention treatment 
package. 
RR Risk Ratio 
RSI Rough Sleepers Initiative 
SACAM Scottish Advisory Committee on Alcohol Misuse 
SBU Swedish Council on Technology Assessment in 
Healthcare 
Scottish Executive The Scottish Executive is the devolved government for 
Scotland. It is responsible for most of the issues of day-
to-day concern to the people of Scotland, including 
health, education, justice, rural affairs and transport. 
SD Standard Deviation 
SEHD Scottish Executive Health Department 
Sensitivity The probability that a test result is positive given the 
subject has the disease. 
Sensitivity Analysis An exploration of the impact upon results of changing 
parameter values within a model. 
SF-36 Short Form 36 Health Questionnaire  
SHO Senior House Officer 
Side-effect A side-effect is an unpleasant and unwanted effect of 
treatment. 
SIGN Scottish Intercollegiate Guideline Network 
Social Learning Theory A cognitive and behavioural intervention focussing on 
attention, memory and motivation. 
Solution Focussed Therapy Please refer to definition of CBT. 
SPC Summary of Product Characteristics 
SPS Scottish Prison Service 
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SS Social Skills  
The focus of social skills training is to help clients 
increase social support and improve their ability to 
establish rewarding interpersonal relationships.  The 
content of training will focus on a range of areas 
including body language, listening skills, assertiveness 
etc. 
SSRI Selective Serotonin Reuptake Inhibitor 
STRADA Scottish Training on Drugs and Alcohol 
Stress Management A relapse prevention technique. 
Supportive-Expressive 
Psychotherapy 
Is a  time limited, focused psychotherapy.  (This 
approach has been adapted for heroin and cocaine use.) 
    The therapy has two main components: 
· Supportive techniques to help patients feel 
comfortable in discussing their personal 
experiences. 
· Expressive techniques to help patients feel 
comfortable in discussing their personal 
experiences. 
Special Attention is paid to the role of drugs in relation 
to problem feelings and behaviours and how problems 
may be solved without recourse to drugs.   
SW Social Worker 
Tachycardia An abnormally rapid heart rate.  
Task Centred Counselling  A method of cognitive behavioural therapy. 
Trust There are two types of trust in Scotland: Acute Hospital 
Trusts and Primary Care Trusts. Acute Hospital Trusts 
are responsible for a defined set of acute hospital 
services. Primary Care Trusts have the responsibility for 
the provision of the full range of primary care, 
community and mental health services. Both types of 
trust operate within the geographical boundaries of an 
individual NHS Board. 
TSF Twelve-Step Facilitation 
Please see definition of Twelve-Step Model. 
TSG Topic Specific Group. 
Twelve-Step Model/Alcohol 
Anonymous  
A self-help or mutual support group with explicitly 
religious/spiritual aspects.  The philosophy is that 
alcoholics drink because of compulsion to do so and 
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that they have lost control over their drinking whether 
or not they are aware of this. 
UK United Kingdom 
US United States 
USA United States of America 
Vocational Training Focuses on developing skills to enhance employment 
prospects, often through re-training, further education 
or government employment initiatives.  
WHO World Health Organisation 
 
 
 
 
 
